docetaxel anhydrous has been researched along with paclitaxel in 2544 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (paclitaxel) | Trials (paclitaxel) | Recent Studies (post-2010) (paclitaxel) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 31,874 | 5,729 | 15,395 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 625 (24.57) | 18.2507 |
| 2000's | 1260 (49.53) | 29.6817 |
| 2010's | 542 (21.31) | 24.3611 |
| 2020's | 117 (4.60) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Capuano, B; DeBono, A; Scammells, PJ | 1 |
| Brett, ML; Colley, HE; Coole, SF; Danson, SJ; Dossetter, AG; Griffen, EJ; Harrison, J; Jackson, LV; Jennings, LR; Lockey, PM; Mason, DP; Muthana, M; Norman, D; Thompson, MJ; Tulasi, V; Williams, L; Wong, M | 1 |
| Bougeret, C; Guillou, C; Kozielski, F; Labrière, C; Talapatra, SK; Thoret, S | 1 |
| Alim, Z; Beydemir, Ş | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bishop, WR; Bogen, SL; Doll, RJ; Gibeau, CR; Hicklin, DJ; Lahue, BR; Lin, Y; Lipari, P; Liu, M; Liu, S; Ma, Y; Mirza, A; Nair, LG; Nomeir, A; Pan, W; Prosise, W; Reichert, P; Rindgen, D; Scapin, G; Seidel-Dugan, C; Seigel, E; Shipps, GW; Strickland, C; Tian, Y; Wang, X; Wang, Y | 1 |
| Bai, R; Bastian, A; Choudhary, S; Gangjee, A; Hamel, E; Ihnat, MA; Pavana, RK | 1 |
| Dong, Y; Li, Z; Liu, G; Ma, Y; Wang, C; Wang, S | 1 |
| Talele, TT | 1 |
| Cai, P; Fang, WS; Gago, F; Guo, M; Jia, WQ; Lei, L; Ma, YT; Sánchez-Murcia, PA; Sun, DY; Wang, H; Yang, Y; Zhang, XY | 1 |
| Arnst, KE; Banerjee, S; Deng, S; Kumar, G; Li, GB; Li, W; Miller, DD; Wang, Y; White, SW; Yang, J; Yang, L | 1 |
| Horwitz, SB; Ojima, I; Wang, C; Yang, CH | 1 |
| Ding, N; Gao, D; Li, Y; Ren, S; Wang, J; Wang, Y; Zhang, M | 1 |
| Afratis, K; Gavras, H; Karamanos, NK; Koutsakis, C; Leonardi, S; Papaioannou, D; Piperigkou, Z; Rassias, G; Rigopoulou, D; Vachlioti, E | 1 |
| Arya, GC; Jaitak, V; Kaur, K | 1 |
| Amato, I | 1 |
| Blume, E | 1 |
| Bissery, MC; Degen, D; Hanauske, AR; Hilsenbeck, SG; Von Hoff, DD | 1 |
| Abel, G; Kelland, LR | 1 |
| Bayssas, MM; Benvenuto, J; Bready, B; Fuentes, A; Jaiyesimi, I; Moore, D; Newman, BM; Newman, RA; Pazdur, R; Vreeland, F | 1 |
| Furuse, K; Kawahara, M | 1 |
| Kaye, SB; Schwartsmann, G; Workman, P | 1 |
| Arbuck, SG; Canetta, RM; Onetto, N; Rowinsky, EK | 1 |
| Bruno, R; Frydman, A; Montay, G; Vergniol, JC | 1 |
| Guénard, D; Guéritte-Voegelein, F; Potier, P | 2 |
| Lavelle, F; Naudin, A; Riou, JF | 1 |
| Hatae, M; Hokanishi, H; Kume, H; Maeda, Y; Nakagawa, S; Onishi, Y | 1 |
| Horwitz, SB; Ringel, I | 1 |
| Bissery, MC; Guénard, D; Guéritte-Voegelein, F; Lavelle, F | 1 |
| Culine, S; Extra, JM; Giacchetti, S; Madelaine, I; Marty, M; Rousseau, F | 1 |
| Fumoleau, P; Lemevel, B; Maugard-Louboutin, C; Perrocheau, G | 1 |
| Aapro, M; Bruno, R; Clavel, M; Cosson, V; Iliadis, A; Launay-Iliadis, MC; Le Bail, N; Marty, M; Oulid-Aissa, D; Vergniol, JC | 1 |
| Bissery, MC; Dykes, DJ; Harrison, SD; Waud, WR | 1 |
| Pujade-Lauraine, E | 1 |
| Giaccone, G | 1 |
| Francis, PA; Grant, SC; Kris, MG; Miller, VA; Rigas, JR | 1 |
| Ettinger, DS | 1 |
| Ali, SM; Aubé, J; Georg, GI; Hoemann, MZ; Jayasinghe, LR; McCall, R; Mitscher, LA | 1 |
| Anand, A | 1 |
| Mastrangelo, S; Puggioni, P; Riccardi, A; Riccardi, R; Rumi, C; Servidei, T; Tornesello, A | 1 |
| Bissery, MC | 2 |
| Eisenhauer, EA; Trudeau, M | 1 |
| Aapro, M; Kavanagh, J; Kaye, SB; Piccart, M | 1 |
| Rigas, JR | 4 |
| Aamdal, S; Catimel, G; Sternberg, C; Sulkes, A; van Hoesel, Q; Verweij, J; Wolff, I | 1 |
| Aapro, M; Bruno, R | 1 |
| Braguer, D; Briand, C; Carles, G; Garcia, P | 2 |
| Raymond, MN; Robin, P; Rossignol, B | 2 |
| Cortes, JE; Pazdur, R | 1 |
| Bessa, EH; Bonneterre, J; Genouville, C; Lemenager, M | 1 |
| Brayer, GD; Camerman, A; Camerman, N; Luo, Y; Mastropaolo, D | 1 |
| Beijnen, JH; Huizing, MT; Misser, VH; Pieters, RC; Pinedo, HM; ten Bokkel Huinink, WW; Veenhof, CH; Vermorken, JB | 1 |
| Kaye, SB | 4 |
| Franklin, H; Kaye, SB; Schoffski, P; Sessa, C; Smith, IE; Smyth, JF; Wanders, J | 1 |
| Aamdal, S; Franklin, HR; Kaplan, S; Kerger, J; Paridaens, R; Schachter, J; Verweij, J; Wanders, J; Wolff, I | 1 |
| Bayssas, M; Bruntsch, U; de Mulder, PH; Franklin, H; Heinrich, B; Kaye, SB; Paridaens, R; van Oosterom, A; Vermorken, JB; Wanders, J | 1 |
| Shparik, IV | 1 |
| Bissery, MC; Lavelle, F; Nohynek, G; Sanderink, GJ | 1 |
| Schriivers D [corrected to Schrijvers, D]; Schrijvers, D; van Oosterom, AT | 1 |
| McNeil, C | 1 |
| Aapro, MS; Zulian, GB | 1 |
| Klastersky, J | 1 |
| Niitani, H | 1 |
| Taguchi, T | 2 |
| Aapro, MS | 4 |
| Ravdin, PM; Valero, V | 1 |
| Berille, J; Fossella, FV; Hong, WK; Lee, JS | 1 |
| André, S; Bissery, MC; Combeau, C; Lavelle, F; Riou, JF; Vrignaud, P | 1 |
| Azli, N; Bayssas, M; Chevallier, B; Dieras, V; Fumoleau, P; Kerbrat, P; Van Glabbeke, M | 1 |
| Amadori, D; Bajorko, P; De Paola, F; Flamigni, A; Frassineti, GL; Gasperi-Campani, A; Milandri, C; Zoli, W | 1 |
| Bayssas, M; Franklin, H; Gore, M; Kaye, S; Piccart, MJ; Ten Bokkel Huinink, W; Van Oosterom, A; Verweij, J; Wanders, J | 1 |
| Chabner, BA; Chabner, ES | 1 |
| Favaudon, V; Giocanti, N; Hennequin, C | 2 |
| Grant, SC; Kris, MG; Miller, VA; Pisters, KM; Rigas, JR | 1 |
| Abe, S; Fujii, M; Furuse, K; Inoue, Y; Kurita, Y; Oizumi, K; Onoshi, T; Sato, K; Sugiura, T; Watanabe, K | 1 |
| Depenbrock, H; Hanauske, AR; Rastetter, J; Shirvani, D | 1 |
| Arbuck, SG; McGuire, WP; Trimble, EL | 1 |
| Francis, PA; Grant, SC; Heelan, RT; Kris, MG; Miller, VA; Pisters, KM; Rigas, JR; Venkatraman, ES; Woolley, K | 1 |
| Azli, N; Bayssas, M; Chevallier, B; Dieras, V; Fumoleau, P; Kerbrat, P; Krakowski, I; Lentz, MA; Roche, H; Van Glabbeke, M | 1 |
| Burris, HA; Cook, G; Irvin, R; Keeling, JH; Kuhn, J; McCollough, ML; Von Hoff, DD; Zimmerman, GC | 1 |
| Benner, S; Calayag, M; Fossella, FV; Glisson, B; Huber, M; Lee, JS; Lippman, S; Murphy, WK; Perez-Soler, R; Shin, DM | 1 |
| Hill, BT; Hosking, LK; McClean, S; Shellard, SA; Whelan, RD | 1 |
| Aapro, MS; Bissery, MC; Block, T; Danhauser-Riedl, S; Depenbrock, H; Fellbaum, C; Hilsenbeck, SG; Nekarda, H; Rastetter, J; Vogel, M | 1 |
| Kanamaru, R; Murata, K; Sato, T | 1 |
| Oriana, S; Orlandi, L; Silvestrini, R; Zaffaroni, N | 1 |
| Hepp, H; Konecny, G; Korell, M; Nestle-Krämling, C; Sevin, BU; Untch, A; Untch, M | 1 |
| Burris, HA; Keeling, JH; Lowry, M; Medina, J; Von Hoff, DD; Zimmerman, GC | 1 |
| Bruno, R; Sanderink, GJ | 1 |
| Cox, C; Miller, A; Niell, H; Rangel, C | 1 |
| Guenard, D; Gueritte-Voegelein, F; Lavelle, F | 1 |
| Carlier, MF; Maggs, AC; Pantaloni, D; Venier, P | 1 |
| Cuvier, C; Espie, M; Extra, JM; Giacchetti, S; Marty, M | 1 |
| Foa, R; Norton, L; Seidman, AD | 1 |
| Eisenhauer, EA; Ernst, S; Jolivet, J; Mertens, WC; Moore, M; Muldal, A | 1 |
| Angioli, R; Averette, HE; Koechli, O; Perras, JP; Sevin, BU; Untch, A; Untch, M | 1 |
| Francis, PA; Heelan, RT; Kris, MG; Orazem, JP; Pisters, KM; Rigas, JR; Woolley, KJ | 1 |
| Benner, S; Calayag, M; Chasen, M; Fossella, FV; Glisson, B; Lee, JS; Lippman, SM; Murphy, WK; Pang, A; Shin, DM | 1 |
| Aubert, F; Combeau, C; Commerçon, A; Goeldner, M; Mioskowski, C; Rousseau, B | 1 |
| Braakhuis, BJ; Kegel, A; Welters, MJ | 1 |
| Dubois, J; Guénard, D; Guéritte-Voegelein, F; Potier, P | 1 |
| Auzannet, V; Awada, A; de Valeriola, D; Kerger, J; Lips, S; Lossignol, D; Piccart, MJ; Ravoet, C; Sculier, JP; Tomiak, E | 1 |
| Barasoain, I; Barra, Y; Braguer, D; Briand, C; Carles, G; de Ines, C; el Khyari, S; Garcia, P | 1 |
| Abrams, JS; Friedman, M; Moore, TD | 1 |
| Verweij, J | 2 |
| Bruntsch, V; Dirix, LY; Franklin, H; Kaye, SB; Le Bail, N; Pavlidis, NA; Smyth, JF; Sternberg, CN; ten Bokkel Huinink, WW; Wanders, S | 1 |
| Dirix, LY; Franklin, H; Kaye, S; LeBail, N; Sessa, C; Smyth, J; Sulkes, A; Vermorken, JB; Verweij, J; Wanders, J | 1 |
| Cerny, T; Epelbaum, R; Franklin, HR; Kaplan, S; Kaye, S; Pavlidis, N; Schöffski, P; van Meerbeek, J; Wanders, J | 1 |
| Bissery, MC; Combeau, C; Duclos, O; Lavelle, F; Ojima, I; Riou, JF; Vrignaud, P; Zucco, M | 1 |
| Ali, SM; Datta, A; Georg, GI; Jayasinghe, LR; Vander Velde, DG; Zygmunt, J | 1 |
| Abbruzzese, JL; Ajani, JA; Bready, B; Lassere, Y; Levin, B; Patt, Y; Pazdur, R; Soh, LT; Soo, E; Sugarman, S | 1 |
| Frappier, F; Grellier, P; Guénard, D; Potier, P; Schrével, J; Sinou, V | 1 |
| D'Incalci, M; Giavazzi, R; Lucchini, V; Nicoletti, MI | 1 |
| Ariyoshi, Y; Fukuoka, M; Furue, H; Furuse, K; Hasegawa, K; Ishitani, K; Kanamaru, R; Niitani, H; Noda, K; Taguchi, T | 1 |
| Chevalier, B; Clavel, M; Verweij, J | 1 |
| Alakl, M; Clavel, M; Franklin, H; Piccart, M; Prove, AM; Steward, W; ten Bokkel Huinink, WW; Tursz, T; Verweij, J; Wanders, J | 1 |
| Catimel, G; Clavel, M; Franklin, H; Hanauske, A; Kaye, SB; Le Bail, N; Mattijssen, V; Piccart, M; Verweij, J; Wanders, J | 1 |
| Catimel, G; Clavel, M; Kerbrat, P; Kerger, J; Tursz, T; van Glabbeke, M; van Hoesel, QG; van Oosterom, AT; van Pottelsberghe, C; Verweij, J | 1 |
| Boge, TC; Georg, GI; Himes, RH; Vander Velde, DG | 1 |
| Adachi, I; Hirata, K; Kitajima, M; Kunii, Y; Sano, M; Shimada, H; Suwa, T; Tabei, T; Taguchi, T; Tominaga, T | 1 |
| Hirabayashi, K; Kono, I; Noda, K; Ogita, Y; Taguchi, T; Terajima, Y; Yakushiji, M | 1 |
| Hidalgo, IJ; Lechardeur, D; Phung-Ba, V; Raeissi, S; Scherman, D; Warnery, A; Wils, P | 1 |
| Chuang, L; Cook, K; Lotzová, E; Morris, M; Munkarah, A; Wharton, JT | 1 |
| Balmaceda, C; Barakat, R; Francis, P; Hakes, T; Hann, L; Phillips, M; Schneider, J | 1 |
| Gelmon, K | 1 |
| Ariyoshi, Y; Sugiura, T | 1 |
| Kurita, Y; Minoda, S; Nakano, M; Negoro, S; Niitani, H; Ogura, T; Taguchi, T; Watanabe, K; Yokoyama, A | 1 |
| Arita, K; Fujita, A; Hino, M; Igarashi, T; Kudo, S; Niitani, H; Taguchi, T | 1 |
| Abe, R; Enomoto, K; Fujita, M; Hamano, K; Hasegawa, K; Mori, S; Morishita, Y; Sasaki, Y; Tabei, T; Taguchi, T | 1 |
| Andreu, JM; Bordas, J; Briand, C; de Pereda, JM; Díaz, JF; García de Lacoba, M; Gil, R; Peyrot, V; Towns-Andrews, E | 1 |
| Datta, A; Georg, GI; Jayasinghe, LR | 1 |
| Karantanis, E; Morris, DL; Nicholson, S | 1 |
| Hisakatsu, S; Niitani, H | 1 |
| Auzannet, V; Bissett, D; Cassidy, J; Chadwick, GA; Graham, MA; Kaye, SB; Kerr, DJ; Le Bail, N; Setanoians, A; Wilson, P | 1 |
| Einzig, AI; Goldberg, GL; Horwitz, SB; Runowicz, CD; Wiernik, PH | 1 |
| Bruno, R; Clavel, M; Extra, JM; Le Bail, N; Marty, M; Rousseau, F | 1 |
| Andreu, JM; Díaz, JF | 1 |
| Burris, H; Eckardt, J; Fields, S; Irvin, R; Kalter, S; Kuhn, J; Rodriguez, G; Shaffer, D; Smith, L; Weiss, G | 1 |
| Bissery, MC; Boven, E; Erkelens, CA; Pinedo, HM; Venema-Gaberscek, E | 1 |
| Hirst, BH; Hunter, J; Simmons, NL | 1 |
| Manthey, CL; Qureshi, N; Stütz, PL; Vogel, SN | 1 |
| Bissett, D; Kaye, SB | 1 |
| Baker, WJ; Burris, HA; Keeling, JH; Von Hoff, D; Vukelja, SJ | 1 |
| Dirix, L; Kaye, S; Prove, A; Schrijvers, D; van Oosterom, A; Vonck, I; Wanders, J | 1 |
| Andreu, JM; Díaz, JF; Menéndez, M | 1 |
| Arbuck, SG; Cheson, BD; Phillips, PH | 1 |
| Cohen, PR; Kavanagh, JJ; Kudelka, AP; Pazdur, R; Raber, MN | 1 |
| Eisenhauer, E | 1 |
| Bellet, RE; Bierman, WA; Burris, HA; Cook, G; Eisenberg, P; Genevois, E; Kane, M; Mortimer, J; Ravdin, PM | 1 |
| Bellet, RE; Buzdar, AU; Esparza, L; Fonseca, GA; Fraschini, G; Holmes, FA; Hortobagyi, GN; Theriault, RL; Valero, V; Walters, RS | 1 |
| Bedikian, AY; Burris, HA; Buzaid, AC; Eckardt, JR; Eton, O; Jenkins, J; Legha, SS; Smetzer, L; Von Hoff, DD; Weiss, GR | 1 |
| Chou, TC; Otter, GM; Sirotnak, FM | 1 |
| Adachi, I; Aoyama, H; Horikoshi, N; Narabayashi, M; Taguchi, T; Takashima, S; Watanabe, T | 1 |
| Cresteil, T; Monsarrat, B; Royer, I; Sonnier, M; Wright, M | 1 |
| de Boer-Dennert, M; Kolker, HJ; Loos, WJ; Ma, J; Planting, AS; Schellens, JH; Stoter, G; van der Burg, ME; Verweij, J | 1 |
| Pronk, LC; Stoter, G; Verweij, J | 1 |
| Balmaceda, C; Baselga, J; Bruno, R; Crown, JP; Currie, V; Freilich, R; Gilewski, TA; Gollub, M; Hakes, TB; Hudis, CA; Lebwohl, DE; Norton, L; Raptis, G; Robles, M; Seidman, AD | 1 |
| Hilkens, PH; Stoter, G; van den Bent, MJ; van Putten, WL; Vecht, CJ; Verweij, J | 1 |
| Barohn, RJ; Burris, H; Jackson, CE; New, PZ; Rinaldi, D | 1 |
| Apfel, SC | 2 |
| Dubois, J; Guénard, D; Guéritte-Voegelein, F; Le Goff, MT; Tollon, Y; Wright, M | 1 |
| Piccart, MJ | 2 |
| Edelman, MJ; Gandara, DR | 1 |
| Trudeau, ME | 4 |
| van Oosterom, AT | 2 |
| Ravdin, PM | 6 |
| Bissery, MC; Lavelle, F; Vrignaud, P | 1 |
| Burris, HA; Fields, S; Peacock, N | 1 |
| Fan, Y; Juneja, SK; Luzinat, R; Matthews, JP; Michael, M; Millward, MJ; Rischin, D; Toner, GC | 1 |
| Capri, G; Fulfaro, F; Gianni, L; Tarenzi, E | 1 |
| Furuse, K; Kunitoh, H; Niitani, H; Onoshi, T; Taguchi, T; Watanabe, K | 1 |
| Busse, PM; Clark, JR; Costello, R; Dreyfuss, AI; Lucarini, JW; Norris, CM; Posner, MR; Poulin, MD; Rossi, RM; Thornhill, L | 1 |
| Macdonald, JS; Schnall, SF | 1 |
| Battafarano, DF; Burris, HA; Keeling, JH; Older, SA; Zimmerman, GC | 1 |
| Delorme, F; Eisenhauer, EA; Higgins, BP; Letendre, F; Lofters, WS; Muldal, AM; Norris, BD; Trudeau, ME; Vandenberg, TA | 1 |
| Fojo, A | 1 |
| de Sousa, G; Gaillard, C; Marre, F; Martinet, M; Rahmani, R; Sanderink, GJ | 1 |
| Guy, RK; Nicolaou, KC; Potier, P | 1 |
| Auguste, L; Baselga, J; Currie, V; Edelman, B; Fennelly, D; Francis, P; Gilewski, TA; Gollub, M; Hochhauser, D; Hudis, CA; Moynahan, ME; Norton, L; O'Donaghue, M; Salvaggio, R; Seidman, AD; Spriggs, D; Tong, W; Yao, TJ | 1 |
| Obata, T; Sasaki, T; Tanaka, M | 1 |
| Armand, JP; Couteau, C; Goncalves, E; Terret, C; Yakendji, K | 1 |
| Chan, S; Gardner, S; Winterbottom, L | 1 |
| Cardenal, F; Llort, G; Mesía, R; Montes, A; Seguí, J | 1 |
| Chirlian, LE; Heerding, JM; Moyna, G; Scott, AI; Swindell, CS; Williams, DK; Williams, HJ | 1 |
| Catimel, G; Talon, A | 1 |
| Dombernowsky, P; Tuxen, MK | 1 |
| Drengler, R; Eckardt, J; Eckhardt, G; Villalona-Calero, M; Von Hoff, D | 1 |
| Balmaceda, C; DeAngelis, LM; Freilich, RJ; Rubin, M; Seidman, AD | 1 |
| Faure, P; Madelaine-Chambrin, I; Piquet-Sevrin, V | 1 |
| Fulton, B; Spencer, CM | 1 |
| Piccart, M | 3 |
| Le Chevalier, T | 1 |
| Rougier, P | 1 |
| Bernacki, RJ; Ojima, I; Sharma, A; Straubinger, RM | 1 |
| Bove, L; Innocenti, P; Jandolo, B; Pace, A; Pietrangeli, A | 1 |
| Azli, N; Chevallier, B; Dieras, V; Fumoleau, P; Kerbrat, P; Krakowski, I; Lentz, MA; Misset, JL; Murawsky, M; Pouillart, P; Riva, A; Roche, H | 1 |
| Arioka, H; Eguchi, K; Fukuoka, K; Funayama, Y; Ishida, T; Kunito, H; Kurokawa, H; Nishio, K; Nomoto, T; Ohe, Y; Ohta, S; Ohtsu, T; Saijo, N; Sasaki, Y; Shinkai, T; Tamura, T; Yamamoto, N | 1 |
| Azli, N; Bougon, N; Chevallier, B; Dieras, V; Fumoleau, P; Kerbrat, P; Krakowski, Y; Maugard-Louboutin, C; Misset, JL; Riva, A; Roche, H | 1 |
| Beijnen, JH; Boesen, JJ; Huizing, MT; Nooijen, WJ; Scherrenburg, EJ; Sparreboom, A; Van Tellingen, O; Versluis, C | 1 |
| Barnicle, M; Blendowski, C; Goodman, M; Lydon, J; Petersen, J; Stewart, I; Wickham, R | 1 |
| Bissery, MC; Fellous, A; Fromes, Y; Gounon, P; Veitia, R | 1 |
| Cormier, Y; Eisenhauer, EA; Fisher, B; Goss, G; Latreille, J; Martins, H | 1 |
| Edwards, CL; Ende, K; Fishman, A; Freedman, RS; Kaplan, A; Kavanagh, JJ; Kieback, DG; Kudelka, AP; Levy, T; Mante, R; Steger, M; Verschraegen, CF | 1 |
| Bissery, MC; Chabot, GG; Lavelle, F; Vrignaud, P | 1 |
| Bernacki, RJ; Bissery, MC; Bounaud, PY; Kuduk, SD; Michaud, E; Ojima, I; Pera, P; Slater, JC; Veith, JM; Vrignaud, P | 1 |
| Grellier, P; Schrevel, J; Sinou, V | 1 |
| Halle, M | 1 |
| Blaschke, G; Boos, J; Hempel, G; Krümpelmann, S; Lehmkuhl, D | 1 |
| Norton, L | 1 |
| Valero, V | 5 |
| Fumoleau, P | 3 |
| Burris, HA | 6 |
| Aapro, M | 2 |
| Armand, JP | 2 |
| Azli, N; Bourgeois, H; Dieras, V; Fumoleau, P; Misset, JL; Pouillart, P | 1 |
| Khayat, D | 1 |
| Ogawa, M | 1 |
| Bruno, R; De Phillips, SL; Montay, G; Sheiner, LB; Vergniol, JC; Vivier, N | 1 |
| Sakata, Y; Suzuki, H; Takemori, H | 1 |
| Renick-Ettinger, A | 1 |
| Griffon-Etienne, G; Marchal, C; Merlin, JL | 1 |
| Barré, J; Montay, G; Morin, C; Paccaly, A; Tillement, JP; Urien, S | 1 |
| Cairncross, G; Eisenhauer, E; Forsyth, P; Goodyear, M; Stewart, D; Wainman, N | 1 |
| Ebbert, LP; Edmonson, JH; Gerstner, JB; Jung, SH; McGaw, H; Nascimento, AG | 1 |
| Schrijvers, D; van Dam, P; van Oosterom, A | 1 |
| Kennedy, MJ | 1 |
| Verlag, GT | 1 |
| Boyer, R; Halme, M; Jekunen, A; Mattson, K; Pyrhönen, S; Roubille, N; Saarinen, A; Tamminen, K | 1 |
| Basu, A; Croce, CM; Haldar, S | 1 |
| Benson, AB; Einzig, AI; Karp, DD; Neuberg, D; O'Dwyer, PJ; Remick, SC; Stewart, JA | 1 |
| Coatsworth, S; Einzig, AI; Recio, A; Rodriquez, R; Schuchter, LM; Wiernik, PH | 1 |
| Hilkens, PH; Pronk, LC; van den Bent, MJ; van Putten, WL; Vecht, CJ; Verweij, J | 1 |
| Bernacki, RJ; Gimi, RH; Kuduk, SD; Ojima, I; Park, YH; Pera, P; Slater, JC; Sun, CM; Takeuchi, CS; Veith, JM | 1 |
| Bernacki, RJ; Kuduk, SD; Ojima, I; Pera, P; Veith, JM | 1 |
| Mitsuhashi, H | 1 |
| Rowinsky, EK | 1 |
| Bishop, JF; Blanc, C; Bruno, R; Cosolo, W; James, R; Laird, J; Loret, C; Millward, MJ; Rischin, D; Toner, GC; Urch, M; Webster, LK; Zalcberg, J; Zimet, A | 1 |
| Blanc, C; Bruno, R; de Boer-Dennert, M; Harteveld, M; Hilkens, PH; Ma, J; Planting, AS; Pronk, LC; Schellens, JH; Stoter, G; van den Bent, MJ; van der Burg, ME; Verweij, J | 1 |
| Christensen, IJ; Holm, B; Jensen, PB; Sehested, M; Sorensen, M | 1 |
| Benedetti Panici, P; Bombardelli, E; Distefano, M; Fattorossi, A; Ferlini, C; Filippini, P; Isola, G; Mancuso, S; Riva, A; Scambia, G | 1 |
| Denis, P; Mazzo, DJ; Nguyen-Huu, JJ; Pagniez, S | 1 |
| Barra, Y; Bourgarel, V; Braguer, D; Briand, C; el Khyari, S | 1 |
| Davison, JD; Francis, PA; Ganju, V; Michael, M; Millward, MJ; Rischin, D; Shapiro, JD; Toner, GC | 1 |
| Rodenhuis, S; ten Bokkel Huinink, WW; Westermann, AM | 1 |
| Kavanagh, JJ; Kudelka, AP; Seetalarom, K; Verschraegen, CF | 1 |
| Breton-Gilet, A; Combeau, C; Commerçon, A; Ehret-Sabatier, L; Faucher, D; Goeldner, M; Loeb, C; Rousseau, B | 1 |
| Sheldon, T | 1 |
| Hilkens, PH; Stoter, G; van den Bent, MJ; Vecht, CJ; Verweij, J | 1 |
| Baldeyrou, P; Le Cesne, A; Le Chevalier, T; Merad, M; Mesurolle, B | 1 |
| Linsenmeyer, ME; Millward, MJ; Rischin, D; Urch, ME; Webster, LK; Woodcock, DM | 1 |
| Bessa, E; Bonneterre, J; Bonneterre, ME; Dauba, J; Lecomte, S; Lemenager, M | 1 |
| Bajorin, DF; Hilton, S; Kelly, WK; Mazumdar, M; McCaffrey, JA; Sadan, S; Scher, HI | 1 |
| Andreu, JM; Bordas, J; Diakun, G; Diaz, JF; Towns-Andrews, E | 1 |
| Ardizzoni, A; Bertelli, G; Cafferata, MA; Dini, D; Gozza, A; Rosso, R | 1 |
| MacConnachie, AM | 1 |
| Cresteil, T; Monsarrat, B; Royer, I; Wright, M | 1 |
| Adamson, PC; Balis, FM; Berg, SL; Blaney, SM; Krailo, MD; Mosher, R; O'Brien, M; Poplack, DG; Reaman, GH; Seibel, NL | 1 |
| Sculier, JP | 1 |
| Boyer, MJ; Clarke, SJ | 1 |
| Béhar, A; Brun, MD; Chauvin, FF; Feuilhade de Chauvin, F; Hille, D; Maurel, A; Oulid-Aissa, D; Pujade-Lauraine, E | 1 |
| Loos, WJ; Nooter, K; Sparreboom, A; Stoter, G; Verweij, J | 2 |
| Hortobágyi, G | 2 |
| Diéras, V | 3 |
| Delorme, F; Janowska, A; Mackey, J; Nabholtz, JM; Noel, D; Paterson, A; Riva, A; Smylie, M | 1 |
| Azli, N; Delecroix, V; Féty, R; Fumoleau, P; Perrocheau, G | 1 |
| Aylesworth, C; Bellet, R; Burris, H; Drengler, R; Peacock, N; Ravdin, P; Rodriguez, G; Rowinsky, E; Smith, L; Von Hoff, D; White, L | 1 |
| Slee, PH | 1 |
| Tsukagoshi, S | 1 |
| Devriendt, D; Klastersky, J | 1 |
| Pestalozzi, BC | 1 |
| André, J; Song, M; Vandenbossche, L; Vandeveire, A; Vanhooteghem, O; Vindevoghel, A | 1 |
| Antoine, EC; Auclerc, G; Khayat, D; Rixe, O; Weil, M | 1 |
| Johnson, PJ; Leung, SF; Yeo, W | 1 |
| Di Leo, A; Piccart, MJ | 1 |
| Belani, CP; Ramanathan, RK | 1 |
| Fossella, FV; Hong, WK; Lee, JS | 1 |
| Dapunt, O; Daxenbichler, G; Gastl, G; Kaern, J; Ludescher, C; Marth, C; Tropé, C; Widschwendter, M; Zeimet, AG | 1 |
| Awada, A; Bontenbal, M; Coleman, R; Klijn, J; Mauriac, L; Nooij, M; Paridaens, R; Piccart, MJ; Selleslags, J; Van Glabbeke, M; Van Vreckem, A | 1 |
| Beijnen, JH; Koopman, FP; Lustig, V; Rosing, H; ten Bokkel Huinink, WW | 1 |
| Bombardelli, E; De Vincenzo, R; Distefano, M; Fattorossi, A; Ferlini, C; Gaggini, C; Mancuso, S; Ojima, I; Panici, PB; Riva, A; Scambia, G | 1 |
| Chaitchik, S; Inbar, M; Merimsky, O | 1 |
| de Vries, EG; Haaxma-Reiche, H; Hofstra, LS; van der Graaf, WT; Willemse, PH | 1 |
| Hortobagyi, GN | 4 |
| Von Hoff, DD | 1 |
| Antoine, E; Khayat, D | 1 |
| D'Andrea, GM; Seidman, AD | 1 |
| Grant, SC; Kris, MG; Miller, VA; Ng, KK | 1 |
| Jekunen, A; Mattson, K; Saarinen, A | 1 |
| Agelidou, M; Androulakis, N; Apostolopoulou, F; Bouros, D; Georgopoulou, T; Georgoulias, V; Halkiadakis, G; Hatzidaki, D; Kakolyris, S; Kourousis, C; Papadakis, E; Souglakos, J | 1 |
| Miller, VA | 2 |
| Crown, JP; Donnellan, PP | 1 |
| Androulakis, N; Bouros, D; Dimopoulos, MA; Georgoulias, V; Hatzakis, K; Hatzidaki, D; Heras, P; Kakolyris, S; Kalbakis, K; Kotsakis, T; Kourousis, C; Meramveliotakis, N; Papadimitriou, C; Vardakis, N | 1 |
| Golomb, HM; Haraf, DJ; Hoffman, PC; Masters, GA; Mauer, AM; Vokes, EE | 1 |
| Harper, P | 1 |
| Barcos, M; Budman, DR; Cooper, MR; Johnson, JL; Peterson, BA; Petroni, GR; Schlossman, DM | 1 |
| Viens, P | 1 |
| Bonneterre, J; Launois, RJ; Reboul-Marty, JM | 1 |
| Fukuda, S; Inuyama, Y; Satoh, N | 1 |
| Furuse, K | 1 |
| Sasaki, T | 1 |
| Sugiyama, T; Ushijima, K; Yakushiji, M | 1 |
| Gradishar, WJ | 5 |
| Chan, S | 1 |
| Aapro, MS; Alaki, M; Bezwoda, WR; Deschênes, L; Douma, J; Drbal, J; Melnychuk, D; Murawsky, M; Nabholtz, JM; Rapoport, B; Riva, A; Rosso, R; Thuerlimann, B; Trillet-Lenoir, V; Vandenberg, TA | 1 |
| al-Tweigeri, T; Au, D; Delorme, F; Mackey, JR; Nabholtz, JM; Noel, D; Paterson, AH; Riva, A; Sansregret, E; Smylie, M | 1 |
| Belani, CP | 6 |
| Negoro, S | 1 |
| Llombart-Cussac, A; Pivot, X; Spielmann, M | 1 |
| Balat, O; Edwards, CL; Kavanagh, JJ; Kudelka, AP; Verschraegen, CF | 1 |
| Hirota, Y; Iimura, S; Ishiyama, T; Mitsui, I; Ohsuki, S; Soga, T; Takenoshita, H; Terasawa, H; Uoto, K | 1 |
| Bornens, M; Favaudon, V; Giocanti, N; Paoletti, A | 1 |
| Eckardt, JR | 1 |
| Kraynak, MA | 1 |
| Yee, GC | 1 |
| Bruno, R; Hille, D; Lebecq, A; Riva, A; Thomas, L | 1 |
| Saijo, N | 1 |
| Boyer, MJ | 1 |
| Ghaemmaghami, M; Jett, JR | 1 |
| Golomb, HM; Haraf, DJ; Hoffman, PC; Masters, GA; Mauer, AM; Vokes, EE; Watson, SM | 1 |
| Bruno, R; Burris, HA; Chevallier, B; Fossella, FV; Fumoleau, P; Hille, D; Kaye, SB; Ravdin, PM; Rigas, JR; Riva, A; Seidman, AD; Sheiner, LB; ten Bokkel Huinnink, WW; Valero, V; van Oosterom, AT; Verweij, J; Vivier, N | 1 |
| Bhuyan, BK; Lopes, NM; Miller, HP; Young, ND | 1 |
| Manegold, C | 4 |
| Dörken, B; Köhne, CH; Kretzschmar, A | 1 |
| Costa, SD; von Minckwitz, G | 1 |
| Alloatti, G; Appendino, G; Bombardelli, E; Gallo, MP; Levi, RC; Penna, C | 1 |
| de Bruijn, EA; Groult, V; Locci-Tonelli, D; Planting, AS; Pronk, LC; Schellens, JH; Schrijvers, D; van Oosterom, AT; Verweij, J | 2 |
| Nelson, NJ | 2 |
| Eisenhauer, EA; Vermorken, JB | 1 |
| Aapro, M; Francis, P; Kavanagh, J; Kaye, SB; Piccart, M | 1 |
| Clemons, M; Howell, A; Jayson, G; Leahy, M; Ranson, M; Valle, J | 1 |
| Bontenbal, M; Hilkens, PH; Sillevis Smitt, PA; van den Bent, MJ; van Raaij-van den Aarssen, VJ; Verweij, J | 1 |
| Rubens, RD | 1 |
| Azli, N; Diéras, V; Fumoleau, P; Kalla, S; Misset, JL; Pouillart, P | 1 |
| Dubbelman, R; Hiemstra, A; Lustig, V; Rodenhuis, S; ten Bokkel Huinink, WW | 1 |
| Cottu, PH; Espié, M; Extra, JM; Marty, M | 1 |
| Beijnen, JH; Nooijen, WJ; Sparreboom, A; van Tellingen, O | 1 |
| D'Incalci, M | 1 |
| Cao, S; Harstrick, A; Rustum, YM; Seeber, S; Vanhoefer, U | 1 |
| Eckert, K; Grünberg, E; Maurer, HR | 1 |
| Behm, FG; Campana, D; Consolini, R; Pui, CH; Raimondi, SC | 1 |
| Muggia, F; O'Leary, J; Volm, M; Wasserheit, C | 1 |
| Büchholz, E; Drings, P; Manegold, C | 1 |
| Kato, M; Kawabata, T; Suzuki, A | 1 |
| Adak, S; Barton, JJ; Busse, PM; Colevas, AD; Costello, R; Dreyfuss, A; Fabian, RL; Fitzgerald, TJ; Fried, M; Norris, CM; Peters, ES; Posner, MR; Poulin, M; Tishler, RB | 1 |
| Asseryanis, E; Bancher-Todesca, D; Barrada, M; Binder, M; Kubista, E; Obermair, A | 1 |
| Fukase, Y; Ishikawa, T; Ishitsuka, H; Nishida, M; Sawada, N; Yoshikubo, T | 1 |
| Bhalla, K; Harris, WB | 1 |
| Mamounas, EP | 1 |
| Kokawa, Y; Oura, S; Sakurai, T; Tamaki, T; Umemura, T; Yoshimura, G | 3 |
| Hortobagyi, GN; Hung, MC; Ibrahim, N; Jing, T; Liu, B; Price, JE; Singletary, SE; Sun, D; Yu, D | 1 |
| Eckhardt, S | 1 |
| Barter, C; Berille, J; Bishop, J; Bougan, N; Friedlander, M; James, R; Loret, C; McKeage, M; Millward, M; Rischin, D; Toner, G; Zalcberg, J; Zimet, A | 1 |
| Agelidou, M; Androulakis, N; Apostolopoulou, F; Dimopoulos, AM; Georgoulias, V; Hatzidaki, D; Heras, P; Kakolyris, S; Kourousis, C; Mavromanolakis, E; Papadakis, E; Papadimitriou, C; Tzannes, S; Vlachonicolis, J; Vossos, A | 1 |
| Di Nunno, L; Herrington, JD; Rinehart, JJ | 1 |
| Bunn, PA; Kelly, K | 1 |
| Etienne, B; Guérin, JC; Nesme, P; Pérol, M; Robinet, G; Vuillermoz, S | 1 |
| Braguer, D; Briand, C; Kadi, A; Lehmann, M; Luis, J; Marvaldi, J; Pichard, V; Rognoni, JB | 1 |
| Schrijvers, D; Vermorken, JB | 3 |
| Ando, S; Hirota, Y; Mitsui, I; Soga, T; Takenoshita, H; Terasawa, H; Uoto, K; Yoshino, T | 1 |
| Eliel, MR; Nortier, JW; Rodenburg, CJ; Slee, PH | 1 |
| Eland, IA; Krommendijk, R; Otter, R; Stricker, BH | 1 |
| Bressolle, F; Grosse, PY; Pinguet, F | 1 |
| Braguer, D; Briand, C; Carles, G; Sabeur, G | 1 |
| Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Thomas, M | 1 |
| Bodin, F; Dumontet, C; Michal, Y | 1 |
| Andre, AM; Clark, TB; Conti, JA; Huang, Y; Kemeny, NE; Stockman, J | 1 |
| Anderson, N; Lokich, J | 1 |
| Bruno, R; Kearns, CM; Kuhn, JG; McLeod, HL | 1 |
| Adachi, I; Ando, M; Fujii, H; Igarashi, T; Itoh, K; Katsumata, N; Narabayashi, M; Ohtsu, T; Omuro, Y; Sasaki, Y; Taguchi, T; Tokue, Y; Wakita, H; Watanabe, T; Ying, DF | 1 |
| Anagnostopoulos, A; Athanassiades, P; Deliveliotis, C; Dimopoulos, C; Dimopoulos, MA; Mitropoulos, D; Moulopoulos, LA; Papadimitriou, C | 1 |
| Armstrong, J; Crown, J; Donnellan, P; Fennelly, D; Lynch, V; McDonnell, T; McNicholas, W; Rowan, S | 1 |
| Haraf, DJ; Hoffman, PC; Mauer, AM; Vokes, EE | 1 |
| Fitzpatrick, FA; Moos, PJ | 1 |
| Carney, DN | 1 |
| Bissery, MC; Filipski, E; François, E; Lemaigre, G; Lévi, F; Li, XM; Liu, XH; Tampellini, M; Vrignaud, P | 1 |
| Antoine, EC; Khayat, D | 1 |
| Jacob, CI; Patten, SF | 1 |
| Bontenbal, M; de Wit, R; Klijn, JG; Seynaeve, C | 1 |
| Bissery, MC; Fellous, A; Martinez, C; Veitia, R | 1 |
| Schiller, JH | 1 |
| Arlet, P; Auvinet, M; Dahan, S; Dingremont, C; Juchet, H; Ollier, S | 1 |
| Tankanow, RM | 1 |
| Booser, DJ; Burris, HA; Earhart, RH; Erban, JK; Esparza-Guerra, L; Holmes, FA; Hortobagyi, GN; Jones, SE; Mennel, RG; Rahman, Z; Ravdin, PM; Schottstaedt, MW; Valero, V; Von Hoff, DD | 1 |
| Engelholm, SA; Kamby, C; Lund, B; Sengeløv, L | 1 |
| Aamdal, S; Oian, P; Semb, KA | 1 |
| Colevas, AD; Posner, MR | 1 |
| Battaglia, A; Bonanno, G; Fattorossi, A; Leone, G; Mancuso, S; Menichella, G; Panici, PB; Perillo, A; Pierelli, L; Scambia, G | 1 |
| Paridaens, R; Thomas, J; Van Oosterom, A; Van Vaerenbergh, W; Wildiers, J | 1 |
| Jackisch, C | 1 |
| Archer, CD; Coombes, RC; English, J; Khan, S; Lowdell, C; Sinnett, HD | 1 |
| Androulakis, N; Bahlitzanakis, N; Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Kamilaki, M; Kotsakis, A; Koukouraki, S; Koukourakis, MI; Kourousis, C | 1 |
| Hirabayashi, N; Kanamaru, R; Kurihara, M; Ota, J; Sakata, Y; Suminaga, M; Taguchi, T | 1 |
| Delorme, F; Giguere, M; Goel, R; Lotfolahi, A; Molepo, JM; Rouini, MR; Shirazi, FH; Stewart, DJ; Tomiak, E; Vergniol, JC; Vernillet, L | 1 |
| Ebneth, A; Godemann, R; Illenberger, S; Mandelkow, E; Stamer, K; Trinczek, B | 1 |
| Abbruzzese, JL; Hunter, NR; Mason, KA; Milas, L; Milas, M | 1 |
| Baille, P; Bruno, R; Millward, M; Montay, G; Schellens, JH; Verweij, J; Webster, LK | 1 |
| Cohen, P; de Leon, CG; Edwards, CL; Finnegan, MB; Forman, A; Freedman, RS; Hord, M; Kavanagh, JJ; Kim, EE; Kudelka, AP; Tresukosol, D; Varma, D; Verschraegen, CF | 1 |
| de Boer, M; de Wit, R; Kerger, J; Kruit, WH; Stoter, G; Verweij, J | 1 |
| Gelboin, HV; Gonzalez, FJ; Korzekwa, KR; Krausz, KW; Martinet, M; Shou, M | 1 |
| Androulakis, N; Chalkiadakis, G; Georgoulias, V; Kakolyris, S; Kourousis, C; Maltezakis, G; Metaxaris, G; Samonis, G; Souglakos, J; Vlachonikolis, J | 1 |
| Ajani, JA | 2 |
| Hilkens, PH; Pronk, LC; Stoter, G; van den Bent, MJ; van Putten, WL; Verweij, J | 1 |
| Jones, J; Laufman, LR; Nicol, S; Rhodes, VA; Spiridonidis, CH; Wallace, K | 1 |
| Androulakis, N; Apostopoloulou, F; Bouros, D; Chatzakis, K; Georgopoulou, T; Georgoulias, V; Hatzidaki, D; Kotsakis, T; Kouroussis, C; Panagos, G; Papadakis, M; Souklakos, J; Vlachonikolis, J | 1 |
| Beijnen, JH; Crommentuyn, KM; Schellens, JH; van den Berg, JD | 1 |
| Cuvier, C; Espié, M; Gorins, A; Marty, M | 1 |
| Crown, J; Nabholtz, JM | 1 |
| Sparano, JA | 3 |
| Colombo, T; D'Incalci, M; Riva, A; Schüller, J; Zucchetti, M | 1 |
| Burris, H | 1 |
| Crown, J | 5 |
| Pagani, O | 1 |
| Mackey, J; Nabholtz, JM; Smylie, M; Tonkin, K | 1 |
| Löffler, TM | 1 |
| Iimura, S; Mitsui, I; Nakayama, K; Ohsuki, S; Soga, T; Terasawa, H; Uoto, K | 1 |
| Benjapibal, M; Edwards, CL; Kavanagh, JJ; Kudelka, AP; Vadhan-Raj, S; Valero, V; Vasuratna, A; Verschraegen, CF | 1 |
| Ohnishi, K; Ohno, R | 1 |
| Criée, CP; Dalichau, H; Griesinger, F; Hannemann, P; Hemmerlein, B; Herse, B; Hess, CF; Hiddemann, W; Schmidberger, H; Wörmann, B | 1 |
| Fitzpatrick, FA; Moos, PJ; Muskardin, DT | 1 |
| Brown, RE; Hutton, J | 1 |
| Espie, M | 1 |
| Alexopoulos, K; Androulakis, N; Georgoulias, V; Kakolyris, S; Kouroussis, C; Papadakis, E; Patila, E; Samantas, E; Samelis, G; Vaslamatzis, M; Vossos, A | 1 |
| Hunter, N; Kishi, K; Mason, KA; Milas, L; Schimming, R; Weil, M | 1 |
| de Boer-Dennert, M; Pronk, LC; Stoter, G; van Beurden, V; van Putten, WL; Verweij, J | 1 |
| Orel, NF | 1 |
| Armand, JP; Couteau, C | 1 |
| Baba, S; Ebihara, S; Horiuchi, M; Ichikawa, G; Inuyama, Y; Kamata, S; Kanzaki, J; Kataura, A; Kida, A; Konno, A; Kono, N; Kubota, A; Matsunaga, T; Matsuura, H; Miyake, H; Moriyama, H; Saijo, S; Saito, H; Sakai, M; Sasaki, Y; Satake, B; Taguchi, T; Takeoda, S; Togawa, K; Tsukuda, M | 1 |
| Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Koukourakis, MI; Schiza, S | 1 |
| Burris, HA; Hoff, PM; Patt, YZ; Pazdur, R; Rinaldi, DA; Rodriguez, GI; Royce, ME | 1 |
| Belli, L; Bérille, J; Bougon, N; Douillard, JY; Ibrahim, N; Le Chevalier, T; Monnier, A; Ruffie, P; Sun, XS | 1 |
| Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Katsogridakis, K; Kotsakis, T; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N; Vlachonikolis, J | 1 |
| Agelidou, A; Androulakis, N; Apostolopoulou, F; Bouros, D; Dimopoulos, MA; Georgoulias, V; Hatzakis, K; Kakolyris, S; Kalbakis, K; Kotsakis, A; Kouroussis, C; Papadakis, E; Papadimitriou, C; Vardakis, N; Vlachonicolis, J | 1 |
| Bagiella, E; Balog, J; Benson, M; Fine, R; Heitjan, D; Judge, T; Macarthur, RB; O'Connor, J; Olsson, CA; Petrylak, DP; Pfaff, C; Sawczuk, I; Shelton, G; Zuech, N | 1 |
| Miller, KD; Sledge, GW | 1 |
| Barile, B; Budman, DR; Fetten, J; Gonzales, AL; Kreis, W; Vinciguerra, V | 1 |
| Catimel, G; Droz, JP; Gras, L; Hanauske, AR; Planting, AS; Schöffski, P; Schrijvers, A; Schrijvers, D; Verweij, J; Wanders, J | 1 |
| Cabral, F; Reed, E; Sarosy, G; Trimble, E | 1 |
| Clarke, SJ; Rivory, LP | 1 |
| Barrett-Lee, PJ; Bizzari, JP; Eggleton, SP; Leonard, RC; O'Brien, ME | 1 |
| Agelaki, S; Alexopoulos, A; Apostolaki, F; Georgoulias, V; Giannakakis, T; Kakolyris, S; Kalbakis, K; Kosmas, C; Kourousis, C; Malamos, N; Mavroudis, D; Potamianou, A; Rigatos, G; Samonis, G; Sarra, E; Vlachonicolis, J | 1 |
| Aylesworth, C; Bellet, R; Burris, H; Peacock, N; Petit, T; Ravdin, P; Rodriguez, G; Rowinsky, EK; Smetzer, L; Smith, L; Von Hoff, DD | 1 |
| Furue, H; Hirabayashi, N; Kanamaru, R; Kurihara, M; Mai, M; Ota, J; Sakata, Y; Suminaga, M; Taguchi, T | 1 |
| Buckner, CD; Franco, C; Hazelton, B; Moore, M; Schwartzberg, LS; Smith, R; Van Amburg, A; Weaver, CH; White, L; Zhen, B | 1 |
| Lønning, PE | 1 |
| Berdeaux, G; Hurteloup, P | 1 |
| Bonneterre, J; Henry, B; Launois, R; Reboul-Marty, J | 1 |
| Janowska-Wieczorek, A; Mackey, J; Nabholtz, JM; Smylie, M; Tonkin, K | 1 |
| Mason, KA; Milas, L; Milas, MM | 1 |
| de Graaff, M; Floot, BJ; Maliepaard, M; Pluim, D; Schellens, JH; Slaper-Cortenbach, IC | 1 |
| Balis, FM; Blaney, SM; Hutchinson, R; Krailo, M; Mosher, RB; O'Brien, M; Reaman, GH; Seibel, NL | 1 |
| Agrawal, S; Bianco, AR; Caputo, R; Ciardiello, F; Mendelsohn, J; Pepe, S; Pomatico, G; Tortora, G | 1 |
| Asano, S; Hibino, H; Ikebuchi, K; Nakahata, T; Nakazaki, Y; Sugimoto, Y; Sugiyama, H; Suzuki, S; Takahashi, S; Tanabe, T; Tani, K; Tanioka, Y; Tojo, A; Wu, MS | 1 |
| Culine, S | 2 |
| Hamel, E; Nicolaou, KC; Sackett, DL; Vourloumis, D | 1 |
| Aapro, M; Alakl, M; Bezwoda, WR; Deschênes, L; Douma, J; Drbal, J; Genot, JY; Hupperets, PS; Melnychuk, D; Molino, A; Murawsky, M; Nabholtz, JM; Nagykalnai, T; Nortier, JW; Pannuti, F; Rapoport, B; Richel, DJ; Rosso, R; Senn, HJ; Siedlecki, P; Skarlos, D; Tomiak, EM; Trillet-Lenoir, V; Vandenberg, TA; Wilking, N | 1 |
| Nabholtz, JM; Vogel, CL | 1 |
| Lamb, HM; Wiseman, LR | 1 |
| Colombo, T; D'Incalci, M; Goldhirsch, A; Parisi, I; Sessa, C; Zucchetti, M | 1 |
| Azevedo, C; Braga Cruz, F; Correia, O; Pinto Ferreira, E; Polónia, J | 1 |
| Kuroda, M; Mizuno, A; Noguchi, S; Ohishi, A; Sakuma, F; Takagi, T; Terashima, K | 1 |
| Abe, R; Kimijima, I; Ohtake, T; Sagara, H; Tsuchiya, A; Watanabe, T | 1 |
| Arakawa, H; Harada, N; Hashiyama, T; Nakanishi, N; Oda, K; Ozaki, K; Tsujihara, K; Yamaguchi, T | 1 |
| Asmar, L; Hortobagyi, GN; Pivot, X | 1 |
| Nabholtz, JM | 3 |
| Au, HJ; Au, R; Mackey, J; Morrish, D; Nabholtz, JM; Salter, E; Smylie, M; Tonkin, K | 1 |
| Creane, M; Mothersill, C; Seymour, CB | 1 |
| Colucci, S; Creane, M; Mothersill, C; Seymour, CB | 1 |
| Candalh, E; Kramar, A; Lebecq, A | 1 |
| Kurihara, M; Matsuno, S; Ohashi, Y; Okada, S; Sakata, Y; Sasaki, Y; Taguchi, T | 1 |
| Kokawa, Y; Naito, Y; Oura, S; Sakurai, T; Suzuma, T; Tamaki, T; Tanino, H; Umemura, T; Yoshimura, G | 1 |
| Bauer, J; Borner, M; Buonadonna, A; Crivellari, D; Goldhirsch, A; Graffeo, R; Hess, D; Martinelli, G; Pagani, O; Riva, A; Sessa, C; Thürlimann, B; Zampino, G; Zimatore, M | 1 |
| Agelaki, S; Alexopoulos, A; Georgoulias, V; Giannakakis, T; Kakolyris, S; Kouroussis, C; Malamos, N; Mavroudis, D; Panagos, G; Papadouris, S; Potamianou, A; Samonis, G; Sara, E; Xydakis, E | 1 |
| Aussel, JP; Azli, N; Beuzeboc, P; Bourgeois, H; Bozec, L; Cvitkovic, E; Dieras, V; Gruia, G; Jasmin, C; Kalla, S; Misset, JL; Pouillart, P; Riva, A | 1 |
| Blohmer, JU; Costa, SD; Dresel, V; Eidtmann, H; Gademann, G; Hilfrich, J; Jackisch, C; Kaufmann, M; Merkle, E; Raab, G; von Minckwitz, G | 1 |
| Krämer, I; Thiesen, J | 1 |
| Kris, MG; Millward, M | 1 |
| Edelman, MJ; Gandara, DR; Lau, D | 1 |
| Miller, V | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD | 2 |
| Mattson, K | 3 |
| Anastasopoulos, D; Briasoulis, E; Fountzilas, G; Karavasilis, V; Kostadima, V; Pavlidis, N; Rammou, D; Tzamakou, E | 1 |
| Boucher, Y; Brekken, C; Griffon-Etienne, G; Jain, RK; Suit, HD | 1 |
| Alexopoulos, A; Alexopoulos, CG; Efremidis, AP; Papacharalambous, A; Patila, E; Rigatos, G; Vassilomanolakis, M | 1 |
| Hamaguchi, Y; Hasegawa, S; Hisatomi, H; Ichikawa, Y; Ishikawa, T; Kamiyama, M; Momiyama, N; Narita, T; Shimada, H | 1 |
| Rosell, R | 2 |
| Fossella, FV | 4 |
| Fossella, FV; Rigas, J | 1 |
| Bérille, J; Bizzari, JP; Bougon, N; Douillard, JY; James, R; Le Chevalier, T; Loret, C; McKeage, MJ; Millward, MJ; Monnier, A; Soulas, F; Zalcberg, JR | 1 |
| Rizvi, NA | 1 |
| Greco, FA | 1 |
| Bernard, S; van Deventer, H | 1 |
| Distelmans, W; Storme, G | 1 |
| Bahlitzanakis, N; Beroukas, K; Christodoulou, M; Froudarakis, M; Georgoulias, V; Giatromanolaki, A; Kostantelos, J; Koukourakis, MI; Koumiotaki, S; Kyrias, G; Skarlatos, J | 1 |
| Barbaroux, C; de Cremoux, P; Dieras, V; Liva, S; Magdelenat, H; Martin, EC; Pouillart, P; Sastre-Garau, X; Vincent-Salomon, A | 1 |
| Boissier, S; Clezardin, P; Delmas, PD; Magnetto, S | 1 |
| Hunter, NR; Mason, KA; Milas, L; Schimming, R | 1 |
| Aiba, K; Hanai, M; Horikoshi, N; Ito, Y; Osawa, H; Takahashi, S; Uno, S; Yamada, Y | 1 |
| Aoki, T; Kaise, H; Koyanagi, Y; Kusama, M; Matsunaga, T; Nakamura, Y; Nakayama, S; Yoneda, K | 1 |
| Inoue, H; Kim, R; Ohi, Y; Toge, T | 1 |
| Ardizzoni, A; de Cupis, A; Favoni, RE; Grossi, F; Loprevite, M; Merlo, F; Pirani, P | 1 |
| Khattab, J; Urba, SG | 1 |
| Aritake, N; Fukunaga, M; Gotoh, K; Hasegawa, S; Imamoto, H; Kan, K; Kim, Y; Maruyama, H; Oozato, H; Takatsuka, Y; Touno, T; Yamazaki, K | 1 |
| Hada, M; Hagiwara, J; Kamiya, K; Koshizuka, K; Muto, S; Nakagomi, H; Tada, Y; Takano, K | 1 |
| Budman, DR; Kreis, W; Liu, XM; Wang, LG | 1 |
| Loesch, DM; McCaskill-Stevens, W; Miller, KD; Monaco, F; Seshadri, R; Sisk, J; Sledge, GW | 1 |
| Dranitsaris, G; Leung, PP; Oza, AM; Puodziunas, A; Tannock, IF | 1 |
| Armand, JP; Bordessoule, S; Chouaki, N; Couteau, C; De Forni, M; Domenge, C; Groult, V; Janot, F; Lebecq, A; Leyvraz, S; Oulid-Aissa, D | 1 |
| Bateman, AC; Cook, T; Dunsford, ML; Mead, GM; Tung, K | 1 |
| Anibali-Charpiat, MF; Calluaud, L; Fabre-Guillevin, E; Ravaud, A; Tchen, N | 1 |
| Brodowicz, T; Köstler, WJ; Wiltschke, C; Zielinski, CC | 1 |
| Bliukhterova, NV; Fomina, MM; Korman, DB; Ostrovskaia, LA; Rykova, VA | 1 |
| Beijnen, JH; Nooijen, WJ; Scherrenburg, EJ; Sparreboom, A; van Tellingen, O; Verweij, J | 1 |
| Eckardt, A; Fokas, K; Haindl, J; Hüttmann, C | 1 |
| Freijs, A; Karlsson, MO; Sandström, M; Simonsen, LE | 1 |
| Choy, H | 3 |
| Harada, K; Konishi, T; Maeda, Y; Mori, N; Nishida, M; Oka, M; Somura, H; Takao, T; Tamesa, T; Tangoku, A | 1 |
| Kadota, M; Masuda, N; Miyazaki, M; Monden, M; Ohue, M; Ooka, M; Sakita, I; Sekimoto, M; Tamaki, Y; Tomita, N | 1 |
| Kim, SJ; Maeura, Y; Matsunaga, S; Saito, M; Ueda, N | 1 |
| Bergman, M; Ekholm, E; Huhtala, S; Salminen, E | 1 |
| Angiolini, C; Bergaglio, M; Del Mastro, L; Esposito, M; Garrone, O; Lunardi, G; Rosso, R; Tolino, G; Vannozzi, MO; Venturini, M; Viale, M | 1 |
| Androulakis, N; Aravantinos, G; Dimopoulos, MA; Genatas, K; Georgoulias, V; Kakolyris, S; Karabekios, S; Kourousis, C; Papadimitriou, C; Samelis, G; Stathopoulos, GP; Tsavaris, N | 1 |
| Blohmer, JU; Costa, SD; Eiermann, W; Jackisch, C; Kaufmann, M; Tulusan, AH; von Minckwitz, G | 1 |
| Atkinson, R; Birt, A; Coleman, R; Crawford, SM; Davis, J; Eggleton, SP; Graham, J; Junor, EJ; Kaye, SB; Paul, J; Reed, NS; Symonds, RP; Thomas, H; Vasey, PA | 1 |
| Alakl, M; Bodrogi, I; Buzzi, F; Chan, S; Crown, J; Duarte, R; Friedrichs, K; Gil Gil, M; González Mancha, R; Korec, S; Murawsky, M; Murray, E; Noel, D; Pintér, T; Richardson, G; Riva, A; Ronzoni, M; Simmonds, P; Van Belle, S; von Minckwitz, G; Vorobiof, D; Walpole, E; Yelle, L | 1 |
| Denoulet, P; Desbruyères, E; Eddé, B; Regnard, C | 1 |
| Engblom, P; Grènman, S; Kulmala, J; Rantanen, V | 1 |
| Amadori, D; Bacci, F; Barzanti, F; Dal Susino, M; Folli, S; Frassineti, GL; Ricotti, L; Tesei, A; Zoli, W | 1 |
| Antoniou, F; Aspropotamitis, A; Athanassiou, A; Batzios, S; Halikia, A; Kalantaridou, A; Karvounis, N; Pectasides, D; Visvikis, A | 1 |
| Nervi, AM; Ornstein, DL; Rigas, JR | 1 |
| Evtushenko, OI | 1 |
| Hayashi, K; Kuroi, K; Nagai, S; Toi, M; Tominaga, T | 1 |
| Funahashi, H; Hayashi, H; Imai, T; Itoh, T; Kikumori, T; Mase, T; Oiwa, M; Sekiya, M; Shibata, A | 1 |
| Krug, LM; Miller, VA | 1 |
| Bhargava, P; Dahut, W; Davis, TH; Figuera, M; Hawkins, MJ; Marshall, JL; Rizvi, NA; Spiridonidis, CH | 1 |
| Adjei, AA; Argiris, A; Murren, JR | 1 |
| Gnant, M; Jakesz, R; Locker, GJ; Schmidinger, M; Steger, GG; Taucher, S; Wenzel, C | 1 |
| Miller, M | 1 |
| Bolognesi, A; Bordogna, G; Canal, N; Fazio, R; Nemni, R; Previtali, S; Quattrini, A; Villa, E | 1 |
| Vogelzang, NJ | 1 |
| Stein, CA | 1 |
| Earhart, RH | 1 |
| Picus, J; Schultz, M | 1 |
| Cohen, J; Dimitt, B; Friedland, D; Gluckman, R; Keating, M; Lembersky, B; Miller, R; Reilly, N; Voloshin, M; Zidar, B | 1 |
| Bagiella, E; Benson, M; England-Owen, C; Hetjan, D; Judge, T; Macarthur, R; Newhouse, J; O'Connor, J; Olsson, C; Petrylak, DP; Pfaff, C; Sawczuk, I; Shelton, G; Weitzman, A; Zuech, N | 1 |
| Budman, D; Kreis, W | 1 |
| Halabi, S; Hars, V; Kreis, W; Savarese, D; Taplin, ME; Vogelzang, N | 1 |
| Carducci, M; Eisenberger, M; Laufer, M; Sinibaldi, VJ | 1 |
| Kantoff, PW; Oh, WK | 1 |
| Crawford, D; Fisher, E; Hussain, M; Petrylak, D; Tangen, C | 1 |
| Reese, DM; Small, EJ; Vogelzang, NJ | 1 |
| Hussain, M; Jasti, BR; Parchment, RE; Vaishampayan, U | 1 |
| Gleave, ME; Goldie, J; Miayake, H; Nelson, C; Tolcher, A | 1 |
| Anderson, H; Bengtsson, NO; Bergh, J; Blomqvist, C; Mjaaland, I; Mouridsen, H; Ostenstad, B; Ottosson-Lönn, S; Palm-Sjövall, M; Pluzanska, A; Sjöström, J; Valvere, V; Wist, E | 1 |
| Baccala, P; Berg, D; Clark, JW; Finkelstein, D; Fuchs, CS; Grenon, N; Grossbard, ML; Lynch, TJ; Mayer, RJ; Ryan, DP; Seiden, MV | 1 |
| Gottwald, F; Maier, W; Proft, J; Seitz, HM; Wingen, F | 1 |
| Belani, C; Bonomi, P; Carbone, D; Comis, R; Devore, R; Gandara, DR; Green, M; Karp, D; Vokes, E | 1 |
| Armand, JP; Cunningham, D; Kohne, CH; Misset, JL; van Cutsem, E | 1 |
| Crown, JP | 2 |
| Belani, CP; Fossella, F; Rigas, JR | 1 |
| Colpaert, C; Schrijvers, D; Van den Brande, J; Vermorken, JB | 1 |
| Cascinu, S; Catalano, G; Catalano, V; Gasparini, G; Gattuso, D; Giordani, P; Morabito, A; Pancera, G; Silva, RR | 1 |
| Anagnostopoulos, A; Aravantinos, G; Bakoyannis, C; Bamias, A; Deliveliotis, C; Dimopoulos, MA; Fountzilas, G; Georgoulias, V; Giannopoulos, A; Karayannis, A; Kosmidis, P; Kyriakakis, Z; Moulopoulos, LA; Pantazopoulos, D; Papadimitriou, C; Varkarakis, I; Zervas, A | 1 |
| Akimoto, T; Buchmiller, L; Hunter, N; Kishi, K; Komaki, R; Mason, KA; Milas, L | 1 |
| Aikin, JL | 1 |
| Furukawa, T; Irie, K; Iwanaga, K; Katoh, O; Kuroki, S | 1 |
| De Mulder, PH | 1 |
| Forastiere, AA | 1 |
| Cascinu, S; Graziano, F | 1 |
| Le Cesne, A; Llombart, A; Rixe, O; Spielmann, M; Sverdlin, R; Zelek, L | 1 |
| Cortesi, E; Leone, G; Mancuso, S; Martelli, O; Perillo, A; Pierelli, L; Scambia, G | 1 |
| Amorino, GP; Choy, H; Hamilton, VM | 1 |
| Lyerly, HK; Morse, MA; Vredenburgh, JJ | 1 |
| Ando, Y | 1 |
| Adenis, A; Conroy, T; Paillot, B | 1 |
| Alexandre, J; Bensmaïne, A; Bleuzen, P; Bonneterre, J; Chahine, A; Cvitkovic, E; Faivre, S; Guastalla, J; Mahjoubi, M; Marty, M; Misset, JL; Spielman, M; Sutherland, W; Viens, P | 1 |
| Holton, RA; Wang, HJ; Yang, LX | 1 |
| Bartholomeus, S; Bleiberg, H; Brassinne, C; Cazenave, I; de Valeriola, D; Hennebert, P; Kerger, J; Kusenda, Z; Lefresne-Soulas, F; Piccart, M; Selleslags, J; Van Den Neste, E; Wythouck, H | 1 |
| Fukunaga, K; Inoue, T; Kameyama, K; Kawada, I; Oyamada, Y; Takeshita, K; Yamaguchi, K; Yamazaki, K | 1 |
| Doi, K; Inoue, K; Ishihara, A; Kimura, Y; Kudo, S; Ochiai, T; Ohchi, T; Sakae, T; Sakamoto, T; Takahashi, M | 1 |
| Bombardelli, E; Cantelmo, F; Distefano, M; Fattorossi, A; Ferlini, C; Gaggini, C; Gallo, D; Mancuso, S; Proietti, E; Riva, A; Scambia, G | 1 |
| Beijnen, JH; Bult, A; Huizing, MT; Lustig, V; Rodenhuis, S; Rosing, H; Schellens, JH; ten Bokkel Huinink, WW; van Warmerdam, LJ | 1 |
| Aoyama, N; Kasuga, M; Komada, F; Okumura, K; Sakaeda, T; Shirakawa, K; Takara, K; Tanigawara, Y | 1 |
| Olszewski, W | 1 |
| Bergerat, JP; Bonneterre, J; Bourgeois, H; Chollet, P; Fumoleau, P; Guastalla, JP; Mahjoubi, M; Marty, M; Mauriac, L; Misset, JL; Namer, M; Roché, H; Spielman, M; Trandafir, L; Viens, P | 1 |
| Boehnke-Michaud, L; Buzdar, AU; Dubrow, RA; Hortobagyi, GN; Ibrahim, NK; Lynch, PM; Sahin, AA; Valero, V | 1 |
| Goto, K; Hojo, F; Hosomi, Y; Kakinuma, R; Kodama, K; Matsumoto, T; Mito, K; Moriyama, E; Niho, S; Nishiwaki, Y; Ohe, Y; Ohmatsu, H; Tanaka, K; Uramoto, H | 1 |
| Bagiella, E; Benson, M; Judge, T; Katz, A; Newhouse, JH; Olsson, CA; Owen, CE; Petrylak, DP; Pfaff, C; Sawczuk, I; Shelton, G; Weitzman, AL; Zuech, N | 1 |
| Bollbuck, B; Downing, KH; Fojo, T; Giannakakou, P; Gussio, R; Nicolaou, KC; Nogales, E; Poy, G; Sackett, D; Zaharevitz, D | 1 |
| Adjei, AA; Alberts, SR; Atherton, P; Erlichman, C; Goldberg, RM; Hanson, LJ; Kastrissios, H; Klein, CE; Pitot, HC; Reid, JM; Rubin, J; Sloan, JA | 1 |
| Antonopoulos, M; Kosmas, C; Malamos, NA | 1 |
| Achterrath, W; Feldmann, HJ; Heinrich, B; Hesse, K; Kau, R; Molls, M; Sommer, G; Zimmermann, F | 1 |
| Bonoron-Adèle, S; Platel, D; Pouna, P; Robert, J | 1 |
| Aasebo, U; Berille, J; Krzakowski, M; Olivares, R; Parisi, A; Pham Tran, N; Pluzanska, A; Roszkowski, K; Saigi, E; Smith, AP | 1 |
| Heelan, RT; Kris, MG; Krug, LM; Miller, VA; Ng, KK; Perez, W; Pizzo, B | 2 |
| Ajaikumar, BS; Cleveland, MG; Reganti, R | 1 |
| Bargellesi, A; Cosulich, E; Fabbi, M; Gangemi, RM; Santamaria, B | 1 |
| Bianco, AR; Caputo, R; Ciardiello, F; De Laurentiis, M; De Placido, S; Pomatico, G; Tortora, G | 1 |
| Hudis, CA; Münster, PN | 1 |
| Bunnell, CA; Burstein, HJ; Clarke, KD; Garber, JE; Manola, J; Matulonis, UA; Parker, LM; Scheib, R; Shulman, LN; Winer, EP; Younger, J | 1 |
| Barbaud, A; Schmutz, JL; Tréchot, P | 1 |
| Tsukuda, M | 2 |
| Kobayashi, T; Maeda, Y; Okamoto, R; Omuro, Y; Sasaki, T; Takeda, N | 1 |
| Aiba, K | 1 |
| Kamura, T; Sugiyama, T; Ushijima, K | 1 |
| Akaza, H; Hattori, K | 1 |
| Naito, Y; Oura, S; Sakurai, T; Suzuma, T; Tanino, H; Yamamiti, N; Yoshimasu, T | 1 |
| Aspropotamitis, A; Athanassiou, A; Dimitriadis, M; Halikia, A; Karvounis, N; Pectasides, D; Visvikis, A | 1 |
| Amsrud, T; Chen, V; Forler, PA; Menon, K; Phares, VG; Shih, C; Teicher, BA | 1 |
| de Matteis, A; Landi, G; Nuzzo, F; Perrone, F; Rossi, E | 1 |
| Gagnon, GA; Sallah, S | 1 |
| Bessa, EH; Lena, H; Paillotin, D; Pérol, M; Robinet, G; Schuller-Lebeau, MP; Taytard, A; Thomas, P; Vergnenègre, A | 2 |
| Bargetzi, M; Bérille, J; Fillet, G; Gatzemeier, U; Jekunen, A; Mattson, K; Olivares, R; Saarinen, A; Soussan-Lazard, K; Stupp, R; Teixeira, M; Vansteenkiste, J | 1 |
| Ardiet, CJ; Bernard, E; Droz, JP; Guillot, A; Peguy, M; Rebattu, P; Tranchand, B; Zanetta, S | 1 |
| Bartholomeus, S; Crown, J; Di Leo, A; Dolci, S; Duffy, K; Larsimont, D; Nogaret, JM; O'Higgins, N; Paesmans, M; Piccart, MJ; Riva, A; Rowan, S | 1 |
| Burris, HA; Erland, JB; Gray, J; Greco, FA; Hainsworth, JD; Hermann, RC; Morrissey, LH; Steis, R; Thompson, D | 1 |
| Agelaki, S; Androulakis, N; Dimou, T; Georgoulias, V; Giannakakis, T; Hatzidaki, D; Kakolyris, S; Mavroudis, D; Parashos, M; Sarra, E; Vlachonikolis, J; Ziras, N | 1 |
| Bamias, A; Katsimbri, P; Pavlidis, N | 1 |
| Ah-See, AK; Chilcott, F; Eremin, O; Gilbert, FJ; Heys, SD; Hutcheon, AW; Miller, ID; Payne, S; Sharp, PF; Smith, IC; Waikar, S; Welch, AE; Whitaker, T | 1 |
| Figgitt, DP; Wiseman, LR | 1 |
| Boukis, H; Janinis, J; Lefantzis, D; Panagos, G; Papadakou, M; Poulis, A; Xidakis, E | 1 |
| Carpino, A; Cognetti, F; D'Ottavio, AM; Ferraresi, V; Giannarelli, D; Marsella, A; Milella, M; Nisticò, C; Papaldo, P; Terzoli, E; Thorel, MF; Vaccaro, A | 1 |
| Kelly, K | 2 |
| Collins, JM | 1 |
| Baker, LH; Bruno, R; Hirth, J; Schott, A; Strawderman, M; Watkins, PB | 1 |
| Bol, CJ; Palmer, PA; Sparreboom, A; van Beurden, V; van der Burg, ME; van der Gaast, A; van Zuylen, L; Verweij, J; Woestenborghs, R | 1 |
| Herscowtiz, HB; Meehan, KR; Miao, Y; Ojeifo, JO; Wu, AG | 1 |
| Jekunen, A; Knuuttila, A; Linnainmaa, K; Mattson, K; Ollikainen, T; Suhonen, S; Taavitsainen, M | 1 |
| Amano, G; Furuta, A; Harada, Y; Ikegaki, H; Kijima, G; Ohnuki, K; Ohuchi, N; Satomi, S; Yoshida, R | 1 |
| Kuwahara, M; Motohiro, A; Takahashi, N; Tsukamoto, S; Ueda, H | 1 |
| Gen, T; Hara, Y; Igarashi, K; Jibiki, M; Kawasaki, T; Kikuchi, M; Kudoh, A; Noguchi, N; Yabata, E | 1 |
| Crown, J; O'Leary, M | 1 |
| Schrijvers, D; Van Den Brande, J; Vermorken, JB | 1 |
| Kris, MG; Miller, VA | 1 |
| Au, HJ; Au, R; Mackey, J; Morrish, D; Nabholtz, JM; North, S; Salter, E; Smylie, M; Tonkin, K | 1 |
| Petrylak, DP | 4 |
| Aapro, MS; Alberto, P; Borner, MM; Castiglione, M; Cavalli, F; Fazio, N; Goldhirsch, A; Herrmann, R; Honegger, H; Maibach, R; Martinelli, G; Morant, R; Pagani, O; Roth, AD | 1 |
| Botti, G; Capasso, I; Comella, G; Comella, P; Cortino, GR; D'Aiuto, G; De Rosa, V; Elmo, M; Frasci, G; Lapenta, L; Petrillo, A; Thomas, R; Vallone, P | 1 |
| Buesa, J; Coleman, R; di Paola, ED; Judson, IR; Lee, SM; Ruka, W; Seynaeve, C; Tonelli, D; van Glabbeke, M; van Hoessel, R; Verweij, J | 1 |
| Berille, J; Burkes, R; Coughlin, S; Dancey, J; Gralla, R; Gressot, L; Kim, Y; Levitan, N; Mattson, K; O'Rourke, M; Ramlau, R; Shepherd, FA; Vincent, M | 1 |
| Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; Pomatico, G; Tortora, G | 1 |
| Andreu, JM; Díaz, JF; Engelborghs, Y; Souto, AA; Strobe, R | 1 |
| Fukuoka, M | 1 |
| Kamiya, Y; Kunitoh, H; Saijo, N; Sekine, I; Tamura, T; Yamamoto, N | 1 |
| Langer, CJ | 1 |
| Brodowicz, T; Herscovici, V; Koestler, WJ; Steger, GG; Tomek, S; Vaclavik, I; Wiltschke, C; Zielinski, CC | 1 |
| Eucker, J; Possinger, K; Sezer, O | 1 |
| Rajdev, L; Sparano, JA | 1 |
| Brockstein, B | 1 |
| Combeau, C; Commerçon, A; Lavelle, F | 1 |
| Bishop, J; Boyer, M; Davison, J; Emmett, E; McClure, B; Michael, M; Millward, M; Rischin, D; Smith, J; Zalcberg, J | 1 |
| Bombardelli, E; Bonanno, G; Distefano, M; Ferlini, C; Mancuso, S; Ojima, I; Pierelli, L; Riva, A; Scambia, G | 1 |
| Bennouna, J; Berille, J; Douillard, JY; Lemarie, E; Milleron, B; Monnier, A; Rivière, A; Soussan-Lazard, K; Trillet-Lenoir, V | 1 |
| Crawford, J; DeVore, R; Dunphy, F; Fossella, FV; Gamza, F; Gandara, D; Hammershaimb, L; Kalman, L; Karp, D; Kerr, RN; Kim, Y; Kris, M; Lee, JS; Miller, V; Moore, M; Natale, RR; Vokes, E | 1 |
| Falkson, CI; O'Neill, A; Schaefer, PL; Sparano, JA; Wood, WC | 1 |
| Androulakis, N; Dimopoulos, MA; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kotsakis, T; Kouroussis, C; Samonis, G; Souglakos, J; Voloudaki, A | 1 |
| Abad, A; Guillot, M; Martin, C; Plasencia, C; Taron, M | 1 |
| Chan, CC; Chua, ET; Goh, BC; Kong, HL; Lee, SC; Lehnert, M; Lim, HL; Ng, AW; Wee, J; Wong, JE | 1 |
| Bahlitzanakis, N; Froudarakis, M; Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Koukourakis, MI; Retalis, G | 1 |
| Alderson, PO; Cannon, P; Katz, J; Kline, RP; Petrylak, DP; Szabolcs, M; Weisfeldt, ML; Wu, EX | 1 |
| Aita, P; Bearz, A; Boiocchi, M; Colussi, AM; Corona, G; Crivellari, D; Robieux, I; Sorio, R; Stocco, F; Toffoli, G | 1 |
| Gordon, RJ; Osterwalder, B; Planting, AS; Pronk, LC; Reigner, B; Sparreboom, A; Twelves, C; Vasey, P; Verweij, J | 1 |
| Adenis, A; Armand, JP; Baille, P; Blanc, C; Bonneterre, J; Clouet, P; de Forni, M; Dembak, M; Ducreux, M; Lebecq, A; Lefresne-Soulas, F; Rougier, P | 1 |
| Atkinson, EN; Guedes, Ed; Kavanagh, JJ; Kudelka, AP; Nelson-Taylor, T; Rogers, R; Sittisomwong, T; Steger, M; Verschraegen, CF; Vincent, M | 1 |
| Darwis, I; Muthalib, A; Prayogo, N | 1 |
| Beijnen, JH; Bo, M; Lustig, V; Mackay, M; Pronk, L; Schellens, JH; Ten Bokkel Huinink, WW; van Tinteren, H; Verweij, J | 1 |
| Halme, M; Jekunen, A; Kivisaari, L; Knuuttila, A; Linnainmaa, K; Mali, P; Mattson, K; Ollikainen, T | 1 |
| Bergh, J; Blomqvist, C; Hakamies-Blomqvist, L; Luoma, M; Malmström, P; Mjaaland, I; Mouridsen, H; Ostenstad, B; Ottosson-Lönn, S; Pluzanska, A; Sjödin, M; Sjöström, J | 1 |
| Budman, D; Kreis, W; Petrylak, D; Savarese, D | 1 |
| Adak, S; Amrein, PC; Barton, JJ; Colevas, AD; Costello, R; Posner, MR | 1 |
| Coleman, RE; Eggleton, SP; Howell, A; Maling, SJ; Miles, DW | 1 |
| Brouwer, E; Nooter, K; Sparreboom, A; Stoter, G; van Zuylen, L; Verweij, J | 1 |
| Barton, JH; Bradof, JE; Burris, HA; Greco, FA; Hainsworth, JD; Litchy, S; Morrissey, LH | 1 |
| Aravantinos, G; Bafaloukos, D; Fountzilas, G; Kalofonos, H; Kalogera-Fountzila, A; Nicolaides, C; Pavlidis, N; Samelis, G | 1 |
| Kikuchi, K; Nakayama, M; Yamahata, T; Yamashita, M | 1 |
| Hashimoto, T; Ito, Y; Kawakami, M; Morita, T; Nakao, K; Otsuki, Y; Sasaki, S; Tachibana, S; Tokitsu, H; Tokuhara, T | 1 |
| Kunisue, H; Kurebayashi, J; Shimozuma, K; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, S; Yamamoto, Y | 1 |
| Amaya, H; Aotake, T; Chiba, Y; Fujii, H; Horiuchi, T; Shimomatsuya, T; Uchinami, M; Yokomachi, J | 1 |
| Buekers, TE; Geisler, JP; Raley, J; Sorosky, JI | 1 |
| Fiebiger, WC; Greul, R; Hejna, M; Kornek, GV; Marosi, L; Raderer, M; Scheithauer, W; Schneeweiss, B; Ulrich-Pur, H | 1 |
| Comer, AM; Goa, KL | 1 |
| Chan, OT; Yang, LX | 1 |
| Belani, CP; Bonomi, P; Capozzoli, MJ; Cohen, LJ; Dobbs, T; Earhart, R; Einzig, A; Luketich, JD | 1 |
| Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Kremos, S; Mavroudis, D; Souglakos, J | 1 |
| Fukuoka, M; Kudoh, S; Masuda, N; Nakagawa, K; Negoro, S; Niitani, H; Saka, H; Sugiura, T; Takada, M | 1 |
| Fujii, H; Igarashi, T; Imoto, S; Ishizawa, K; Ito, K; Kubota, K; Minami, H; Saeki, T; Sasaki, Y; Takashima, S | 1 |
| Kubota, K | 1 |
| Barbier, P; Bissery, MC; David, S; Fellous, A; Gounon, P; Vantard, M; Veitia, R | 1 |
| de la Brassinne, M; Richert, B; Vandenbossche, L; Vandeveire, A; Vanhooteghem, O; Vindevoghel, A | 1 |
| Kamradt, JM; Korenchuk, S; Muenchen, HJ; Pienta, KJ; Williams, JF | 1 |
| Colevas, AD; Posner, MR; Tishler, RB | 1 |
| Glisson, BS; Hong, WK; Khuri, FR; Lippman, SM; Shin, DM | 1 |
| Bengtsson, NO; Bergh, J; Blomqvist, C; Boguslawski, KV; Heikkilä, P; Malmström, P; Mjaaland, I; Ostenstadt, B; Räisänen-Sokolowski, A; Saksela, E; Sjöström, J; Valvere, V; Wist, E | 1 |
| Agelaki, S; Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Kalbakis, K; Kourousis, C; Mavroudis, D; Sarmonis, G; Sarra, E; Souglakos, J; Vardakis, N | 1 |
| Feenstra, J; Stricker, BH; Vermeer, RJ | 1 |
| Bruno, R; De Bruijn, E; Highley, M; Locci-Tonelli, D; Pronk, L; Schrijvers, D; Van Oosterom, AT; Verweij, J | 1 |
| Cappuzzo, F; Green, MR; Rocha Lima, CM; Sherman, CA | 1 |
| Buccheri, G; Ferrigno, D | 1 |
| Chau, GY; Chi, CW; Lin, HL; Liu, TY; Lui, WY | 1 |
| Endo, T; Fujimoto, K; Haseyama, Y; Koike, T; Koizumi, K; Nishio, M; Sawada, K; Takashima, H; Yamamoto, S | 1 |
| Austin Seymour, MM; Bellon, JR; Ellis, GK; Gralow, JR; Lindsley, KL; Livingston, RB | 1 |
| Besenval, M; Boisdron-Celle, M; Delva, R; Gamelin, E; Lortholary, A; Maillard, P; Perard, D; Vernillet, L | 1 |
| Bernacki, RJ; Ferlini, C; Lin, S; Ojima, I; Pera, P; Scambia, G; Slater, JC; Wang, T | 1 |
| Sandler, A | 1 |
| Antonopoulos, M; Kosmas, C; Malamos, NA; Tsavaris, N | 1 |
| Brooks, SE; Day, RS; Dobson, JM; Doyle, LA; Egorin, MJ; Meisenberg, BR; Nemieboka, NN; Tait, NS; Tkaczuk, KH; Van Echo, DA; Zamboni, WC | 1 |
| Berille, J; Bosquee, L; Brägas, B; Dabouis, G; Douillard, JY; Le Chevalier, T; Le Groumellec, A; Marien, S; Mattson, K; Olivares, R; Pujol, JL; Stupp, R | 1 |
| Hansen, HS; Larsen, SK; Specht, L | 1 |
| Briasoulis, E; Karavasilis, V; Pavlidis, N | 1 |
| Chen, YZ; Fan, W; Fu, L; Johnson, KR; Zeng, S | 1 |
| Britten, RA; Klein, K | 1 |
| Apostolaki, S; Georgoulias, V; Kotsakis, A; Koukourakis, M; Mavromanomakis, E; Peraki, M; Sarra, E; Souglakos, J; Vlachonikolis, J | 1 |
| Camidge, DR; Kunkler, IH | 1 |
| Fukuda, H; Fukuda, K; Kim, YH; Kitano, H; Kokufu, I; Taniguchi, H; Yamada, K; Yamamoto, M; Yano, T | 1 |
| Blakey, D; Brettell, M; Briggs, P; Chapple, P; Eerhard, S; Gates, P; Januszewicz, EH; Juneja, S; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Seymour, JF; Toner, GC; Wall, D; Wolf, M | 1 |
| Takatsuka, Y | 1 |
| Tashiro, H | 1 |
| Fujii, H | 1 |
| Naito, Y; Oura, S; Tanino, H | 1 |
| Ames, FC; Breslin, TM; Buzdar, AU; Cohen, L; Delpassand, ES; Feig, BW; Fleming, JB; Hortobagyi, GN; House, R; Hunt, KK; Kuerer, HM; Newman, LA; Ross, MI; Sahin, A; Singletary, SE | 1 |
| Armand, JP; Bruno, R; Couteau, C; Ducreux, M; Lebecq, A; Lefresne-Soulas, F; Lokiec, F; Risse, ML; Riva, A; Rougier, P; Ruffié, P | 1 |
| Bevers, M; Freedman, R; Kavanagh, JJ; Kudelka, AP; Moon, C; Verschraegen, CF | 1 |
| Naito, Y; Sakurai, T; Suzuma, T; Tamaki, T; Umemura, T; Yoshimura, G | 1 |
| Ascherman, JA; Attkiss, K; Knowles, SL | 1 |
| Bauer, J; Borner, M; Crivellari, D; D'Incalci, M; Goldhirsch, A; Graffeo, R; Hess, D; Lombardi, D; Martinelli, G; Nolè, F; Pagani, O; Sessa, C; Thürlimann, B; Zucchetti, M | 1 |
| Hyman, W; Lawson, JM; Maples, PB; Nemunaitis, J; Ordonez, G; Richards, D; Seamour, B; Stein, L; Tong, AW; Vukelja, S | 1 |
| Awada, A; Piccart, MJ | 1 |
| Fujii, H; Igarashi, T; Itoh, K; Kashimura, M; Minami, H; Ohashi, Y; Ohtsu, T; Onozawa, Y; Sasaki, Y; Wakita, H; Watanabe, Y | 1 |
| Ballatori, E; Del Favero, A; Roila, F | 1 |
| Asanuma, F; Kawamura, E; Suzuki, T; Yamada, T; Yamada, Y | 1 |
| Arita, K; Daido, K; Nakamura, K; Ohashi, N | 1 |
| Khan, KS; Kleijnen, J; Lister-Sharp, D; McDonagh, MS | 1 |
| Chang, HK; Chen, JS; Liaw, CC; Lin, YC; Wang, CH | 1 |
| Hortobagyi, G; Michaud, LB; Valero, V | 1 |
| Azama, T; Furukawa, J; Hashimoto, T; Katsumoto, Y; Nakaguchi, K; Okajima, S; Shingai, T; Sue, F; Takekuni, K; Yoshihara, W; Yukawa, M | 1 |
| Doi, K; Ishihara, A; Kudo, S; Ochiai, T; Ohchi, T; Sakae, T; Sakamoto, T; Takahashi, M | 1 |
| Ackland, SP; Garg, MB | 1 |
| Danielová, V; Gut, I; Holubová, J; Klucková, H; Soucek, P | 1 |
| Bernstein, BJ | 1 |
| Blakey, D; Brettell, M; Briggs, P; Chapple, P; Eerhard, S; Gates, P; Januszewicz, EH; Juneja, S; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Seymour, JF; Toner, GC; Wolf, M | 1 |
| Kubota, T | 1 |
| Ohtsu, A; Tahara, M | 1 |
| Aoki, H; Fukai, S; Hashimoto, K; Hayashihara, K; Ishida, T; Kuwahara, K; Minegishi, Y; Nemoto, E; Okano, T; Saito, T; Watanabe, K; Watanabe, S; Yanai, N | 1 |
| Carey, M; Winquist, E | 1 |
| Agelaki, S; Alexopoulos, A; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Malamos, N; Mavroudis, D; Potamianou, A; Rigatos, G; Tsavaris, N; Ziras, N | 1 |
| Baldelli, AM; Battelli, N; Cascinu, S; Catalano, G; Catalano, V; Giordani, P; Graziano, F; Lai, V; Testa, E | 1 |
| Depisch, D; Haider, K; Kornek, G; Kwasny, W; Lang, F; Penz, M; Scheithauer, W; Ulrich-Pur, H; Valencak, J | 1 |
| Meunier, L; Meynadier, J; Nocera, T; Stoebner, PE | 1 |
| Briasoulis, E; Constantopoulos, S; Froudarakis, M; Milionis, HJ; Pavlidis, N; Peponis, I | 1 |
| Börgermann, C; Krege, S; Otto, T; Rembrink, V; Rübben, H | 1 |
| Bishop, WR; Hajian, G; Liu, M; Nielsen, LL; Shi, B; Terracina, G; Yaremko, B | 1 |
| Agelaki, S; Georgoulias, V; Kakolyris, S; Kourousis, CH; Malliotakis, P; Mavroudis, D; Sarra, E; Souglakos, J | 1 |
| Doyle, LA; Edelman, MJ; Egorin, MJ; Hausner, PF; Meisenberg, BR; Tait, NS; Tkaczuk, KH; Van Echo, DA; Zamboni, WC | 1 |
| Agelaki, S; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Reppa, D; Samonis, G; Souglakos, J; Vardakis, N | 1 |
| Cunha, KS; de Andrade, HH; Graf, U; Reguly, ML | 1 |
| Fujita, A; Sekine, K; Tagaki, S; Takabatake, H | 1 |
| Iñiguez, C; Larrodé, P; Mauri, JA; Mayordomo, JI; Morales, F; Trés, A | 1 |
| Brugarolas, A; Fernández-Hidalgo, O; Martín-Algarra, S; Pérez-Calvo, J; Salgado, E; Subirá, ML | 1 |
| Lokich, J | 1 |
| Heinemann, V | 6 |
| Amodio, A; Belli, F; Botti, C; Conti, F; Di Lauro, L; Ferraironi, A; Foggi, P; Gionfra, T; Lopez, M; Morelli, MF; Vici, P | 1 |
| Kris, MG; Miller, VA; Scher, HI; Sirotnak, FM; Zakowski, MF | 1 |
| Depisch, D; Haider, K; Kornek, GV; Kovats, E; Kwasny, W; Lang, F; Penz, M; Scheithauer, W; Schneeweiss, B; Ulrich-Pur, H | 1 |
| Atkinson, R; Coleman, R; Crawford, M; Cruickshank, M; Eggleton, P; Fleming, D; Graham, J; Kaye, SB; Parkin, D; Paul, J; Reed, NS; Vasey, PA | 1 |
| Kim, R; Minami, K; Nishimoto, N; Toge, T | 1 |
| Fleming, DR; Goldsmith, GH; Goldsmith, J; Herzig, RH; Stevens, DA | 1 |
| Hunter, N; Mason, K; McBride, W; Milas, L; Petersen, S; Staab, A; Terry, N | 1 |
| Bruno, R; Chaikin, P; Olivares, R; Rhodes, GR; Veyrat-Follet, C | 1 |
| Al-Sarraf, M; Colevas, AD; Frenette, G; Garay, CA; Glisson, B; Norris, CM; Olivares, R; Posner, MR; Seroskie, JD; Shin, DM | 1 |
| Beijnen, JH; Koopman, FJ; Malingré, MM; Richel, DJ; Rosing, H; Schellens, JH; Schot, ME; Ten Bokkel Huinink, WW | 1 |
| Muenchen, HJ; Pienta, KJ; Poncza, PJ | 1 |
| Chen, YM; Chou, KC; Lee, YC; Perng, RP; Shih, JF; Tsai, CM | 1 |
| Akashi-Tanaka, S; Fukutomi, T; Matsuo, K; Miyakawa, K; Nakamura, T; Shimizu, C; Tsuda, H | 1 |
| Köhne, CH; Wilke, HJ; Wils, JA | 1 |
| Endo, M; Kadou, T; Kotani, Y; Ohbayashi, K; Satouchi, M; Takada, Y | 1 |
| Wang, H | 1 |
| Culine, S; Droz, JP | 1 |
| Hirabayashi, K; Hoshiai, H; Katsumata, N; Kohno, I; Noda, K; Ogita, S; Taguchi, T; Tanaka, K; Terashima, Y; Tsunematsu, R; Yakushiji, M | 1 |
| Fumoleau, P; Schöffski, P; Verweij, J; Wanders, J | 1 |
| Braess, J; Friedrichsen, S; Hiddemann, W; Kaufmann, CC; Kern, W; Schleyer, E | 1 |
| Heilmann, M; Langer-Nitsche, C; Lück, HJ | 1 |
| Baldelli, AM; Barni, S; Casaretti, R; Cascinu, S; Catalano, G; Catalano, V; Comella, G; Frontini, L; Graziano, F; Labianca, R | 1 |
| Al-Tweigeri, T; Azli, N; Mackey, JR; Nabholtz, JM; Noël, DR; North, S; Paterson, A; Riva, A; Smylie, M; Tonkin, K | 1 |
| Adachi, I; Ando, M; Katsumata, N; Nagata, K; Narabayashi, M; Watanabe, T | 1 |
| Bos, GD; Burns, BS; Edin, ML; Lester, GE; Tuttle, HG; Wall, ME; Wani, MC | 1 |
| Chiba, J; Iimura, S; Iwahana, M; Jimbo, T; Ohsuki, S; Soga, T; Terasawa, H; Uoto, K; Yoshino, T | 1 |
| Amin, P; Chen, Y; Dilley, J; Embry, M; Henderson, DR; Li, Y; Nguyen, N; Oh, J; Yu, DC; Zhang, H | 1 |
| Gu, B; Li, M; Lü, H; Wu, D | 1 |
| Brescia, FJ; Green, MR; Rocha Lima, CM; Sherman, CA; Urbanic, JJ | 1 |
| Blach, M; Brodowicz, T; Budinsky, AC; Hojas, S; Ilsinger, P; Kubista, E; Locker, GJ; Maca, S; Pluschnig, U; Schmidinger, M; Seewann, L; Steger, GG; Wenzel, C; Zabernigg, A; Zielinski, CC | 1 |
| Bonomi, P; Shirazi, W | 1 |
| Belani, CP; Calvo, AR | 1 |
| Esteva, FJ; Fornier, M; Seidman, AD | 1 |
| Akashi-Tanaka, S; Fukutomi, T; Katsumata, N; Matsuo, K; Miyakawa, K; Nanasawa, T; Tsuda, H; Watanabe, T | 1 |
| Doihara, H; Hino, M; Ishibe, Y; Nagahiro, I; Ogasawara, Y; Sano, Y; Shimizu, N; Teramoto, A; Yoshitomi, S | 1 |
| Agelaki, S; Aravantinos, G; Georgoulias, V; Kakolyris, S; Karabekios, S; Kouroussis, C; Mavroudis, D; Rigatos, SK; Stathopoulos, GP; Tsavaris, N | 1 |
| Eichelmann, K; Fahlke, J; Gebauer, T; Kettner, E; Kröning, H; Lippert, H; Meyer, F; Ridwelski, K | 1 |
| Blair, S; Carman, L; Colborn, D; George, C; Jones, J; Kuebler, JP; Laufman, LR; Moore, T; Patel, T; Roach, R; Rupert, R; Spiridonidis, CH; Zangmeister, J | 1 |
| Georgoulias, VA | 1 |
| Broët, P; Delattre, JY; Hoang-Xuan, K; Keime-Guibert, F; Napolitano, M; Sanson, M; Yaya, R | 1 |
| Hara, A; Harada, T; Hashimoto, K; Izumi, N; Matsubara, C; Miyazaki, H; Satake, K; Tsunematsu, I | 1 |
| Kamata, S; Kiyosawa, Y; Kudo, T; Nakagawa, T; Ogawa, J; Onuki, M; Seto, T | 1 |
| Boghun, O; Hess, CF; Lehmann, J; Lücke, E; Pradier, O; Rave-Fränk, M; Schmidberger, H | 1 |
| Anjo, A; Bissery, MC; D'Attino, RM; Filipski, E; Granda, TG; Lévi, F; Vrignaud, P | 1 |
| Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K | 1 |
| Kris, MG; Manegold, C | 1 |
| Belani, C; Lynch, T | 1 |
| Douillard, JY; Eckardt, J; Georgoulias, V; Manegold, C; Miller, V; Scagliotti, G | 1 |
| Hainsworth, JD; Vokes, EE | 1 |
| Green, M; Gumerlock, P; Rosell, R | 1 |
| Armand, JP; Fossella, FV; Kris, MG; Lynch, T; Rigas, JR; Shepherd, FA | 1 |
| Blesch, K; Reigner, B; Weidekamm, E | 1 |
| Baron, R; Hilpert, F; Pfisterer, J; Wasner, G | 1 |
| Malkowicz, SB; Vaughn, DJ | 1 |
| Avallone, A; Biglietto, M; Caponigro, F; Comella, G; Comella, P; De Lucia, L; Mantovani, G; Manzione, L; Massa, E; Rosati, G; Sganga, P; Sguotti, C | 1 |
| Pegram, M; Slamon, D | 1 |
| Baur, M; Berghammer, P; Dittrich, C; Pöhnl, R | 1 |
| Heilman, DK; Miller, KD; Nozaki, S; Shen, J; Sissons, SE; Sledge, GW; Sweeney, CJ | 1 |
| Fujimoto-Ouchi, K; Tanaka, Y; Tominaga, T | 1 |
| Cornett, B; Downing, KH; Nettles, JH; Nogales, E; Snyder, JP | 1 |
| Calderoni, A; Cerny, T | 1 |
| Mileshkin, L; Prince, HM; Rischin, D; Zimet, A | 1 |
| Milla, L; Milla-Santos, A; Rallo, L; Solano, V | 1 |
| Ahmadi, MA; Booser, D; Esmaeli, B; Valero, V | 1 |
| Agelaki, S; Androulakis, N; Bania, E; Chainis, K; Georgoulias, V; Kakolyris, S; Kalofonos, C; Kouroussis, C; Papadakis, E; Rapti, A; Sarra, E; Toubis, M; Tsiafaki, X; Vardakis, N | 1 |
| Dussault, I; Forman, BM; Synold, TW | 1 |
| Kokawa, Y; Matsuyama, K; Naito, Y; Nakamura, T; Oura, S; Sakurai, T; Tanino, H; Yoshimasu, T | 1 |
| Akerley, WL; Godley, PA; Halabi, S; Hars, V; Hussain, A; Savarese, DM; Small, EJ; Taplin, ME; Vogelzang, NJ | 1 |
| Bauer, J; Borner, M; Crivellari, D; Goldhirsch, A; Graffeo, R; Hess, D; Lombardi, D; Martinelli, G; Nolè, F; Pagani, O; Sessa, C; Thürlimann, B; Veronesi, A | 1 |
| Hanby, AM; Miles, DW; Plunkett, TA; Rubens, RD | 1 |
| Ardizzoia, A; Conti, A; Fumagalli, E; Gardani, G; Lissoni, P; Maestroni, GJ; Tancini, G; Vaghi, M | 1 |
| Goto, K; Kakinuma, R; Kubota, K; Kunitoh, H; Matsumoto, T; Niho, S; Nishiwaki, Y; Ohe, Y; Ohmatsu, H; Saijo, N | 1 |
| Aapro, M; Rowinsky, E | 1 |
| Green, MR | 2 |
| Small, EJ | 1 |
| Posner, MR | 1 |
| Miller, ID; Smith, IC | 1 |
| Gandara, DR; Goldberg, Z; Lara, PN; Lau, DH; Roberts, P | 1 |
| Pintér, T; Szántó, J | 1 |
| Pagani, O; Sessa, C | 1 |
| Pegram, MD | 1 |
| Baselga, J; Tabernero, JM | 1 |
| Tolcher, AW | 2 |
| al Raheb, K; Bemer, M; Muhizi, J; Platini, C; Steinbach, G; Tomassini, E | 1 |
| Barboni, L; Datta, A; Dutta, D; Georg, GI; Himes, RH; Snyder, JP; Vander Velde, DG; Wang, M | 1 |
| Bittner, C; Feyerabend, T; Peters, SO; Raap, M; Remmert, S; Robins, IH; Sieg, P; Sommer, K; Wiedemann, GJ | 1 |
| Fleming, GF; Grinblatt, DL; Laport, GG; Waggoner, S; Williams, SF; Zimmerman, TM | 1 |
| Prescott, LM | 1 |
| Aydiner, A; Karadeniz, A; Sakar, B; Tas, F; Tenekeci, N; Topuz, E | 1 |
| Alexopoulos, A; Georgoulias, V; Palamidas, P; Papadakis, E; Rapti, A; Tsiafaki, X; Veslemes, M; Vlachonikolis, I | 1 |
| Ikeda, H; Koshiba, R | 1 |
| Christen, RD; Gerhold, M; Lin, X; Nehmé, A; Niedner, H; Sellakumar, G; Varadarajan, P; Zhang, Q | 1 |
| Doehmer, J; Jackson, FC; McFadyen, MC; McLeod, HL; Melvin, WT; Murray, GI | 1 |
| Athanasiadis, A; Constantinidis, TC; Delis, D; Fachantidou, E; Goutsikas, J; Hatziapostolou, P; Kontakiotis, T; Patakas, D; Zarogoulidis, K | 1 |
| Arakawa, S; Hara, I; Hara, S; Kamidono, S; Miyake, H | 1 |
| Beijnen, JH; Bouma, M; Nuijen, B; Schellens, JH | 1 |
| Beijnen, JH; Malingré, MM; Schellens, JH | 1 |
| Bruno, R; Montay, G; Rhodes, GR; Veyrat-Follet, C; Vivier, N | 1 |
| Ratain, MJ; Sawyer, M | 1 |
| Gianni, L; Grasselli, G; Locatelli, A; Vigano, L | 1 |
| Baldini, E; Bengala, C; Conte, P; Donati, S; Gennari, A; Guarneri, V; Landucci, E; Orlandini, C; Salvadori, B | 1 |
| Egawa, C; Miyoshi, Y; Noguchi, S; Taguchi, T; Takamura, Y; Tamaki, Y | 1 |
| Dokianakis, G; Georgoulias, V; Hatzidaki, D; Janinis, J; Lefantzis, D; Panagos, G; Panousaki, A; Papadakou, M | 1 |
| Samur, M | 1 |
| Hopkins, U; Malik, U; Rajdev, L; Sarta, C; Sparano, JA; Wolff, AC | 1 |
| Fine, RL; Sherman, WH | 1 |
| Kuroi, K; Tanaka, C; Toi, M | 1 |
| Calafiore, AM; Gianni, L; Licata, S; Menna, P; Minotti, G; Saponiero, A; Teodori, G | 1 |
| Bojko, P; Borquez, D; Kasimir-Bauer, S; Mayer, S; Neumann, R; Seeber, S | 1 |
| Ohtsu, A; Yoshida, M | 1 |
| Minato, K; Mori, M; Saitoh, R; Sato, K; Takei, Y; Tsuchiya, S; Watanabe, S | 1 |
| Bando, H; Hayashi, K; Kuroi, K; Nagai, S; Tanaka, C; Toi, M | 1 |
| Haga, S; Hirano, A; Imamura, H; Kajiwara, T; Kimura, K; Kinoshita, J; Nagumo, H; Okabe, T; Shimizu, T; Utada, Y; Watanabe, O | 2 |
| Kato, Y; Nosaka, S; Tamura, K; Tumori, M; Yamane, Y; Yamauti, M | 1 |
| Godley, PA; Herndon, JE; Kornblith, AB; Savarese, D; Vogelzang, NJ; Zuckerman, E | 1 |
| Kasparian, J; Meurer-Grob, P; Wade, RH | 1 |
| Botwood, N | 1 |
| Green, M; Kawahara, M; Kris, MG; Kunitoh, H | 1 |
| Belani, C | 1 |
| Gandara, DR; Goldberg, Z; Lara, PN; Lau, DH | 1 |
| Lynch, TJ | 1 |
| Hamazoe, R; Komuro, I; Murata, Y; Shimoyama, M; Sumi, KI | 1 |
| Ambrosini, G; Antoine, EC; Azli, N; Benhammouda, A; Borg-Olivier, O; Chollet, P; Khayat, D; Mazen, MF; Monfardini, S; Ramazeilles, C; Riva, A; Sorio, R | 1 |
| Ahond, A; Dubois, J; Guénard, D; Guéritte, F; Mercklé, L; Place, E; Potier, P; Poupat, C; Thoret, S | 1 |
| Appert, HE; Howard, JM; Iwamura, T; Liu, B; Staren, ED | 1 |
| Guéritte, F | 1 |
| Delozier, T; Fumoleau, P; Guastalla, JP; Kerbrat, P; Roché, H; Viens, P | 1 |
| Pawlicki, M; Rolski, J; Rysz, B; Utych, G; Wiczyńska, B; Zemełka, T | 1 |
| Carpini, RD; Fedier, A; Fink, D; Haller, U; Schwarz, VA; Walt, H | 1 |
| Donaldson, KL; Mixan, BJ; Siegall, CB; Trail, PA; Wahl, AF | 1 |
| Bando, H; Miyata, J; Sano, T; Sumitomo, M | 1 |
| Aoyama, H; Asaga, T; Iwase, H; Kimura, M; Mitsuyama, S; Nishimura, R; Tominaga, T | 1 |
| Baker, M; Bradof, JE; Burris, HA; Erland, JB; Greco, FA; Grimaldi, M; Hainsworth, JD; Kalman, LA; Sullivan, T; Yardley, DA | 1 |
| Blohmer, JU; Costa, SD; Eidtmann, H; Eiermann, W; Gademann, G; Graf, E; Hilfrich, J; Jackisch, C; Kaufmann, M; Merkle, E; Raab, G; Tulusan, AH; von Minckwitz, G | 1 |
| Agelaki, S; Alexopoulos, A; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kosmas, C; Kouroussis, C; Malamos, N; Mavroudis, D; Rigatos, G; Sarra, E; Vlachonicolis, J | 1 |
| Fujitaka, K; Fujiwara, Y; Isobe, T; Kohno, N; Oguri, T | 1 |
| Murren, JR | 1 |
| Bunnell, CA; Burstein, HJ; Winer, EP | 1 |
| Blachon, MF; Catalin, J; Ciccolini, J; Durand, A | 1 |
| Chalas, E; Hindenburg, A; Jeyakumar, A | 1 |
| Azli, N; Bissery, MC; Borg-Olivier, O; Campone, M; Delecroix, V; Deporte-Fety, R; Fumoleau, P; Louboutin, JP; Perrocheau, G; Riva, A; Vernillet, L | 1 |
| Hada, M; Koshizuka, K; Mouri, N; Muto, S; Nakagomi, H; Serizawa, M; Tada, Y; Takano, K | 1 |
| Hudes, GR; Obasaju, C | 1 |
| Baker, AF; Dorr, RT | 1 |
| Berry, D; Cooper, BW; Goldberg, S; Gray, R; Jennis, A; Lazarus, HM; Pecora, AL; Preti, R; Stadtmauer, EA; Van Vliet, A; Winter, J | 1 |
| Beijnen, JH; Mackay, M; Malingré, MM; Schellens, JH; Ten Bokkel Huinink, WW | 1 |
| Holmes, FA; Rowinsky, EK | 1 |
| Dieras, V; Perez, E; Valero, V | 1 |
| Pagani, O; Trudeau, M | 1 |
| Atkinson, EN; Ji, L; Levy, LB; Meyn, RE; Nishizaki, M; Roth, JA; White, RA | 1 |
| Kim, KM; Larson, M; Leu, KM; Schiller, JH | 1 |
| Fujimoto, K; Hirai, K; Koizumi, T; Koyama, S; Kubo, K; Nomura, H; Okada, K; Tsunoda, T | 1 |
| Desai, PB; Genter, MB; Nallani, SC | 1 |
| Bhargava, P; Dahut, W; Figuera, M; Fried, K; Gehan, E; Hanfelt, J; Hawkins, MJ; Lefebvre, P; Marshall, JL; Rizvi, NA; Williams, M | 1 |
| Haas, NB | 1 |
| Beer, TM; Bubalo, JS | 2 |
| Fujii, H; Igarashi, T; Imoto, S; Ishizawa, K; Itoh, K; Minami, H; Saeki, T; Sasaki, Y; Shigeoka, Y | 1 |
| Gatzemeier, U | 1 |
| Androulakis, N; Aravantinos, G; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Papakostas, P; Samelis, G; Sarra, E; Souglakos, J | 1 |
| Law, S; Wong, J | 1 |
| Andres, R; Bueso, P; Escudero, P; Filipovich, E; Isla, MD; Martí, JL; Mayordomo, JI; Murillo, L; Saenz, A; Tres, A | 1 |
| Bergaglio, M; Cognetti, F; Del Mastro, L; Donati, S; Frevola, L; Lionetto, R; Lunardi, G; Michelotti, A; Papaldo, P; Rosso, R; Sguotti, C; Venturini, M | 1 |
| Choy, H; Kim, JS; MacRae, R; Pyo, H | 1 |
| Giesel, BU; Kutz, GG; Thiel, HJ | 1 |
| Belette, F; Blaustein, A; Davila, E; Lilenbaum, RC; Schwartz, MA; Seigel, L; Wittlin, FN | 1 |
| Eriguchi, M; Matsuzawa, A; Nonaka, Y; Takeda, Y; Yanagie, H; Yoshizaki, I | 1 |
| Akashi-Tanaka, S; Fukutomi, T; Hasegawa, T; Katsumata, N; Miyakawa, K; Takahashi, T; Tsuda, H; Watanabe, T | 1 |
| Satoh, H; Sekizawa, K | 1 |
| Markman, M; Zanotti, KM | 1 |
| Albain, KS; Clark, JI; Fisher, S; Hantel, A; Kancharla, K; Millbrandt, L; Panganiban, J; Qamar, R | 1 |
| Airoldi, M; Bumma, C; Cattel, L; Delprino, L; Recalenda, V; Rocco, F; Tagini, V | 1 |
| Suzuki, Y; Tokuda, Y | 1 |
| Fujita, S; Hasegawa, T; Ikeda, A; Kaneshiro, E; Katakami, N; Nishimura, T; Nishio, C; Okazaki, M; Umeda, B | 1 |
| Ishikawa, T; Itasaka, H; Kume, K; Matsusaka, T; Ohshiro, T; Ohta, M; Sonoda, K; Tashiro, H; Yamamura, S | 1 |
| Akaike, H; Ashizawa, I; Chiba, S; Imamura, K; Mitui, T; Miyauchi, Y; Muto, S; Nakagomi, H; Nakazawa, M; Okuda, J; Takahashi, M | 1 |
| Pienta, KJ | 1 |
| Asmar, L; Berry, W; Dakhil, S; Gregurich, MA | 1 |
| Bolton, M; Hake, L; Hauke, R; Ledakis, P; Lynch, J; Muhvic, J; Norvell, M; Sitka Copur, M; Tarantolo, S; Wendt, J | 1 |
| Amin, P; Chen, T; Dawson, N; Engstrom, C; Hussain, A; Naslund, M | 1 |
| Bubley, GJ; Ko, YJ; Morganstern, DE; Rajeshkumar, B; Shuster, T; Taplin, ME | 1 |
| George, DJ; Kantoff, PW; Kaufman, DS; Moss, K; Oh, WK; Richie, JP; Smith, MR | 1 |
| Dreicer, R; Klein, EA | 1 |
| Beer, TM; Garzotto, M; Henner, WD; Hough, KM; Lowe, BA | 1 |
| Ryan, CW; Stadler, WM; Vogelzang, NJ | 1 |
| Arlen, P; Dahut, WL; Fedenko, K; Fernandez, P; Figg, WD; Gulley, J; Hamilton, M; Kruger, EA; Noone, M; Parker, C; Pluda, J | 1 |
| Bok, R; Frohlich, M; Reese, DM; Small, EJ; Sudilovsky, D | 1 |
| Senzer, NN | 1 |
| Bonfill, X; Losa, F; Montesinos, J; Nogué, M; Sacristán, M; Serra, C | 1 |
| Schwetz, BA | 1 |
| Beuzeboc, P; Diéras, V; Laurence, V; Pierga, JY; Pouillart, P | 1 |
| Leyland-Jones, B; Smith, I | 1 |
| Carman, L; Colborn, D; Gutterman, L; Jones, J; Kuebler, JP; Larrimer, N; Laufman, LR; Moore, T; Patel, T; Pritchard, J; Roach, R; Segal, M; Spiridonidis, CH; Zangmeister, J | 1 |
| Beer, TM; Henner, WD; Lowe, BA; Pierce, WC | 1 |
| Amann, G; Attems, Y; Brodowicz, T; Fiebiger, WC; Hejna, M; Köstler, WJ; Krainer, M; Tomek, S; Wiltschke, CH; Zielinski, CC | 1 |
| Mark, M; Meredith, DO; Reinhart, WH; Walter, R | 1 |
| Ishitobi, M; Kikkawa, N; Shin, E | 1 |
| Honda, S; Kawaguchi, Y; Kimura, A; Kunieda, K; Matsui, K; Miya, K; Saji, S; Sugiyama, Y; Takao, H | 1 |
| Kawano, R; Kuroki, S; Matsuo, K; Nagata, S; Ogawa, T; Onzuka, T; Shinohara, M; Sumitomo, K; Suzuki, H; Yamanaka, N; Yoshida, J | 1 |
| Ezumi, K; Furukawa, H; Ikeda, M; Imamura, H; Ishida, H; Kawasaki, T; Masuda, N; Masutani, S; Miya, A; Satomi, T; Shimizu, J; Tatsuta, M | 1 |
| Oka, M; Saito, K; Takano, N; Tangoku, A | 1 |
| Blohmer, JU; Caputo, A; Costa, SD; du Bois, A; Eidtmann, H; Gademann, G; Gerber, B; Graf, E; Hilfrich, J; Jackisch, C; Kaufmann, M; Lampe, D; Merkle, E; Raab, G; Schütte, M; Sinn, HP; Tulusan, AH; von Minckwitz, G | 1 |
| Bastert, G; Beldermann, F; Geberth, M; Goerner, R; Lenz, F; Schneeweiss, A; Solomayer, E | 1 |
| Kunisue, H; Kurebayashi, J; Kurosumi, M; Otsuki, T; Sonoo, H; Tanaka, K; Yamamoto, S | 1 |
| Hiraga, K; Honda, O; Matsuo, K | 1 |
| Alexander, W; Chang, EH; Huang, CC; Pirollo, KF; Rait, A; Tang, WH; Xiang, LM; Xu, L | 1 |
| Banerjee, D | 1 |
| Choy, H; DeVore, RF; Hande, KR; Johnson, DH; Laporte, K; Porter, LL; Rosenblatt, PA; Shyr, Y; Slovis, B | 1 |
| Airoldi, M; Arpicco, S; Brusa, P; Bumma, C; Cattel, L; Recalenda, V; Tagini, V | 1 |
| Perng, RP; Wang, GS; Yang, KY | 1 |
| Datta, A; Georg, GI; Krishna Reddy, SH; Lee, S | 1 |
| Aiba, K; Hashimoto, D; Horikoshi, N; Irie, T; Ito, Y; Mizunuma, N; Nakane, M; Saotome, T; Sugiyama, K; Takahashi, S; Tanigawara, Y; Yoshida, N | 1 |
| Chino, Y; Ogata, M; Suzuki, Y; Tani, T; Ubukata, N; Yoshihara, K | 1 |
| Ishihama, H | 1 |
| Brown, RE; Burrell, A; Hutton, J | 1 |
| Ahmadi, MA; Esmaeli, B | 1 |
| Abratt, R; Avril, I; Krofta, K; Mattson, K; Ten, GV; Tonelli, D | 1 |
| Agosta, G; Armata, MG; Bajardi, E; Cicero, G; Gebbia, N; Grassi, N; Gulotta, G; Latteri, MA; Modica, G; Pantuso, G; Russo, A; Valerio, MR | 1 |
| Boccieri, MG; Bruschi, G; Lo Re, G; Saracchini, S; Toffoli, G; Tumolo, S | 1 |
| Alexopoulos, A; Georgoulias, V; Giannakakis, T; Grigoratou, T; Kakolyris, S; Kouroussis, C; Mavroudis, D; Palamidas, P; Papadakis, E; Rapti, A; Samonis, G; Tsiafaki, X; Veslemes, M; Vlachonikolis, J | 1 |
| Caffo, O | 1 |
| Frenkel, EP; Hsieh, JT; Li, Y; Lombardi, DP; Okegawa, T | 1 |
| Belani, CP; Harrington, D; Johnson, DH; Krook, J; Langer, C; Sandler, AB; Schiller, J; Sweeney, CJ; Zhu, J | 1 |
| Blum, JL; Buzdar, A; Dieras, V; Horton, J; Lo Russo, PM; Osterwalder, B; Rutman, O | 1 |
| Baker, M; Billings, FT; Bradof, JE; Burris, HA; Greco, FA; Hainsworth, JD | 1 |
| Kobina, S; Moyano, A; Rubio-Terrés, C; Tisaire, JL | 1 |
| Kalofonos, HP; Kosmas, C; Koutras, A; Malamos, N; Onyenadum, A; Polyzos, A; Rokana, S; Stavroyianni, N; Tsavaris, N; Vadiaka, M | 1 |
| DeNardo, GL; DeNardo, SJ; Kukis, DL; Lamborn, KR; Meyers, FJ; Miers, LA; O'Donnell, RT | 1 |
| Miyazaki, M; Mukohara, T; Negoro, S; Takeda, K; Takifuji, N; Terakawa, K | 1 |
| Bischoff, J; Forstpointner, R; Geuenich, S; Gutschow, K; Heinemann, V; Hiddemann, W; Kentenich, CH; Malekmohammadi, M; Sommer, H; Stemmler, HJ | 1 |
| Buyse, M; Duchateau, L; Lohrisch, C; Piccart, MJ | 1 |
| Ando, A; Miyoshi, Y; Noguchi, S; Taguchi, T; Takamura, Y; Tamaki, Y | 1 |
| Guan, X; Li, L; Zou, Y | 1 |
| Ahn, YC; Bang, YJ; Choi, EK; Kim, YW; Lim, TH; Park, CI; Park, K; Suh, C; Wu, HG | 1 |
| Li, Y; Shi, T; Zhao, W | 1 |
| Abella, E; Baynes, RD; Cassells, L; Dansey, RD; Hamm, C; Karanes, C; Klein, JL; Peters, WP | 1 |
| Barbaro, P; Console, G; Iacopino, P; Irrera, G; Martino, M; Messina, G; Morabito, F; Oliva, E; Palazzo, S; Pucci, G | 1 |
| Peng, L; Wang, Q; Wang, Z | 1 |
| Belani, CP; Harrington, D; Johnson, DH; Krook, J; Langer, C; Sandler, A; Schiller, JH; Zhu, J | 1 |
| Bafaloukos, D; Briassoulis, E; Fountzilas, G; Georgoulias, V; Gogas, H; Kalofonos, Ch; Karabelis, A; Kosmidis, P; Samantas, E; Skarlos, D | 1 |
| Kumazaki, T; Matsukawa, M; Nishiyama, M; Okamoto, R; Park, JS; Sasaki, M; Sekikawa, T; Tanimoto, K; Ukon, K; Yamamoto, W | 1 |
| Rosenblum, MD; Shivers, RR | 1 |
| Adlam, DJ; Allen, TD; Eden, RD; Gearey, D; Tetlow, LC; Ward, TH; Woolley, DE | 1 |
| Beer, TM; Hayes-Lattin, BM; Henner, WD; Kovach, PA | 1 |
| Besova, NS; Bliumenberg, AG; Chekalova, MA; Gorbunova, VA; Khokhlova, SV; Kuznetsov, VV; Orel, NF; Poddubnyĭ, BK; Sinitsyna, ME; Smirnova, NB | 1 |
| Doi, S; Fukuda, M; Kanda, T; Kawabata, S; Kinoshita, A; Kohno, S; Nagashima, S; Nakamura, Y; Narasaki, F; Oka, M; Soda, H; Suenaga, M; Takatani, H; Tsurutani, J | 1 |
| Awada, A; Brassinne, C; de Valeriola, D; Freyer, G; Gil, T; Hennebert, P; Kerger, J; Piccart, M; Selleslags, J | 1 |
| Favaudon, V; Hennequin, C | 1 |
| Airoldi, M; Bumma, C; Cattel, L; Marchionatti, S; Pedani, F; Recalenda, V; Tagini, V | 2 |
| Goto, K; Kakinuma, R; Kubota, K; Matsumoto, T; Niho, S; Nishiwaki, Y; Ohe, Y; Ohmatsu, H | 1 |
| Hazama, K; Kagisaki, K; Matsuda, H; Miyoshi, S; Ohta, M; Shintani, Y | 1 |
| Clegg, A; Hewitson, P; Scott, DA; Sidhu, M; Waugh, N | 2 |
| Brugnatelli, S; Danova, M; De Bella, MT; Manuguerra, G; Palmeri, S; Riccardi, A; Vaglica, M | 1 |
| Clark, JW; Earle, CC; Fuchs, CS; Grossbard, ML; Grossman, SR; Kim, H; Kulke, MH; Mayer, RJ; Morgan, JA; Ryan, DP; Shivdasani, R | 1 |
| Appert, H; Howard, J; Iwamura, T; Liu, B; Staren, E | 2 |
| Glaspy, J; Hill, LR; Holmes, FA; Jones, SE; Liang, BC; Meza, L; Moore, M; Neumann, TA; O'Shaughnessy, JA; Savin, M; Shogan, J; Vukelja, S; Wiznitzer, I | 1 |
| Fleming, D; Hahl, M; Morkas, M | 1 |
| Arkad'eva, TV; Artamonova, EV; Davidenko, IS; Manziuk, LV; Poddubnaia, IV | 1 |
| Reddy, HK; Sturek, M | 1 |
| Arai, T; Gohda, M; Matsuda, T; Nakayama, Y; Noguchi, T; Nonogi, H; Tsutsui, N; Yasuda, S | 1 |
| Caruso, A; De Carolis, S; De Santis, M; Ferrazani, S; Lucchese, A | 1 |
| Kaneko, M; Oguchi, S; Saida, T; Uhara, H | 1 |
| Hirata, H; Matsuba, Y; Naito, M; Sato, S; Tsuruo, T | 1 |
| Wilke, H | 1 |
| Heicappell, R | 1 |
| Dammacco, F; Iurlaro, M; Merchionne, F; Nico, B; Ria, R; Ribatti, D; Vacca, A | 1 |
| Frye, D; Hortobagyi, GN; Ibrahim, NK; Murray, JL; Rahman, Z; Valero, V | 1 |
| Mortimer, JE; Picus, J; Read, WL | 1 |
| Dimitropoulos, D; Kalofonos, HP; Kosmas, C; Makatsoris, T; Onyenadum, A; Rokana, S; Sepsas, E; Stavroyianni, N; Tsavaris, NB; Vadiaka, M | 1 |
| Cohen, Y; Hertzanu, Y; Mermershtain, W; Schulman, H | 1 |
| Yokoyama, J | 1 |
| Aihara, T; Akisada, T; Fukuda, K; Gyoten, M; Harada, T; Hiratsuka, J; Imai, S; Imajo, Y; Kajihara, Y; Morita, N; Takemoto, T | 1 |
| Burkes, RL; Feld, R; Goodwin, PJ; Kwong, R; Leighl, NB; Shepherd, FA | 1 |
| de Wit, R; Loos, WJ; Louwerens, M; Smorenburg, C; Sparreboom, A; Verweij, J | 1 |
| Bengtsson, NO; Bergh, J; Blomqvist, C; Collan, J; Franssila, K; Malmström, P; Mjaaland, I; Saksela, E; Sjöström, J; Skiöld-Petterson, D; Valvere, V; von Boguslawski, K; Wist, E; Østenstad, B | 1 |
| Krauss, T | 1 |
| Araki, S; Hongo, A; Kawanishi, K; Kodama, J; Kudo, T; Miyagi, Y; Yamamoto, J; Yoshinouchi, M | 1 |
| Carles, J; Climent, MA; Garcia del Muro, X; Germá, JR; Gumá, J; Marcuello, E; Maroto, P; Parra, MS; Paz-Ares, L; Tisaire, JL | 1 |
| Boudny, V; Nakano, S | 1 |
| Bougnoux, Ph; Eymard, JC; Lotz, V; Mansouri, H; Namer, M; Spielmann, M; Tubiana-Hulin, M; Tubiana-Mathieu, N | 1 |
| Ahmadi, MA; Arbuckle, R; Booser, D; Delpassand, E; Esmaeli, B; Esteva, F; Hortobagyi, G; Ibrahim, N; Valero, V | 1 |
| Athanassiou, A; Bountouroglou, N; Glotsos, J; Karvounis, N; Kouloubinis, A; Mitakidis, N; Pectasides, D; Ziras, N | 1 |
| Bighin, C; Del, ML; Esposito, M; Lunardi, G; Schettini, G; Tolino, G; Vannozzi, MO; Venturini, M | 1 |
| Aihara, T; Kim, Y; Takatsuka, Y | 1 |
| Merlano, M; Numico, G | 1 |
| Sun, Y | 1 |
| Alila, H; Bunn, PA; Chan, DC; Earle, K; Helfrich, B; Kelly, K; Pamukcu, R; Piazza, G; Thompson, W; Whitehead, CM; Zhao, TL | 1 |
| Miller, ML; Ojima, I | 1 |
| Cassidy, PB; Fitzpatrick, FA; Kelly, RC; Moos, PJ | 1 |
| Ensley, JF; Kim, H; Lonardo, F; Nguyen, T; Piechocki, MP; Yoo, GH | 1 |
| Alila, H; Baron, A; Bunn, PA; Chan, DC; Earle, KA; Helfrich, B; Nelson, P; Pamukcu, R; Piazza, G; Thompson, WJ; Whitehead, CM; Zeng, C; Zhao, TL | 1 |
| Ah-See, AK; Eggleton, SP; Eremin, O; Gilbert, FJ; Heys, SD; Hutcheon, AW; Miller, ID; Ogston, KN; Payne, S; Sarkar, TK; Smith, IC; Walker, LG | 1 |
| Forastiere, AA; Frenette, G; Glisson, BS; Khuri, FR; Murphy, BA | 1 |
| Maher, JF; Villalona-Calero, MA | 1 |
| Haegele, P; Lehmann, S; Moyses, B; Petit, T; Rodier, JF; Schraub, S; Velten, M | 1 |
| Partridge, A; Winer, E | 1 |
| Alvinerie, P; Cresteil, T; Dubois, J; Gueritte, F; Monsarrat, B; Sonnier, M | 1 |
| Kato, Y; Saijo, N | 1 |
| Fuwa, N | 1 |
| Cameron, DA; Camidge, DR | 1 |
| Bourlon-Cuellar, R; Candelaria, M; Noel-Ettiene, LM; Sánchez-Sánchez, JM; Zubieta, JL | 1 |
| Iimura, S; Ishiyama, T; Ohsuki, S; Soga, T; Terasawa, H; Uoto, K | 1 |
| Gnant, MF; Jakesz, R; Locker, GJ; Rudas, M; Schmidinger, M; Steger, GG; Taucher, S; Wenzel, C | 1 |
| Arun, B; Booser, D; Cristofanilli, M; Esmaeli, B; Esteva, FJ; Fritsche, HA; Guerra, LT; Hortobagyi, GN; Murray, JL; Pusztai, L; Smith, TL; Sneige, N; Valero, V | 1 |
| Chiou, WL; Jeong, HY; Ma, C; Wu, TC | 1 |
| Botti, G; D'Aiuto, G; De Maio, E; de Matteis, A; Labonia, V; Landi, G; Mastro, AA; Nuzzo, F; Perrone, F; Rossi, E | 1 |
| Carducci, MA; Eisenberger, MA; Laufer, M; Moore-Cooper, S; Sinibaldi, VJ; Zahurak, M | 1 |
| Inaji, H; Kobayashi, H; Motomura, K; Noguchi, S; Taguchi, T; Takamura, Y | 1 |
| Morere, JF | 1 |
| Mavroudis, D | 1 |
| Hisada, T; Ito, T; Masuda, S; Mochida, A; Morinari, H; Nakahara, K; Nishi, K; Saito, K; Sasaki, S; Tahara, M; Yakumaru, K | 1 |
| Adak, S; Colevas, AD; Costello, R; Fried, MP; Goguen, LA; Gopal, HV; Lamb, CC; Norris, CM; Posner, MR; Read, R; Tishler, RB | 1 |
| Guillet, G; Karam, A; Labat, JP; Leroy, JP; Metges, JP | 1 |
| Alvarez, I; Andres, R; Escudero, P; Filipovich, E; Isla, D; Marti, JL; Mayordomo, JI; Polo, E; Saenz, A; Tres, A | 1 |
| Amayed, P; Carlier, MF; Pantaloni, D | 1 |
| Hirai, K; Ishii, M; Ishiko, O; Kanaoka, Y; Nakajima, S; Nakamura, Y; Ogita, S; Oiso, N | 1 |
| Georgoulias, V | 1 |
| Doval, DC; Pavithran, K | 1 |
| Nabholtz, JM; Riva, A | 1 |
| Brandl, M; Burger, AM; Fiebig, HH; Massing, U; Moog, R; Schubert, R; Schüler, J; Unger, C | 1 |
| Antila, K; Ekholm, E; Jalonen, J; Rantanen, V; Salminen, E; Syvänen, K | 1 |
| Davis, JA; Kaye, SB; O'Neill, VJ; Paul, J; Reed, NS; Vasey, PA | 1 |
| Thomssen, C | 1 |
| Boven, E; Duyndam, MC; Hulscher, TM; Kolfschoten, GM; Pinedo, HM | 1 |
| Abratt, RP; Chasen, MR; Cronje, N; Fourie, L; Hacking, D; McMichael, G; Rapoport, BL; Vorobiof, DA | 1 |
| Forastiere, AA; Heath, EI; Marshall, J; Piantadosi, S; Urba, S | 1 |
| Depisch, D; Haider, K; Kornek, GV; Kovats, E; Kwasny, W; Lang, F; Payrits, T; Raderer, M; Scheithauer, W; Schüll, B | 1 |
| Bol, CJ; Brouwer, E; de Vries, R; Eskens, FA; Nooter, K; Palmer, PA; Sparreboom, A; van der Gaast, A; van Zuylen, L; Verweij, J | 1 |
| Dierlamm, T; Dürk, H; Fiedler, W; Knuffmann, C; Kurt Hossfeld, D; Laack, E; Popp, J; Schmied, B; Verpoort, K; Wacker-Backerhaus, G; Zeller, W | 1 |
| Shepherd, FA | 1 |
| Booser, DJ; Cristofanilli, M; Frye, DK; Hortobagyi, GN; Rivera, E; Rosales, MM; Valero, V | 1 |
| Choi, YH; Hong, DS; In, KH; Jeong, TJ; Kim, HK; Kim, JS; Kim, YH; Lee, KS; Lee, SN; Lee, YY; Nam, E; Park, HS | 1 |
| Fang, QC; Fang, WS; Liu, HY; Liu, Y; Wang, L; Xu, SF | 1 |
| Baker, SD; Brahmer, JR; Sparreboom, A; Verweij, J; Zhao, M | 1 |
| Clinton, S; Erdal, S; Hauger, M; Kraut, E; Monk, P; Nadella, P; Otterson, GA; Shah, M; Shapiro, C; Stanek, M; Villalona-Calero, MA | 1 |
| Abdi, EA; Denman, JP; Gilbar, PJ | 1 |
| Kato, H; Tsuboi, M | 1 |
| Emoto, T; Fujii, M; Fujikawa, M; Hamada, E; Komaki, T; Naka, Y; Yoshikawa, K; Yoshioka, Y | 1 |
| Asai, M; Iwahori, K; Komuta, K; Minami, S | 1 |
| Athanassiou, A; Bountouroglou, N; Glotsos, J; Karvounis, N; Kouloubinis, A; Pectasides, D; Visvikis, A; Ziras, N | 1 |
| Ahmadi, MA; Arbuckle, R; Booser, D; Delpassand, E; Esmaeli, B; Esteva, FJ; Guerra, L; Hortobagyi, GN; Rivera, E; Valero, V | 1 |
| Haller, DG; Misset, JL | 1 |
| Fujita, A; Hoshino, H; Ohkubo, T; Sekine, K; Tagaki, S; Takabatake, H | 1 |
| Perrin, MA | 1 |
| Angiolini, C; Baldini, A; Bergaglio, M; Canavese, G; Del Mastro, L; Garrone, O; Lambiase, A; Merlano, M; Rosso, R; Tolino, G; Venturini, M | 1 |
| Hensley, ML | 1 |
| Bruckner, HW; Kozuch, P; Petryk, M | 1 |
| Ayoub, JP; Cervantes, G; Fumoleau, P; Jones, S; Leonard, R; Lui, WY; Mauriac, L; Miles, D; Moiseyenko, V; O'Shaughnessy, J; Twelves, C; Van Hazel, G; Verma, S; Vukelja, S | 1 |
| Aghajanian, C; Barakat, R; Geller, G; Hensley, ML; Lovegren, M; Maki, R; Sabbatini, P; Spriggs, DR; Tong, W; Venkatraman, E | 1 |
| Kovács, AF; Schiemann, M; Turowski, B | 1 |
| Kalofonos, HP; Kosmas, C; Tsavaris, N | 1 |
| Larsson, LI; Lichtenberg, J | 1 |
| Belleguic, C; Blanchon, F; Coste, E; Fournel, P; Le Caer, H; Léna, H; Pérol, M; Pham, E; Robinet, G; Schuller-Lebeau, MP; Thomas, P; Vergnenègre, A; Vernejoux, JM | 1 |
| Bengtsson, NO; Blomqvist, C; Heikkilä, R; Malmström, P; Ostenstad, B; Paavonen, T; Saksela, E; Sjöström, J; Tynninen, O; Valvere, V; von Boguslawski, K; Wist, E | 1 |
| Boulamatsis, D; Kanelopoulos, P; Kosmas, C; Tsavaris, N; Vadiaka, M | 1 |
| Alexopoulou, A; Deutsch, M; Dourakis, SP; Sevastianos, VA; Stavrianeas, N | 1 |
| Kato, Y; Kitagaki, H; Maruyama, R; Nishiki, M; Tumori, M; Uchida, N; Yamane, Y; Yamauti, M; Yoshida, M | 1 |
| Abbruzzese, JL; Evans, DB; Lenzi, R; Yalcin, S | 1 |
| Chen, Y; Dilley, J; Li, Y; Ramesh, N; Working, P; Yu, DC; Zhang, J | 1 |
| Takigawa, N | 1 |
| Takeda, K | 1 |
| Watanabe, H | 1 |
| Kubota, K; Yoh, K | 1 |
| Okamoto, H; Watanabe, K | 1 |
| Marchettini, P; Mohamed, F; Stuart, OA; Sugarbaker, PH; Yoo, D | 1 |
| Logothetis, C; Millikan, R | 1 |
| Esteva, FJ | 1 |
| Khuri, FR | 1 |
| Logothetis, CJ | 1 |
| Kavanagh, JJ | 1 |
| Glisson, BS | 1 |
| Hong, WK | 1 |
| Khuri, FR; Kim, ES | 1 |
| Potter, DM | 1 |
| Hida, T; Ito, H; Kozaki, K; Matsuo, K; Miyaishi, O; Ogawa, M; Sugiura, T; Suzuki, T; Takahashi, T; Tatematsu, Y | 1 |
| Baur, M; DeSantis, M; Dittrich, C; Gerber, E; Hudec, M; Kienzer, HR; Pont, J; Schratter-Sehn, AU; Schweiger, J; Wicke, W | 1 |
| Ernst, DS | 1 |
| Brassard, M; Budman, DR; Cohen, G; Dhami, M; George, T; Glaspy, J; Hackett, J; Holmes, FA; Jones, SE; Liang, BC; Meza, L; O'Shaughnessy, J; Richards, D; Savin, M; Vukelja, S; Yang, BB | 1 |
| Diepolder, H; Heinemann, V; Kenngotte, S; Stemmler, HJ | 1 |
| Chiu, HC; Chu, CY; Yang, CH | 1 |
| Ikeda, H; Koshiba, R; Ohsawa, H; Tanaka, A | 1 |
| Fife, K; Ganjoo, KN; Gordon, MS; Loehrer, PJ; Poirier, S; Sandler, AB; Seshadri, R; Warner, RE | 1 |
| Ligibel, JA; Winer, EP | 1 |
| Perez, EA; Qu, G | 1 |
| Abad, A; Barnadas, A; Font, A; Guillot, M; Manzano, JL; Margeli, M; Martinez, E; Rosell, R; Sanchez, JM; Taron, M | 1 |
| Hara, A; Harada, T; Iwamoto, S; Izumi, N; Matsubara, C; Satake, K; Tsunematsu, I | 1 |
| Budman, DR; Calabro, A | 1 |
| Baron, R; Binder, A; Hilpert, F; Pfisterer, J; Schattschneider, J; Wasner, G | 1 |
| Degendorfer, P; Furlan, M; McCarthy, JS; Panzarella, T; Siu, LL; Tannock, IF | 1 |
| Hortobagyi, GN; Kris, MG | 1 |
| Kaye, SB; Vasey, PA | 1 |
| Lindsay, MA; Nabholtz, JM; Reese, DM; Riva, A | 2 |
| de Boeck, G; de Bruijn, E; de Jonge, MJ; Dumez, H; Guetens, G; Highley, M; Louwerens, M; Mantel, M; Pawinsky, A; Planting, AS; Van Oosterom, AT; Verweij, J | 1 |
| Chan, AT; Chiu, SK; Ho, WM; Johnson, PJ; Kwan, WH; Lam, KC; Leung, TW; Mo, FK; Mok, TS; Tse, KK; Yeo, W | 1 |
| Friedrichs, K; Hölzel, F; Jänicke, F | 1 |
| Bourhis, J; Faivre, S; Monnerat, C; Raymond, E; Temam, S | 1 |
| Bahlitzanakis, N; Froudarakis, M; Koukourakis, GV; Koukourakis, MI; Kyrgias, G; Retalis, G; Romanidis, K | 1 |
| Adjei, AA; Baron, AT; Geeraerts, L; Hatfield, AK; Ingle, JN; Kugler, JW; Kuross, SA; Lafky, JM; Maihle, N; Michalak, JC; Perez, EA; Suman, VJ | 1 |
| Antonopoulos, MJ; Gregoriou, A; Kosmas, C; Malamos, NA; Rokana, S; Stamataki, M; Tsavaris, NB; Vartholomeou, M | 1 |
| O'Brien, ME; Waters, JS | 1 |
| Akashi-Tanaka, S; Fukutomi, T; Hasegawa, T; Matsuo, K; Tsuda, H; Watanabe, T | 1 |
| de Wit, R; Petrylak, DP | 1 |
| Eichelmann, K; Fahlke, J; Hribaschek, A; Kuhn, R; Ridwelski, K; Rudolph, S | 1 |
| Fan, L; Goh, BC; Guo, JY; Lamba, J; Lee, HS; Lee, SC; Lim, HL; Lim, R; Ong, AB; Schuetz, E; Wang, LZ | 1 |
| Jacobs, AD | 1 |
| Ideguchi, K; Ikeda, Y; Mori, T; Nakagawa, K; Okamoto, K; Sakata, K; Yasumitsu, T | 1 |
| Goker, E; Karabulut, B; Omay, SB; Sanli, UA; Saydam, G; Sezgin, C; Uslu, R | 1 |
| Ahmadi, MA; Esmaeli, B; Hutto, T; Jackson, DM; Newman, RA; Rivera, E; Valero, V | 1 |
| Agelaki, S; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kotsakis, A; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vlachonikolis, J | 1 |
| Akerley, W; Hixson, DC; Makarovskiy, AN; Siryaporn, E | 1 |
| Busse, PM; Case, M; Colevas, AD; Costello, R; Frankenthaler, R; Karp, D; Lake-Willcutt, B; Lamb, CC; Nixon, A; Norris, CM; Posner, MR; Tishler, RB | 1 |
| Burian, M; Cartellieri, M; Fiebiger, W; Formanek, M; Gedlicka, C; Kornek, GV; Kornfehl, J; Marks, B; Selzer, E | 1 |
| Morales, C; Vaquero, J; Zurita, M | 1 |
| Bang, YJ; Boudraa, Y; Daglish, B; Heo, DS; Jacques, C; Kang, WK; Kang, YK; Kim, HC; Kim, NK; Kim, WS; Zuber, E | 1 |
| Avancès, C; Culine, S; Jacot, W; Sénesse, P | 1 |
| Ichinose, Y | 1 |
| Aruga, E; Karasawa, K; Kimura, T; Kohno, M; Maebayashi, K; Mitsuhashi, N; Muramatsu, H; Nasu, S; Saitou, M; Seki, K; Suzuki, K; Ueda, M; Umeda, M | 1 |
| Aida, Y; Chishima, Y; Kitajima, A; Noro, M; Okamoto, H; Satou, Y; Takano, S | 1 |
| Asaumi, Y; Hara, T; Hirano, M; Kikkawa, H; Kikuchi, T; Murakami, N; Nozawa, H; Takizawa, M; Uno, Y | 1 |
| Street, JC; Taguchi, T | 1 |
| Ashley, DM; Baum, CM; Caruso, DA; Koina, C; Radcliff, FJ; Riordan, MJ; Roberts, AW; Tang, ML; Woulfe, SL | 1 |
| Colella, G; Daidone, MG; Gatti, L; Pennati, M; Perego, P; Pilotti, S; Supino, R; Zaffaroni, N; Zunino, F | 1 |
| Popa, IE; Rizvi, NA; Smith, FP; Stewart, K | 1 |
| Borsellino, N; Cazzato, C; Colucci, G; Durini, E; Galetta, D; Gebbia, V; Giotta, F; Pezzella, G; Romito, S | 1 |
| Ackland, S; Hall, K; Levi, J; Lewis, C; Marx, G | 1 |
| Bleickardt, E; Kwong, MS; Murren, JR | 1 |
| Twelves, CJ; Wright, TL | 1 |
| Ansari, R; Einhorn, LH; Fata, F; McClean, JW; Miller, KD; Porcu, P; Sledge, GW; Soule, SE; Zon, R | 1 |
| Campos, B; Carrete, N; Constenla, M; Garcia-Arroyo, R; Lorenzo, I; Palacios, P | 1 |
| Hyodo, I; Katsu, K; Mitachi, Y; Miyata, Y; Ohtsu, A; Sairenji, M; Saitoh, S; Sakata, Y; Sato, T; Suwa, T | 1 |
| Accurso, V; Agostara, B; Failla, G; Fanelli, M; Ferraù, F; Gasparini, G; Leonardi, V; Massidda, B; Morabito, A; Palmeri, S; Tamburo De Bella, M; Vaglica, M; Valenza, R | 1 |
| Chang, JY; Chen, LT; Chung, TR; Jan, CM; Liu, JM; Liu, TW; Shiah, HS; Whang-Peng, J; Wu, CW | 1 |
| Bucana, C; Dinney, CP; Fan, D; Fidler, IJ; Huang, SF; Karashima, T; Kedar, D; Killion, JJ; Kim, SJ; Lee, AT; Mian, B; Shepherd, D; Sweeney, P | 1 |
| Bournique, B; Lemarié, A | 1 |
| Chen, YM; Lin, WC; Perng, RP; Tsai, CM; Whang-Peng, J; Wu, HW | 1 |
| Asola, R; Ekholm, E; Hinkka, S; Korpela, J; Mali, P; Pyrhönen, S; Salminen, E; Varjo, P; Varpula, M | 1 |
| Bleiweiss, I; Gurry, R; Lehrer, D; Paciucci, PA; Raptis, G; Weltz, C | 1 |
| Breidenbach, M; König, E; Kurbacher, C; Mallmann, P; Schwonzen, M | 1 |
| Fukuoka, M; Inoue, A; Kunitoh, H; Mori, K; Nukiwa, T; Saijo, N | 1 |
| Azli, N; Bisset, D; Kaye, SB; Ramazeilles, C; Riva, A; Roché, H; Terret, C; Twelves, CJ; Vasey, PA; Vernillet, L | 1 |
| Fujimura, T; Fushida, S; Kinami, S; Miwa, K; Miyamoto, K; Nao, F; Ninomiya, I; Nishimura, G; Ohta, T; Yokogawa, K | 1 |
| Kawabori, S; Taniguchi, M; Watanabe, A | 1 |
| Brugarolas, A; Calvo, E; Cortes, J; Fernández-Hidalgo, O; Martínez-Monge, R; Perez-Calvo, J; Rodríguez, J; Santisteban, M | 1 |
| Hahn, PF; Halpern, EF; Jhaveri, KS; Prasad, SR; Saini, S; Sumner, JE | 1 |
| Benezery, K; Lagrange, JL; Magné, N; Namer, M; Otto, J | 1 |
| Bardelmeijer, HA; Beijnen, JH; Buckle, T; Huisman, MT; Ouwehand, M; Schellens, JH; van Tellingen, O | 1 |
| Krempien, R; Piroth, MD; Wannenmacher, M; Zierhut, D | 1 |
| Aravantinos, G; Bafaloukos, D; Briasoulis, E; Fountzilas, G; Gogas, H; Kosmidis, P; Mylonakis, N; Samonis, G; Skarlos, DV; Stathopoulos, G | 1 |
| Bachmann, N; Barberi-Heyob, M; Merlin, JL | 1 |
| Ackland, SP; Clarke, S; Garg, MB; Millward, MJ; Rischin, D; Smith, J; Toner, GC; Zalcberg, J | 1 |
| Howard, A; Nicolopoulos, J | 1 |
| Krüger, I; Lindenfelser, R; Scherwitz, P | 1 |
| Cantin, J; Chang, J; Guevin, R; Lindsay, MA; Mackey, J; Nabholtz, JM; Patel, R; Reese, D; Riva, A; Tkaczuk, K; Vodvarka, P | 1 |
| Blohmer, JU; Caputo, A; Costa, SD; Eidtmann, H; Gademann, G; Gerber, B; Hilfrich, J; Jackisch, C; Kaufmann, M; Lampe, D; Merkle, E; Raab, G; Schütte, M; Tulusan, AH; von Minckwitz, G | 1 |
| Harper, P; Marx, G | 1 |
| Geney, R; Li, D; Ojima, I; Ungureanu, lM | 1 |
| O'Shaughnessy, J | 2 |
| Di Leo, A | 1 |
| Eremin, O; Heys, SD; Hutcheon, AW; Miller, ID; Ogston, KN; Payne, S; Sarkar, TK; Smith, I; Walker, LG | 1 |
| Davidson, NE | 1 |
| Chang, EH; Pirollo, KF; Rait, AS; Ulick, D; Xiang, L | 1 |
| Assadourian, S; Bonneterre, J; Fargeot, P; Guastalla, JP; Monnier, A; Namer, M; Roché, H | 1 |
| Budman, DR | 1 |
| Balañá, C; Font, A; Guillot, M; Manzano, JL; Margelí, M; Richardet, M; Rosell, R; Sánchez, JJ; Sánchez, JM | 1 |
| Depierre, A; Jacoulet, P; Westeel, V | 1 |
| Gerinière, L; Souquet, PJ | 1 |
| Choma, D; Jacot, W; Pujol, JL; Quantin, X | 1 |
| André, T; Artru, P; Louvet, C | 1 |
| Besse, B; Spano, JP | 1 |
| André, T; Culine, S; Epaud, C; Gligorov, J | 1 |
| Egorin, MJ; Parise, RA; Ramanathan, RK; Zamboni, WC | 1 |
| Aapro, M; O'Shaughnessy, J; Twelves, C | 1 |
| Miles, D; Seidman, AD; von Minckwitz, G | 1 |
| Terao, I | 1 |
| Blohmer, JU; Breidenbach, M; Göhring, UJ; König, E; Kurbacher, CM; Mallmann, P; Rein, DT; Schmidt, T; Schöndorf, T | 1 |
| Belani, CP; Ramalingam, S | 1 |
| Ensley, JF; Kewson, D; Lonardo, F; Meng, H; Nguyen, T; Oliver, J; Piechocki, MP; Shibuya, TY; Tainsky, MA; Yoo, GH | 1 |
| Kelly, K; Morris, MJ; Santamauro, J; Scher, H; Schwartz, L; Shia, J; Vander Els, N | 1 |
| Eich, D; Eich, HT; Krieg, T; Scharffetter-Kochanek, K; Tantcheva-Poor, I | 1 |
| Abali, H; Celik, I | 1 |
| Ashton, AW; Hotchkiss, KA; Mahmood, R; Russell, RG; Schwartz, EL; Sparano, JA | 1 |
| Fossella, FV; Lynch, T; Shepherd, FA | 1 |
| Belani, CP; Langer, C | 1 |
| Douillard, JY; Eckardt, J; Scagliotti, GV | 1 |
| Choy, H; Gandara, D; Mattson, K; Vokes, EE | 1 |
| Gridelli, C; Hainsworth, J | 1 |
| Abebe, L; Bhagwati, N; Jain, D; Marcoullis, G; Talusan, R; Wiernik, PH | 1 |
| Mokbel, K; Singh-Ranger, G | 1 |
| Crawford, J | 1 |
| Baselga, J; Clemens, MR; Galid, A; Gascon, P; Green, MD; Guillem, V; Koelbl, H; Lalisang, RI; Liang, BC; Piccart, MJ; Renwick, J; Samonigg, H; Siena, S; Zani, V | 1 |
| Abratt, RP; Krofta, K; Mattson, KV; ten Velde, G | 1 |
| Friberg, LE; Henningsson, A; Karlsson, MO; Maas, H; Nguyen, L | 1 |
| Kurihara, M; Matsukawa, M; Nakamachi, M; Sato, A; Shimada, K; Ushio, J; Yamamoto, W | 1 |
| Budd, GT; Bukowski, RM; Elson, P; Hutson, TE; Mekhail, T; Olencki, T; Peereboom, D; Pelley, R; Srkalovic, G | 1 |
| Gimbert, Y; Greene, AE; Lucatelli, C; Viton, F | 1 |
| Andre, F; Fandi, A; Fossella, F; Herbst, RS; Le Chevalier, T; Lee, JJ; Liu, DD; Massarelli, E; Ochs, J; Wolf, M | 1 |
| Ceciarini, F; Correale, P; Fiaschi, AI; Francini, G; Gotti, G; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M; Voltolini, L | 1 |
| Beer, TM; Egorin, MJ; Eilers, KM; Garzotto, M; Henner, WD; Lowe, BA | 1 |
| Goto, H; Miki, T; Ogawa, H; Shiraga, M; Sone, S; Yamamoto, A; Yano, S; Zhang, H | 1 |
| Busse, P; Case, MA; Colevas, AD; Costello, R; Goguen, L; Haddad, R; Lake-Willcutt, B; Norris, CM; Posner, M; Sullivan, C; Tishler, R | 1 |
| Du, CW; Li, DR; Lin, W; Lin, Y; Lin, YC; Wu, MY | 1 |
| Bando, H; Kuroi, K; Saji, S; Toi, M | 1 |
| Besova, NS; Gorbunova, VA; Khokhlova, SV; Komarova, BP; Orel, NF | 1 |
| Dicker, AP; Grant, DS; Williams, TL; Zahaczewsky, M | 1 |
| Remlinger, KA | 1 |
| Hudis, C | 1 |
| Anderson, SJ; Brown, A; Desai, AM; Kardinal, CG; Lembersky, BC; Mamounas, EP; Scholnik, AP; Smith, RE | 1 |
| Bernard-Marty, C; Bissery, MC; Cardoso, F; Di Leo, A; Dumontet, C; Fellous, A; Gancberg, D; Larsimont, D; Paesmans, M; Piccart, MJ; Treilleux, I | 1 |
| Conte, PF; Gennari, A; Guarneri, V; Landucci, E; Orlandini, C; Ricci, S; Rondini, M; Salvadori, B | 1 |
| Camerlo, J; Catalin, J; Ciccolini, J; Genre, D; Giovanini, M; Gonçalves, A; Gravis, G; Maraninchi, D; Viens, P; Viret, F | 1 |
| Postmus, P | 1 |
| Antila, K; Ekholm, E; Korpela, J; Salminen, E; Syvänen, K; Varjo, P; Varpula, M | 1 |
| Antman, K; Brafman, L; Fine, R; Nelsen, C; Petrylak, DP; Shriberg, L; Talbot, S; Tiersten, AD; Troxel, A; Vahdat, L | 1 |
| Lefebvre, JL; Posner, MR | 1 |
| Odagiri, K; Okami, K; Onuki, J; Sakai, A; Takahashi, M | 1 |
| Adachi, S; Iijima, T; Ito, K; Kimura, T; Nakatsuji, Y; Nobunaga, T | 1 |
| Mansutti, M; Minisini, AM; Piraccini, BM; Puglisi, F; Sacco, C; Sobrero, AF; Tosti, A | 1 |
| Gedlicka, C; Kornek, GV; Scheithauer, W; Schmid, K | 1 |
| Hofer, S; Hunziker, S; Ludwig, CU; Tornillo, L | 1 |
| Leonard, GD; Zujewski, JA | 1 |
| Aihara, T; Hiraki, S; Horikoshi, N; Inaji, H; Itoh, K; Katsumata, N; Noguchi, S; Sasaki, Y; Sonoo, H; Tabei, T; Takatsuka, Y; Watanabe, T | 1 |
| Beijnen, JH; de Bree, E; Georgoulias, V; Michalakis, J; Romanos, J; Rosing, H; Tsiftsis, DD | 1 |
| Fukushima, M; Furuse, K; Harada, H; Hosoe, S; Iwamoto, Y; Kawahara, M; Komuta, K; Morioka, T; Ohsaki, Y; Origasa, H; Shibata, K | 1 |
| Antón, A; Cuevas, JM; Estévez, LG; Florián, J; Fortes, J; Herrero, A; Lobo, F; López-Vega, JM; Velasco, A | 1 |
| Chikazawa, M; Fukata, S; Inoue, K; Shuin, T; Yoshikawa, C | 1 |
| Amadori, D; De Paola, F; Frassineti, GL; Milandri, C; Ricotti, L; Tesei, A; Ulivi, P; Zoli, W | 1 |
| Chinchilli, V; Engle, L; Lipton, A; Santala, SM; Witters, LM | 1 |
| Aglietta, M; Alabiso, O; Capaldi, A; Choa, G; Donadio, M; Faggiuolo, R; Minischetti, M; Montemurro, F; Salomone, A; Sperti, E; Vietti-Ramus, G | 1 |
| Abbruzzese, JL | 1 |
| Fujimura, M; Iwasa, K; Kasahara, K; Kimura, H; Myo, S; Nakao, S; Nishi, K; Shibata, K; Shintani, H; Shirasaki, H; Yasuda, U | 1 |
| Filippa, DA; Kris, MG; Krug, LM; Miller, VA; Ng, KK; Venkatraman, E | 1 |
| Curiel, TJ; Hartz, R; Kovitz, K; Mudad, R; Nedzi, LL; Ramsey, M; Weiner, RS; Zakris, EL | 1 |
| Chen, MC; Chen, YM; Lee, CS; Lin, WC; Perng, RP; Shih, JF; Tsai, CM | 1 |
| Ball, HG; Blessing, JA; DeGeest, K; Hoffman, J; Moore, DH; Rose, PG; Warshal, D | 1 |
| Bighin, C; Colozza, MA; Contu, A; Del Mastro, L; Durando, A; Garrone, O; Genta, F; Lambiase, A; Stevani, I; Venturini, M | 1 |
| Colowick, AB; Fleishman, A; Glaspy, JA; Jadeja, JS; Justice, G; Rossi, G | 1 |
| Naito, K | 1 |
| Nishimura, K; Nonomura, N; Okuyama, A; Takahara, S | 1 |
| Ando, M; Katsumata, N; Mukai, H; Watanabe, T | 1 |
| Aoki, Y; Fujita, K; Kurata, H; Matsushita, H; Obata, H; Tanaka, K; Watanabe, M; Yahata, T | 1 |
| Alba, E; Antón, A; Florián, J; Godes, MJ; Llanos, M; López-Vega, JM; Menéndez, M; Pelegri, A; Pérez-Carrión, R; Ribelles, N | 1 |
| Borsellino, N; Colombo, A; Ferrera, P; Gebbia, V; Marrazzo, A; Mauceri, G; Musso, M; Porretto, F; Testa, A; Tirrito, ML | 1 |
| Busse, P; Case, MA; Costello, R; Goguen, LA; Haddad, R; Mahadevan, A; Norris, CM; Posner, MR; Sullivan, CA; Tishler, RB; Wirth, L | 1 |
| Hirai, I; Honda, K; Kokawa, Y; Okamura, Y; Oura, S; Sakurai, T; Sasaki, R; Tanino, H; Yoshimasu, T | 1 |
| Fukushima, M; Ono, Y; Sawada, M | 1 |
| Filipits, M; Jakesz, R; Pirker, R; Pohl, G; Rudas, M; Steger, GG; Stranzl, T; Taucher, S | 1 |
| Markman, M | 4 |
| Dörken, B; Krenn, V; Kretzschmar, A; Reichardt, P; Thuss-Patience, PC | 1 |
| Baick, CH; Chiou, JY; Fruehauf, JP; Mehta, RS; Nalcioglu, O; Su, MY; Wang, J; Yu, H | 1 |
| Chaikin, P; Durrleman, S | 1 |
| Arlen, P; Dahut, WL; Figg, WD; Gulley, J; Horne, MK; Lakhani, N; Parker, C; Parnes, H | 1 |
| Apiou, F; Arvelo, F; Bara, J; Boye, K; de Pinieux, G; Dutrillaux, AM; Dutrillaux, B; Legrier, ME; Lidereau, R; Poirson-Bichat, F; Poupon, MF; Sihassen, A | 1 |
| Haidara, K; Mamer, O; Nikolakakis, A; Sauriol, F; Zamir, LO | 1 |
| Buchholz, TA; Davis, DW; Hess, KR; McConkey, DJ; Sahin, AA; Valero, V | 1 |
| Berille, J; Bruno, R; Chaikin, P; Hammershaimb, L; Olivares, R; Rhodes, GR; Rigas, JR; Vivier, N | 1 |
| Emi, M; Inoue, H; Kim, R; Tanabe, K; Toge, T; Uchida, Y | 1 |
| Glaspy, J; Green, MD; Hackett, J; Holmes, FA; Kubista, E; Neumann, T | 1 |
| Hortobagyi, GN; Valero, V | 1 |
| Azli, N; Campos, D; Chan, S; Falkson, C; Kennedy, I; Krzakowski, M; Leonard, R; Martin, M; Murawsky, M; Nabholtz, JM; Pienkowski, T; Pinter, T; Pouillart, P; Riva, A; Szanto, J; Vorobiof, D; Zaluski, J | 1 |
| Bunn, PA; Simon, GR | 1 |
| Aperis, G; Barbounis, V; Demiri, M; Drufakou, S; Efremidis, AP; Koumakis, G; Missitzis, J; Vassilomanolakis, M | 1 |
| Fujiwara, K; Hamasaki, S; Kiura, K; Tabata, M; Tanimoto, M; Ueoka, H | 1 |
| Araki, T; Ishihara, H; Komiyama, T; Kuriyama, K; Nishikawa, K; Onishi, H; Tanaka, S; Yamaguchi, M | 1 |
| Brockstein, BE; Mani, S; Masters, GA; Ratain, MJ | 1 |
| Airoldi, M; Bumma, C; Cortesina, G; Gabriele, P; Giordano, C; Pedani, F | 1 |
| Davies, AM; Gandara, DR; Lara, PN; Mack, PC | 1 |
| Aoki, Y; Furukawa, T; Haruta, Y; Hayashi, S; Iwanaga, K; Kato, O; Koyanagi, K; Kuroki, S; Nagata, M; Naitoh, K; Soejima, Y; Takahashi, K | 1 |
| Du, W; El-Rayes, BF; Fontana, J; Hussain, M; Sakr, W; Smith, DC; Vaishampayan, U; Wood, D | 1 |
| Cheewakriangkrai, R; Napapan, S; Thongprasert, S | 1 |
| Amat-Guerri, F; Jiménez-Barbero, J; Snyder, JP | 1 |
| Geng, CX; Wang, JY; Zeng, ZC | 1 |
| Haritoglou, C; Mueller, AJ | 1 |
| Boyé, K; Bras-Gonçalves, R; De Cremoux, P; De Pinieux, G; Legrier, ME; Oudard, S; Poupon, MF | 1 |
| Katano, M; Matsunaga, H; Morisaki, T; Nagumo, F; Nakahara, C; Sato, N; Tadano, J; Zhang, H | 1 |
| Teitelbaum, BA; Tresley, DJ | 1 |
| Doughman, DJ; Skolnick, CA | 1 |
| Agelaki, S; Alexopoulos, A; Androulakis, N; Ardavanis, A; Bozionelou, V; Georgoulias, V; Kandylis, C; Kouroussis, Ch; Malamos, N; Mavroudis, D; Stavrinidis, E | 1 |
| Fountzilas, G; Gogas, H | 1 |
| Appia, F; Basser, R; Cebon, J; Chipman, M; Davis, ID; Green, M; Grigg, A; Mitchell, PL; Ng, S; Zalcberg, J | 1 |
| Li, WL; Qin, YK; Yao, Q; Zhu, SW | 1 |
| Goto, K; Kakinuma, R; Kubota, K; Matsumoto, T; Niho, S; Nishiwaki, Y; Ohmatsu, H | 1 |
| Arizcun, A; Cruz, JJ; del Barco, E; Diz, P; Fonseca, E; García-Palomo, A; Gómez-Bernal, A; López, Y; Martín, G; Pujol, E; Rodríguez, C; Sánchez, P | 1 |
| Bauduceau, O; Bernard, O; Ceccaldi, B; Dourhte, LM; Hervé, R; Le Moulec, S | 1 |
| Arai, Y; Endo, M; Hagisawa, S; Hiramatu, M; Hoshi, S; Ohyama, C; Satoh, M; Watanabe, R | 1 |
| Betticher, DC; Cerny, T; Egli, F; Furrer, M; Habicht, J; Hansen, E; Honegger, H; Hsu Schmitz, SF; Joss, C; Pless, M; Ris, HB; Roth, AD; Schmid, RA; Spiliopoulos, A; Stahel, R; Stupp, R; Tötsch, M; von Briel, C; Weder, W; Wernli, M | 1 |
| Hatake, K; Sugimoto, Y; Takahashi, S | 1 |
| Enomoto, K; Fukuda, M; Haga, S; Iino, Y; Ikeda, T; Shimizu, T; Taguchi, T | 1 |
| McGuire, WP | 1 |
| Vasey, PA | 1 |
| Albain, KS; Bearden, JD; Burris, H; Chansky, K; Crowley, J; Gandara, DR; Gaspar, LE; Gumerlock, P; Kuebler, JP; Lara, PN; Leigh, BR; Livingston, R | 1 |
| Siderov, J | 1 |
| Kanamori, S; Masunaga, S; Nakamatsu, K; Nishimura, Y; Suzuki, M | 1 |
| O'Shaughnessy, JA | 1 |
| Correale, P; Di Palma, T; Francini, G; Manganelli, A; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M; Salvestrini, F | 1 |
| Breathnach, OS; Fujishita, T; Gentler, M; Johnson, BE; Kashii, T; Loda, M; Turner, RE | 1 |
| Duncan, MW; Eckhardt, SG; Gustafson, DL; Holden, SN; Long, ME; Pierson, AS; Zirrolli, JA | 1 |
| Dreicer, R; George, CS; Manola, J; Roth, BJ; Schneider, DJ; Schwerkoske, JF; Wilding, G | 1 |
| Bergerat, JP; Bischoff, P; Ganansia-Leymarie, V; Holl, V | 1 |
| Besson, D; Bougnoux, P; Bourgeois, H; Delozier, T; Gamelin, E; Lortholary, A; Lotz, V; Monnier, A; Riffaud, JCh; Tubiana-Mathieu, N | 1 |
| Saitoh, S; Sakata, Y | 1 |
| Roth, AD | 1 |
| Ilersich, AL; Verma, S | 1 |
| Mayor, S | 1 |
| Davies, JM; Hancock, BW; Hough, RE; Lorigan, PC; Molife, R; Zekri, JM | 1 |
| Achard, JL; Amat, S; Body, G; Bougnoux, P; Chollet, P; Curé, H; Dauplat, J; Fétissof, F; Kwiatkowski, F; Penault-Llorca, F | 1 |
| Ballot, J; Crown, J; McDonnell, D | 1 |
| Blumenberg, AG; Deberer, LIu; Gorbachëva, LB; Mavletova, DA | 1 |
| Chang, TW; Chen, GY; Chen, WC | 1 |
| Archibald, H; Hutcheon, A; Macduff, C; Mackenzie, T; Melville, L | 1 |
| Alberts, SR; Cha, SS; Goldberg, RM; Jatoi, A; Kardinal, CG; Mailliard, JA; Morton, RF; Nair, S; Rowland, KM; Sargen, D; Stella, PJ; Tirona, MT | 1 |
| Choy, H; Saha, D | 1 |
| Almanza, C; Amenedo, M; Gamazo, JL; Gómez-Martín, C; González-Ageitos, A; González-Quintas, A; Losada, G; Ramos, M; Romero, C; Togores, P | 1 |
| Berghe, KV; Berkenblit, A; Cannistra, SA; Feyler, H; Kim, Y; Niloff, J; Tung, N | 1 |
| Aydiner, A; Camlica, H; Kurul, S; Tas, F; Topuz, E | 1 |
| Elsdon, M; Farrugia, D; Guglani, S; Owen, JR; Parmar, M | 1 |
| Blood, E; Friedenberg, WR; Graham, D; Greipp, P; Winston, RD | 1 |
| Ajani, J; Roth, AD | 1 |
| Beer, TM; Eilers, KM; El-Geneidi, M | 1 |
| Jimbo, T; Kitagawa, M; Shionoya, M; Soga, T; Tohgo, A | 1 |
| Bengtsson, NO; Bergh, J; Blomqvist, C; Hakamies-Blomqvist, L; Luoma, ML; Malmström, P; Mouridsen, H; Ottoson, S; Pluzanska, A; Sjöström, J; Tennvall, L; Valvere, V | 1 |
| Sawabu, N | 1 |
| Belani, CP; Fidias, P; Fossella, F; Gorbounova, V; Kaukel, E; Mattson, KV; Millward, M; Pereira, JR; Pluzanska, A; Ramlau, R; Szczesna, A; von Pawel, J | 1 |
| Widmark, A | 1 |
| Goh, BC; Grigg, ME; Khoo, YM; Lee, HS; Lee, SC; Wang, LZ | 1 |
| Aravantinos, G; Bafaloukos, D; Christodoulou, C; Dimopoulos, MA; Fountzilas, G; Gogas, H; Kalofonos, HP; Kosmidis, P; Papadimitriou, C; Pavlidis, N | 1 |
| Chan, V; Guan, Z; Handoyo, P; Ho, JC; Huang, JS; Jusuf, A; Lam, WK; Leong, SS; Li, R; Liao, M; Luna, G; Sun, Y; Tan, EH; Tsang, KW; Wahid, MI; Wang, CH | 1 |
| Crown, J; Pegram, M | 1 |
| Heys, SD; Hutcheon, AW; Sarkar, TK | 1 |
| Bear, HD; Goble, S | 1 |
| Ahmadi, MA; Burnstine, MA; Esmaeli, B; Prieto, VG | 1 |
| Adinin, RB; Ahmadi, MA; Arbuckle, R; Coats, C; Esmaeli, B; Faustina, M; Hidaji, L; Rivera, E; Tu, SM; Valero, V | 1 |
| Arquette, MA; Fears, CL; Fracasso, PM; Goodner, SA; Govindan, R; Herzog, TJ; Picus, J; Rader, JS; Rodriguez, LC; Tan, BR | 1 |
| Ardizzoni, A; de Cupis, A; Favoni, RE; Loprevite, M; Pirani, P; Semino, C | 1 |
| Aotani, E; Fujiwara, K; Fujiwara, M; Kato, H; Katsumata, N; Kigawa, J; Kohno, I; Numa, F; Oishi, T; Terakawa, N | 1 |
| Mio, H | 1 |
| Behrns, K; Bernard, SA; Calvo, B; Cance, W; Churchel, MA; Detterbeck, FC; Koruda, M; Ollila, D; Poole, ME; Weissler, MC | 1 |
| Dubois, J; Guénard, D; Guéritte, F; Montiel-Smith, S; Querolle, O; Roussi, F; Thoret, S | 1 |
| Brenton, JD; Caldas, C | 1 |
| Allred, DC; Chamness, GC; Chang, JC; Elledge, R; Gutierrez, MC; Hilsenbeck, SG; Mohsin, S; O'Connell, P; Osborne, CK; Tsimelzon, A; Wooten, EC | 1 |
| Kanamori, S; Kawamoto, M; Koike, R; Mori, K; Nakamatsu, K; Nishimura, Y; Suzuki, M | 1 |
| Bernhard, H; Bredenkamp, R; Hennig, M; Lordick, F; Peschel, C; von Schilling, C | 1 |
| Ahiskali, R; Celikel, T; Ceyhan, BB; Duman, D; Duman, DG | 1 |
| Maeno, K; Masuda, A; Nakagawa, T; Saito, H; Takahashi, T | 1 |
| Miyahara, H; Naito, K; Yane, K | 1 |
| Fushiki, H; Maeda, E; Yoshimoto, H | 1 |
| Bessho, A; Eguchi, K; Harada, M; Harita, S; Hiraki, S; Hiraki, Y; Kamei, H; Kiura, K; Okimoto, N; Segawa, Y; Tabata, M; Takemoto, M; Takigawa, N; Tanimoto, M; Ueoka, H; Watanabe, Y | 1 |
| Mohamed, F; Stuart, OA; Sugarbaker, PH | 1 |
| Matta-Muallem, M; Mourad, YA; Shamseddine, A | 1 |
| Bernard-Marty, C; Cardoso, F; Piccart, MJ | 1 |
| Campone, M; Fumoleau, P; Merlin, JL | 1 |
| Cruickshank, ME; Delaney, E; Hutcheon, AW; McNally, OM; Parkin, DE; Petty, RD | 1 |
| Beer, TM; Eilers, KM; Garzotto, M; Henner, WD; Wersinger, EM | 1 |
| Goodger, NM; Pogrel, MA; Wang, J | 1 |
| Fu, LN; Gao, Y; Guo, XL; Lin, GJ; Qian, LP; Wang, JJ; Xu, Q; Xu, SR; Zhao, H | 1 |
| Herbst, RS; Khuri, FR | 1 |
| Bouffette, P; Llory, JF; Nabholtz, JM; Vannetzel, JM | 1 |
| Haller, DG | 1 |
| Davis, TL; Hauke, R; Kakitelashvilli, V; Kellerman, M; Lee, MS; Lin, MF; Lugo, E; Spellman, M; Taylor, R; Zelivianski, S; Zhou, XW | 1 |
| Barbounis, V; Demiri, M; Efremidis, AP; Koumakis, G; Missitzis, J; Vassilomanolakis, M | 1 |
| Estephan, FF; Jones, DV; Lin, JT; Spell, DW | 1 |
| Baker, SD; Boonstra, JG; Loos, WJ; Sparreboom, A; Verweij, J | 1 |
| Bardou, VJ; Bladou, F; Camerlo, J; Genre, D; Gravis, G; Macquart-Moulin, G; Maraninchi, D; Salem, N; Serment, G; Viens, P | 1 |
| Annable, T; Beyer, C; Discafani, CM; Gallagher, P; Greenberger, LM; Liu, H; Loganzo, F; Musto, S; Rios, C; Sampath, D; Tan, X | 1 |
| Mohamed, F; Sugarbaker, PH | 1 |
| Imai, H; Imanaka-Yoshida, K; Kamikura, Y; Saito, K; Sekine, T; Takeda, K | 1 |
| Corral, N; Esteban, E; Estrada, E; Fernández, JL; Fernández, Y; Fra, J; González de Sande, L; Lacave, AJ; Muñiz, I; Palacio, I; Vieitez, JM | 1 |
| Aggarwal, A; Baranda, J; Reed, G; Van Veldhuizen, PJ; Williamson, S; Zulfiqar, M | 1 |
| Allen, HJ; Baker, C; Bosserman, LD; Chapman, Y; Figlin, RA; Gitlitz, BJ; Patel, R; Sanchez, JD; Shapiro, RM | 1 |
| Chun, JH; Han, JY; Hong, EK; Kim, HY; Lee, DH; Lee, HG; Lee, JS; Lee, SY; Shin, EH; Yoon, SM | 1 |
| Hiroi, M; Isobe, K; Kimura, K; Ryo, H; Sano, G; Sugino, K; Toyama, K; Yamada, H | 1 |
| Hamada, K; Ito, S; Kubota, K; Mikami, H; Nakagawa, A; Okada, T; Tagaya, N | 1 |
| Badalamenti, G; Fulfaro, F; Gebbia, N; Russo, A; Valerio, MR | 1 |
| Rose, PG; Smrekar, M | 1 |
| Iba, T; Itamochi, H; Kanamori, Y; Kigawa, J; Naniwa, J; Oishi, T; Sato, S; Shimada, M; Terakawa, N; Uegaki, K | 1 |
| Kawaguchi, Y; Saji, S; Sugiyama, Y | 1 |
| Fitzpatrick, FA; Wheeler, R | 1 |
| Baba, H; Kakeji, Y; Maehara, Y; Oki, E; Tokunaga, E; Ushiro, S; Watanabe, M | 1 |
| Baldelli, E; Battaglia, A; Bombardelli, E; Carenzi, G; Fontana, G; Gambini, A; Gelmi, ML; Guerrini, A; Pocar, D | 1 |
| Cardoso, F; Piccart, MJ | 1 |
| Diéras, V; Guastalla, JP | 1 |
| Hirano, T; Kubo, H; Masaki, K; Ogura, H; Taoka, H; Terauchi, F; Yamamoto, Y | 1 |
| Belinson, J; Kulp, B; Markman, M; Peterson, G; Webster, K; Zanotti, K | 1 |
| Endo, T; Fujita, M; Hosokawa, M; Imai, K; Itoh, F; Kikuchi, T; Kojima, T; Kusano, M; Mita, H; Ogi, K; Sasaki, Y; Satoh, A; Suzuki, H; Tokino, T; Toyota, M; Yamashita, T | 1 |
| Briasoulis, E; Karavasilis, V; Pavlidis, N; Piperidou, C; Rammou, D; Soulti, K; Tzamakou, E | 1 |
| Hsu, Y; Sood, AK; Sorosky, JI | 1 |
| Belinson, J; Kulp, B; Markman, J; Markman, M; Peterson, G; Webster, K; Zanotti, K | 1 |
| Figg, WD; Ng, SS; Sparreboom, A | 1 |
| Ballini, R; Barboni, L; Georg, GI; Giarlo, G; Himes, RH; Lakdawala, A; Ricciutelli, M; Snyder, JP; VanderVelde, DG; Wang, M | 1 |
| Ray-Coquard, I | 1 |
| Berg, A; Brønstad, A; Reed, RK | 1 |
| Bergh, J; Linderholm, B | 1 |
| Aebersold, DM; Altermatt, HJ; Berclaz, G; Djonov, V; Greiner, RH; Gruber, G; Hlushchuk, R | 1 |
| Cottrell, W; Dranitsaris, G; Elia-Pacitti, J | 1 |
| Hayakawa, Y | 1 |
| Lawrence, HJ; Nguyen, VH | 1 |
| Ojima, I | 1 |
| Furui, N; Furukawa, H; Fushida, S; Ishizaki, J; Jin, M; Miwa, K; Miyamoto, K; Nomura, M; Yamazaki, M; Yokogawa, K; Yoshihara, H | 1 |
| Paridaens, R; Wildiers, H | 1 |
| Beryt, M; Konecny, GE; O'Callaghan, C; Pegram, MD; Pietras, R; Slamon, DJ | 1 |
| Anzenbacher, P; Guengerich, FP; Gut, I; Simek, P; Soucek, P; Svobodova, L; Vaclavikova, R | 1 |
| Estévez, LG; Gradishar, WJ | 1 |
| Gligorov, J; Lotz, JP | 1 |
| Van Cutsem, E | 1 |
| Crown, J; O'Leary, M; Ooi, WS | 1 |
| Hirono, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, N; Okubo, S; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, Y | 1 |
| Ghersi, D; Hamilton, A; Nowak, AK; Stockler, MR; Wilcken, NR | 1 |
| Buckley, AR; Buckley, DJ; Desai, PB; Goodwin, B; Nallani, SC | 1 |
| Ardavanis, A; Baziotis, N; Gerasimidis, G; Rigatos, G; Tryfonopoulos, D; Yiotis, I | 1 |
| Broglio, KR; Buzdar, AU; Esteva, FJ; Gonzalez-Angulo, AM; Hortobagyi, GN; Krishnamurthy, S; Pusztai, L; Yamamura, Y | 1 |
| Arné-Bès, MC | 1 |
| Belinsky, MG; Chen, ZS; Hopper-Borge, E; Kruh, GD; Shchaveleva, I | 1 |
| Sulkes, A | 1 |
| Lambert, WE; Mortier, KA; Verstraete, AG; Zhang, GF | 1 |
| Albain, K; Bhoopalam, N; Chansky, K; Clark, JI; Crowley, J; Edelman, MJ; Gandara, DR; Giguere, JK; Kelly, K; Weiss, GR | 1 |
| Lin, DX; Miao, XP; Tan, W; Wang, ZH; Xu, BH; Zhang, XR | 1 |
| Baussanne, I; Benito, JM; Defaye, J; García Fernández, JM; Gómez-García, M; Ortiz Mellet, C | 1 |
| Devries, A; Haidenberger, A; Lukas, P; Nevinny-Stickel, M; Saurer, M; Seppi, T; Skvortsov, S; Skvortsova, I | 1 |
| Currie, VE; D'Andrea, GM; Dang, CT; Dickler, MN; Fornier, M; Hudis, CA; Hurria, A; Lake, D; Moynahan, ME; Norton, L; Panageas, KS; Robson, ME; Seidman, AD; Theodoulou, M | 1 |
| Nortier, JW | 1 |
| Trissel, LA; Xu, QA | 1 |
| Buzdar, AU; Hortobagyi, GN; Ibrahim, NK; Li, Z; Mante Menchu, RP; Theriault, R; Valero, V; Wang, M; Wathen, JK | 1 |
| Clouse, T; Geisler, JP; Gudenkauf, TJ; Linnemeier, G; Manahan, KJ; Wiemann, MC | 1 |
| Ajani, JA; Bresalier, R; Correa, AM; Erasmus, JJ; Komaki, R; Macapinlac, H; Maish, M; Munden, RF; Putnam, JB; Rice, D; Roth, JA; Smythe, WR; Swisher, SG; Vaporciyan, AA; Walsh, GL; Wu, TT | 1 |
| Bielawski, KP; Bosse, U; Schlotter, CM; Vogt, U | 1 |
| Bastert, G; Beldermann, F; Hamerla, R; Huober, J; Krauss, K; Rudlowski, C; Schneeweiss, A; Sinn, HP; Solomayer, E; von Fournier, D; Wallwiener, D | 1 |
| Bradacs, G; Grabowski, P; Heine, B; Höpfner, M; Krahn, A; Maaser, K; Scherübl, H; Schuppan, D; Somasundaram, R; Stein, H; Sutter, AP; Vormbrock, K; Zeitz, M | 1 |
| Hatae, M; Nakamura, T; Onishi, Y | 1 |
| Breton, JL; Gervais, R; Jacot, W; Pujol, JL; Quantin, X; Rebattu, P | 1 |
| Atkinson, R; Coleman, R; Gabra, H; Gordon, A; Hay, A; Jayson, GC; Kaye, SB; Parkin, D; Paul, J; Vasey, PA | 1 |
| Aiba, K; Hagino, T; Hirano, A; Kawase, K; Kobayashi, M; Kobayashi, T; Okawa, Y; Shioya, H; Sugiyama, K; Uno, S; Usui, N; Yoshida, K | 1 |
| Gotoh, M; Hoshino, M; Hoshino, Y; Kanzaki, N; Kashimura, S; Kogure, M; Matsuyama, S; Ogata, T; Ohto, H; Otani, S; Soeta, N; Terashima, M | 1 |
| Herzog, TJ | 1 |
| Huober, J; Mueck, AO; Seeger, H; Wallwiener, D | 1 |
| Besova, NS; Gorbunova, VA | 1 |
| Baki, M; Bodoky, G; Cseh, J; Csejtei, A; Csömör, S; Dank, M; Erfán, J; Esik, O; Faluhelyi, Z; Hernádi, Z; Izsó, J; Kammerer, K; Kásler, M; Krommer, K; Magyar, T; Mayer, A; Megyery, E; Moskovits, K; Pécsi, L; Pikó, B; Pintér, T; Pulay, T; Ruzsa, A; Szánthó, A; Szántó, I; Szántó, J; Szucs, M; Tálos, Z; Thurzó, L | 1 |
| Domchek, SM; Fox, K; Hwang, WT; Schwartz, J | 1 |
| Sugiyama, T | 1 |
| Hennequin, C | 1 |
| Belani, CP; Eckardt, J | 1 |
| Dumontet, C; Sève, P | 1 |
| Castells, M; Feldweg, AM; Lee, CW; Matulonis, UA | 1 |
| Alsina, M; Beam, C; Beaupre, DM; Dalton, W; Gerbino, E; Hamilton, AD; Kerr, WG; Lichtenheld, MG; Mackley, PA; Muro-Cacho, C; Sebti, SM; Zhu, K | 1 |
| Ando, M; Fujiwara, Y; Katsumata, N; Kouno, T; Matsumoto, K; Shimizu, C; Takeuchi, M; Tokunaga, S; Uno, H; Yamanaka, Y; Yonemori, K | 1 |
| Honda, S; Igawa, M; Imai, S; Kikuno, N; Kishi, H; Shigeno, K; Shiina, H; Urakami, S; Yoneda, T; Yoshino, T | 1 |
| Borsotti, P; Dossi, R; Fiordaliso, F; Giavazzi, R; Martinelli, M; Micheletti, G; Ryan, AJ; Taraboletti, G | 1 |
| Epstein, AL; Hu, P; Khawli, LA | 1 |
| Berman, AW; Brufsky, A; Fojo, T; Lee, JJ; Low, JA; Mannan, N; Poruchynsky, MS; Steinberg, SM; Swain, SM; Wedam, SB; Yang, SX | 1 |
| Gao, S; Iyer, SS; Karnes, HT; Kellogg, GE; Zhang, ZP | 1 |
| Beijnen, JH; Chhatta, AA; Huisman, MT; Schinkel, AH; van Tellingen, O | 1 |
| Brown, J; Burke, TW; Deavers, MT; Gershenson, DM; Munsell, MF; Ramondetta, LM; Shvartsman, HS | 1 |
| Grendys, EC; Martino, MA; Miller, E | 1 |
| Burt, HM; Gleave, ME; Jackson, JK; Springate, CM | 1 |
| Colomer, R; Lupu, R; Menendez, JA | 1 |
| Chiudinelli, F; Colombo, N; Fanucchi, A; Gadducci, A; Landoni, F; Lapresa, M; Maggino, T; Maria Ferrero, A; Sartori, E; Zola, P | 1 |
| Barlési, F; Pujol, JL | 1 |
| Canta, A; Cavaletti, G; Galbiati, S; Gilardini, A; Giussani, G; Lanzani, F; Mueller, L; Nicolini, G; Persohn, E; Schoepfer, S; Scuteri, A; Traebert, M | 1 |
| Chin, K; Hatake, K; Inamura, K; Ito, Y; Kobayashi, T; Mishima, Y; Mizunuma, N; Nagasaki, E; Nishimori, H; Shinozaki, E; Takahashi, S; Terui, Y; Yokoyama, M | 1 |
| De Marinis, F; De Petris, L; Gebbia, V | 1 |
| Gasparini, G; Longo, R; Morabito, A; Torino, F | 1 |
| Cascone, T; Ciardiello, F; De Vita, F; Eckhardt, SG; Laus, G; Morelli, MP; Orditura, M; Pepe, S; Tortora, G; Troiani, T | 1 |
| Accurso, A; Cancello, G; Caputo, F; De Laurentiis, M; De Placido, S; Esposito, A; Giordano, A; Giuliano, M; Malorni, L; Montagna, E; Pennacchio, R; Silvestro, L; Zinno, L | 1 |
| Bang, YJ; Heo, DS; Kim, DW; Kim, DY; Kim, NK; Kim, TY; Lee, KW; Yun, T | 1 |
| Besse, B; Le Chevalier, T; Soria, JC | 1 |
| Gligorov, J; Nabholtz, JM | 1 |
| Martin, MC; Ngo, H; Smith, JA; Wolf, JK | 1 |
| Argiris, A; Jayaram, P; Pichardo, D | 1 |
| Ueoka, H | 1 |
| Bartsch, R; Gnant, MF; Hussian, D; Jakesz, R; Locker, GJ; Pluschnig, U; Rudas, M; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Asai, S; Dokoh, J; Ishikawa, M; Komiyama, S; Mikami, M; Tsuji, H | 1 |
| Lambert, WE; Mortier, KA; Renard, V; Van Belle, S; Van Gussem, A; Verstraete, AG | 1 |
| Botti, G; Comella, G; Comella, P; D'Aiuto, G; D'Aiuto, M; D'Aniello, R; De Rosa, V; Di Bonito, M; Frasci, G; Giordano, R; Lapenta, L; Thomas, R; Vallone, P | 1 |
| Au, JL; Lu, Z; Wientjes, TS | 1 |
| Bourbouloux, E; Campone, M; Fumoleau, P; Kerbrat, P; Roché, H | 1 |
| Furukawa, T; Hata, K; Hirai, I; Kawago, M; Kokawa, Y; Okamura, Y; Oura, S; Tanino, H; Yoshimasu, T | 1 |
| Chen, J; Ehrlichova, M; Gut, I; Kovar, J; Kuznetsova, LV; Ojima, I; Pepe, A; Truksa, J; Vaclavikova, R | 1 |
| Budd, GT; Erban, J; Hutchins, L; Jones, SE; Laufman, L; Lower, E; Mennel, R; Meyers, ML; Olsen, S; Overmoyer, B; Pritchard, KI; Ravdin, PM; Richards, D; Sundaram, S; Urba, WJ | 1 |
| Akino, K; Hiratsuka, H; Imai, K; Kashima, L; Mita, H; Nishikawa, N; Noguchi, M; Ogi, K; Sasaki, Y; Satoh, A; Shinomura, Y; Suzuki, H; Tokino, T; Toyota, M | 1 |
| Bartolini, S; Cappuzzo, F; Crinò, L; Finocchiaro, G; Metro, G; Toschi, L; Trisolini, R | 1 |
| Chu, Q; Evans, WK; Logan, D; Mackay, JA; Vincent, M | 1 |
| Mimata, H; Nomura, T; Nomura, Y; Yamasaki, M | 1 |
| Estepa-Alonso, MJ; Liso-Rubio, FJ; Luis-Fernández, J; Rangel-Mayoral, JF | 1 |
| Kruh, GD | 1 |
| Disilvestro, P; Dizon, DS; Gordinier, ME; Granai, CO; Legare, RD; Miller, J; Moore, R; Pires, L; Rojan, A; Schwartz, J | 1 |
| Edinboro, LE; Gao, S; Karnes, HT; Ngoka, LC; Zhang, ZP | 1 |
| Azzoli, CG; Crapanzano, J; Gomez, J; Heelan, RT; Kris, MG; Krug, LM; Miller, VA; Patel, J; Pizzo, B; Ross, JS; Sheehan, C; Tyson, L; Venkatraman, E | 1 |
| Bissery, MC; Noguchi, K; Shakuto, S | 1 |
| Senior, K | 1 |
| Ballard, EE; Dowell, JE; Hunt, WC; Jumper, CA; Krieger, JA; Rabinowitz, I; Shah, SR; Stanford, BL | 1 |
| Eniu, A; Palmieri, FM; Perez, EA | 1 |
| Ellis, PA; Ring, AE | 1 |
| Baba, H; Beppu, T; Okabe, K; Sano, O; Yamanaka, T | 1 |
| Fujimura, M; Inoue, K; Isobe, K; Komagata, H; Sakai, H; Shirai, T; Tabei, T; Yoneda, S | 1 |
| Aamdal, S; Andersen, A; Brunsvig, PF; Kristensen, GB; Olsen, H; Warren, DJ | 1 |
| Bang, SM; Cho, EK; Chung, M; Han, SH; Lee, JH; Lee, WK; Lee, Y; Park, SH; Shin, DB | 1 |
| Boku, N; Fukutomi, A | 1 |
| Inata, J; Kai, T; Kuraoka, T; Miyazaki, K; Murai, H; Tomoda, Y; Yamaoka, N | 1 |
| Bouchet, LG; Bova, FJ; Buatti, JM; Haller, J; Meeks, SL; Pennington, EC; Ryken, TC; Traynelis, V | 1 |
| Lambert, WE; Mortier, KA | 1 |
| Kawauchi, A; Miki, T; Mizutani, Y; Nakamura, T; Nomoto, T | 1 |
| André, N; Meille, C | 1 |
| Dang, CT | 1 |
| Annable, T; Greenberger, LM; Hari, M; Loganzo, F; Morilla, DB; Musto, S; Nettles, JH; Snyder, JP; Tan, X | 1 |
| Muss, HB; Perez, E | 1 |
| Cohn, DE; Copeland, LJ; Eaton, LA; Fowler, JM; Resnick, KE; Valmadre, S | 1 |
| Fujita, F; Fujita, M; Shakuto, S | 1 |
| Bachelez, H; Dandurand, M; Descamps, V; Fardet, L; Kerob, D; Lebbe, C; Meunier, L; Morel, P; Stoebner, PE | 1 |
| Alcaraz, AA; Johnson, SA; Mehta, AK; Snyder, JP | 1 |
| Calafiore, AM; Cascegna, S; Gianni, L; Liberi, G; Menna, P; Minotti, G; Salvatorelli, E | 1 |
| Beijnen, JH; de Bree, E; Georgoulias, V; Michalakis, J; Relakis, K; Romanos, J; Rosing, H; Theodoropoulos, PA; Tsiftsis, DD | 1 |
| Aldaz Pastor, A; Aramendia Beitia, JM; Arrobas Velilla, J; Giraldez Deiró, J; Zufía López, L | 1 |
| Bria, E; Carlini, P; Ciccarese, M; Cognetti, F; Cuppone, F; Giannarelli, D; Milella, M; Natoli, G; Nistico, C; Terzoli, E | 1 |
| Bhalla, S; Guerreiro, M; Laranjeira, L; Pimentel, FL | 1 |
| Fazli, L; Gleave, ME; Miyake, H; Rocchi, P; So, A; Yamanaka, K; Zangemeister-Wittke, U | 1 |
| Blagosklonny, MV | 1 |
| Soria, JC | 1 |
| Baxter, M; Beyer, C; Discafani, C; Greenberger, LM; Hari, M; Liu, H; Rios, C; Sampath, D; Yang, S | 1 |
| Cardenal, F; García, M; Germà-Lluch, JR; Gil, M; Izquierdo, MA; Martínez, M; Mesía, R; Navarro, M; Pérez, X; Pontón, JL; Salazar, R; Valentí, V | 1 |
| Clavarezza, M; Del Mastro, L; Venturini, M | 1 |
| Dang, C; Hudis, C | 2 |
| Babcic, V; Harnam, N; Kantoff, PW; Manola, J; Oh, WK | 1 |
| Antoniou, D; Chaimala, D; Chondrou, E; Dariotaki, F; Karydis, I; Papageorgiou, C; Pavlakou, G; Stathopoulos, GP; Veslemes, M | 1 |
| Saito, Y; Suzuki, Y; Tokuda, Y | 1 |
| Smith, IE | 1 |
| Davies, AM; Gandara, DR; Gumerlock, PH; Ho, C; Lara, PN; Mack, P | 1 |
| Amadori, D; Cecconetto, L | 1 |
| Favaretto, AG | 1 |
| Brown, R; Gifford, G; King, CR; Marsh, S; McLeod, HL; Paul, J | 1 |
| Bustam, A; Khoo, KS; Lehnert, M; Manzoor Zaidi, SH; Nair, R; Ngelangel, CA; Reece, WH; Song, S; Srimuninnimit, V | 1 |
| Bauernhofer, T; Dandachi, N; Holub, R; Samonigg, H; Schippinger, W | 1 |
| Katakami, N | 1 |
| Bisonni, R; Calvani, M; D'Iddio, S; Graziano, F; Lippe, P; Mancinelli, A | 1 |
| Danielová, V; Ehrlichová, M; Gut, I; Holubová, J; Horský, S; Otová, B; Simek, P; Soucek, P; Václavíková, R | 1 |
| Chatelut, E; Henningsson, A; Karlsson, MO; Kloft, C; Wallin, J | 1 |
| Calabrò, F; Sternberg, CN | 1 |
| Mancuso, A; Oudard, S; Sternberg, CN | 1 |
| Beale, P; Buck, M; Fitzharris, B; Gebski, V; Goldrick, A; Rischin, D; Stuart-Harris, R; Tinker, AV | 1 |
| Frense, D | 1 |
| Gianni, L; Menna, P; Minotti, G; Salvatorelli, E | 1 |
| Aoki, D; Banno, K; Hirao, N; Hirasawa, A; Kawaguchi, M; Susumu, N; Tsukazaki, K; Yanokura, M | 1 |
| Abrial, C; Achard, JL; Chollet, P; Cure, H; Durando, X; Ferrière, JP; Gimbergues, P; Leheurteur, M; Mouret-Reynier, MA; Van Praagh, I | 1 |
| Burkett, AM; Cohn, DE; Copeland, LJ | 1 |
| Feng, SQ; Jiang, ZF; Liu, F; Song, ST; Sun, JZ; Zhang, SH | 1 |
| Chang, HK; Chen, JS; Liaw, CC; Lin, YC; Wang, HM; Yang, TS | 1 |
| Andreu, JM; Barasoain, I; Buey, RM; Calvo, E; Cerezo, G; Day, BW; Díaz, JF; Edler, MC; Hamel, E; López, JA; Matesanz, R; Pineda, O; Sorensen, EJ; Vanderwal, CD | 1 |
| Iwama, T; Karasawa, K; Kato, K; Sato, S; Sato, T; Takahashi, T; Tsunozaki, H | 1 |
| Fujino, K; Ishikubo, T; Shimamura, T; Tada, M; Yamaguchi, K | 1 |
| Suzuki, M | 1 |
| Miyade, Y; Ninomiya, M; Ohtani, S; Shimizu, Y; Sugiyama, S | 1 |
| Marsh, S; McLeod, HL | 1 |
| Coleman, RL; Crotzer, DR; Gershenson, DM; Levenback, CF; Sun, CC; Wolf, JK | 1 |
| Golemis, EA; Khazak, V; Menon, S; Skobeleva, N; Weber, L | 1 |
| Chen, YM; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J | 1 |
| Akpolat, B; Aydiner, A; Dilege, S; Senturk, E; Tanju, S; Toker, A; Yilmazbayhan, D; Ziyade, S | 1 |
| Ganesh, T | 1 |
| Hosomi, Y; Shibuya, M | 1 |
| Yoneda, S | 1 |
| Azzoli, CG; Dunne, M; Farmer, A; Ginsberg, MS; Gomez, J; Henry, R; Jones, J; Kris, MG; Krug, LM; Miller, VA; Pizzo, B; Sirotnak, FM; Steffen, R; Tyson, L; Venkatraman, E | 1 |
| Huxham, LA; Kyle, AH; Minchinton, AI; Yeoman, DM | 1 |
| Bartolini, S; Cancellieri, A; Cappuzzo, F; Crino, L; Finocchiaro, G; Hirsch, FR; Ligorio, C; Magrini, E; Paioli, D; Rossi, E; Toschi, L; Trisolini, R; Varella-Garcia, M | 1 |
| Dent, S; Messersmith, H; Trudeau, M | 1 |
| Botta, M; Galletti, E; Magnani, M; Renzulli, ML | 1 |
| Geisler, JP; Linnemeier, GC; Manahan, KJ; Thomas, AJ | 1 |
| Fujiwara, Y; Ono, M | 1 |
| Fujita, H; Honjo, H; Hosokawa, K; Kato, Y; Kinoshita, Y; Kuroboshi, H; Mori, T; Nakata, Y; Watanabe, A; Yamaguchi, T; Yasuda, J | 1 |
| Ewer, MS; O'Shaughnessy, JA | 1 |
| Hamai, Y; Oue, N; Sentani, K; Suzuki, T; Wada, Y; Yasui, W; Yoshida, K | 1 |
| Agostini, C; Bachelot, T; Cassier, PA; Chabaud, S; Cure, H; Guastalla, JP; Jacquin, JP; Martin, C; Orfeuvre, H; Peaud, PY; Pérol, D; Salles, B; Tigaud, JD; Trillet-Lenoir, V | 1 |
| Cheng, KD; Kong, JQ; Wang, W; Zhu, P | 1 |
| Bookman, MA | 1 |
| Fujiwara, Y; Kunitoh, H; Nokihara, H; Ohe, Y; Sekine, I; Tamura, T; Tsuta, K; Yamada, K; Yamamoto, N | 1 |
| Fojo, T; Menefee, M | 1 |
| Chan, AT; Choi, E; Johri, A; Mok, TS; Wong, C; Yau, D; Yeo, W | 1 |
| Bergström, M; Blomqvist, C; Carlsson, J; Josephsson, R; Långström, B; Monazzam, A | 1 |
| Choe, KJ; Choi, HY; Choi, SH; Han, WS; Kim, HA; Kim, HK; Moon, BI; Oh, SY; Park, HK; Sung, SH; Yom, CK; Yoon, EJ | 1 |
| Miyaguni, T; Murayama, S; Nishimaki, T | 1 |
| Masuda, N | 1 |
| Bréchot, JM; Morère, JF; Pailler, M | 1 |
| Furlow, B | 1 |
| Guan, JH; Huan, HY; Mao, F; Sun, Q; Zhou, YD | 1 |
| Akazawa, K; Arai, T; Kim, SJ; Maruyama, N; Miyoshi, Y; Noguchi, S; Taguchi, T; Tamaki, Y | 1 |
| Baggstrom, MQ; Fried, DB; Hensing, TA; Poole, C; Socinski, MA; Stinchcombe, TE | 1 |
| Horwitz, SB; Wiesen, KM; Xia, S; Yang, CP | 1 |
| Paal, K; Shkarupin, A | 1 |
| Davis, S; Hind, D; Rees, A; Simpson, E; Ward, S; Wilkinson, A | 1 |
| Faerber, GJ; Weizer, AZ; Wolf, JS | 1 |
| Daskivich, TJ; Oh, WK; Regan, MM | 1 |
| Berveiller, P; Goffinet, F; Goldwasser, F; Mir, O; Pons, G; Ropert, S; Treluyer, JM | 1 |
| Abe, S; Honda, K; Kondo, H; Makino, K; Mizushima, T; Oura, K; Sumiyoshi, T; Tamura, F; Tanaka, S; Tsuji, Y; Tsushima, T; Yoshizaki, N | 1 |
| Ferguson, T; Ghersi, D; Nowak, AK; Vagg, R; Wilcken, N | 1 |
| Baker, SD; Chatelut, E; Mathijssen, RH; Rowinsky, EK; Sparreboom, A; Verweij, J; Wolff, AC | 1 |
| Carstens, MG; Crommelin, DJ; de Jong, PH; de Leede, LG; Hennink, WE; Kemmink, J; van Nostrum, CF; Verrijk, R | 1 |
| Radaideh, SM; Sledge, GW | 1 |
| Ding, Y; Li, X; Liu, B; Qian, X; Shen, Z; Yang, M; Yu, L | 1 |
| de Lemos, ML; Ellard, S; Hu, F; Kuik, K; Olivotto, IA; Speers, CH; Taylor, SC; Vu, T | 1 |
| DeLoia, JA; Gallion, HH; Jones, JM; Kelley, JL; Strychor, S; Zamboni, WC | 1 |
| Adenis, A; Lansiaux, A; Penel, N | 1 |
| Abe, T; Goto, J; Hishinuma, T; Kobayashi, M; Mano, N; Okada, M; Takeuchi, T; Unno, M; Yamaguchi, H | 1 |
| Wade, RH | 1 |
| Mooberry, SL | 1 |
| Chang, J; Cho, BC; Choi, HJ; Chung, KY; Kim, DJ; Kim, JH; Kim, SH; Kim, SK; Park, MS; Shin, SJ; Sohn, JH | 1 |
| Bianco, AR; Cancello, G; Criscitiello, C; D'Agostino, D; De Laurentiis, M; De Placido, S; Esposito, A; Forestieri, V; Giordano, A; Giuliano, M; Lauria, R; Limite, G; Montagna, E; Montanino, A; Pennacchio, R; Silvestro, L | 1 |
| Ferrell, B; Leong, L; Lowe, T | 1 |
| Hansch, C; Verma, RP | 1 |
| Safavy, A | 1 |
| Bidzinski, M; Kraszewska, E; Kupryjanczyk, J; Madry, R; Markowska, J; Stelmachow, J; Timorek, A; Ziolkowska-Seta, I | 1 |
| Marino, P | 1 |
| Barrett, SV; Glasspool, RM; Hay, A; Kaye, SB; Paul, J; Vasey, PA | 1 |
| Combs, GF; Hu, H; Li, GX; Lü, J; Wang, L; Watts, J | 1 |
| Akashi-Tanaka, S; Ando, M; Fujiwara, Y; Hojo, T; Katsumata, N; Kinoshita, T; Kohno, T; Seki, K; Shibata, T; Shien, T; Shimizu, C | 1 |
| Argiris, A; Axelrod, R; Burtness, BA; Forastiere, AA; Manola, J | 1 |
| Ai, CZ; Dong, PP; Ge, GB; Liu, CX; Liu, Y; Yang, L; Zhang, YY | 1 |
| Brock, M; Canto, MI; Daniels, JA; Gibson, MK; Heath, E; Montgomery, E; Sun, S; Wang, J; Xu, L | 1 |
| Fukushima, M; Garbo, CL; Ishiguro, H; Kitano, T; Toi, M; Ueno, T; Yanagihara, K; Yasuda, H; Yoshibayashi, H | 1 |
| Ardizzoni, A; Bisagni, G; Bortesi, B; Camisa, R; Capelletti, M; Laccabue, D; Missale, G; Musolino, A; Naldi, N; Neri, TM; Pezzuolo, D; Zerbini, A | 1 |
| Böhme, C; Cerny, T; Demmer, R; Gillessen, S; Schmitz, SF; Strasser, F; Thuerlimann, B | 1 |
| Goto, Y; Kunitoh, H; Nokihara, H; Ohe, Y; Sekine, I; Tamura, T; Yamada, K; Yamamoto, N | 1 |
| Akehurst, R; Booth, A; Kaltenthaler, E; Tappenden, P | 1 |
| Marty, M; Pivot, X | 1 |
| Davidson, NE; Jones, V; Martino, S; Perez, EA; Saphner, T; Sledge, GW; Sparano, JA; Wang, M; Wolff, AC; Wood, WC | 1 |
| Ardavanis, A; Baziotis, N; Garoufali, A; Kountourakis, P; Kyriakou, F; Malliou, S; Mantzaris, I; Rigatos, G; Scorilas, A; Yiotis, I | 1 |
| Amar, S; Perez, EA; Roy, V | 1 |
| Bandstra, B; Bischoff, H; Bonomi, P; Bover, I; Digel, W; Eisenfeld, AJ; Freitag, L; García-Campelo, R; Gatzemeier, U; Iannotti, N; Kaukel, E; O'Brien, M; Oldham, FB; Paz-Ares, L; Prendiville, J; Reiterer, P; Riviere, A; Ross, H; Singer, JW; Von Pawel, J | 1 |
| Aravantinos, G; Bafaloukos, D; Briasoulis, E; Christodoulou, C; Dafni, U; Dimopoulos, MA; Fountzilas, G; Gogas, H; Kalofonos, HP; Kalogera-Fountzila, A; Karina, M; Kosmidis, P; Koutras, A; Maniadakis, N; Matsiakou, F; Papadimitriou, C; Papakostas, P; Pectasides, D; Samantas, E; Skarlos, D | 1 |
| Hidaka, T; Horiuchi, A; Ishida, N; Kawachi, K; Nakagawa, H; Sato, K; Sugishita, H; Watanabe, Y; Yamamoto, Y; Yoshida, M; Yukumi, S | 1 |
| Benekli, M; Buyukberber, S; Coskun, U; Dikilitas, M; Kaya, AO; Ozkan, S; Ozturk, B; Uner, A; Yamac, D; Yaman, E; Yildiz, R | 1 |
| Clynes, M; Henry, M; Keenan, J; Meleady, P; Murphy, L | 1 |
| Han, HS; Kang, HS; Kim, SW; Lee, DH; Lee, ES; Lee, H; Lee, KS; Nam, BH; Ro, J; Seo, JA | 1 |
| Cavaletti, G; Marmiroli, P; Nicolini, G | 1 |
| Blackwell, K; Bullock, K | 1 |
| Bachelot, T; Blay, JY; Dufresne, A | 1 |
| Azim, HA; Mok, T | 1 |
| Audran, G; Brémond, P; Monti, H | 1 |
| Baselga, J; Prat, A | 1 |
| Hino, M; Homma, K; Sano, M; Sato, N | 1 |
| Ahn, JS; Ahn, MJ; Ahn, YC; Han, J; Hwang, IG; Kim, J; Lee, S; Park, BB; Park, K; Shim, YM | 1 |
| Eisenkop, SM; McAlpine, JN; Spirtos, NM | 1 |
| Furuiye, M; Inase, N; Ishiwata, N; Jin, Y; Miyake, S; Miyashita, Y; Takano, S; Yoshizawa, M; Yoshizawa, Y | 1 |
| Kami, M; Komatsu, T; Tsubokura, M | 1 |
| Aksoy, S; Altundag, K; Dizdar, O | 1 |
| Ke, B; Qin, Y; Qu, Y; Zhao, F | 1 |
| Al-Adhami, M; Albert, G; Gravenor, D; Hirsh, V; Krieg, AM; Leichman, CG; Manegold, C; Mezger, J; Readett, D; Woytowitz, D | 1 |
| Aggarwal, AN; Singh, N | 1 |
| Biganzoli, L; Di Leo, A; Licitra, S; Moretti, E; Pestrin, M; Zafarana, E | 1 |
| Beesley, J; Brown, R; Byth, K; Chenevix-Trench, G; DeFazio, A; Fereday, S; Harnett, PR; Johnatty, SE; Marsh, S; McLeod, H; Paul, J; Spurdle, AB; Webb, PM | 1 |
| Desai, NP; Gradishar, WJ; Hwang, LY; Soon-Shiong, P; Trieu, V; Wu, R | 1 |
| Carlson, MJ; Cohn, DE; Copeland, LJ; Fowler, JM; O'Malley, DM; Richardson, DL; Seamon, LG | 2 |
| Eggemann, H; Elling, D; Harbeck, N; Janni, W; Kaufmann, M; Kiechle, M; Kümmel, S; Loibl, S; Nekljudova, V; Sommer, H; von Minckwitz, G | 1 |
| Aydin, HH; Celik, HA; Oktem, G; Omay, SB; Sahin, F; Saydam, G | 1 |
| Bobokova, J; Calles Blanco, A; Custodio Carretero, AB; Díaz-Rubio García, E; García Paredes, B; García Sáenz, JA; González Larriba, JL; Hernando Trancho, F; Rodríguez Lajusticia, L | 1 |
| Georgoulias, V; Mavroudis, D; Saloustros, E | 1 |
| Eskiocak, U; Gunduz, U; Iseri, OD; Kars, MD; Sakin, V | 1 |
| Harris, P; Hartwell, D; Loveman, E; Takeda, A; Welch, K | 1 |
| Dafni, U; Fountzilas, G; Fragkoulidi, A; Fragoulakis, V; Galani, E; Grimani, I; Maniadakis, N | 1 |
| Balakumaran, B; Chenette, EJ; Febbo, PG; Hsu, DS; Nevins, J; Pontzer, E; Porrello, A; Potti, A; Riedel, RF | 1 |
| Kraszewska, E; Kupryjańczyk, J; Madry, R; Rembiszewska, A; Szymańska, T; Timorek, A; Ziółkowska-Seta, I | 1 |
| Agostara, B; Belfiglio, M; Bertetto, O; Bruzzi, P; Cascinu, S; Cognetti, F; Conte, P; Crinó, L; D'Amico, R; Di Leo, A; Frassoldati, A; Guarneri, V; Molino, A; Pronzato, P | 1 |
| Gradisar, H; Jerala, R; Keber, MM; Pristovsek, P; Resman, N; Vasl, J | 1 |
| Cecchetto, M; Guo, B; Hembruff, SL; Laberge, ML; Parissenti, AM; Veitch, Z; Villeneuve, DJ | 1 |
| Entwistle, RA; Foland, TB; Himes, RH; Lushington, GH; Winefield, RD | 1 |
| Ahn, JS; Ahn, MJ; Choi, MK; Han, JH; Hong, JY; Lee, J; Park, K; Park, MJ; Park, YH; Uhm, JE | 1 |
| Fujita, Y; Fukushima, M; Furuse, K; Kawahara, M; Komuta, K; Kubota, K; Minato, K; Nishiwaki, Y; Ogawara, M; Teramukai, S | 1 |
| Fu, YJ; Hua, X; Jiang, SG; Wang, JT; Wang, Z; Zhang, L; Zhang, Y; Zu, YG | 1 |
| Fukushima, M; Konishi, K; Okada, M; Sanada, Y; Tsutani, Y; Wada, Y; Yoshida, K | 1 |
| Cottrell, W; Dranitsaris, G; Hopkins, S; Spirovski, B | 1 |
| Furusawa, K; Kobayashi, Y; Mizoguchi, T; Nakamichi, Y; Naramoto, H; Takahashi, M; Takahashi, N; Udagawa, N; Uehara, S; Uematsu, T; Yamaoka, M; Yamashita, T; Yang, S | 1 |
| Liu, BR; Qian, XP; Wang, TT; Wei, J; Yu, LX | 1 |
| Kendrick, JE; Kilgore, LC; Matthews, KS; Numnum, TM; Shipman, KA; Straughn, JM; Whitworth, JM | 1 |
| Cobb, P; Houts, AC; Schwartzberg, LS; Stepanski, EJ; Walker, MS | 1 |
| Gennatas, K; Gennatas, S; Michalaki, V | 1 |
| Fabritius, M; Ip, C; Wu, Y | 1 |
| Chung, HH; Kang, SB; Kim, HS; Kim, JW; Kim, MK; Park, NH; Song, YS | 1 |
| Baba, T; Barnett, JC; Berchuck, A; Chang, JT; Fujii, S; Gray, JW; Gusberg, AH; Huang, Z; Kuo, WL; Lee, PS; Matsumura, N; Mori, S; Murphy, SK; Whitaker, RS | 1 |
| Matard, B; Pinquier, L; Prevezas, C; Reygagne, P | 1 |
| Apte, S; Boren, T; Chan, G; Chen, DT; Dressman, H; Hakam, A; Kamath, SG; Lancaster, JM; Wenham, R; Xiong, Y | 1 |
| Ball, D; Campeau, MP; Drummond, E; Herschtal, A; Hogg, A; Mac Manus, M; Michael, M; Wheeler, G; Wirth, A | 1 |
| Khuri, FR; Ramalingam, SS | 1 |
| Dalrymple, SL; Dannals, RF; Davidson, NE; Frost, JJ; Huang, Y; Isaacs, JT; Madar, I; Ravert, H | 1 |
| Reck, M | 1 |
| Jaén, P; Muñoz-Zato, E; Pérez, B; Truchuelo, M; Vano-Galvan, S | 1 |
| Kunitoh, H; Saijo, N; Takeuchi, M | 1 |
| Greco, FA; Spigel, DR | 1 |
| Kovel, S; Sella, A; Yarom, N; Zisman, A | 1 |
| Cao, Y; Chen, B; Cheng, H; Cheng, L; Feng, J; Ji, J; Li, F; Lu, Z; Ma, J; Qin, S; Sun, N; Sun, X; Zhou, Y | 1 |
| Bhar, P; Cheporov, S; Clawson, A; Gradishar, WJ; Krasnojon, D; Makhson, AN; Manikhas, GM | 1 |
| Choi, SS; Han, SB; Hong, JT; Kim, SM; Kim, Y; Lee, SY; Moon, DC; Oh, KW; Yuk, DY | 1 |
| Coleman, R; Dranitsaris, G; Gradishar, W | 1 |
| Arpaci, F; Gündüz, U; Işeri, OD; Kars, MD | 1 |
| Ito, C; Kamijo, Y; Miyamoto, K; Nomura, M; Sai, Y | 1 |
| Li, J; Li, Y; Lu, M; Shen, L; Xiao, Y; Zhang, J; Zhang, XD | 1 |
| Fujita, M; Matsuura, O; Morohashi, H; Yamada, K; Yamazaki, S | 1 |
| Corry, P; Moros, EG; Peñagarícano, JA; Ratanatharathorn, V; Yan, Y | 1 |
| Beuselinck, B; Dirix, L; Kains, JP; Paridaens, R; Wildiers, H; Wynendaele, W | 1 |
| Bang, YJ; Heo, DS; Im, SA; Kim, DW; Kim, TY; Kim, YW; Lee, JS; Lee, SH; Oh, DY; Sun, JM | 1 |
| Friberg, LE; Hansson, EK; Karlsson, MO; Lindman, H; Sandström, M; Wallin, JE | 1 |
| Aruga, T; Kuroi, K; Matsumoto, G; Muta, M; Nakashima, E; Sai, Y; Saji, S; Suzuki, E; Toi, M; Yanagawa, T | 1 |
| Bozas, G; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Makatsoris, T; Papadimitriou, CA; Papakostas, P; Zagouri, F | 1 |
| Fridley, BL; Jenkins, GD; Kalari, KR; Li, L; Lingle, W; Lou, Z; Pei, H; Petersen, G; Wang, L | 1 |
| Alamara, C; Chatzidarellis, E; Georgiadis, E; Giza, L; Makrilia, N; Syrigos, KN | 1 |
| Aránega, A; Boulaiz, H; Caba, O; Melguizo, C; Ortiz, R; Prados, J; Rama, AR; Ramos, JL; Segura, A; Vélez, C | 1 |
| Ge, GB; Liu, HX; Liu, Y; Sun, J; Wang, LM; Yang, L; Zhang, JW; Zhang, YY | 1 |
| Teng, KY; Xu, RH | 1 |
| Benedict, A; Cameron, DA; Corson, H; Jones, SE | 1 |
| Bohrer, L; Chen, S; Gan, L; Huang, H; Sun, Z; Wang, Y; Watahiki, A | 1 |
| Bender, GP; Masellis, AM; Sielaff, TD | 1 |
| Bond, VK; Im, DD; Matsuo, K; Rosenshein, NB | 1 |
| Candeloro, G; Di Orio, F; Guerriero, G; Piazze, J; Rea, S; Recchia, F | 1 |
| Beijnen, JH; Koolen, SL; Schellens, JH | 1 |
| Bristianou, M; Georgiou, C; Kamposioras, K; Karathanasi, I; Mauri, D; Polyzos, NP; Tsali, L; Valachis, A | 1 |
| Beriwal, S; Edwards, RP; Kelley, JL; Krivak, TC; Lesnock, JL; McBee, WC; Richard, SD; Sukumvanich, P; Zorn, KK | 1 |
| Groe, R; Grothey, A; Kantelhardt, EJ; Kegel, T; Koelbl, H; Mueller, LP; Schmoll, HJ; Seliger, G; Strauss, HG; Thomssen, C | 1 |
| Chang, H; Choi, HJ; Chung, HC; Kim, JH; Kim, SI; Kim, YT; Koo, JS; Moon, YW; Park, BW; Park, S; Roh, JK; Sohn, JH | 1 |
| Alumkal, J; Beer, TM; Eilers, KM; Ryan, C; Ryan, CW; Sun, J | 1 |
| Chen, LM; Dai, CL; Fu, LW; Liang, YJ; Su, XD; Tao, LY; Wang, FP; Yan, YY; Zhang, X | 1 |
| Fujii, A; Hayashi, A; Hidaka, D; Hiyama, J; Ikeda, K; Koshizuka, H; Misumi, Y; Miyagawa, Y; Nakanishi, K; Nakatsubo, S; Omagari, J; Sanada, H; Sawamoto, R; Tomimitsu, S; Tsuru, M | 1 |
| Favaretto, AG; Magro, C; Pasello, G | 1 |
| Dangsuwan, P; Manchana, T | 1 |
| Baba, K; Hasegawa, Y; Ichikawa, M; Imaizumi, K; Kataoka, K; Kondo, M; Kume, H; Matsumoto, S; Noda, Y; Shindo, Y; Shindoh, J; Suzuki, K; Suzuki, R; Takagi, K; Taniguchi, H; Tanikawa, Y | 1 |
| Awad, M; Dakhil, S; Harbison, CT; Hart, LL; Hermann, RC; Horak, CE; Khambata-Ford, S; Lynch, TJ; Weber, MR; Xu, LA | 1 |
| Dakhil, S; Dreisbach, L; Gorton, S; Heim, WJ; Hermann, RC; Iannotti, NO; Lynch, TJ; McCleod, M; Paschold, E; Patel, T; Pautret, V; Weber, MR; Woytowitz, D | 1 |
| Li, T; Liu, YH; Qin, XQ; Wang, YH; Ye, JM; Yin, HF; Zhang, H | 1 |
| Chen, H; Lin, JR; Xie, B; Xu, ZY; Zhang, WM; Zheng, JH; Zhou, J | 1 |
| Imanaka, Y; Ishizaki, T; Sekimoto, M; Shirai, T | 1 |
| Huang, XE; Jiang, W; Li, C; Lin, Y; Shi, MQ; Shu, YQ; Sunh, WL; Ye, Z; Zhang, Q; Zhou, JN | 1 |
| Arakawa, S; Fujisawa, M; Matsumoto, O; Shigemura, K; Yasufuku, T | 1 |
| Bergougnoux, L; Bidard, FC; de Cremoux, P; Degeorges, A; Delva, R; Etienne-Grimaldi, MC; Mathiot, C; Milano, G; Pierga, JY; Pivot, X; Veyret, C | 1 |
| Maehara, Y; Matsuda, H; Nagata, S; Ueda, N; Yoshida, Y | 1 |
| Biganzoli, L; Conte, P; Diéras, V; Glaspy, J; Guarneri, V; Miles, D; Robert, N; Smith, I; Taran, T; Thomssen, C | 1 |
| Gündüz, U; Işeri, OD; Kars, MD | 1 |
| Twelves, C; Woodward, EJ | 1 |
| Bermingham, S; McMahon, GP; O'Connor, R; Regan, F | 1 |
| Hozumi, Y; Masuda, N; Mitsuyama, S; Mukai, H; Murakami, S; Ohashi, Y; Ohmura, T; Takashima, T; Watanabe, T; Yajima, T | 1 |
| Groshen, S; Lee, AS; Lee, E; Nichols, P; Spicer, D | 1 |
| Lv, M; Ren, S; Xu, J; Zhang, J; Zhang, L; Zhou, C; Zhou, S | 1 |
| Etrych, T; Ríhová, B; Sírová, M; Starovoytova, L; Ulbrich, K | 1 |
| Roy, V; Vishnu, P | 1 |
| Ahmad, A; Azmi, AS; Banerjee, S; Kong, D; Li, Y; Sarkar, FH; Wang, Z | 1 |
| Pagani, M | 1 |
| Baricordi, OR; Ferlini, A; Indelli, M; Lelli, G; Rimessi, P; Rizzo, R; Spaggiari, F | 1 |
| Araque Arroyo, P; Calleja Hernández, MA; Cancela Díez, B; Fernández Feijóo, MA; Hernández Magdalena, J; Ubago Pérez, R | 1 |
| Leaw, SJ; Luo, J; Xu, Y; Zheng, D | 1 |
| Socinski, MA; Stinchcombe, TE | 1 |
| Aoki, D; Hatae, M; Hiura, M; Jobo, T; Katsumata, N; Konishi, I; Nomura, H; Takahashi, F; Watanabe, Y; Yaegashi, N | 1 |
| Assaraf, YG; Epstein, D; Livney, YD; Shapira, A | 1 |
| Barnadas, A | 1 |
| Gu, Z; Shen, Y; Wang, M; Xu, Q; Xu, S; Yin, X; Zhang, L; Zhang, N | 1 |
| Ahn, S; Dalton, JT; Li, CM; Lu, Y; Miller, DD; Narayanan, R | 1 |
| Hosono, S; Ito, H; Ito, S; Kawai, H; Kawase, T; Matsuo, K; Muro, K; Sawaki, A; Shibata, T; Shitara, K; Tajima, K; Takahari, D; Tanaka, H; Ura, T; Watanabe, M; Yatabe, Y; Yokota, T | 1 |
| Aohara, F; Fujimura, Y; Harakawa, N; Hasegawa, R; Katori, N; Kim, SR; Maekawa, K; Naito, M; Niwa, T; Okuda, H; Sai, K; Saito, Y; Sawada, J; Tohkin, M; Yoshimura, T | 1 |
| Argenta, PA; Geller, M; Ivy, JJ; Koopmeiners, JS; Kothari, R; Nagel, C; Salani, R | 1 |
| Ahn, EH; Eno, ML; Im, DD; Matsuo, K; Rosenshein, NB; Shahzad, MM; Sood, AK | 1 |
| Aita, M; Cappuzzo, F; de Marinis, F; Douillard, JY; Gridelli, C; Grossi, F; Kubota, K | 1 |
| Becherer, A; De Vries, A; Drexel, H; Gasser, K; Gruber-Moesenbacher, U; Lang, A; Muendlein, A; Schuster, A; Winder, T | 1 |
| Casado, MÁ; Cortés, J; Frías, C; Oyagüez, I; Seguí, MÁ | 1 |
| Hwang, IG; Kang, JH; Kang, WK; Kim, HS; Kwon, JM; Lee, HY; Lee, SC; Lim, DH; Lim, HY; Oh, SY; Park, KW; Park, SH | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kalykaki, A; Kotsakis, A; Saridaki, Z; Vamvakas, L; Vardakis, N | 1 |
| Burt, H; Jackson, J; Tsallas, A | 1 |
| Gemma, A; Inage, S; Ise, Y; Katayama, S; Obayashi, M | 1 |
| Chen, L; Jiao, SC; Li, J; Lv, YL; Shi, Y; Sun, Q; Wang, LX | 1 |
| Brooks, DE; Burt, HM; Chafeeva, I; Guan, D; Heller, M; Jackson, JK; Liggins, RT; Manisali, I; Mugabe, C | 1 |
| Azrak, RG; Rempinski, DR; Rustum, YM; Saifo, MS | 1 |
| Cui, L; Huang, XE; Jiang, Y; Tang, JH; Xiang, J; Yan, PW | 1 |
| Huang, XE; Jiang, Y; Li, Y; Xiang, J; Yan, PW | 1 |
| Baak, JP; Guo, H; Liu, JX; Madebo, T; Xu, L | 1 |
| Nagykálnai, T | 1 |
| Aoyagi, H; Hamada, S; Hasegawa, K; Kaneko, J; Katsuta, E; Maejima, S; Ohkubo, T; Saguchi, M; Someno, Y; Takahata, T | 1 |
| Fietkau, R; Iro, H; Klautke, G; Kuwert, T; Lell, M; Linke, R; Semrau, S; Uder, M; Waldfahrer, F | 1 |
| Duman, BB; Ercolak, V; Günaldi, M; Kara, IO | 1 |
| Amant, F; Beijnen, J; Calsteren, KV; Chai, DC; de Bruijn, E; De Catte, L; de Hoon, J; Demarsin, S; Devlieger, R; Heyns, L; Van Bree, R; Verbesselt, R | 1 |
| Bando, H; Iwata, H; Kashiwaba, M; Mizuno, T; Murakami, S; Nakayama, T; Ohashi, Y; Sawaki, M; Taira, N; Tokudome, N; Uemura, Y; Yamamoto, Y | 1 |
| Beck, SL; Cohen, JA; Lavoie Smith, EM; Pett, MA | 1 |
| Kip, K; Overcash, J; Tofthagen, C | 1 |
| Arimoto, T; Kawana, K; Nakagawa, S; Oda, K; Taketani, Y; Yasugi, T | 1 |
| Biganzoli, L; Bogdanova, N; Chen, Z; Cheng, Y; Chmielowska, E; Crivellari, D; Dalenc, F; Delva, R; Di Vincenzo, E; Espié, M; Hamm, C; Jiang, Z; Just, M; Lichinitser, M; Semiglazov, V; Shen, Z; Smith, I; Vinholes, J; Vivanco, GL | 1 |
| Gao, JM; Kamnaing, P; Kiyota, T; Konishi, Y; Watchueng, J; Yeboah, F | 1 |
| Bebek, G; Budd, GT; De, S; Downs-Kelly, E; Eng, C; Orloff, MS; Stark, GR; Tan, MH; Wesolowski, R | 1 |
| Danno, K; Imaoka, S; Imasato, M; Kanoh, T; Kimura, Y; Monden, T; Nakano, Y; Ohnishi, T; Taniguchi, H; Tono, T; Yano, H | 1 |
| Plummer, RS; Shea, CR | 1 |
| Eller, J; Furák, J; Hideghéty, K; Kahán, Z; Maráz, A; Molnár, J; Pálföldi, R; Szántó, E; Thurzó, L; Tiszlavicz, L | 1 |
| Dai, H; Liu, JW; Yan, D | 1 |
| Andreu, JM; Canales, A; Coderch, C; Díaz, JF; Jiménez-Barbero, J; Nieto, L; Paterson, I; Rodríguez-Salarichs, J; Trigili, C | 1 |
| Agelaki, S; Ardavanis, A; Chandrinos, V; Christophyllakis, C; Georgoulias, V; Giassas, S; Karachaliou, N; Kotsakis, A; Pallis, AG; Polyzos, A; Samonis, G; Saridaki, Z; Syrigos, K; Vamvakas, L; Vardakis, N; Varthalitis, I | 1 |
| Ando, M; Fujiwara, Y; Hirata, T; Katsumata, N; Ono, M; Shimizu, C; Tamura, K; Yamamoto, H; Yonemori, K | 1 |
| Bagot, M; Cosnes, A; Duong, TA; Gantzer, A; Ortonne, N; Regnier, S; Wolkenstein, P | 1 |
| Ducros, C; Montana, M; Rathelot, P; Terme, T; Vanelle, P; Verhaeghe, P | 1 |
| Belinsky, MG; Chen, ZS; Churchill, T; Grinberg, A; Hopper-Borge, EA; Jacobs, JD; Klein-Szanto, AJ; Kruh, GD; Kuang, Y; Ngo, O; Nicolas, E; Paulose, C; Westphal, H | 1 |
| Bennett, CL; Bookstaver, PB; Campbell, W; Garg, V; Norris, LB; Qureshi, ZP; Raisch, DW | 1 |
| Berchuck, A; Havrilesky, LJ; Higgins, RV; Kohler, MF; Myers, ER; Nycum, LR; Pokrzywinski, R; Revicki, D; Secord, AA | 1 |
| Eastwood, A; Epstein, D; Fox, D; Rodgers, M; Soares, M; Yang, H | 1 |
| Huang, XE; Jin, GF; Li, Y; Shen, HB; Xu, L | 1 |
| Fauci, JM; Frederick, PJ; Kilgore, LC; Schneider, KE; Straughn, JM; Subramaniam, A; Whitworth, JM; Zhang, B | 1 |
| Casado, MA; Ginés, J; Grau, M; Martorell, C; Monroy, M; Sabater, E | 1 |
| Bertucci, F; Birnbaum, D; Borg, JP; Finetti, P; Gonçalves, A; Kadra, G; Toiron, Y; Viens, P | 1 |
| Doihara, H; Ikeda, H; Miyoshi, S; Nogami, T; Okada, M; Shien, K; Shien, T; Taira, N | 1 |
| Schwartz, JR | 1 |
| Chen, QH; Chen, XG; She, XK; Song, L; Wang, FP | 1 |
| Aapro, M; Bhar, P; Gradishar, W; Tjulandin, S | 1 |
| Fukushima, M; Furuse, K; Kawahara, M; Kubota, K; Origasa, H; Shinkai, T; Tada, H; Teramukai, S; Tokoro, A | 1 |
| Honda, K; Imaishi, H; Kamura, T; Takemoto, S; Terada, A; Ushijima, K; Wada, H | 1 |
| Dohi, S; Inoue, M; Kyo, S; Ohno, S; Ohno, Y; Soma, G; Sugiyama, H; Takakura, M | 1 |
| Beijnen, JH; Hendrikx, JJ; Hillebrand, MJ; Rosing, H; Schellens, JH; Schinkel, AH; Thijssen, B | 1 |
| Ardisson, P; Asmane, I; Bajard, A; Bergerat, JP; Coeffic, D; Dufresne, A; Guastalla, JP; Kurtz, JE; Labidi Galy, I; Meeus, P; Moullet, I; Ray-Coquard, I; Tredan, O; Vincent, L | 1 |
| Bayraktar, S; Buzdar, AU; Gonzalez-Angulo, AM; Hortobagyi, GN; Kuerer, HM; Lei, X; Melhem-Bertrandt, A; Meric-Bernstam, F; Sahin, AA; Valero, V | 1 |
| Girija Sankar, G; Mastan Vali, R; Nageswara Rao, R; Sarma, VU; Satyanarayana Raju, S | 1 |
| Czúcz, J; Révész, C; Rosivall, L; Rozsnyay, Z; Szebeni, J; Weiszhár, Z | 1 |
| Brown, JB; Kadoyama, K; Kuwahara, A; Okuno, Y; Sakaeda, T; Yamamori, M | 1 |
| Abair, T; O'Shaughnessy, J | 1 |
| Baba, Y; Kim, SJ; Kishi, K; Nakayama, T; Naoi, Y; Noguchi, S; Shimazu, K; Tamaki, Y; Tanei, T; Tominaga, N; Tsunashima, R | 1 |
| Ota, T; Takeshima, N; Takizawa, K | 1 |
| Isonishi, S; Saito, M; Tanaka, T | 1 |
| Hu, D; Li, MQ; Su, J; Xu, H | 1 |
| Kondo, C; Mizota, A; Muro, K; Nomura, M; Shitara, K; Takahari, D; Ura, T; Yokota, T | 1 |
| Fu, JH; Liu, YL; Zhang, GM; Zhang, YL | 1 |
| Alba, E; García-Tapiador, A; González-Sánchez, LA; Jiménez, B; Medina, L; Navarro, V; Romero-García, G; Sánchez-Muñoz, A | 1 |
| Akiyama, F; Ando, M; Aogi, K; Fujiwara, Y; Ino, H; Iwata, H; Kasai, H; Kurosumi, M; Masuda, N; Nakamura, S; Takeuchi, M; Tokuda, Y; Tsuda, H; Yamamoto, N | 1 |
| Bauknecht, T; Benhadji, KA; Davidson, N; Gümüş, M; Soldatenkova, V | 1 |
| Fujitani, K; Hirao, M; Kodama, Y; Mano, M; Tsujinaka, T | 1 |
| Chérel, M; Classe, JM; Collet, M; Dupré, PF; Gouard, S; Muller, M | 1 |
| Bordeleau, L; Kim, S; Seki, J; Sridhar, S; Tannock, I | 1 |
| Armstrong, SR; Guo, B; Hembruff, SL; Kalatskaya, I; Lanner, C; Parissenti, AM; Reed, K; Sprowl, JA; Stein, L; Tam, A | 1 |
| Blackman, RK; Foley, KP; He, S; Koya, K; Liu, Y; Proia, DA; Sang, J; Sequeira, M; Smith, DL; Wada, Y; Ye, S; Zhang, C; Zhou, D | 1 |
| Barg, FK; DeMichele, A; Farrar, JT; Hennessy, S; Mao, JJ; Speck, RM; Stineman, MG | 2 |
| Bessonov, AA; Dashian, GA; Kolar'kova, VV; Paltuev, RM; Pen'kov, KD; Remizov, AS; Semiglazov, VF; Semiglazov, VV; Semiglazova, TIu; Vasil'ev, AG | 1 |
| Kang, HS; Kim, JH; Ro, J; Yoo, HI; Yoon, S | 1 |
| Ando, T; Fujinami, H; Horikawa, N; Hosokawa, A; Itaya, Y; Kajiura, S; Kobayashi, T; Nishikawa, J; Note, M; Ogawa, K; Sugiyama, T; Tsukioka, Y; Ueda, A; Yabushita, K | 1 |
| Furuya, T; Hirowatari, H; Ito, K; Izawa, H; Karasawa, K; Mitsuhashi, N; Ozawa, S; Saito, M; Suzuki, T | 1 |
| Ancoli-Israel, S; Dimsdale, JE; Fiorentino, L; Liu, L; Mills, PJ; Natarajan, L; Parker, BA; Rissling, M; Sadler, GR | 1 |
| Booser, DJ; Brewster, AM; Broglio, K; Buzdar, AU; Gonzalez-Angulo, AM; Green, MC; Hortobagyi, GN; Hunt, KK; Ibrahim, NK; Kelly, CM; Thomas, ES; Valero, V; Walters, RS | 1 |
| Barron, R; Edelsberg, J; Kartashov, A; Lyman, G; Weycker, D | 1 |
| Aissi, M; Kubis, N; Lévy, BI; Milani, P; Osmani, K; Vignes, S; Wade, F | 1 |
| Iitsuka, C; Iwase, H; Nomura, H; Omatsu, K; Sakamoto, K; Takada, T; Takeshima, N; Takizawa, K | 1 |
| Koroleva, IA; Mochalova, AS | 1 |
| Annino, DJ; Balboni, TA; Goguen, LA; Haddad, RI; Lorch, J; Norris, CM; Posner, MR; Sher, DJ; Thotakura, V; Tishler, RB | 1 |
| Kuranami, M; Ohashi, Y; Ohno, S; Ohsumi, S; Shimozuma, K; Suemasu, K; Takeuchi, A; Watanabe, T | 1 |
| Chen, CM; Chen, S; Shao, ZM; Yu, KD; Zhou, RJ | 1 |
| Boulaamane, L; Boutayeb, S; Errihani, H | 1 |
| Ahmad, FJ; Borchard, G; Chaurasiya, A; Jain, GK; Khar, RK; Singh, AK; Sublet, E; Warsi, MH | 1 |
| Jin, W; Lou, LG; Xie, CY; Xu, YP | 1 |
| Barnett, JC; Cohn, DE; Garfield, CF; Havrilesky, LJ | 1 |
| Anderson, R; Balkrishnan, R; Camacho, F; Kamal, AH; Kimmick, G; Wei, W | 1 |
| Berger, AM; Farr, L; Fischer, P; Geary, CR; Hertzog, M | 1 |
| Ebi, M; Hirata, Y; Joh, T; Kamiya, T; Kataoka, H; Kitagawa, M; Mizoshita, T; Mizushima, T; Shimura, T; Tanida, S; Yamada, T; Yoshida, M | 1 |
| Dong, Z; Fauzee, NJ; Juan, P; Li, QG; Lu, X; Mandarry, MT; Wang, T; Wang, YL | 1 |
| Fang, WS; Tao, JY; Wang, SR; Zhang, SE; Zhao, Y; Zhou, D | 1 |
| Adediran, S; Hussain, A; Khan, MA; Livak, F; Ning, Y; Suer, S; Vemula, A; Zhang, B | 1 |
| Aranishi, T; Hausheer, FH; Katsumata, N; Kuranami, M; Kuroi, K; Makino, H; Morita, S; Ohashi, Y; Ohsumi, S; Shimozuma, K; Suemasu, K; Takeuchi, A; Watanabe, T | 1 |
| Baker, SD; de Graan, AJ; Friberg, LE; Loos, WJ; Mathijssen, RH; van der Bol, JM; van der Holt, B; van Doorn, L; Verweij, J; Wiemer, EA | 1 |
| Coulon Sfairi, MA; Dalenc, F; Delva, R; Espié, M; Hardy-Bessard, AC; Kockler, L; Lortholary, A; Monnier, A; Pavlyuk, M; Pierga, JY; Pivot, X; Serin, D; Veyret, C | 1 |
| Bhar, P; Cheporov, S; Clawson, A; Gradishar, WJ; Iglesias, J; Krasnojon, D; Makhson, AN; Manikhas, GM; McGuire, JR | 1 |
| Ahn, S; Chen, J; Costello, TA; Dalton, JT; Dalton, MN; Li, CM; Li, W; Lu, Y; Miller, DD; Narayanan, R; Snyder, LM | 1 |
| Choi, EK; Chung, HK; Jeong, SY; Jung, J; Kang, HW; Lee, SW; Park, HJ; Park, SJ; Seo, MH; Song, SY | 1 |
| Alexis, M; Awonuga, AO; Belotte, J; Bolinjkar, R; Deppe, G; Tabassum, F | 1 |
| Chu, Z; Huang, R; Jiang, J; Liang, X; Zhan, Q; Zhou, X | 1 |
| Adewoye, AH; Chan, A; De Boer, RH; Kaufman, PA; Koczwara, B; Kotasek, D; Mainwaring, P; Melara, R; Sikorski, R; White, S; Ye, Y | 1 |
| Furuya, K; Goto, T; Kato, M; Kita, T; Kudoh, K; Miyamoto, M; Sasaki, N; Takano, M; Watanabe, A; Yoshikawa, T | 1 |
| Bhat, A; Cardonick, E; Gilmandyar, D; Somer, R | 1 |
| Alasino, RV; Beltramo, DM; Bianco, ID; Garro, AG; Heredia, V; Leonhard, V | 1 |
| Inal, A; Isikdogan, A; Kaplan, MA; Karakus, A; Kucukoner, M; Urakci, Z | 1 |
| Hu, LM; Hu, ZB; Huang, MD; Shen, HB; Shu, YQ; Wang, ZW; Xu, JL; Yin, ZQ | 1 |
| Bang, YJ; Han, HS; Han, SW; Han, W; Im, SA; Jeon, YK; Kim, JH; Kim, JS; Kim, JW; Kim, TY; Kim, YJ; Noh, DY; Oh, DY; Park, IA | 1 |
| Lee, A; Lee, JH; Lee, YJ; Oh, JH | 1 |
| Armstrong, DK; DiSilvestro, PA; Fracasso, PM; Gould, N; Mannel, RS; Sill, MW; Thaker, PH; Waggoner, SE; Walker, JL; Yamada, SD | 1 |
| Hao, J; Liu, GY; Wang, DH; Xu, YF; Yu, J; Yuan, BB | 1 |
| Aman, A; Ernsting, MJ; Li, SD; Murakami, M; Press, B; Undzys, E | 1 |
| Belli, C; Cereda, S; Reni, M | 1 |
| Ando-Tanabe, N; Iwamitsu, Y; Kuranami, M; Miyaoka, H; Nakatani, Y; Okazaki, S; Watanabe, M; Yamamoto, K; Yasuda, H | 1 |
| Li, K; Li, W | 1 |
| Braun, M; Feller, AM; Fersching, DM; Gabka, CJ; Hamann, U; Heinemann, V; Holdenrieder, S; Nagel, D; Salat, C; Siegele, B; Steinkohl, O; Stoetzer, OJ | 1 |
| Hayakawa, Y; Hirano, K; Iguchi, K; Ishii, K; Matsumoto, K; Sugimura, Y; Usui, S | 1 |
| Chen, Y; Cohen, RB; Herbst, RS; Kim, S; Kozloff, MF; Martin, LP; Olszanski, AJ; Rado, T; Rosbrook, B; Samuel, TA; Starr, A; Tarazi, J; Tortorici, M | 1 |
| Bell, R; Khasraw, M | 1 |
| Ito, S; Kawai, H; Kondoh, C; Mizota, A; Muro, K; Nomura, M; Sawaki, A; Shitara, K; Takahari, D; Ura, T; Yokota, T | 1 |
| Beijnen, JH; Hendrikx, JJ; Lagas, JS; Rosing, H; Schellens, JH; Schinkel, AH | 1 |
| Date, M; Fujiwara-Honjo, N; Haba, R; Hashimoto, S; Houchi, H; Kontani, K; Kuroda, N; Kushida, Y; Murazawa, C; Norimura, S; Ohtani, M; Tanaka, H; Yamauchi, A; Yokomise, H | 1 |
| Chavez-Macgregor, M; Chen, H; Do, KA; Gonzalez-Angulo, AM; Hortobagyi, GN; Liu, S; Meric-Bernstam, F; Mills, GB; Sahin, A | 1 |
| Antoine, M; Belmont, L; Cadranel, J; Duruisseaux, M; Giroux Leprieur, E; Gounant, V; Lacave, R; Lavolé, A; Milleron, B; Poulot, V; Rabbe, N; Vieira, T; Wislez, M | 1 |
| Dong, HX; Ke, HG; Li, J; Liu, JH; Shen, Y; Shen, ZY; Yan, Y; You, QS | 1 |
| Bustam, AZ; Ng, CH; Phua, CE; Saad, M; Taib, NA; Teh, YC; Yip, CH; Yusof, MM | 1 |
| Berveiller, P; Broutin, S; Camps, S; Deroussent, A; Gil, S; Mir, O; Paci, A; Seck, A; Tréluyer, JM; Vinot, C | 1 |
| Hirayama, M; Kato, J; Kawano, Y; Kobune, M; Kuroiwa, G; Miyanishi, K; Sato, T; Sato, Y; Takada, K; Takahashi, S; Takimoto, R | 1 |
| Grant, AD; Marwick, TH; Negishi, T; Plana, JC; Popović, ZB; Thavendiranathan, P | 1 |
| Annuar, MA; Ho, GF; Jabir, RS; Munisamy, M; Naidu, R; Stanslas, J | 1 |
| He, AN; Lin, F; Min, DL; Qi, WX; Shen, Z; Sun, YJ; Tang, LN; Yao, Y | 1 |
| Tkaczuk, KH; Yared, JA | 1 |
| Akazawa, N; Ebuchi, M; Maruyama, M; Maruyama, S; Murakata, A; Ono, S; Sakoma, T; Satoh, E; Sugano, N; Suzuki, K; Tanami, H; Uehira, D; Yonekura, K | 1 |
| Cao, Y; Han, Y; Huang, H; Qu, L; Shou, C; Xiao, Z; Zhang, W | 1 |
| Lu, Y; Penrod, JR; Philipson, T; Sood, N; Woodby, S | 1 |
| Agelaki, S; Apostolaki, S; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kalykaki, A; Mavroudis, D; Perraki, M; Vardakis, N; Xenidis, N; Xyrafas, A | 1 |
| Barlow, LJ; Benson, MC | 1 |
| Lin, B; Shao, L; Song, Z; Zhang, Y | 1 |
| Baek, K; Cheng, J; Dobrucki, LW; Fan, TM; Tong, R; Xu, Y; Yin, Q | 1 |
| Gonzalez-Angulo, AM; Hernandez-Aya, LF | 1 |
| Armstrong, DK; Coleman, RL; Phillips, M; Weil, SC; White, AJ | 1 |
| Cuff, CF; Li, JM; Li, QQ; Reed, E; Zhao, J; Zou, B | 1 |
| Han, W; Im, SA; Moon, HG; Moon, WK; Noh, DY; Park, IA; Park, SJ; Shin, HC | 1 |
| Enomoto, T; Fujita, M; Kimura, T; Kobayashi, E; Matsuzaki, S; Tsutsui, T; Ueda, Y; Yoshino, K | 1 |
| Cheng, J; Gao, J; Liu, X; Wang, J; Wang, L; Xiong, L | 1 |
| Chen, J; Forman, BM; Gu, L; Kane, SE; Synold, TW | 1 |
| Han, JC; Li, HB; Li, XD; Wu, XY; Zhang, YJ | 1 |
| Boy, D; Bruzzi, P; Ceccarelli, M; Cognetti, F; De Laurentiis, M; De Placido, S; Del Mastro, L; Durando, A; Fabi, A; Kazeem, G; La Torre, I; Mansutti, M; Marchi, P; Merlo, DF; Venturini, M | 1 |
| Hertz, DL; Krens, SD; McLeod, HL | 1 |
| Allen, P; Buchholz, TA; Buzdar, AU; Gonzalez-Angulo, AM; Hortobagyi, GN; Hunt, KK; Kim, MM; Kuerer, HM; Litton, JK; Meric-Bernstam, F; Mittendorf, EA; Woodward, WA | 1 |
| Bhar, P; Gradishar, WJ; Iglesias, J; O'Shaughnessy, J | 1 |
| Chen, AB; Johnson, BE; Schrag, D; Sharma, DB; Weeks, JC; Zhu, J | 1 |
| Borzási, E; Együd, Z; Fodor, E; Furák, J; Hideghéty, K; Kahán, Z; Maráz, A; Pálföldi, R; Tiszlavicz, L; Varga, Z | 1 |
| Seidman, AD | 1 |
| Abonyi-Tóth, Z; Katona, L; Kovács, G; Moldvay, J; Rokszin, G | 1 |
| Cai, RG; Li, Q; Wang, JY; Wang, X; Xu, BH; Xu, XZ; Yin, Y; Yuan, P; Zhang, BL; Zhang, P | 1 |
| Ouahab, A; Shao, C; Shen, Y; Tu, J | 1 |
| Dahlberg, SE; Hoang, T; Johnson, DH; Schiller, JH | 1 |
| Czepas, J; Gwoździński, K; Koceva-Chyła, A; Piasecka-Zelga, J; Pieniążek, A | 1 |
| Ayadi, M; Boussen, H; Chraiet, N; Gligorov, J; Krimi, S; Labidi, S; Lagha, A | 1 |
| Chen, B; Cheng, H; Cheng, L; Li, F; Lu, Z; Qin, Q; Sun, N; Sun, X | 1 |
| Ballardini, P; Borghi, A; Corazza, M; Minghetti, S; Virgili, A | 1 |
| Backes, FJ; Cohn, DE; Copeland, LJ; Eisenhauer, EL; Fowler, JM; McCann, GA; O'Malley, DM; Richardson, DL; Salani, R; Smith, B | 1 |
| Nicolaou, KC; Valiulin, RA | 1 |
| Berger, M; Layman, R; Lustberg, M; Mrozek, E; Olson, E; Poi, MJ; Ramaswamy, B; Shapiro, CL; Wesolowski, R | 1 |
| Akino, H; Aoki, Y; Ishida, H; Ito, H; Kusukawa, N; Ooyama, N; Tanase, K; Yokoyama, O | 1 |
| He, XM; Xiang, H; Yang, HJ; Yu, Y; Zong, XY | 1 |
| Darwiche, K; Freitag, L; Goldberg, EP; Huang, H; Li, Q; Petridis, D; Ritzoulis, C; Spyratos, D; Yarmus, L; Zarogoulidis, K; Zarogoulidis, P | 1 |
| Crawford, J; Dale, DC; Lyman, GH; Tomita, D; Whittaker, S | 1 |
| Goto, S; Kamigaki, T; Saito, M; Yano, K | 1 |
| Chang, J; Hao, XD; Liu, HR; Sun, X; Xie, C; Yu, JM | 1 |
| Tang, N; Tao, L; Wang, Q; Wu, D; Zhang, S; Zhang, Y | 1 |
| Awasthi, N; Hinz, S; Schwarz, AM; Schwarz, MA; Schwarz, RE; Wang, C; Williams, NS; Zhang, C | 1 |
| Kudlowitz, D; Muggia, F | 1 |
| Ramfidis, VS; Saif, MW; Syrigos, KN | 1 |
| Abdel-Naim, AB; Abdel-Rahman, SZ; Al-Abd, AM; Azab, SS; Esmat, A; Khalifa, AE; Mosli, HA; Tolba, MF | 1 |
| Enomoto, T; Fujita, M; Kimura, T; Miyatake, T; Nagamatsu, M; Nishio, Y; Tsutsui, T; Ueda, Y; Yamasaki, M; Yoshino, K | 1 |
| Chansky, K; Edelman, MJ; Franklin, WA; Gandara, DR; Hirsch, FR; Kelly, K; Lara, PN; Mack, PC; Williamson, SK; Wozniak, AJ | 1 |
| Che, CL; Dong, FS; Lu, B; Lv, FZ; Sang, YL; Zhang, HH; Zhang, LJ; Zhang, YM | 1 |
| Atkins, JN; Azar, CA; Biggs, DD; Brufsky, AM; Costantino, JP; Donnellan, PP; Fehrenbacher, L; Geyer, CE; Levine, EA; Mamounas, EP; Northfelt, DW; Paik, S; Polikoff, JA; Provencher, L; Rastogi, P; Robidoux, A; Swain, SM; Tang, G; Wolmark, N; Zapas, JL | 1 |
| DeMichele, A; Farrar, JT; Hennessy, S; Mao, JJ; Sammel, MD; Speck, RM; Stineman, MG | 1 |
| Cataruozolo, PE; Cesari, R; Collier, M; Cortés, J; Curigliano, G; Elias, A; Goldhirsch, A; Huang, X; Kern, KA; Khosravan, R; Pivot, X | 1 |
| Kolek, V | 1 |
| Chang, J; Hao, XD; Hao, YP; Lu, HF; Sun, X; Yu, JM | 2 |
| Lopes, Gde L | 1 |
| Beijnen, JH; Hendrikx, JJ; Rosing, H; Schellens, JH; Schinkel, AH | 1 |
| Stinchcombe, TE | 1 |
| Armesilla, AL; Brown, S; Darling, JL; Jiang, W; Kannappan, V; Kumar, IS; Liu, P; Tang, JZ; Tawari, PE; Wang, W | 1 |
| Chen, WW; Cheng, AL; Hsu, CH; Huang, TC; Lin, CC; Yeh, KH | 1 |
| Bautista, MA; Dudley, A; Gazda, LS; Laramore, MA; Martis, PC; Smith, BH; Vinerean, HV | 1 |
| Al-Sakaff, N; Bell, R; Chang, J; Feng, FY; Heinzmann, D; Jassem, J; Láng, I; Lopez, RI; Semiglazov, V | 1 |
| Chen, L; Feldman, LE; Garnett, A; Herman, LC; Smith, B; Spiotto, MT; Weichselbaum, RR | 1 |
| La Flamme, AC; Miller, JH; Northcote, PT; O'Sullivan, D | 1 |
| Ozdemir, O; Ozdemir, P; Ozhan, MH; Uluer, H; Veral, A | 1 |
| Ahn, SJ; Ban, HJ; Chung, WK; Kim, KS; Kim, YC; Kim, YI; Kwon, YS; Lim, SC; Nam, TK; Oh, IJ; Song, JY; Yoon, MS | 1 |
| Asami, K; Atagi, S; Fujita, Y; Fukuoka, K; Kawahara, M; Kawasaki, M; Komuta, K; Kubota, K; Minato, K; Nogami, N; Ogushi, F; Shibata, K; Tomizawa, Y; Tsuchiya, M; Yamanaka, T; Yonei, T; Yoshioka, H | 1 |
| Chaigneau, L; Chelly, J; Fiteni, F; Limat, S; Meneveau, N; Monnot, T; Montcuquet, P; Nerich, V; Perrin, S; Pivot, X; Villanueva, C; Voidey, A | 1 |
| Elsing, C; Hannig, CV; Herrmann, C; Herrmann, T; Jäger, D; Stremmel, W | 1 |
| Hall, RG; Jean, GW; Shah, S; Sigler, M | 1 |
| Chen, W; Feng, J; Gao, S; Miao, H; Tao, X; Yun, Y; Zhang, F; Zhou, J | 1 |
| Biondo, A; Cassier, PA; Chen, E; de Bono, JS; Minton, S; Molife, LR; Papadopoulos, KP; Patnaik, A; Siu, LL; Sullivan, DM; Tetteh, E; Tolcher, AW; Vitfell-Rasmussen, J; Yan, L; Zernhelt, AM | 1 |
| Antoine, M; Bonnette, P; Cadranel, J; Cazes, A; Duruisseaux, M; Girard, N; Mazieres, J; Monnet, I; Ung, M; Vieira, T; Wislez, M | 1 |
| Aono, T; Deguchi, K; Deguchi, T; Endo, S; Fujitani, K; Fukui, A; Fushimi, H; Higashi, S; Iwase, K; Kawada, J; Matsuda, C; Nishikawa, K; Noguchi, Y; Nomura, M; Okumura, Y; Takagi, M; Tamagawa, H; Tanaka, Y; Yoshida, H | 1 |
| Li, C; Li, X; Liu, N; Qiu, Y; Yao, Z | 1 |
| Chen, G; Chen, L; Chen, YL; Gao, L; Gu, X; Liu, X; Shen, J; Wang, X; Xi, W; Xiong, B; You, Q | 1 |
| Fan, J; Li, H; Li, Y; Ouyang, J; Wang, J; Wu, L; Zhang, Z; Zuo, L | 1 |
| Bloomfield, A; Dorton, R; Guan, J; Leamon, CP; Nelson, M; Reddy, JA; Vetzel, M | 1 |
| Brindley, DN; Chen, X; Hajar, A; Li, S; Parissenti, AM; Vo, T; Wang, H; Wang, Z | 1 |
| Chen, ML; Li, K; Zhang, J; Zhu, ZL | 1 |
| Mooberry, SL; Rohena, CC | 1 |
| Gao, X; Jing, T; Sun, Y; Wang, F; Xu, C; Zhang, C | 1 |
| Barranger, E; Bertheau, P; Bousquet, G; de Bazelaire, C; Ferreira, I; Feugeas, JP; Janin, A; Jourdan, N; Vercellino, L | 1 |
| Christopoulou, A; Emmanouilidis, C; Georgoulias, V; Kalbakis, K; Kalykaki, A; Koinis, F; Papadimitraki, E; Polyzos, A; Samonis, G; Zafeiriou, Z | 1 |
| Chen, X; Gao, G; He, Y; Li, W; Li, X; Ren, S; Zhang, L; Zhou, C; Zhou, F | 1 |
| Furuse, H; Ishii, Y; Kai, F; Nagata, M; Otsuka, A; Ozono, S; Sugiyama, T; Suzuki, T; Takayama, T; Yajima, T | 1 |
| Hoye, TR; Kalscheuer, S; Macosko, CW; Michel, AR; Panyam, J; Wohl, AR | 1 |
| Cai, L; Li, CH; Li, DD; Liu, MY; Liu, W | 1 |
| Balci, S; Cascione, L; Croce, CM; Fassan, M; Gasparini, P; Guler, G; Huebner, K; Irkkan, C; Lovat, F; Morrison, C; Shapiro, CL | 1 |
| Beijnen, JH; de Weger, VA; Schellens, JH | 1 |
| Arce-Lara, C; Kelley, MJ; Santana-Davila, R; Szabo, A; Whittle, J; Williams, CD | 1 |
| Gemma, A; Harada, T; Inoue, A; Ishimoto, O; Kambe, M; Maemondo, M; Minegishi, Y; Miwa, K; Morikawa, N; Nukiwa, T; Sakakibara, T; Sugawara, S; Ube, K; Usui, K; Watanabe, K | 1 |
| Gu, JK; Ma, WX; Wang, H; Wang, TT; Yang, Y | 1 |
| Charalambous, E; Dimopoulos, MA; Dionysopoulos, D; Fountzilas, G; Kotoula, V; Koutras, A; Kouvatseas, G; Papandreou, CN; Papazisis, K; Pectasides, D; Pentheroudakis, G; Samantas, E; Zagouri, F | 1 |
| Muggia, FM | 1 |
| Arun, B; Cohen, L; Lam, CY; Ratcliff, CG; Valero, V | 1 |
| Amant, F; Beijnen, JH; Han, S; Heyns, L; Huitema, ADR; Mhallem Gziri, M; Schellens, JHM; van Calsteren, K; van Hasselt, JGC | 1 |
| Cheng, Y; Cun, Y; Li, M; Li, Z; Peng, Y; Qian, C; Ren, T; Wang, D; Xia, L; Xiong, Y; Zhang, S | 1 |
| de Bruijn, P; Ghobadi Moghaddam-Helmantel, IM; Gibson, AA; Gui, C; Hagenbuch, B; Hu, S; Mathijssen, RH; Nieuweboer, AJ; Sparreboom, A | 1 |
| Beijnen, JH; Hendrikx, JJ; Lagas, JS; Rosing, H; Schellens, JH; Schinkel, AH; Wagenaar, E | 1 |
| Ah Lee, S; Gwe Ahn, S; Jeong, J; Min Lee, H; Woo Lee, H | 1 |
| da Silva Simão, DA; de Paula Lima, ED; Souza, RS; Teixeira, AL | 1 |
| Fujimoto, M; Fujisawa, Y; Kadono, T; Miyagawa, T; Nakamura, Y; Yoshino, K | 1 |
| Lammertsma, AA; van der Veldt, AA | 1 |
| Hamburger, T; Nechushtan, H; Peretz, T; Salmon, AY; Stainberg, H; Vainer, G | 1 |
| Blakely, T; Kvizhinadze, G; Rivalland, G; Webber-Foster, R | 1 |
| Guan, Y; Liu, J; Liu, S; Liu, X; Niu, Y; Wang, L; Wang, Y; Zhang, W | 1 |
| Barcenas, CH; Buchholz, TA; Elting, LS; Giordano, SH; Hortobagyi, GN; Niu, J; Smith, BD; Zhang, N; Zhang, Y | 1 |
| Ding, C; Jia, L; Li, W; Li, Y; You, W; Zhai, B; Zhang, B; Zhi, H | 1 |
| Bahleda, R; Capri, G; Daglish, B; Del Conte, G; Gianni, L; Hospitel, M; Oprea, C; Sessa, C; Soria, JC; Varga, A | 1 |
| Conte, M; Ellingrod, VL; King, AN; O'Malley, M; Ramnath, N | 1 |
| Lin, GN; Liu, DY; Peng, JW; Xia, ZJ; Xiao, JJ | 1 |
| Brana, I; Calles, A; Calvo, E; de Boer, CJ; LoRusso, PM; Puchalski, TA; Seetharam, S; Tabernero, J; Yee, LK; Zhong, B | 1 |
| Cai, KQ; Domanitskaya, N; Egleston, B; Foster, K; Hopper-Borge, E; Jacobs, J; Mahdaviyeh, Y; Malofeeva, E; Paulose, C; Peiffer, E; Wangari-Talbot, J; Zhou, Y | 1 |
| Chan, EC; Chen, KT; Huang, CY; Lan, CC; Lee, CH; Wu, YK; Yang, MC | 1 |
| Feng, Q; Gao, S; He, J; Huang, J; Jiang, Y; Liu, Y; Lyu, X; Mao, Y; Shao, K; Wang, J | 1 |
| Eskander, RN; Tewari, KS | 1 |
| Chakravarty, A; Dorner, A; Ecsedy, JA; Huck, JJ; Hyer, ML; Kannan, K; Kleinfield, R; Manfredi, MG; Mettetal, J; Shinde, V; Shyu, WC; Venkatakrishnan, K; Zhang, M; Zhou, X | 1 |
| Cai, XY; Chen, XX; Guo, GF; He, WZ; Jiang, C; Liao, FX; Qiu, HJ; Rong, YM; Xia, LP; Yang, Q; Yin, CX; Zhang, B | 1 |
| Kingston, DG; Snyder, JP | 1 |
| Arrieta, O; Dorantes-Gallareta, Y; Flores-Estrada, D; Macedo-Pérez, EO; Mendoza-García, VO; Morales-Oyarvide, V | 1 |
| Kulhari, H; Mukherjee, S; Pooja, D; Rachamalla, SS; Singh, MK; Sistla, R | 1 |
| Kaddis, N; Saif, MW | 1 |
| Bai, C; Chen, H; Gao, Z; Han, B; Jin, L; Li, Q; Li, X; Lu, D; Qian, J; Shao, M; Song, X; Wang, J; Wang, S; Wu, J; Zhao, X | 1 |
| Berveiller, P; Mir, O; Selleret, L | 1 |
| Adachi, S; Endo, I; Ichikawa, Y; Ishikawa, T; Kida, K; Narui, K; Sasaki, T; Satake, T; Shimada, K; Shimizu, D; Sugae, S; Tanabe, M; Yamada, A | 1 |
| Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Nagashima, K; Nishikawa, A; Okita, N; Sasaki, Y; Sawada, R; Shimada, Y; Shirakawa, T; Shoji, H; Takahashi, N; Takashima, A; Yamada, Y | 1 |
| Bartlett, JM; Cunningham, CA; Kenicer, J; Lambros, M; Liao, L; Lyttle, N; MacKay, A; Reis-Filho, J; Spears, M; Taylor, KJ; Yao, C | 1 |
| Burt, HM; Jackson, JK; Letchford, K; Leung, D; Wan, CPL | 1 |
| Cho, H; Kim, JH; Kim, S; Kim, SW; Kim, YT; Lee, M; Nam, EJ | 1 |
| Nahta, R; O'Regan, RM; Paplomata, E | 1 |
| Joerger, M | 2 |
| Athanasiadis, A; Boukovinas, I; Christophyllakis, C; Georgoulias, V; Kakolyris, S; Kentepozidis, N; Kouroussis, C; Makrantonakis, P; Malamos, N; Mavroudis, D; Polyzos, A; Saloustros, E; Ziras, N | 1 |
| Bellmunt, J; Choueiri, TK; Di Lorenzo, G; Federico, P; Mullane, S; Necchi, A; Pond, GR; Qu, AQ; Rosenberg, JE; Sonpavde, G | 1 |
| Chenchik, A; Kandel, ES; Makhanov, M; Matveev, V; Zynda, ER | 1 |
| Aliño, SF; Bosó, V; de la Cueva, H; Herrero, MJ; Marqués, MR; Megias, JE; Montalar, J; Palomar, L; Poveda, JL; Rojas, L; Santaballa, A | 1 |
| Burger, RA; Chase, DM; Foss, CD; Huang, H; Monk, BJ; Wenzel, LB | 1 |
| Liang, H; Liu, E; Pan, F; Qin, H; Ruan, Z; Zhang, K | 1 |
| Annede, P; Bauduceau, O; Bosacki, C; Ceccaldi, B; Chargari, C; Dulou, R; Falk, AT; Ferrand, FR; Guy, JB; Helissey, C; Jacob, J; Langrand-Escure, J; Le Moulec, S; Magné, N; Mbagui, R; Mery, B; Vedrine, L | 1 |
| Cao, C; Dong, WL; Tian, Y; Wang, XF; Yang, L; Zhang, XY; Zhang, ZQ; Zheng, LY | 1 |
| Dent, S; Earle, C; Eisen, A; Enright, K; Ghannam, M; Grunfeld, E; Kaizer, L; Krzyzanowska, MK; Moineddin, R; Trudeau, M; Yun, L | 1 |
| Izzo, C | 1 |
| Adkins, DR; Diaz, J; Gay, H; Lewis, J; Ley, J; Michel, L; Nussenbaum, B; Paniello, RC; Rich, J; Schell, A; Thorstad, W; Trinkaus, K; Wildes, TM; Wu, N | 1 |
| Bai, X; Gou, X; Hou, X; Huang, M; Jin, J; Li, D; Liu, B; Zhong, G | 1 |
| Bria, E; Brunelli, M; Carbognin, L; Giannarelli, D; Nortilli, R; Pellini, F; Pollini, GP; Sperduti, I; Tortora, G; Vicentini, C | 1 |
| Babacan, NA; Deveci, K; Kacan, T; Sancakdar, E; Seker, A; Seker, MM; Turesin, AK; Yilmaz, A | 1 |
| Liu, D; Qian, J; Su, B; Xu, W; Zhang, J; Zhang, ZW; Zheng, H | 1 |
| Belum, VR; Capriotti, JA; Capriotti, K; Goldfarb, S; Lacouture, ME; Lessin, S; Wu, S | 1 |
| Aksoy, S; Altundag, K; Berk, V; Karaca, H; Ozdemir, N; Ozkan, M; Ozturk, B; Sendur, MA; Yazici, O; Yazilitas, D; Zengin, N | 1 |
| Aoi, J; Fukushima, S; Ihn, H; Jinnin, M; Kajihara, I; Kanemaru, H; Masuguchi, S; Miyake, T | 1 |
| Ageshio, F; Kagawa, H; Kimura, H; Matsui, H; Mori, M; Niinaka, M; Satomi, A; Uenami, T; Yamaguchi, T; Yano, Y; Yokota, S; Yoneda, T | 1 |
| Bai, C; Cao, S; Chen, H; Chen, J; Dai, J; Han, B; Hu, Z; Jin, G; Li, Q; Lu, D; Ma, H; Shen, H; Shu, Y; Song, X; Sun, C; Tang, S; Wang, C; Wang, S; Wu, J; Xu, L; Yin, R | 1 |
| Doki, Y; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M | 1 |
| Andre, F; Arnould, L; Beuzeboc, P; Coeffic, D; Ferrero, JM; Lortholary, A; Spano, JP | 1 |
| Jamil, K; Jayaraman, A; Subhani, S | 1 |
| Hasebe, T; Hirokawa, E; Kuji, I; Matsuura, K; Osaki, A; Saeki, T; Shigekawa, T; Shimada, H; Sugitani, I; Sugiyama, M; Takahashi, T; Takeuchi, H; Ueda, S; Yamane, T | 1 |
| Abesada-Terk, G; Alemany, C; Brown, RH; Cartwright, TH; Faig, D; Fulp, WJ; Jacobsen, PB; Kim, GP; Lee, JH; Levine, RM; Malafa, M; Markham, MJ; Schreiber, F; Sharp, PV; Tanvetyanon, T | 1 |
| Churchill, CD; Klobukowski, M; Tuszynski, JA | 1 |
| Deng, J; Deng, JH; Niu, PG; Ouyang, XN; Shi, DH | 1 |
| Ayoub, AT; Banerjee, A; Cass, CE; Churchill, CD; Damaraju, S; Klobukowski, M; Ludueña, RF; St George, M; Tuszynski, JA; Winter, P | 1 |
| De Brabander, JK; Gellert, G; Krauth, M; Meyer, CJ; Miller, JH; Northcote, PT; Shay, JW; Wick, MJ | 1 |
| Davidson, NE; Ligibel, JA; Martino, S; Perez, EA; Saphner, T; Sledge, GW; Sparano, JA; Wolff, AC; Wood, WC; Zhao, F | 1 |
| Fujiwara, K; Hasegawa, T; Hasumi, Y; Kigawa, J; Matsumoto, T; Nagao, S; Nakamura, K; Nishio, S; Okada, S; Otsuki, T; Shimada, M; Suzuki, M; Takano, M; Takei, Y; Takekuma, M; Tanabe, H | 1 |
| Antolín-Novoa, S; Antón, A; Blanco-Campanario, E; de la Cruz-Merino, L; Galán-Brotons, A; Gallegos-Sancho, MI; Murías-Rosales, A; Peláez, I; Pérez-Carrión, R | 1 |
| Al-Massarani, G; Alammar, M; Banat, I; Najjar, F | 1 |
| de Bruijn, P; de Graan, AJ; de Jonge, E; Mathijssen, RH; Sparreboom, A; van der Holt, B; van Schaik, RH; Verweij, J; Wiemer, EA | 1 |
| Logie, J; McLaughlin, CK; Shoichet, MS; Tam, RY | 1 |
| Bartoń, S; Biernacka, B; Krawczyk, P; Małecka-Massalska, T; Milanowski, J; Mlak, R; Powrózek, T | 1 |
| Gomez, D; Komaki, R; Lee, MS; Levy, LB; Liao, Z; Lu, C; Tang, C; Zhuang, Y | 1 |
| Behera, M; Belani, CP; Chen, Z; Khuri, FR; Kim, S; Owonikoko, TK; Pillai, RN; Ramalingam, SS; Saba, NF; Steuer, C | 1 |
| Skoropad, VY | 1 |
| Albers, P; Bellmunt, J; Buonerba, C; Choueiri, TK; Di Lorenzo, G; Kitamura, H; Kume, H; Lee, JL; Matsumoto, K; Mullane, S; Necchi, A; Niegisch, G; Pond, GR; Rozzi, A; Sonpavde, G | 1 |
| De Laurentiis, M; Mustacchi, G | 1 |
| Ban, X; Guan, XY; Li, L; Li, XD; Li, Y; Xie, D; Yang, H; Yun, J; Zeng, TT; Zhang, BZ; Zhou, Y | 1 |
| Rexer, H | 1 |
| Ball, DW; Busaidy, NL; Byrd, D; Callender, G; Dickson, P; Duh, QY; Ehya, H; Haddad, RI; Haymart, M; Hoffmann, KG; Hoh, C; Hughes, M; Hunt, JP; Iagaru, A; Kandeel, F; Kopp, P; Lamonica, DM; Lydiatt, WM; McCaffrey, JC; Moley, JF; Parks, L; Raeburn, CD; Ridge, JA; Ringel, MD; Scheri, RP; Shah, JP; Smallridge, RC; Sturgeon, C; Wang, TN; Wirth, LJ | 1 |
| Bradley, WH; Eng, KH; Hanlon, BM; Szender, JB | 1 |
| Arya, S; Bhattacharjee, A; D'Cruz, A; Dhumal, S; Joshi, A; Juvekar, S; Kane, S; Muddu, V; Noronha, V; Patil, VM; Prabhash, K | 1 |
| Hao, X; Li, C; Su, W; Zhang, J; Zhang, S | 1 |
| Aggarwal, C; Bauml, J; Brady, AK; Cohen, RB; Evans, TL; Judy, B; Langer, C; McNeill, JD; Vachani, A | 1 |
| Bosenberg, MW; Held, MA; Iyidogan, P; Langdon, CG; Levy, F; Mamillapalli, R; Platt, JT; Stern, DF; Theodosakis, N; Vuagniaux, G; Wang, S; Wiedemann, N | 1 |
| Chang, YJ; Cheng, WL; Huang, CY; Hung, CS; Tu, CC; Uyanga, B; Wei, PL | 1 |
| Bai, Y; Chen, M; Hu, Y; Li, H; Li, J; Li, Q; Li, T; Lu, B; Lu, Y; Ma, Z; Ouyang, W; Su, S; Wang, X; Wang, Y | 1 |
| Brewer, JR; Dolan, ME; Fleming, GF; Morrison, G | 1 |
| Boven, E; Frederiks, CN; Guchelaar, HJ; Lam, SW | 1 |
| Ahn, SJ; Ban, HJ; Chung, WK; Jeong, JU; Kim, KS; Kim, YC; Kim, YH; Nam, TK; Oh, IJ; Song, JY; Yoon, MS | 1 |
| Hara, F; Hozumi, Y; Imoto, S; Matsubara, N; Mukai, H; Nishimura, R; Ohashi, Y; Park, Y; Sagara, Y; Saito, T; Shimozuma, K; Takano, T; Takashima, T; Toyama, T; Tsurutani, J; Watanabe, T | 1 |
| Lee, S; Lichtenthal, B; Ojima, I; Wang, C; Wang, X | 1 |
| Fushida, S; Harada, S; Hayashi, H; Kinoshita, J; Makino, I; Miyanaga, S; Miyashita, T; Nakagawara, H; Nakamura, K; Nakanuma, S; Ninomiya, I; Ohta, T; Okamoto, K; Oyama, K; Sakai, S; Tajima, H; Takamura, H; Tsukada, T | 1 |
| Feng, S; Liu, L; Ma, W; Xie, Y; Yao, X; Yuan, Z | 1 |
| Berlin, ST; Caiado, J; Campos, SM; Castells, MC; Galvão, VR; Giavina-Bianchi, P; Matulonis, UA; Picard, M; Pur, L | 1 |
| Gridelli, C; Sacco, PC | 1 |
| Aliustaoglu, M; Aydin, D; Ercelep, O; Gemici, C; Gumus, M; Isik, D; Korkmaz, T; Mayadagli, A; Mert, AG; Odabas, H; Ozcelik, M; Ozdemir, P; Seker, M; Surmeli, H; Yuksel, S | 1 |
| Benepal, T; Cadranel, J; Christoph, DC; Das, M; Fennell, DA; Ferry, D; Lal, R; Maxwell, F; Summers, Y; Visseren-Grul, C | 1 |
| Audigier-Valette, C; Auliac, JB; Baize, N; Bérard, H; Bota, S; Chouaïd, C; Corre, R; Dansin, E; Daurès, JP; Decroisette, C; Descourt, R; Dujon, C; Falchero, L; Greillier, L; Lamy, R; Le Caër, H; Léna, H; Marcq, M; Massuti, B; Monnet, I; Pérol, M; Plassot, C; Vergnenègre, A | 1 |
| Chen, XX; Gao, F; Qu, XX; Tian, XC; Wang, D; Wen, G; Zhou, XL | 1 |
| Qin, RQ; Wang, WP; Wen, YS; Xi, KX; Yu, XY; Zhang, LJ | 1 |
| Hou, W; Lin, HS; Liu, J; Wang, XQ | 1 |
| Ji, ZH; Li, Y; Peng, KW; Sun, JH; Wu, HT; Yonemura, Y; Zhang, Q | 1 |
| Cho, S; Han, J; Jin, Z; Ko, SY; Nguyen, VD; Park, JO; Park, S; Zheng, S | 1 |
| Cantürk, F; Güvenç, M; Özdamar, S; Sariözkan, S; Türk, G; Yay, AH; Yüce, A | 1 |
| Chikamatsu, S; Imai, H; Ishioka, C; Kasahara, Y; Kobayashi, A; Komine, K; Oishi, T; Okada, Y; Okita, A; Saijo, K; Shimodaira, H; Shirota, H; Takahashi, M; Takahashi, S | 1 |
| Choi, AR; Kim, HS; Kim, JH; Woo, YH; Yoon, S | 1 |
| Alpert, Y; Bruchim, I; Fishman, A; Piura, E; Sade, D; Weeg, N | 1 |
| Alvarez, RD; Becker, DA; Bevis, KS; Boone, JD; Gilbert, AL; Huh, WK; Leath, CA; Straughn, JM; Thomas, ED | 1 |
| Ameri, A; Khoshbakht Ahmadi, H; Mortazavi, N; Novin, K | 1 |
| Chi, DS; Gardner, GJ; Long Roche, K; Mueller, JJ; O'Cearbhaill, RE; Schlappe, BA; Sonoda, Y; Zivanovic, O | 1 |
| Chung, HY; Kang, BW; Kim, JG; Kwon, OK; Yu, W | 1 |
| Pugliano, L; Ryan, C; Tsoi, D; White, M; Woodward, N | 1 |
| Cui, S; Hu, X; Liao, N; Liu, D; Luo, R; Sun, Q; Wang, X; Xu, B; Yu, S; Zhang, Q; Zheng, H | 1 |
| Chaudhari, AMW; Loprinzi, CL; Lustberg, MB; Monfort, SM; Pan, X; Patrick, R; Singaravelu, J | 1 |
| Apolo, AB; De Santis, M; Galsky, MD; Leibovich, BC; Milowsky, MI; Pham, MN; Pisters, LL; Siefker-Radtke, AO; Sonpavde, G; Steinberg, GD; Sternberg, CN; Tagawa, ST; Weizer, AZ; Woods, ME | 1 |
| Arabshahi, HJ; Błauż, A; Hartinger, CG; Plażuk, D; Reynisson, J; Rychlik, B; Wieczorek, A; Żal, A | 1 |
| Gill, HS; Mody, MD; Saba, NF | 1 |
| Lu, M; Wang, J; Wang, T | 1 |
| Fujiwara, Y; Hashimoto, J; Hirakawa, A; Kodaira, M; Koizumi, F; Komori, O; Nakatochi, M; Okuma, HS; Shimizu, C; Tamura, K; Yamamoto, H; Yonemori, K; Yunokawa, M | 1 |
| Adam, JP; Gauthier, P; Letarte, N | 1 |
| Chekerov, R; Darvin, ME; Eucker, J; Fuss, H; Jung, S; Kühnhardt, D; Lademann, J; Lee, BN; Patzelt, A; Sehouli, J; Yu, RX | 1 |
| Beijnen, JH; Nuijen, B; Sawicki, E; Schellens, JH | 1 |
| Kamimura, K; Matsumoto, Y; Moriyama, M; Saijo, Y; Zhou, Q | 1 |
| Arbea, L; Cano, D; Ceniceros, L; Chopitea, A; Diaz-Gonzalez, JA; Hernandez, JL; Iragorri, Y; Legaspi, J; Martin-Romano, P; Martínez-Regueira, F; Ponz-Sarvise, M; Rodríguez, J; Sola, JJ; Subtil, JC | 1 |
| Andre, V; Enas, N; Gueorguieva, I; Ribba, B; Tate, SC | 1 |
| Belum, VR; Dalenc, F; Deslandres, M; Eche, A; Gladieff, L; Lacouture, ME; Lebœuf, NR; Montastruc, M; Roche, H; Sibaud, V; Vigarios, E | 1 |
| Liu, CC; Lu, Y; Tang, H; Wang, H; Zhu, J | 1 |
| Capelan, M; Lote, H; Mohammed, K; Papadimitraki, E; Redana, S; Ring, A; Sharp, A | 1 |
| Gao, JJ; Pohlmann, PR; Swain, SM; Tan, M | 1 |
| Altundag, K; Barnadas, A; Botha, M; Chan, A; Cinieri, S; Coskun, U; Dodyk, P; Lazzarelli, S; Rauch, D; Tubiana-Mathieu, N; Vandebroek, A; Villanova, G | 1 |
| Fujiwara, Y; Goto, K; Horinouchi, H; Hozumi, H; Kanda, S; Kitazono, S; Kubo, E; Mizugaki, H; Nokihara, H; Shiraishi, H; Sunami, K; Tamura, T; Tanaka, A; Utsumi, H; Yamamoto, N | 1 |
| Cheng, SY; Du, J; Li, J; Li, KC | 1 |
| Gao, B; Guo, LJ; Hao, S; Jiang, Y; Luo, DL; Tian, WG; Zhang, S; Zhang, XH | 1 |
| Cesana, P; Conen, K; Gotta, V; Hammann, F; Medinger, M; Rochlitz, C; Taegtmeyer, AB | 1 |
| Abesamis-Tiambeng, ML; Akewanlop, C; Baczkowski, M; Baramidze, K; Barve, A; Bondarenko, I; Hernandez-Bronchud, M; Herson, J; Kothekar, M; Loganathan, S; Mamillapalli, G; Manikhas, A; Mukhametshina, G; Nemsadze, G; Parra, JD; Pennella, E; Ray, S; Rugo, HS; Sharma, R; Sriuranpong, V; Vynnychenko, I; Waller, CF; Yanez Ruiz, EP; Yuan, J | 1 |
| An, N; Cai, J; Li, Q; Li, Z; Niu, H; Zhang, Y; Zhao, Q | 1 |
| Chang, CL; Chen, JH; Chen, TM; Lai, MT; Lee, FP; Lin, KC; Wu, CC; Wu, SY; Yen, YC; Yuan, KS | 1 |
| Gajra, A | 1 |
| Argenziano, M; Battaglia, A; Bosco, O; Catalano, MG; Cavalli, R; D'Amelio, P; Fortunati, N; Frairia, R; Gontero, P; Marano, F; Peluso, R; Rinella, L; Sassi, F | 1 |
| Adkins, D; Daly, K; Ley, J; Oppelt, P; Wildes, TM | 1 |
| Aldonza, MB; Hong, JY; Lee, SK | 1 |
| Geshi, M; Matoba, S; Nagai, T; Parnpai, R; Pitchayapipatkul, J; Somfai, T; Vongpralub, T | 1 |
| Chuang, JC; Das, M; Diehn, M; Huang, J; Liang, Y; Neal, JW; Stehr, H; Wakelee, HA | 1 |
| Cheng, Y; Ding, X; Jia, X; Jiang, J; Li, Y; Sharma, A; Wang, G; Xie, G | 1 |
| Bajorin, DF; Bellmunt, J; Choueiri, TK; Climent, MA; Culine, S; de Wit, R; Fong, L; Fradet, Y; Gerritsen, W; Gurney, H; Lee, JL; Mai, Y; Necchi, A; Perini, RF; Petrylak, DP; Poehlein, CH; Quinn, DI; Sternberg, CN; Vaughn, DJ; Vogelzang, NJ | 1 |
| Chung, HC; Gho, SG; Kim, GM; Kim, SI; Paik, S; Park, HS; Park, S; Sohn, J | 1 |
| de Boer, M; Dercksen, MW; Joore, MA; Lobbezoo, DJA; Peters, FPJ; Peters, NAJB; Ramaekers, BLT; Smilde, TJ; Tjan-Heijnen, VCG; van de Wouw, AJ; van den Berkmortel, F; van Kampen, RJW; van Riel, JMG | 1 |
| Bai, S; Burnett, JP; Li, Y; Lim, G; Lim, R; McDermott, SP; Paholak, HJ; Shah, RB; Sun, D; Sun, L; Tsume, Y; Wicha, MS; Zhang, T | 1 |
| Bou-Dargham, MJ; Liu, JS; Lively, T; Lung, PY; Sang, QA; Sheffield, C; Tan, W; Yu, K; Zhang, J | 1 |
| Takahari, D | 1 |
| Christensen, IJ; Ekmann-Gade, AW; Hansen, A; Høgdall, C; Høgdall, E; Jensen, PB; Jensen, T; Karlsen, MA; Knudsen, S; Mirza, MR; Nedergaard, L; Novotny, GW; Prahm, KP | 1 |
| Ahn, JS; Awada, A; Cortés, J; Diéras, V; Gómez-Pardo, P; Hannah, AL; Hoch, U; Im, SA; Mailliez, A; Moreno-Aspitia, A; O'Shaughnessy, J; Perez, EA; Potter, DA; Rugo, HS; Schwartzberg, LS; Tagliaferri, M; Twelves, C; Yardley, DA; Zhao, C | 1 |
| Duran, GE; Francisco, EB; Moisan, F; Sikic, BI; Wang, YC | 1 |
| Bharadwaj, G; Lam, KS; Li, X; Li, Y; Macarenco, AC; Narayanan, A; Nhan, V; Shi, Y; Vieira, LS; Xiao, W; Yang, D; Yang, S | 1 |
| Akita, T; Kiuchi, Y; Kogo, M; Kurihara, T; Nakajima, H; Nakamura, S; Shikama, Y; Sunaga, T; Tobe, T; Yoneyama, K | 1 |
| Freedman, RA; Gross, C; Haddad, TC; Hashmi, SK; Herrin, J; Jemal, A; Mougalian, S; Ruddy, KJ; Sangaralingham, LR; Shah, N; Thompson, CA; Van Houten, HK | 1 |
| Mahdi, H; Maurer, K; Michener, C; Rose, PG | 1 |
| Hoshino, A; Kawada, K; Kawano, T; Nakajima, Y; Okada, T; Tokairin, Y | 1 |
| Damhuis, RA; den Bakker, MA; Derks, JL; Dingemans, AC; Groen, HJ; Smit, EF; Speel, EM; Thunnissen, E; van den Broek, EC; van Suylen, RJ | 1 |
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Allende, D; Fadare, O; Forscher, C; Roma, AA; Rutgers, JK | 1 |
| Czepas, J; Gwozdzinski, K; Kilanczyk, E; Koceva-Chyla, A; Piasecka-Zelga, J; Tabaczar, S | 1 |
| Andriguetti, NB; Antunes, MV; Linden, R; Perassolo, MS; Raymundo, S; Suyenaga, ES; Verza, SG | 1 |
| Amital, H; Bragazzi, N; Grysman, Luigi; Mahagna, H; Watad, A | 1 |
| Al, MJ; Armstrong, N; Blommestein, HM; Büyükkaramikli, NC; Clay, FJ; Kleijnen, J; Riemsma, R; Ross, J; Severens, J; Worthy, G | 1 |
| Carey, LA; Dusetzina, SB; Hinton, SP; Meng, K; Meyer, AM; Reeder-Hayes, KE | 1 |
| Burugu, S; Chen, B; Gao, D; Gelmon, KA; Kos, Z; Leung, S; Liu, S; Nielsen, TO; Parulekar, WR; Shepherd, L; Virk, S | 1 |
| Moeller, M; Moore, HCF; Mustafa Ali, M; Rybicki, L | 1 |
| Lan, R; Lu, F; Wang, Q | 1 |
| Chen, S; Chen, Y; Hu, Y; Jiao, S; Li, J; Yan, X; Zhang, G; Zhang, Y | 1 |
| Binder, PS; Cusworth, S; Divine, LM; Hagemann, AR; Kuroki, LM; Massad, LS; McCourt, CK; Mutch, DG; Powell, MA; Thaker, PH; Zhao, P | 1 |
| DeLuca, AN; Esserman, LJ; Melisko, ME; Rice, BA; Rugo, HS; Ver Hoeve, ES | 1 |
| Bignon, L; Caron, O; Faivre, L; Fricker, JP; Gesta, P; Gladieff, L; Hamimi, A; Lasset, C; Lortholary, A; Mari, V; Mouret-Fourme, E; Nogues, C; Petit, T; Stoppa-Lyonnet, D; Velten, M | 1 |
| Picard, M | 1 |
| Goto, A; Horita, N; Ito, K; Kaneko, T; Nagashima, A; Nakashima, K; Shibata, Y; Yamanaka, T | 1 |
| Freedman, RA; Gross, CP; Haddad, TC; Jemal, A; Keegan, THM; Leal, AD; Loprinzi, CL; Mougalian, SS; Mutter, RW; Neuman, HB; Ruddy, KJ; Sangaralingham, L; Shah, N; Van Houten, H | 1 |
| Boggiani, D; Musolino, A; Palli, D; Pellegrino, B; Tommasi, C | 1 |
| Higashida, M; Hirai, T; Kubota, H; Matsumoto, H; Miyake, S; Ogo, A; Teramoto, F | 1 |
| Li, SY; Lin, XQ; Liu, YQ; Ouyang, M; Qin, YY; Xie, ZH; Zhang, DH; Zhang, JX; Zhou, CZ | 1 |
| Chiu, L; Chiu, N; Chow, E; Chow, R; DeAngelis, C; Drost, L; Ganesh, V; Lao, N; Lee, J; Wan, BA; Zhang, L | 1 |
| Kamal, MM; Nazzal, S | 1 |
| Leandersson, K; Mehmeti, M; Millrud, CR | 1 |
| Chen, C; Chen, Y; Jiang, X; Li, S; Shi, F; Wang, X; Xiong, H; Yan, T; Zhang, W; Zhu, Y | 1 |
| Albain, KS; Crew, KD; Fehrenbacher, L; Fisch, MJ; Greenlee, H; Hershman, DL; Lew, DL; Lynn Henry, N; Minasian, LM; Moinpour, CM; Till, C; Unger, JM; Wade, JL; Wong, SF | 1 |
| Hu, Q; Xie, B; Xu, Z; Zhang, W; Zhang, X; Zheng, J; Zhou, J | 1 |
| Borel, C; Burgy, M; Leblanc, J | 1 |
| Belum, VR; Blinder, VS; Goldfarb, SB; Gucalp, A; Kamboj, M; Lacouture, ME; Virgen, CA | 1 |
| Jing, Y; Ojima, I; Wang, C; Wang, X | 1 |
| Chen, SJ; Li, ZH; Wei-Cai, - | 1 |
| Bernöster, K; Häder, T; Herbener, P; Schönfeld, K; Schüttrumpf, J; Uherek, C; Zuber, C | 1 |
| Boon, U; Huijbers, IJ; Jonkers, J; Linder, S; Maia, ARR; Medema, RH; Pritchard, CEJ; Song, JY; Vaarting, C; van Tellingen, O; Velds, A | 1 |
| Becker, DA; Bevis, KS; Leath, CA; Smith, BQ; Walters-Haygood, CL | 1 |
| Iguchi, T; Kato, M; Kuratsukuri, K; Nakatani, T; Nishihara, C; Takeyama, Y; Tamada, S; Yamasaki, T | 1 |
| Bang, SM; Choi, IS; Choi, M; Kang, B; Kim, JH; Kim, JW; Kim, SH; Kim, YJ; Lee, JH; Lee, JO; Lee, JS; Lee, JY; Lee, KW; Suh, KJ | 1 |
| Bloomfield, A; Dircksen, C; Dorton, R; Kleindl, P; Leamon, CP; Nelson, M; Reddy, JA; Santhapuram, H; Vetzel, M; Vlahov, IR | 1 |
| Li, W; Ma, H; Xu, K; Yang, L; Yuan, L | 1 |
| Arakawa, A; Asai-Sato, M; Hongo, A; Inokuchi, Y; Kamiura, S; Kato, K; Komiyama, S; Matsumoto, T; Sugiyama, T; Tabata, T; Takano, H; Takeshima, N | 1 |
| Bongiorno, C; Dahm, P; Gartlehner, G; Hwang, EC; Jung, JH; Kahlmeyer, A; Kunath, F; Narayan, V; Patel, N; Risk, MC; Skoetz, N | 1 |
| Clemons, M; Fergusson, D; Hilton, J; Hutton, B; Mazzarello, S; Stober, C; Vandermeer, L | 1 |
| Auduteau, L; Boughanem, C; Caudron, E; Jaccoulet, E; Prognon, P | 1 |
| Hayashi, N; Kitani, A; Kuwayama, T; Nakamura, S; Okuyama, H; Sato, T; Takano, T; Tsugawa, K; Yamauchi, H | 1 |
| Choi, HG; Hong, SS; Kim, JH; Kim, JK; Kim, JO; Kim, SY; Lim, SJ; Thapa, RK | 1 |
| Bandapalli, OR; Campo, C; da Silva Filho, MI; Försti, A; Goldschmidt, H; Hemminki, K; Mahmoudpour, SH; Merz, M | 1 |
| Wu, HL | 1 |
| Chen, N; He, M; Li, F; Li, Y; Liao, J; Pai, MP; Palmisano, M; Sun, D; Yu, A; Yuan, H; Zhang, H; Zhou, S | 1 |
| Bavbek, S; Bonadonna, P; Caralli, M; Castells, M; Cernadas, J; Cortellini, G; Costantino, MT; Dursun, AB; Gelincik, A; Lucchini, G; Pagani, M | 1 |
| Aksoy, S; Aktas, BY; Alacacioglu, A; Aliyev, A; Artac, M; Basaran, G; Beypinar, I; Bilen, E; Bilici, A; Cabuk, D; Cetin, B; Cicin, I; Cil, T; Degirmencioglu, S; Demir, A; Demir, H; Demirci, U; Er, O; Erdur, E; Eren, T; Erturk, I; Esin, E; Evrensel, T; Gumusay, O; Haksoyler, V; Harputluoglu, H; Imamoglu, I; Kaplan, MA; Karaagac, M; Karadurmus, N; Kocer, M; Korkmaz, T; Kostek, O; Oksuzoglu, B; Olgun, P; Oyan, B; Ozdemir, O; Paydas, S; Pilanci, KN; Sakalar, T; Sakin, A; Seker, M; Sumbul, AT; Tanrikulu, E; Urun, Y; Yetisir, E; Yildirim, N; Yilmaz, H; Yumuk, PF | 1 |
| Begier-Krasińska, B; Książek, K; Mikuła-Pietrasik, J; Niklas, A; Pakuła, M; Tykarski, A; Uruski, P; Witucka, A | 1 |
| Albrecht, TL; Beebe-Dimmer, JL; Greenwald, MK; Ruterbusch, JJ; Schwartz, AG; Simon, MS | 1 |
| Bengala, C; Bisagni, G; Brandes, AA; Cagossi, K; Gianni, L; Gori, S; Iannacone, C; Montemurro, F; Morandi, P; Stell, A; Zamagni, C; Zambetti, M | 1 |
| Gong, Y; Hao, S; Jiang, YZ; Jin, X; Ren, YX; Shao, ZM; Ye, FG | 1 |
| Antonuzzo, L; Aprile, G; Avallone, A; Bordonaro, R; Cinieri, S; Di Donato, S; Fanotto, V; Fornaro, L; Gerratana, L; Giampieri, R; Leone, F; Melisi, D; Nichetti, F; Pellegrino, A; Rimassa, L; Rosati, G; Santini, D; Scartozzi, M; Silvestris, N; Stragliotto, S; Tomasello, G; Vasile, E | 1 |
| Daido, W; Funaishi, K; Hattori, N; Kawamoto, K; Matsumoto, N; Matsumoto, Y; Ohashi, N; Taniwaki, M; Yamasaki, M | 1 |
| Cao, S; Han, B; Teng, J; Xu, J; Zhong, H | 1 |
| Chen, QY; Guo, L; Guo, SS; Li, XY; Liang, YJ; Lin, C; Lin, HX; Liu, LT; Liu, SL; Mai, HQ; Sun, XS; Tang, LQ; Tang, QN; Wen, YF; Xie, HJ; Yan, JJ; Yang, ZC | 1 |
| Fukuda, Y; Harada, T; Koga, S; Mukae, H; Ogawara, D; Okuno, D; Soda, H; Taniguchi, H; Tomono, H; Umemura, A; Yamaguchi, H; Yoshida, M | 1 |
| Blumenschein, GR; Garden, AS; Ginsberg, LE; Glisson, BS; Gold, KA; Haddad, RI; Hutcheson, K; Johnson, FM; Kies, MS; Lee, JJ; Lewis, J; Lin, HY; Massarelli, E; Myers, J; Papadimitrakopoulou, V; Pharaon, RR; Pickering, C; Rabinowits, G; Tishler, RB; William, WN; Williams, MD | 1 |
| Killock, D | 1 |
| Ajani, JA; de Haas, SL; Harle-Yge, ML; Hoersch, S; Kang, YK; Ohtsu, A; Shah, MA; Thuss-Patience, PC; Van Cutsem, E | 1 |
| Kim, S; Kim, SW; Kim, YT; Lee, J; Li, LY; Nam, EJ | 1 |
| Altshuler, D; Castro, MG; Doherty, R; Edwards, M; Kadiyala, P; Kamran, N; Kuai, R; Li, D; Lowenstein, PR; Moon, JJ; Nuñez, FM; Schwendeman, A; Yu, M | 1 |
| Agapito, G; Altomare, E; Arbitrio, M; Arpino, G; Cannataro, M; Caracciolo, D; Di Martino, MT; Fabiani, F; Galeano, T; Grillone, F; Iuliano, E; Santini, D; Scionti, F; Staropoli, N; Tagliaferri, P; Tassone, P | 1 |
| Goodwin, A; O'Connell, DL; Wilcken, N; Willson, ML; Zaheed, M | 1 |
| Bauer, TM; Faessel, H; Faller, DV; Harvey, RD; Lockhart, AC; Nemunaitis, J; Sedarati, F; Venkatakrishnan, K; Zhou, X | 1 |
| Albert-Marí, A; Climente-Martí, M; Jiménez-Torres, NV; Martínez-Gómez, MA; Sendra-García, A | 1 |
| Chon, HJ; Chung, HC; Jung, M; Kang, B; Kim, C; Kim, HS; Kim, JH; Nam, CM; Rha, SY | 1 |
| Beith, J; De Boer, RH; Redfern, A; Truman, M; White, M; Woodward, N; Young, J | 1 |
| Chi, KN; Eigl, BJ; Forbes, C; Parimi, S; Tsang, ES | 1 |
| Bajorin, DF; Bellmunt, J; Choueiri, TK; Climent, MA; Culine, S; de Wit, R; Fong, L; Fradet, Y; Frenkl, TL; Gerritsen, W; Gurney, H; Lee, JL; Nam, K; Necchi, A; Perini, RF; Petrylak, DP; Quinn, DI; Sternberg, CN; Vaughn, DJ; Vogelzang, NJ | 1 |
| Savitsky, K; Yu, X | 1 |
| De Grève, J; Decoster, L; Fontaine, C; Joris, S; Schallier, D; Vanacker, L | 1 |
| Anders, CK; Basch, E; Carey, LA; Choi, SK; Deal, AM; Dees, EC; Jolly, TA; Karuturi, MS; Kimmick, GG; Lee, JT; Muss, HB; Nyrop, KA; Reeder-Hayes, KE; Reeve, BB; Reinbolt, RE; Shachar, SS; Speca, JC; Wood, WA | 1 |
| Alshreef, A; Chalkidou, K; Culyer, AJ; Dawkins, B; Dixon, S; Edoka, I; MacQuilkan, K; Meads, D; Riddin, J; Ruiz, F; Taylor, M; Ward, S | 1 |
| Fang, WS; Gago, F; Mills, A; Wang, TE; Zhao, Y | 1 |
| Hua, YM; Huang, KL; Huang, TW; Lin, KY; Loh, EW; Su, HC; Tam, KW | 1 |
| Futsuhara, K; Hata, S; Inoue, K; Kimizuka, K; Kojima, M; Kuroda, T; Nagai, SE; Saito, T; Sakurai, T; Yamada, H; Yamazaki, Y | 1 |
| Amin, M; Bakos, K; Ben Abdallah, A; Frey, K; Haroutounian, S; Hincker, A; Kagan, L; Karlsson, P; Kosicka, K; Rao, L; Shah, R; Tan, B; Wagner-Johnston, N; Wildes, T | 1 |
| Aoki, D; Iwamori, M; Kiguchi, K; Mikami, M; Tanaka, K | 1 |
| Alp, D; Benovic, JL; Jacinto, AZ; Lagman, J; Lee, CS; Peng, N; Sayegh, P; So, CH; Sok, V; Sulon, SM | 1 |
| Cai, S; Cai, Y; Cheng, X; Dai, Z; Jia, H; Jiang, R; Luan, Y; Pu, H; Shi, T; Tang, J; Tu, D; Tu, R; Wang, H; Yang, H; Zang, R; Zhang, Y | 1 |
| Chworos, A; Janaszewska, A; Klajnert-Maculewicz, B; Marcinkowska, M; Sobierajska, E; Stanczyk, M | 1 |
| Anazodo, A; Dickinson, JE; Li, Z; Lui, K; Safi, N; Sullivan, EA; Wang, AY | 1 |
| Brunken, L; Hassan, N; Jackson, J; Mellor, C; Mitchell, E; Ng'andu, K; O'Brien, A; Paus, R; Purba, TS; Shahmalak, A; Smart, E | 1 |
| Chan, YN; Chen, CY; Jheng, YW; Lin, MW; Wang, PJ; Wang, YJ | 1 |
| Ben Kridis, W; Khanfir, A | 2 |
| Bland, KA; Bovard, J; Campbell, KL; Davis, MK; Gelmon, KA; Kirkham, AA; McKenzie, DC; Shenkier, T; Zucker, D | 1 |
| Aoki, D; Arai, M; Mizuno, M; Nakai, H; Nakanishi, T; Nishio, S; Nomura, H; Susumu, N; Takehara, K; Tokunaga, H; Watanabe, Y; Yaegashi, N; Yokoyama, Y | 1 |
| Guan, H; Liu, G; Sheng, Y; Shi, L; Xie, F | 1 |
| Chung, S; Cooper, J; Dadwal, S; Jung, J; Kruper, L; Mortimer, JE; Stewart, D; Wong, L; Yu, KW; Yuan, Y | 1 |
| Ding, T; Dong, L; Jiang, YF; Li, JB; Xie, BJ; Zhu, LN; Zhu, ZN | 1 |
| Fujii, T; Horiguchi, J; Inoue, K; Kurosumi, M; Kurozumi, S; Matsumoto, H; Oyama, T; Shirabe, K | 1 |
| Bajorin, D; Bellmunt, J; Enokida, H; Frenkl, T; Fujimoto, K; Fukasawa, S; Imai, K; Nishimura, K; Nishiyama, H; Perini, R; Sassa, N; Shimamoto, T; Takahashi, K; Tanaka, Y; Yamamoto, Y; Yokoyama, M | 1 |
| Ang, E; Ang, S; Bandla, A; Chan, A; Chan, G; Hairom, Z; Huang, Y; Kumarakulasinghe, NB; Lee, SC; Lee, YM; Lim, JSJ; Magarajah, G; Ngoi, N; Sundar, R; Tan, S; Thakor, N; Wilder-Smith, E; Wong, A | 1 |
| Abasi, S; Ahmadi, Z; Ashrafizadeh, M; Dehghannoudeh, G; Khanbabaei, H; Mohamadi, N; Mohammadinejad, R; Tamaddondoust, RN; Thakur, VK; Zarrabi, A | 1 |
| Bibera, MAT; Lo, KMK; Steele, A | 1 |
| Chen, J; Chen, S; Fan, Y; Kong, H; Li, W; Li, Z; Wang, H; Xue, B; Zhao, J | 1 |
| Bi, J; Chen, S; Diao, C; Dong, Y; Fan, H; Fan, W; Feng, Q; Geng, D; Han, X; Huang, G; Li, F; Li, G; Li, P; Li, Q; Li, T; Li, W; Li, Y; Liu, B; Meng, M; Meng, Q; Ni, Y; Ren, H; Sheng, L; Sun, D; Sun, L; Sun, W; Sun, Y; Tian, H; Wang, C; Wang, J; Wei, Z; Xu, X; Xu, Y; Xue, G; Yang, X; Ye, X; Yu, G; Zhang, B; Zhang, K; Zhang, L; Zheng, A; Zou, Z | 1 |
| Ji, J; Jia, Y; Li, S; Li, Z; Shan, F; Ying, X; Zhang, L | 1 |
| Cheng, L; Li, L; Lu, Y; Majumdar, A; Stover, D; Wu, S | 1 |
| Jin, L; Yang, W; Zhang, Y | 1 |
| Liang, MR; Liu, H; Wang, YN; Zeng, SY; Zhong, ML | 1 |
| Li, J; Li, W; Liang, L; Liu, Z; Wang, Y; Xu, F; Xu, H; Yang, G; Yang, L; Ying, J; Zhang, Q; Zhang, S | 1 |
| Fujiwara, Y; Goto, Y; Horinouchi, H; Kanda, S; Nokihara, H; Ohe, Y; Tamura, T; Yamamoto, N; Yamamoto, T | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Fujiwara, Y; Hasegawa, J; Hashimoto, K; Ikeda, K; Kawabata, H; Nishizawa, D; Ozaki, Y; Shimizu, C; Shimomura, A; Shiraishi, S; Takano, T; Tamura, K; Tamura, N; Tanabe, Y; Yonemori, K; Yunokawa, M | 1 |
| Calixto, JB; Campos, MM; da Costa, R; Fernandes, ES; Maia, JRLCB; Passos, GF; Quintão, NLM | 1 |
| Cramer-van der Welle, CM; Groen, HJM; Schramel, FMNH; van de Garde, EMW; van Leeuwen, AS | 1 |
| Lü, X; Schaefer, HF; Song, C; Wang, C; Xie, Y; Zhang, C; Zhang, M; Zhu, L | 1 |
| Ebata, T; Fujiwara, K; Fujiwara, Y; Hasegawa, K; Kato, T; Nishikawa, T; Noguchi, E; Shimomura, A; Sudo, K; Tamura, K; Yonemori, K | 1 |
| Abraham, P; Gricar, J; Shankaran, V; Zhang, Y | 1 |
| Cai, R; Chen, S; Chen, X; Chen, Y; Fan, Y; Guan, Y; Lan, B; Li, Q; Luo, Y; Ma, F; Mo, H; Wang, J; Xu, B; Zhang, P; Zhao, W | 1 |
| Lambertini, M; Perachino, M; Poggio, F | 1 |
| Hamauchi, S; Kawakami, T; Mori, K; Ogawa, H; Onitsuka, T; Onoe, T; Onozawa, Y; Shirasu, H; Yokota, T | 1 |
| Chowdhury, N; Singh, M | 1 |
| Emami, J; Kazemi, M; Rezazadeh, M; Ziaei, E | 1 |
| Bi, Z; Chen, P; Liu, YB; Song, XR; Sun, X; Wang, YS; Zhao, T | 1 |
| Akdeniz, N; Alan, Ö; Bilen, E; Ebinç, S; Ercelep, Ö; Işıkdoğan, A; Kaplan, MA; Karhan, O; Küçüköner, M; Laçin, Ş; Sezgin, Y; Teke, F; Urakçı, Z; Yumuk, PF | 1 |
| Hu, CG; Liu, J; Xue, D; Xue, YF; Yao, B | 1 |
| Chen, Q; Feng, SL; Liu, RM; Xie, Y; Xu, P | 1 |
| Adenis, A; Al-Rajabi, R; Bennouna, J; Bhagia, P; Chen, J; de la Fouchardiere, C; Doi, T; Enzinger, P; Ferreira, P; Francois, E; Girotto, G; Hsu, CH; Kang, SP; Kato, K; Kim, SB; Kojima, T; Lee, SH; Lordick, F; Metges, JP; Moriwaki, T; Muro, K; Qin, SK; Senellart, H; Shah, MA; Shen, L; Suryawanshi, S; Wang, R | 1 |
| Jurášek, M; Rimpelová, S; Ruml, T; Škubník, J | 1 |
| Chung, H; Kim, HS; Kim, JW; Kim, SI; Lee, EJ; Lee, M; Park, NH; Song, YS | 1 |
| Beer, TM; Beltran, H; Bergman, AM; Bianchini, D; Castro, E; Chi, KN; Conteduca, V; Cotait Maluf, F; De Giorgi, U; Di Lorenzo, G; Gillessen, S; Hansen, AR; Higano, C; Karalis, K; Klingbiel, D; Kuppen, MCP; Lavaud, P; Le, ML; Ledet, E; Martinez Chanza, N; Mehra, N; Morales-Barrera, R; Oh, WK; Omlin, A; Pezaro, C; Sartor, O; Schär, S; Schmid, S; Suzuki, H; Sweeney, C; Tsao, CK; Tucci, M; Vargas Pivato de Almeida, D; Yip, SM; Zivi, A; Zürrer-Härdi, U | 1 |
| Bao, B; Chen, Y; Lv, Y; Sun, D; Wang, J; Zhang, L; Zhao, W | 1 |
| Dalvin, LA; Fortes, BH; Liou, H | 1 |
| Chang Lee, R; Hsieh, AH; Moldovan, M; Price, T; Tomita, Y; Townsend, A | 1 |
| Joerger, M; Kloft, C; Muth, M; Ojara, FW | 1 |
| de Bree, E; Katsougkri, D; Michelakis, D; Polioudaki, H; Theodoropoulos, P; Tsangaridou, E; Zoras, O | 1 |
| Aizawa, M; Bamba, T; Kakuta, T; Maruyama, S; Matsuki, A; Nakagawa, S; Nogami, H; Nomura, T; Takii, Y; Yabusaki, H | 1 |
| Hertz, DL | 1 |
| Ayari, J; Balti, M; Ben Abdallah, I; Ben Hassen, M; Ben Nasr, S; Doghri, Y; Fendri, S; Haddaoui, A; Trigui, E; Zribi, A | 1 |
| Amant, FCH; Beijnen, JH; Bekkers, R; Boere, I; Dorlo, TPC; Drochytek, V; Fruscio, R; Halaska, MJ; Huitema, ADR; Janssen, JM; Ottevanger, P; Painter, RC; Schröder, CP; Van Calsteren, K; Witteveen, PO | 1 |
| Hiraiwa, R; Iguma, Y; Imai, S; Iwamitsu, Y; Kawaguchi-Sakita, N; Kotake, T; Koyanagi, M; Matsubara, K; Matsumoto, M; Nagayasu, K; Nakagawa, S; Nakagawa, T; Ntogwa, M; Ogihara, T; Omura, T; Saigo, M; Yonezawa, A | 1 |
| Bhutta, OA; Khan, I; Masood, W; Saleem, Z; Shammas, S | 1 |
| Casazza, G; Cheli, S; Clementi, E; Cona, MS; Dalu, D; Demurtas, S; Fasola, C; Ferrario, S; Filipazzi, V; Gambaro, A; La Verde, N; Montrasio, C; Rota, S; Tosca, N | 1 |
| Pakiari, AH; Salarhaji, M | 1 |
| Cathcart-Rake, EJ; Friday, BB; Lacouture, M; Loprinzi, CL; McCue, S; O'Connor, A; Piens, J; Register, T; Smith, D; Thomé, S; Young, S; Zahrieh, D | 2 |
| Dakhlallah, D; Eubank, TD; Gencheva, M; Guo, NL; Hu, G; Ivanov, AV; Kolluri, SK; Marsh, CB; Mohamed, R; Pearce, MC; Ye, Q | 1 |
| Gu, X; Liu, X; Xu, M; Zeng, T; Zhang, W; Zhang, X; Zhao, F | 1 |
| Aref, AR; Ashrafizadeh, M; Daneshi, S; Hashemi, F; Hushmandi, K; Khan, H; Kumar, AP; Mirzaei, S; Saleki, H; Samarghandian, S; Sharifzadeh, SO; Soleymani, L; Zabolian, A; Zarrabi, A | 1 |
| Chiu, M; Cutler, L; Kim, G; Wang, H | 1 |
| Biedermann, S; Colevas, AD; He, Z; Lansinger, OM | 1 |
| He, ZG; Sun, J; Tian, CT; Wang, HL | 1 |
| Aguera, KN; Davis, GE; Griffin, CT; Kemp, SS; Koller, GM; Lin, PK; Salvador, J; Xie, J | 1 |
| Alsherbiny, MA; Bhuyan, DJ; Chang, D; Li, CG; Low, MN | 1 |
| Han, C; Li, H; Li, Z; Liu, Z; Sun, Z; Wu, Y; Zhang, J; Zhang, X | 1 |
| Ligtenberg, M; Steegers, M; van den Heuvel, S; van Haren, F; Vissers, K | 1 |
| Adenis, A; Al-Rajabi, R; Amonkar, M; Bhagia, P; de la Fouchardiere, C; Girotto, GC; Kulkarni, AS; Mansoor, W; Metges, JP; Norquist, J; Senellart, H; Suryawanshi, S; van Laarhoven, HWM | 1 |
| Hikita, K; Honda, M; Iwamoto, H; Kawamoto, B; Morizane, S; Shimizu, R; Takenaka, A; Teraoka, S; Yamaguchi, N; Yumioka, T | 1 |
| Abdeddaim, C; Clatot, F; Even, C; Guiard, E; Johnson, A; Perréard, M; Rambeau, A; Vauléon, E | 1 |
| Banerji, A; Blumenthal, KG; Cogan, AS; McMahon, AE; Robinson, LB; Saff, RR; Wolfson, AR | 1 |
| Habrowska-Górczyńska, DE; Kowalska, K; Kozieł, MJ; Piastowska-Ciesielska, AW | 1 |
| Chen, B; Guo, J; Jiang, J; Li, D; Li, Y; Sui, Y; Xu, H | 1 |
| Basu, D; Dastidar, SG; Majumdar, S; Mandal, N | 1 |
| He, F; Li, G; Li, Q; Liu, J; Shen, X; Wang, Z | 1 |
| Almotlak, H; André, T; Baba-Hamed, N; Borg, C; Bouché, O; Buecher, B; de la Fouchardiere, C; Desrame, J; El Hajbi, F; Ghiringhelli, F; Jacquin, M; Jary, M; Kaminsky, MC; Kim, S; Meurisse, A; Nguyen, T; Parzy, A; Pernot, S; Saint, A; Samalin, E; Smith, D; Stouvenot, M; Taieb, J; Vernerey, D; Vienot, A; Zoubir, M | 1 |
| Al-Batran, SE; Ettrich, T; Goetze, TO; Gökkurt, E; Hinke, A; Lordick, F; Lorenzen, S; Pauligk, C; Pink, D; Probst, S; Reichardt, P; Sökler, M; Stahl, M; Thuss-Patience, P | 1 |
| Kim, YJ; Lee, YJ; Park, Y | 1 |
| Chatterjee, B; Ganti, S; Pandya, M | 1 |
| Min, S; Zheng, Q; Zhou, Y | 1 |
| Ichikawa, G; Nakanishi, K; Okazaki, S; Suzuki, S | 1 |
| Baker, S; Blanchard, E; Brahmer, JR; Celano, P; Duma, N; Elkins, IB; Ellis, PM; Haddad, RY; Hesketh, PJ; Jain, D; Jaiyesimi, IA; Johnson, DH; Leighl, NB; Mamdani, H; Masters, G; Moffitt, PR; Phillips, T; Riely, GJ; Robinson, AG; Rosell, R; Schiller, JH; Schneider, BJ; Singh, N; Spigel, DR; Temin, S | 1 |
| Chen, J; Chen, Y; Lin, YT; Liu, TX; Wang, C | 1 |
| Du, D; Ji, J; Ma, H; Qiu, Y; Xie, B; Zhang, W; Zhou, J; Zhu, L | 1 |
| Ali, A; Atifa, U; Iqbal, Z; Khuroo, A; Khuroo, T; Mirza, MA | 1 |
| Chakrabarti, P; Dehghani, M; Gholamzadeh, MJ; Kamali, AM; Mousavi, SZ; Nami, M; Owrangi, M; Vasaghi Gharamaleki, M | 1 |
| Etminan, M; Maberley, D; Mikelberg, F; Sodhi, M; Yeung, SN | 1 |
| Lukong, KE; Mandapati, A | 1 |
| Bąk, W; Bargieł, J; Cabaj, J; Góralczyk, A; Grabarska, A; Wróblewska-Łuczka, P; Łuszczki, JJ | 1 |
| Christensen, SB | 1 |
| Bonnabry, P; Fleury-Souverain, S; Guillarme, D; Maurin, J; Rudaz, S | 1 |
| Coffeen, U; Velasco-González, R | 1 |
| Behroozaghdam, M; Bishayee, A; De Greef, D; Dehghani, M; Hasani Sadi, F; Hashemi, M; Javanshir, S; Kamali, D; Mirzaei, S; Rashidi, M; Tabari, T; Zabolian, A; Zarepour, A; Zarrabi, A | 1 |
| Guo, S; Li, S; Ma, K; Wang, J; Wei, S; Xu, Y; Zhang, F | 1 |
| Borisyuk, BO; Bororov, LV; Ganul, AV; Maliarchuk, K; Shevchenko, AI; Sovenko, VM | 1 |
| Dilawari, A; Graham, D; Isaacs, C; Kurian, S; Lynce, F; Mainor, C; McNamara, D; Mohebtash, M; Ottaviano, Y; Pohlmann, PR; Rao, S; Swain, SM; Swanson, N; Tan, M; Warren, R; Wu, T | 1 |
| Accetta, C; Carbognin, L; D'Angelo, T; Di Giorgio, D; Di Leone, A; Fabi, A; Franceschini, G; Fuso, P; Garganese, G; Giannarelli, D; Magno, S; Masetti, R; Muratore, M; Paris, I; Pavese, F; Sanchez, AM; Scambia, G; Terribile, DA; Tiberi, G | 1 |
| Cao, M; Li, H; Lv, Z; Ma, F; Mo, H; Pan, B; Song, G; Sun, X; Teng, Y; Xu, B; Yan, X; Zhai, J; Zhao, F; Zhao, J | 1 |
| Smith, ER; Wang, JQ; Xu, XX; Yang, DH | 1 |
| Alawi, M; Alsdorf, W; Böckelmann, L; Bokemeyer, C; Dyshlovoy, SA; Gild, P; Graefen, M; Hauschild, J; Kaune, M; Krisp, C; Langebrake, C; Mansour, W; Oh-Hohenhorst, SJ; Perner, S; Rohlfing, T; Saygi, C; Schlüter, H; Tilki, D; von Amsberg, G; Zielinski, A; Zilles, M | 1 |
| Kalabova, H; Melichar, B; Ondruskova, A; Purova, D; Rusarova, N; Studentova, H; Vitaskova, D | 1 |
| Amanuma, Y; Arimitsu, Y; Chin, K; Kadowaki, S; Kanda, M; Kimura, Y; Kitagawa, Y; Kubota, Y; Nogi, Y; Okada, M; Takahashi, M; Yamamoto, S | 1 |
| Abkenar, ZO; Babaei, R; Entezari, M; Hashemi, M; Hushmandi, K; Khorrami, R; Nabavi, N; Nejad, MM; Rahmanian, P; Rajabi, R; Rashidi, M; Ren, J; Rezaei, S; Sadi, FH; Shafiee, SS; Taheriazam, A; Talebi, Y; Zandieh, MA | 1 |
| Chen, R; He, J; Huang, X; Li, X; Ma, L; Shi, W; Wan, X; Wang, J; Wang, L; Wang, Y; Xu, L; Xu, Y; Zha, X; Zhang, W; Zheng, R | 1 |
| Cai, B; Ma, X; Pu, Y; Yu, P; Zhang, C; Zhu, S | 1 |
| Cardoso, AM; Coelho, RS; Maia, CJ; Nascimento, D; Passarinha, LA; Rocha, SM; Socorro, S | 1 |
| Costa, J; Jabaley, T; Lynch, DM; Mazzola, E; Menon, S | 1 |
| Heibloem, RE; Ilozumba, OUC; Komen, MMC; van den Hurk, CJG | 1 |
| Jiang, Y; Li, X; Liu, C; Wang, J; Xing, H; Zhang, H; Zhang, Y | 1 |
| Aksoy, S; Arslan, C; Basaran, G; Bilici, A; Cakar, B; Cicin, I; Cubukcu, E; Demirci, U; Erdem, D; Gumus, M; Harputluoglu, H; Kaplan, MA; Karadag, I; Karadurmus, N; Oksuzoglu, B; Olmez, OF; Selcukbiricik, F; Sendur, MAN; Sezer, A; Sezgin Goksu, S; Shbair, ATM; Sumbul, AT | 1 |
| Kubota, K; Kunitoh, H; Maruyama, R; Matsuda, A; Ohira, T; Okamoto, H; Seto, T; Tsuboi, M; Yamaoka, K | 1 |
| Hirabayashi, T; Kushida, S; Miki, I; Mimura, T; Nishikawa, M; Takegawa, N; Tanaka, S; Tokuyama, N; Tsuda, M; Tsumura, H; Yamamoto, Y | 1 |
| Dang, CT; Du Toit, Y; Hurvitz, SA; Knott, A; Polito, L; Restuccia, E; Sanglier, T; Shim, J; Swain, SM | 1 |
| Góralczyk, A; Wróblewska-Łuczka, P; Łuszczki, JJ | 1 |
| Bui-Linh, C; Olivieri, M; Thornton, JM; Uba, AI; Wu, C | 1 |
| Contorno, T; McGwin, G; Owsley, C; Vicinanzo, MG | 1 |
| Amant, FCH; Beijnen, JH; Damoiseaux, D; Dorlo, TPC; Huitema, ADR; Janssen, JM; van Calsteren, K; van Hasselt, JGC | 1 |
| Decuzzi, P; Di Mascolo, D; Guerriero, I; Palange, AL; Pesce, C; Spanò, R | 1 |
| Egawa, G; Endo, Y; Fujii, H; Ishikawa, M; Kabashima, K; Yonekura, S | 1 |
| Li, J; Liu, J; Meng, L; Sun, L; Wang, J; Zhang, H; Zhou, Q | 1 |
| Chen, R; He, J; Huang, X; Shi, W; Wan, X; Wang, J; Wang, Y; Xu, L; Xu, Y; Zha, X; Zhang, W | 1 |
| Ai, X; Hao, X; Lei, S; Li, W; Wang, Y; Xu, H; Yang, G; Yang, Y; Zhang, S | 1 |
| Leistner, E | 1 |
| de Vos, FY; van Laarhoven, HM | 1 |
634 review(s) available for docetaxel anhydrous and paclitaxel
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.
Topics: Animals; Biological Products; Chemistry, Pharmaceutical; Humans | 2018 |
Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Drug Screening Assays, Antitumor; Female; Humans; Isoxazoles | 2021 |
[Recent results of anticancer drugs acting on microtubules--navelbine, taxol and taxotere for the treatment of lung cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Microtubules; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1992 |
Laboratory and phase I studies of new cancer drugs.
Topics: Antineoplastic Agents; Bryostatins; Camptothecin; Docetaxel; Humans; Lactones; Macrolides; Neoplasms; Paclitaxel; Taxoids | 1992 |
Taxol: the first of the taxanes, an important new class of antitumor agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Evaluation; Drug Evaluation, Preclinical; Drugs, Investigational; Female; Forecasting; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids | 1992 |
New cytotoxic drugs in clinical development.
Topics: Alkaloids; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Docetaxel; Humans; Paclitaxel; Taxoids; Topotecan | 1991 |
[Paclitaxel (Taxol) and docetaxel (Taxotere): results of phase II trials in monochemotherapy].
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Drug Hypersensitivity; Drug Tolerance; Female; Humans; Male; Neoplasms; Neutropenia; Organoplatinum Compounds; Paclitaxel; Taxoids | 1995 |
New drugs in non-small cell lung cancer. An overview.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Design; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Vinblastine; Vinorelbine | 1995 |
Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1995 |
New drugs for treating small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan | 1995 |
Preclinical pharmacology of docetaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Mice; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1995 |
Early clinical studies with docetaxel. Docetaxel Investigators Group.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase I as Topic; Docetaxel; Drug Administration Schedule; Female; Humans; Male; Neoplasms; Paclitaxel; Taxoids | 1995 |
Docetaxel.
Topics: Adult; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1995 |
Taxanes: a new class of antitumor agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Drug Screening Assays, Antitumor; Humans; Mice; Neoplasms; Neoplasms, Experimental; Paclitaxel; Taxoids | 1995 |
[Taxenes: a new hope of clinical oncology in the 90-ies].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids | 1995 |
Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1995 |
Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1995 |
New drug for therapy of non-small cell lung cancer.
Topics: Aminopterin; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1994 |
[Phase II study].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Practice Guidelines as Topic; Taxoids | 1995 |
[Recent advance in chemotherapy for breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Docetaxel; Female; Humans; Irinotecan; Mitoxantrone; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids | 1994 |
Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1995 |
Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Treatment Failure | 1995 |
Preclinical evaluation of docetaxel (Taxotere).
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance; Drug Screening Assays, Antitumor; Humans; Microtubules; Paclitaxel; Structure-Activity Relationship; Taxoids | 1995 |
Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1995 |
Current status of Taxotere (docetaxel) as a new treatment in breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Tolerance; Humans; Paclitaxel; Taxoids | 1995 |
Mitotic inhibitors.
Topics: Animals; Docetaxel; Humans; Mitosis; Paclitaxel; Taxoids; Vinca Alkaloids | 1994 |
New chemotherapeutic agents for non-small cell lung cancer.
Topics: Aminopterin; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Quinoxalines; Sulfanilamides; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1995 |
Options for primary chemotherapy of epithelial ovarian cancer: taxanes.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds; Bridged-Ring Compounds; Cisplatin; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Remission Induction; Taxoids | 1994 |
Pharmacokinetics and metabolism of Taxotere (docetaxel).
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1993 |
Taxoids, a new class of antitumour agents of plant origin: recent results.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Molecular Structure; Paclitaxel; Structure-Activity Relationship; Taxoids | 1994 |
Taxoids: a new class of cytotoxic agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Neoplasms; Paclitaxel; Taxoids | 1994 |
Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Arrhythmias, Cardiac; Cell Cycle; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Hypersensitivity; Drug Screening Assays, Antitumor; Gastrointestinal Diseases; Humans; Mice; Microtubules; Neoplasms; Neoplasms, Experimental; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Polyethylene Glycols; Taxoids; Tubulin | 1994 |
New chemotherapeutic agents for breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 1994 |
Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Dogs; Drug Screening Assays, Antitumor; Female; Humans; Mice; Ovarian Neoplasms; Paclitaxel; Rats; Taxoids; Tumor Cells, Cultured | 1994 |
The taxoids: paclitaxel and docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Hypersensitivity; Drug Interactions; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids | 1994 |
[New promising anticancer drugs for lung cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Organoplatinum Compounds; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1994 |
[Antimicrotubule agents].
Topics: Aminophenols; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Leukemia, Experimental; Lung Neoplasms; Mice; Microtubules; Paclitaxel; Sulfonamides; Taxoids; Vinblastine; Vinorelbine | 1993 |
Taxol in ovarian cancer.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Injections, Intraperitoneal; Ovarian Neoplasms; Paclitaxel; Taxoids | 1993 |
Taxol and taxotere--current status and future prospects.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids | 1993 |
The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere).
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids | 1993 |
Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lethal Dose 50; Lung Neoplasms; Microtubules; Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1995 |
Taxoid compounds in breast cancer: current status and future prospects.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 1995 |
Promising new agents in the treatment of non-small cell lung cancer.
Topics: Aminopterin; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1996 |
Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Female; Humans; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 1995 |
Taxoids: effective agents in anthracycline-resistant breast cancer.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Taxoids | 1995 |
Docetaxel (Taxotere) in combination: a step forward.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Clinical Trials as Topic; Docetaxel; Female; Humans; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 1995 |
The role of taxanes in the treatment of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Clinical Trials, Phase II as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction; Taxoids | 1996 |
Chemotherapy of adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Growth Substances; Humans; Immunologic Factors; Octreotide; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Prognosis; Survival Rate; Taxoids | 1996 |
Taxanes.
Topics: Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Clinical Trials as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Humans; Paclitaxel; Taxoids | 1996 |
[Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
Topics: Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Irinotecan; Loperamide; Male; Neoplasms; Neutropenia; Paclitaxel; Remission Induction; Taxoids; Topoisomerase I Inhibitors | 1996 |
New anticancer agents in clinical development.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; DNA Topoisomerases, Type I; Docetaxel; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Irinotecan; Paclitaxel; Prodrugs; Taxoids; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan | 1995 |
[Current therapeutic methods in onco-hematology].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cladribine; Docetaxel; Humans; Keratolytic Agents; Leukemia; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Tretinoin; Vidarabine | 1996 |
Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Humans; Paclitaxel; Taxoids | 1996 |
Docetaxel: a new defence in the management of breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Doxorubicin; Female; Humans; Liver Neoplasms; Middle Aged; Multicenter Studies as Topic; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 1995 |
Docetaxel: meeting the challenge of non-small cell lung cancer management.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Cricetinae; Docetaxel; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 1995 |
Docetaxel delivers new management opportunities for gastrointestinal carcinomas.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Docetaxel; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Stomach Neoplasms; Taxoids | 1995 |
Progress in preclinical and clinical studies for the development of new anticancer drugs in Japan, with emphasis on taxanes.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Drug Evaluation, Preclinical; Humans; Japan; Microtubule-Associated Proteins; Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured; Vinblastine; Vindesine; Vinorelbine | 1996 |
Docetaxel (Taxotere) for advanced breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Humans; Paclitaxel; Taxoids | 1996 |
Docetaxel: a review of its pharmacology and clinical activity.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Division; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Eruptions; Drug Resistance, Neoplasm; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Microtubules; Neutropenia; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Taxoids; Tubulin | 1996 |
Treatment of advanced breast cancer: current status.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1996 |
Treatment of patients with liver metastases.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Humans; Liver Neoplasms; Paclitaxel; Taxoids | 1996 |
Optimal use of docetaxel (Taxotere): maximizing its potential.
Topics: Antineoplastic Agents, Phytogenic; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Docetaxel; Hematologic Diseases; Humans; Paclitaxel; Taxoids | 1996 |
The scientific rationale for developing taxoids.
Topics: Animals; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Therapy, Combination; Humans; Microtubules; Neoplasms; Paclitaxel; Taxoids | 1996 |
The clinical rationale for developing docetaxel (Taxotere).
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Therapy, Combination; Humans; Paclitaxel; Taxoids | 1996 |
Taxoids in combination chemotherapy for metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Humans; Paclitaxel; Taxoids | 1996 |
New systemic drugs in the treatment of gastrointestinal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Docetaxel; Gastrointestinal Neoplasms; Humans; Irinotecan; Paclitaxel; Quinazolines; Taxoids; Thiophenes; Thymidylate Synthase | 1996 |
[Chemotherapy for pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Interferon-alpha; Irinotecan; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Taxoids | 1996 |
Taxotere.
Topics: Adult; Antineoplastic Agents, Phytogenic; Chemistry, Pharmaceutical; Child; Docetaxel; Drug Storage; Humans; Paclitaxel; Taxoids | 1996 |
Metastatic breast cancer.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Diphosphonates; Docetaxel; Doxorubicin; Enzyme Inhibitors; Female; Gemcitabine; Humans; Imides; Intercalating Agents; Isoquinolines; Naphthalimides; Neoplasm Metastasis; Neoplasm Proteins; Organophosphonates; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Topoisomerase II Inhibitors; Treatment Outcome | 1996 |
[Progress and perspectives in palliative therapy of breast carcinoma].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Docetaxel; Female; Goserelin; Humans; Paclitaxel; Palliative Care; Tamoxifen; Taxoids | 1996 |
The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Humans; Microtubules; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 1997 |
Taxanes in ovarian cancer treatment.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Ovarian Neoplasms; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 1997 |
The international experience with docetaxel in the treatment of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Taxoids | 1997 |
Docetaxel (taxotere, Rhone-Poulenc Rorer).
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Drug Monitoring; Humans; Neoplasms; Paclitaxel; Taxoids | 1997 |
Biotransformation of taxoids by human cytochromes P450: structure-activity relationship.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Docetaxel; Drug Interactions; Humans; In Vitro Techniques; Isoenzymes; Microsomes, Liver; Mixed Function Oxygenases; Paclitaxel; Rats; Species Specificity; Structure-Activity Relationship; Taxoids | 1997 |
[New wave of chemotherapeutic agents: update in pulmonary oncology].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1997 |
Docetaxel in breast cancer and a rationale for combination therapy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Models, Animal; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; In Vitro Techniques; Mice; Paclitaxel; Taxoids | 1997 |
[Development of a new tubulin-interacting agent, docetaxel (taxotere) in Japan].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Synergism; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Tubulin | 1997 |
New cytostatic agents for the treatment of head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Ifosfamide; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Taxoids | 1997 |
Docetaxel. A review of its role in breast cancer treatment.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Paclitaxel; Remission Induction; Safety; Taxoids | 1997 |
Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Paclitaxel; Taxoids; Treatment Outcome | 1997 |
Future perspectives of docetaxel (Taxotere) in front-line therapy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Paclitaxel; Taxoids | 1997 |
Chemotherapy for advanced non-small cell lung cancer: past, present, and future.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1997 |
Management strategies for recurrent non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Taxoids; Treatment Failure | 1997 |
Paclitaxel and docetaxel in breast and ovarian cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids | 1997 |
[Taxanes: a breakthrough in cancer chemotherapy].
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1997 |
The taxoids: same roots, different drugs.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1997 |
Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids | 1997 |
Docetaxel in combination chemotherapy for metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1997 |
Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Resistance; Female; Humans; Paclitaxel; Taxoids | 1997 |
[A medico-economic evaluation of second line chemotherapy in metastatic breast cancer: comparison between docetaxel, paclitaxel, and vinorelbine].
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cost-Benefit Analysis; Docetaxel; Drug Administration Schedule; Female; Humans; Neoplasm Metastasis; Paclitaxel; Quality of Life; Sensitivity and Specificity; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1997 |
[Head and neck cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Fluorouracil; Head and Neck Neoplasms; Humans; Organoplatinum Compounds; Paclitaxel; Taxoids | 1997 |
[Lung cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1997 |
[New anti-cancer drugs for gastrointestinal cancers].
Topics: Amino Acids; Antidotes; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Fluorouracil; Gastrointestinal Neoplasms; Humans; Interferons; Irinotecan; Leucovorin; Paclitaxel; Taxoids | 1997 |
[Promising new drugs for gynecological cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase I as Topic; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Genital Neoplasms, Female; Humans; Irinotecan; Organoplatinum Compounds; Paclitaxel; Taxoids; Topotecan | 1997 |
Review of docetaxel/doxorubicin combination in metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 1997 |
Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate; Taxoids | 1997 |
Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Synergism; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Neoplasm Metastasis; Nervous System Diseases; Paclitaxel; Remission Induction; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 1997 |
Docetaxel in combination with fluorouracil for advanced solid tumors.
Topics: Adult; Aged; Animals; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Models, Animal; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Leucovorin; Mice; Middle Aged; Mucous Membrane; Neoplasms; Neutropenia; Paclitaxel; Taxoids | 1997 |
["State-of-the-art" chemotherapy for small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vincristine | 1997 |
Prolonged remission of platinum-refractory ovarian cancer with docetaxel: brief report and review of literature.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Remission Induction; Salvage Therapy; Taxoids | 1997 |
Antitumor activity of docetaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1997 |
Pharmaceutical aspects of docetaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1997 |
Cost-utility analysis of taxane therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cost-Benefit Analysis; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1997 |
Pharmacokinetic and pharmacodynamic properties of docetaxel: results of phase I and phase II trials.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1997 |
Efficacy and safety of docetaxel in clinical trials.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Male; Paclitaxel; Taxoids | 1997 |
New chemotherapeutic agents for the treatment of non-small cell lung cancer: the Japanese experience.
Topics: Alkaloids; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbazoles; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Glucosides; Humans; Irinotecan; Japan; Lung Neoplasms; Mitomycin; Mitomycins; Neoplasms, Experimental; Paclitaxel; Purine Nucleosides; Staurosporine; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
New chemotherapeutic agents in the treatment of non-small cell lung cancer: the Australian experience.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Australia; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 1998 |
New agents in the treatment of small cell lung cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drugs, Investigational; Gemcitabine; Humans; Immunologic Factors; Irinotecan; Lung Neoplasms; Menogaril; Paclitaxel; Taxoids; Teniposide; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
[Docetaxel (taxotere) in non-small-cell bronchial carcinoma].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 1997 |
[Docetaxel in treatment of other solid tumors].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 1997 |
[Docetaxel (taxotere) for therapy of breast carcinoma. Highest effectiveness with moderate side effects].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Drug Synergism; Female; Humans; Liver Neoplasms; Paclitaxel; Survival Rate; Taxoids | 1997 |
The taxoids. Comparative clinical pharmacology and therapeutic potential.
Topics: Alopecia; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Docetaxel; Female; Humans; Lung Neoplasms; Neoplasms; Neutropenia; Ovarian Neoplasms; Paclitaxel; Taxoids | 1998 |
Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; CA-125 Antigen; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 1997 |
Review of recent trials of chemotherapy for advanced breast cancer: the taxanes.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1997 |
The role of docetaxel in improving treatment outcomes in advanced breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 1997 |
Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Taxoids | 1997 |
Docetaxel in combination with doxorubicin or vinorelbine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Female; Humans; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1997 |
Prospects with docetaxel in the treatment of patients with breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1997 |
Preclinical pharmacokinetics of paclitaxel and docetaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Docetaxel; Feces; Molecular Structure; Paclitaxel; Protein Binding; Taxoids; Tissue Distribution | 1998 |
Taxanes in adjuvant and neoadjuvant therapies for breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 1998 |
Ifosfamide and docetaxel in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Taxoids | 1998 |
Molecular and biologic determinants of neoadjuvant chemotherapy of locoregional breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers; Breast Neoplasms; Cell Cycle; Cell Survival; Chemotherapy, Adjuvant; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Phenotype; Taxoids | 1998 |
Primary chemotherapy regimens and schedules.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Humans; Paclitaxel; Taxoids | 1998 |
Overview of National Surgical Adjuvant Breast Project neoadjuvant chemotherapy studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Humans; Lymph Node Excision; Mastectomy; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 1998 |
[The effect of docetaxel on malignant tumors].
Topics: Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 1998 |
New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1998 |
Update on the taxoids and other new agents in head and neck cancer therapy.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; DNA Replication; DNA, Neoplasm; Docetaxel; Drug Administration Schedule; Enzyme Inhibitors; Head and Neck Neoplasms; Humans; Interferon-alpha; Microtubules; Neoplasm Proteins; Organoplatinum Compounds; Paclitaxel; Radiation-Sensitizing Agents; Remission Induction; Taxoids; Topoisomerase II Inhibitors; Treatment Outcome; Tubulin Modulators | 1998 |
Do newer chemotherapeutic agents improve survival in non-small cell lung cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 1998 |
Single agents in the second-line treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Treatment Failure; Vinblastine; Vinorelbine | 1998 |
Docetaxel in the management of advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1998 |
New agents in the management of advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1998 |
[The role of new drugs in the treatment of locally advanced urothelial tumors of the bladder].
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Paclitaxel; Taxoids; Urinary Bladder Neoplasms | 1998 |
[Chemotherapy in metastasized breast carcinoma].
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Neoplasm Metastasis; Neoplasms, Second Primary; Paclitaxel; Palliative Care; Quality of Life; Survival Rate; Taxoids | 1998 |
Role of taxanes in lung-cancer chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1998 |
Docetaxel: a taxoid for the treatment of metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 1998 |
Docetaxel in head and neck cancer: a review.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Paclitaxel; Radiation-Sensitizing Agents; Taxoids | 1998 |
[Current developments in use of docetaxel (taxotere) in gynecologic oncology].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 1998 |
[Docetaxel (taxotere): current status of clinical development in non-small-cell bronchial carcinoma (NSCLC)].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 1998 |
Chemotherapy for gastric carcinoma: new and old options.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Drug Combinations; Enzyme Inhibitors; Etoposide; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Oxonic Acid; Paclitaxel; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids; Tegafur; Uracil | 1998 |
In-vitro metabolism of anti-cancer drugs, methods and applications: paclitaxel, docetaxel, tamoxifen and ifosfamide.
Topics: Animals; Antineoplastic Agents; Cytochrome P-450 Enzyme System; Docetaxel; Drug Interactions; Humans; Ifosfamide; Models, Chemical; Paclitaxel; Species Specificity; Tamoxifen; Taxoids; Tumor Cells, Cultured | 1998 |
[Taxanes in the treatment of breast and ovarian cancers: current indications and results].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 1998 |
An expanding role for docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Humans; Paclitaxel; Taxoids | 1998 |
Evolution in the treatment of advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1998 |
[New antitumor drugs for non-Hodgkin's lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Humans; Lymphoma, Non-Hodgkin; Paclitaxel; Prednisone; Rituximab; Taxoids; Vincristine | 1998 |
[Taxotere in various solid tumors].
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Melanoma; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Prostatic Neoplasms; Sarcoma; Skin Neoplasms; Soft Tissue Neoplasms; Taxoids; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 1998 |
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Enzyme Inhibitors; Etoposide; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
["Taxanes: an action mechanism at the cellular level, significant clinical progress in the treatment of cancers of the ovary and breast"].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Research Design; Taxoids | 1998 |
Taxanes in the treatment of breast cancer: a prodigy comes of age.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Metastasis; Neoplasm Proteins; Paclitaxel; Palliative Care; Survival Analysis; Taxoids; Tubulin; Vinca Alkaloids | 1999 |
Future directions with taxane therapy.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Female; Genital Neoplasms, Female; Humans; Paclitaxel; Taxoids | 1999 |
Clinical pharmacokinetics of docetaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Child; Clinical Trials as Topic; Docetaxel; Drug Interactions; Forecasting; Humans; Kidney Diseases; Liver Diseases; Paclitaxel; Protein Binding; Taxoids | 1999 |
A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Review of docetaxel and doxorubicin-based combinations in the management of breast cancer: from metastatic to adjuvant setting.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Combining new agents with anthracyclines in metastatic breast cancer: an overview of recent findings.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Recently initiated studies: neoadjuvant treatments in the next century.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Survival; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 1999 |
Combination of taxanes with radiation: preclinical studies.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Radiation; Mice; Neoplasms, Experimental; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Taxoids; Tumor Cells, Cultured | 1999 |
[Taxotere as second-line for metastatic breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 1999 |
Monotherapy of metastatic breast cancer: a review of newer agents.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Paclitaxel; Palliative Care; Taxoids; Vinblastine; Vinorelbine | 1999 |
Docetaxel. A pharmacoeconomic review of its use in the treatment of metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Economics, Pharmaceutical; Female; Humans; Paclitaxel; Taxoids | 1998 |
The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer (Review).
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Taxoids; Treatment Outcome | 1999 |
Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 1999 |
Phase III randomized trials of docetaxel in patients with metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Mitomycin; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Vinblastine | 1999 |
Docetaxel and anthracycline polychemotherapy in the treatment of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 1999 |
Single-agent docetaxel (Taxotere) in randomized phase III trials.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Failure | 1999 |
Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Clinical Trials as Topic; Docetaxel; Doxorubicin; Heart; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Recent progress in the clinical development of docetaxel (Taxotere).
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Emerging role of docetaxel (Taxotere) in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Treatment Failure | 1999 |
Docetaxel (Taxotere) and gemcitabine phase I and early phase II studies: results to date and an overview of ongoing studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Docetaxel (Taxotere) in combination with platinum-based regimens in non-small cell lung cancer: results and future developments.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Weekly administration of docetaxel (Taxotere): summary of clinical data.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Humans; Paclitaxel; Taxoids | 1999 |
Docetaxel (Taxotere) and neoadjuvant chemotherapy for non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Overview of docetaxel (Taxotere) in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Docetaxel (Taxotere) and gemcitabine in combination therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Docetaxel (Taxotere) in non-small cell lung cancer: ongoing studies in Heidelberg and future plans.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Palliative Care; Radiotherapy, Adjuvant; Taxoids | 1999 |
New approaches in the adjuvant and neoadjuvant therapy of non-small cell lung cancer, including docetaxel (Taxotere) combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Chemotherapy in head and neck cancer. Overview of newer agents.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Head and Neck Neoplasms; Humans; Organoplatinum Compounds; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1999 |
The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cyclic AMP-Dependent Protein Kinases; Docetaxel; Estramustine; Genes, bcl-2; Humans; Microtubules; Mitogen-Activated Protein Kinases; Multigene Family; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Taxoids; Tumor Cells, Cultured; Vinblastine; Vincristine; Vinorelbine | 1999 |
A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Female; Head and Neck Neoplasms; Humans; Life Tables; Male; Metabolic Clearance Rate; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Tomography, X-Ray Computed | 1999 |
Taxanes in combined-modality therapy for solid tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Paclitaxel; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Stomach Neoplasms; Taxoids | 1999 |
Docetaxel (Taxotere) in combination chemotherapy and in association with thoracic radiotherapy for the treatment of non-small-cell lung cancer. Thoracic Oncology Program.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1999 |
[The administration of Docetaxel (taxoter): a new stage in chemotherapy of cancer].
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1999 |
Docetaxel in the treatment of non-small cell lung cancer: review of single-agent trials.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Taxoids | 1999 |
Phase II trials of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 1999 |
Docetaxel and gemcitabine combinations in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Mechanisms of action of taxanes in prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Male; Microtubules; Neoplasms, Hormone-Dependent; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tumor Suppressor Protein p53 | 1999 |
Docetaxel (Taxotere): preclinical and general clinical information.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Drug Evaluation, Preclinical; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Estramustine; Humans; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Docetaxel; Estramustine; Humans; Male; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Hormone-refractory prostate cancer: an evolving standard of care.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Taxanes: an overview of the pharmacokinetics and pharmacodynamics.
Topics: Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Docetaxel; Drug Interactions; Humans; Male; Mitosis; Molecular Structure; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Enzyme Inhibitors; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Platinum; Quinazolines; Taxoids; Thiophenes; Topoisomerase I Inhibitors | 1999 |
Expanding options in breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
New options in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Ifosfamide; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 1999 |
Progress in the treatment of ovarian cancer. Scottish Gynaecological Cancer Trials Group.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Randomized Controlled Trials as Topic; Taxoids | 1999 |
The chemotherapy of head and neck cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Neoadjuvant Therapy; Paclitaxel; Taxoids | 1999 |
Taxoids in head and neck cancer: the American approach.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; United States | 1999 |
[New drugs in gastrointestinal oncology. Current status and future directions].
Topics: Antineoplastic Agents; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Quinazolines; Taxoids; Tegafur; Thiophenes; Vinblastine; Vinorelbine | 1999 |
Role of taxanes in adjuvant therapy.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 2000 |
[Recent regimen of chemotherapy for advanced head and neck carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Neoadjuvant Therapy; Paclitaxel; Prognosis; Taxoids | 2000 |
[New combination therapies for gastrointestinal cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Docetaxel; Fluorouracil; Humans; Irinotecan; Leucovorin; Paclitaxel; Prognosis; Stomach Neoplasms; Survival Analysis; Taxoids | 2000 |
[New combination chemotherapies for breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2000 |
[New regimens for the treatment of gynecologic cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Taxoids; Thrombocytopenia; Uterine Cervical Neoplasms | 2000 |
[New combination chemotherapy in urological cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Methotrexate; Paclitaxel; Prostatic Neoplasms; Taxoids; Testicular Neoplasms; Urinary Bladder Neoplasms; Vinblastine | 2000 |
Docetaxel: an update of its use in advanced breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Economics, Pharmaceutical; Female; Humans; Metabolic Clearance Rate; Paclitaxel; Taxoids; Tissue Distribution; Tumor Cells, Cultured | 2000 |
Paclitaxel and docetaxel combinations in non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2000 |
New chemotherapy agents for small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Topotecan; Vinblastine; Vinorelbine | 2000 |
The taxanes: an update.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2000 |
Docetaxel (Taxotere) in the treatment of cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Prognosis; Prostatic Neoplasms; Taxoids | 2000 |
Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Humans; Lung Neoplasms; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Doxorubicin; Female; Humans; Paclitaxel; Taxoids | 2000 |
Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Paclitaxel; Prognosis; Receptor, ErbB-2; Taxoids; Trastuzumab | 2000 |
Docetaxel (Taxotere) in hormone-refractory prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2000 |
[Current perspectives of new agents in lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2000 |
Advanced non-small cell lung carcinoma: the emerging role of docetaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Salvage Therapy; Taxoids | 2000 |
[Taxoids: structural and experimental properties].
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Microtubules; Paclitaxel; Structure-Activity Relationship; Taxoids | 1995 |
Role of taxoids in head and neck cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Docetaxel; Head and Neck Neoplasms; Humans; Microtubules; Paclitaxel; Taxoids | 2000 |
Docetaxel (Taxotere) in the treatment of non-small cell lung cancer (NSCLC)--is there a role for a new chemotherapy programme?
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2000 |
Combining taxanes with radiation for solid tumors.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 2000 |
Managing the neurotoxicity of paclitaxel (Taxol) and docetaxel (Taxotere) with neurotrophic factors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Docetaxel; Glial Cell Line-Derived Neurotrophic Factor; Humans; Insulin-Like Growth Factor I; Nerve Growth Factor; Nerve Growth Factors; Nerve Tissue Proteins; Neurons; Paclitaxel; Taxoids | 2000 |
Docetaxel: a review of its use in non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Taxoids | 2000 |
The immunological effects of taxanes.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cytokines; Docetaxel; Humans; Immune System; Immunosuppressive Agents; Lipopolysaccharides; Macrophages; Models, Biological; Paclitaxel; Taxoids | 2000 |
[Evidence for Taxotere treatment with solid tumors].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Evidence-Based Medicine; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel; Stomach Neoplasms; Taxoids | 2000 |
[Vinorelbine in the treatment of non-small-cell lung cancer and breast cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Evidence-Based Medicine; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2000 |
The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Decision Making; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Paclitaxel; Taxoids | 2000 |
Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Gemcitabine; Head and Neck Neoplasms; Humans; Ifosfamide; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2000 |
Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Remission Induction; Taxoids; Vinblastine; Vinorelbine | 2000 |
Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drugs, Investigational; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine | 2000 |
Chemotherapy in metastatic non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Mitomycin; Paclitaxel; Taxoids; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 2000 |
Chemotherapy-induced complete regression of choroidal metastases and subsequent isolated leptomeningeal carcinomatosis in advanced breast cancer: a case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Choroid Neoplasms; Combined Modality Therapy; Docetaxel; Female; Humans; Meningeal Neoplasms; Methotrexate; Mitoxantrone; Paclitaxel; Survival Analysis; Taxoids | 2000 |
[Neoadjuvant chemotherapy for locally advanced breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Paclitaxel; Premedication; Tamoxifen; Taxoids | 2000 |
[Standard chemotherapy for metastatic breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Paclitaxel; Practice Guidelines as Topic; Prognosis; Taxoids | 2000 |
[Docetaxel hydrate for treatment of advanced breast cancers].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Paclitaxel; Taxoids | 2000 |
[Chemosensitivity test of breast cancer].
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Lymphatic Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Predictive Value of Tests; Taxoids; Tumor Cells, Cultured | 2000 |
State-of-the-art chemotherapy for advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Fluorouracil; Humans; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2000 |
A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Quality of Life; Survival Analysis; Taxoids | 2000 |
Risks and benefits of taxanes in breast and ovarian cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Female; Humans; Ovarian Neoplasms; Paclitaxel; Premedication; Taxoids | 2000 |
Docetaxel as an alternative to paclitaxel after acute hypersensitivity reactions.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Drug Hypersensitivity; Female; Humans; Lung Neoplasms; Middle Aged; Ovarian Neoplasms; Paclitaxel; Taxoids | 2000 |
[Recent advance in gastric cancer chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Mitomycin; Paclitaxel; Prognosis; RNA, Messenger; Stomach Neoplasms; Taxoids; Thymidylate Synthase | 2000 |
[Latest progress on chemotherapy for advanced gastric cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Oxonic Acid; Paclitaxel; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2000 |
Second-line chemotherapy for non-small-cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Health Status; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2000 |
[Peripheral nervous system neurotoxicity secondary to chemotherapy treatment] .
Topics: Anti-HIV Agents; Antineoplastic Agents; Cyclosporine; Depsipeptides; Docetaxel; Doxorubicin; Humans; Neoplasms; Neuromuscular Diseases; Oligopeptides; Organoplatinum Compounds; Paclitaxel; Peripheral Nervous System Diseases; Procarbazine; Reverse Transcriptase Inhibitors; Suramin; Taxoids; Vinca Alkaloids | 2000 |
Gemcitabine: progress in the treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Irinotecan; Matrix Metalloproteinase Inhibitors; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Developments in the treatment of gastric cancer in Europe.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Docetaxel; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Analysis; Taxoids | 2000 |
Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Paclitaxel; Palliative Care; Prednisolone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2000 |
Docetaxel followed by gemcitabine and irinotecan in solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Survival Rate; Taxoids | 2001 |
Chemoradiation in locally advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Forecasting; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Treatment of extensive stage small cell lung cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Genes, Dominant; Growth Substances; Humans; Irinotecan; Lung Neoplasms; Metalloendopeptidases; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasm Staging; Oncogenes; Paclitaxel; Palliative Care; Protease Inhibitors; Randomized Controlled Trials as Topic; Salvage Therapy; Signal Transduction; Taxoids; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Genes, erbB-2; Humans; Paclitaxel; Taxoids; Trastuzumab | 2000 |
Taxanes in combined modality therapy for solid tumors.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 2001 |
Docetaxel/gemcitabine: salvage chemotherapy in anthracycline-pretreated patients with advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Taxoids | 2001 |
Docetaxel (Taxotere) in combination with platinums in patients with non-small cell lung cancer: trial data and implications for clinical management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Radiation-Sensitizing Agents; Taxoids | 2001 |
Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Radiation-Sensitizing Agents; Taxoids | 2001 |
Advances in the treatment of non-small cell lung cancer: molecular markers take the stage.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Neoplasm Proteins; Neoplasm Staging; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins; Taxoids | 2001 |
Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2001 |
Clinical pharmacokinetics of capecitabine.
Topics: Antacids; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Fluorouracil; Food; Humans; Intestinal Absorption; Leucovorin; Liver Diseases; Paclitaxel; Protein Binding; Taxoids | 2001 |
Recent advances in bladder cancer chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Urinary Bladder Neoplasms | 2001 |
Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Docetaxel; Drug Synergism; Genes, erbB-2; Heart Failure; Humans; Paclitaxel; Prognosis; Proto-Oncogene Mas; Taxoids; Trastuzumab | 2001 |
The platinum agents: a role in breast cancer treatment?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cisplatin; Clinical Trials as Topic; Docetaxel; Humans; Paclitaxel; Taxoids; Trastuzumab | 2001 |
Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Genes, erbB-2; Humans; Paclitaxel; Taxoids; Trastuzumab | 2001 |
Taxanes in lung cancer: a review with focus on the European experience.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Taxoids | 2001 |
Severe interstitial pneumonitis following high-dose cyclophosphamide, thiotepa and docetaxel: two case reports and a review of the literature.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Female; Hematopoietic Stem Cell Transplantation; Humans; Lung Diseases, Interstitial; Methylprednisolone; Middle Aged; Paclitaxel; Taxoids; Thiotepa | 2001 |
Docetaxel: assessing a range of activity.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 2001 |
The current status of docetaxel for advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2001 |
Docetaxel in prostate cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Male; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2001 |
Docetaxel in squamous cell cancer of the head and neck.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Head and Neck Neoplasms; Humans; Paclitaxel; Taxoids | 2001 |
Issues involved in research into the neoadjuvant treatment of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Research; Taxoids | 2001 |
Neoadjuvant therapy for non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2001 |
Docetaxel: overview of an active drug for breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2001 |
Docetaxel and epirubicin in advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Paclitaxel; Taxoids | 2001 |
Nonanthracycline containing docetaxel-based combinations in metastatic breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2001 |
Docetaxel and herceptin: foundation for future strategies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Therapy, Combination; Forecasting; Humans; Paclitaxel; Taxoids; Trastuzumab | 2001 |
Weekly docetaxel in breast cancer: applying clinical data to patient therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Chronotherapy; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2001 |
Novel compounds in the therapy of breast cancer: opportunities for integration with docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Epidermal Growth Factor; ErbB Receptors; Female; Humans; Oligonucleotides, Antisense; Paclitaxel; Taxoids | 2001 |
Progress in the development of alternative pharmaceutical formulations of taxanes.
Topics: Animals; Antineoplastic Agents, Phytogenic; Chemistry, Pharmaceutical; Cyclodextrins; Docetaxel; Drug Compounding; Emulsions; Humans; Neoplasms; Paclitaxel; Prodrugs; Solvents; Surface-Active Agents; Taxoids | 2001 |
Oral delivery of taxanes.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Cyclosporine; Cyclosporins; Docetaxel; Humans; Mice; Mice, Knockout; Neoplasms; Paclitaxel; Taxoids | 2001 |
Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Computer Simulation; Docetaxel; Humans; Lung Neoplasms; Models, Statistical; Neoplasms; Nonlinear Dynamics; Paclitaxel; Prospective Studies; Research Design; Taxoids | 2001 |
Body surface area as a determinant of pharmacokinetics and drug dosing.
Topics: Adult; Animals; Anthropometry; Antineoplastic Agents; Area Under Curve; Body Surface Area; Carboplatin; Cardiac Output; Child; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Humans; Kidney; Liver; Medical Oncology; Neoplasms; Paclitaxel; Taxoids | 2001 |
Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Chemistry, Pharmaceutical; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Interactions; Glycerol; Humans; Neoplasms; Paclitaxel; Pharmaceutical Vehicles; Radiotherapy, Adjuvant; Taxoids; Vinca Alkaloids | 2001 |
Epirubicin/taxane combinations in breast cancer: experience from several Italian trials.
Topics: Breast Neoplasms; Bridged-Ring Compounds; Docetaxel; Drug Therapy, Combination; Epirubicin; Female; Humans; Italy; Meta-Analysis as Topic; Paclitaxel; Taxoids | 2001 |
[New drugs for unresectable or recurrent gastric cancer--paclitaxel and docetaxel].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Docetaxel; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Stomach Neoplasms; Taxoids; Treatment Outcome | 2001 |
New drug and multimodality combinations in the treatment of advanced non--small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Survival Rate; Taxoids | 2001 |
Phase III randomized trial of docetaxel in combination with cisplatin or carboplatin or vinorelbine plus cisplatin in advanced non--small cell lung cancer: interim analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2001 |
Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non--small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Survival Rate; Taxoids | 2001 |
Integration of new chemotherapeutic agents into chemoradiotherapy for stage III non--small cell lung cancer: focus on docetaxel.
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Survival Rate; Taxoids | 2001 |
Review of two phase III randomized trials of single-agent docetaxel in previously treated advanced non--small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Quality of Life; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2001 |
General and recent aspects of the chemistry and structure-activity relationships of taxoids.
Topics: Animals; Antineoplastic Agents, Phytogenic; Binding Sites; Docetaxel; Humans; Molecular Conformation; Paclitaxel; Structure-Activity Relationship; Taxoids | 2001 |
Preclinical evaluation of new taxoids.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Docetaxel; Neoplasms, Experimental; Paclitaxel; Taxoids | 2001 |
Rationale for non-platinum chemotherapy in advanced NSCLC.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2001 |
New cytotoxic agents and schedules for advanced breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Female; Fluorouracil; Gemcitabine; Humans; Liposomes; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Trastuzumab; Vinblastine; Vinorelbine | 2001 |
Paclitaxel and docetaxel in prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estramustine; Etoposide; Genes, bcl-2; Humans; Hydrocortisone; Male; Microtubules; Mitosis; Mitoxantrone; Multicenter Studies as Topic; Neoplasm Proteins; Oligodeoxyribonucleotides, Antisense; Paclitaxel; Palliative Care; Prostatic Neoplasms; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Survival Analysis; Taxoids; Treatment Outcome; Tubulin | 2001 |
Drug interactions with the taxanes: clinical implications.
Topics: Anticonvulsants; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Interactions; Humans; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia | 2001 |
Pharmacokinetic profiles of doxorubicin in combination with taxanes.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Drug Interactions; Humans; Paclitaxel; Taxoids | 2001 |
Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Heart Diseases; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2001 |
Epirubicin in combination with the taxanes.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Epirubicin; Heart Diseases; Humans; Paclitaxel; Taxoids | 2001 |
Can chemotherapy alter the course of prostate cancer?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Neoplasm Staging; Paclitaxel; Prostatic Neoplasms; Quality of Life; Taxoids | 2001 |
Complications of chemotherapy for prostate cancer.
Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Docetaxel; Gastrointestinal Diseases; Humans; Male; Mitoxantrone; Nervous System Diseases; Paclitaxel; Prednisone; Prostatic Neoplasms; Taxoids | 2001 |
Indications for chemotherapy in stage IV non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Taxoids; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 2001 |
New adjuvant therapies for esophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Digestive System Surgical Procedures; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Paclitaxel; Radiotherapy, Adjuvant; Taxoids | 2001 |
Role of taxanes in the combined modality treatment of patients with locally advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Guidelines as Topic; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
[Recall dermatitis caused by re-exposure to docetaxel following irradiation of the brain. Case report and review of the literature].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Drug Eruptions; Female; Humans; Middle Aged; Paclitaxel; Radiation-Sensitizing Agents; Radiodermatitis; Radiotherapy Dosage; Taxoids | 2001 |
Prevention and management of antineoplastic-induced hypersensitivity reactions.
Topics: Antineoplastic Agents; Asparaginase; Docetaxel; Drug Hypersensitivity; Humans; Neoplasms; Organoplatinum Compounds; Paclitaxel; Podophyllotoxin; Taxoids | 2001 |
[Docetaxel].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Paclitaxel; Taxoids | 2001 |
Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Cell Cycle; Docetaxel; Drug Evaluation, Preclinical; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Male; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tubulin; Tumor Cells, Cultured | 2001 |
Prostate cancer: multimodality approaches with docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Docetaxel; Humans; Male; Paclitaxel; Prostatic Neoplasms; Radiation-Sensitizing Agents; Taxoids | 2001 |
Second-line chemotherapy for non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2001 |
Interaction between Herceptin and taxanes.
Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Heart Diseases; Humans; Mice; Mice, Nude; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; Nervous System Diseases; Neutropenia; Paclitaxel; Palliative Care; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptor, ErbB-3; Salvage Therapy; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome; Xenograft Model Antitumor Assays | 2001 |
Role of Herceptin in primary breast cancer: views from North America and Europe.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Interactions; Europe; Female; Humans; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; North America; Paclitaxel; Palliative Care; Pilot Projects; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Research Design; Safety; Survival Analysis; Tamoxifen; Taxoids; Trastuzumab; Treatment Outcome | 2001 |
[Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Female; Germany; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Taxoids; Treatment Outcome | 2001 |
Chemotherapy for advanced non-small cell lung cancer: standards.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Decision Making; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Palliative Care; Patient Selection; Practice Guidelines as Topic; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2001 |
Cost effectiveness of treatment options in advanced breast cancer in the UK.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cost-Benefit Analysis; Decision Making, Computer-Assisted; Docetaxel; Female; Humans; Paclitaxel; Quality-Adjusted Life Years; Salvage Therapy; Taxoids; United Kingdom; Vinblastine; Vinorelbine | 2001 |
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2001 |
Radiosensitization with chemotherapeutic agents.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Platinum Compounds; Radiation-Sensitizing Agents; Taxoids; Vinblastine; Vinorelbine | 2001 |
Thymic carcinoma successfully resected with superior vena cava after chemoradiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Pericardial Effusion; Pleural Effusion, Malignant; Taxoids; Thymus Neoplasms; Vena Cava, Superior | 2001 |
Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost of Illness; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Controversies in chemotherapy of prostate cancer.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Androgen Antagonists; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clinical Trials as Topic; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Paclitaxel; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Suramin; Taxoids; Testosterone; Treatment Outcome | 2002 |
[Present role and future prospect of superselective intra-arterial infusion chemotherapy for head and neck cancer].
Topics: Adult; Aged; Antidotes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Paclitaxel; Prospective Studies; Taxoids; Thiosulfates | 2002 |
Gemcitabine-based combination treatment of pancreatic cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Patient Selection; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Disease Models, Animal; Docetaxel; Humans; Immunohistochemistry; Lung Neoplasms; Mice; Paclitaxel; Rats; Sulindac; Survival Analysis; Taxoids; Treatment Outcome; Tumor Cells, Cultured | 2002 |
Chemistry and chemical biology of taxane anticancer agents.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Models, Molecular; Paclitaxel; Structure-Activity Relationship; Taxoids | 2001 |
Taxanes and capecitabine in combination: rationale and clinical results.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Synergism; Fluorouracil; Humans; Paclitaxel; Survival Analysis; Taxoids; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation | 2002 |
Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Evidence-Based Medicine; Female; Genes, erbB-2; Humans; Infusions, Intravenous; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Use of taxanes in the treatment of patients with breast cancer has increased dramatically over the past 8 years.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Utilization; Female; Humans; Medical Oncology; Paclitaxel; Patient Selection; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
[Developed new agents for lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2002 |
[Current and future state of chemoradiotherapy for head and neck cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intra-Arterial; Organoplatinum Compounds; Paclitaxel; Taxoids | 2002 |
[New therapeutic approaches in non-small-cell lung carcinoma (NSCLC), stages IV].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2001 |
The choice of adjuvant combination therapies with taxanes: rationale and issues addressed in ongoing studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Decision Making; Docetaxel; Doxorubicin; Female; Humans; Paclitaxel; Prognosis; Research Design; Taxoids | 2001 |
Trials of new combinations of Herceptin in metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Paclitaxel; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2001 |
[Current status of the chemotherapy for lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate; Taxoids | 2002 |
Docetaxel in advanced gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Humans; Paclitaxel; Stomach Neoplasms; Taxoids; Treatment Outcome | 2002 |
[Crystallography of drug polymorphism: emergence of new resolution methods and prediction of crystalline structures].
Topics: Crystallization; Docetaxel; Indolizines; Molecular Conformation; Paclitaxel; Pharmaceutical Preparations; Pyridines; Taxoids | 2002 |
Epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Practice Guidelines as Topic; Tamoxifen; Taxoids; Topotecan; Vinblastine; Vinorelbine | 2002 |
A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Epirubicin; Fluorouracil; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Interferon alpha-2; Interferon-alpha; Irinotecan; Leucovorin; Multicenter Studies as Topic; Organoplatinum Compounds; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Recombinant Proteins; Respiratory Distress Syndrome; Taxoids; Treatment Outcome | 2002 |
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; England; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Survival Rate; Taxoids; Vinblastine; Vinorelbine; Wales | 2001 |
Effects of docetaxel on pain due to metastatic androgen-independent prostate cancer.
Topics: Aged; Androgens; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Humans; Male; Paclitaxel; Pain; Prostatic Neoplasms; Taxoids | 2002 |
Present and future treatment of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Taxoids | 2002 |
The present and future of combination chemotherapy in bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Glutamates; Guanine; Humans; Methotrexate; Paclitaxel; Pemetrexed; Taxoids; Urinary Bladder Neoplasms; Vinblastine | 2002 |
[Docetaxel].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Radiotherapy, Adjuvant; Taxoids | 2002 |
[Gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2002 |
[Carboplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
[New treatment strategy for stage III non-small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Quinazolines; Radiotherapy; Taxoids; Treatment Outcome; Vinblastine | 2002 |
[Chemotherapy for elderly patients with lung cancer].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vincristine; Vinorelbine | 2002 |
Docetaxel in the management of advanced or metastatic urothelial tract cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Paclitaxel; Taxoids; Urologic Neoplasms | 2002 |
The current status of docetaxel for metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Taxoids | 2002 |
Integration of docetaxel into adjuvant breast cancer treatment regimens.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2002 |
Primary chemotherapy with docetaxel for the management of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2002 |
Docetaxel for previously treated non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2002 |
Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Quality of Life; Taxoids | 2002 |
Docetaxel in the integrated management of prostate cancer. Current applications and future promise.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Forecasting; Humans; Male; Neoadjuvant Therapy; Paclitaxel; Prostatic Neoplasms; Recurrence; Taxoids | 2002 |
Docetaxel in the treatment of ovarian cancer.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids | 2002 |
The role of docetaxel in the management of squamous cell cancer of the head and neck.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Squamous Cell; Paclitaxel; Radiation-Sensitizing Agents; Taxoids | 2002 |
Docetaxel for gastric and esophageal carcinomas.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Clinical Trials as Topic; Docetaxel; Esophageal Neoplasms; Humans; Paclitaxel; Stomach Neoplasms; Taxoids | 2002 |
Docetaxel and radiation as combined-modality therapy.
Topics: Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Taxoids | 2002 |
The role of chemotherapy in advanced prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Estramustine; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids | 2002 |
Trastuzumab/chemotherapy combinations in metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Platinum Compounds; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2002 |
Gemcitabine and targeted therapy in metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2002 |
Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
[Prevention and treatment for adverse events induced by chemotherapy].
Topics: Anaphylaxis; Antineoplastic Agents; Brain Diseases; Cisplatin; Docetaxel; Fluorouracil; Humans; Neoplasms; Neutropenia; Paclitaxel; Taxoids; Vomiting, Anticipatory | 2002 |
Expanding horizons: an update on the use of docetaxel in non-small cell lung, ovarian, and breast cancers.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2002 |
Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Perspectives and opportunities: Docetaxel in the current and future treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
Docetaxel in ovarian cancer: phase III perspectives and future development.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Docetaxel in the treatment of breast cancer: an update on recent studies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Trastuzumab | 2002 |
Combination of taxanes and anthracyclines in first-line chemotherapy of metastatic breast cancer: an interim report.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Female; Hematologic Diseases; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2002 |
End points for new agents in induction chemotherapy for locally advanced head and neck cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Docetaxel; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiation-Protective Agents; Radiotherapy; Radiotherapy Dosage; Taxoids; Time Factors; Treatment Outcome | 2002 |
The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Europe; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Palliative Care; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome; United Kingdom; Vinblastine; Vinorelbine | 2002 |
Chemotherapy for androgen-independent prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Prostatic Neoplasms; Taxoids | 2002 |
Gemcitabine-based therapy in pancreas cancer: gemcitabine-docetaxel and other novel combinations.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Trastuzumab | 2002 |
[Randomized controlled trials in Japan--lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Irinotecan; Lung Neoplasms; Meta-Analysis as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2002 |
Camptothecin and taxane regimens for small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Small Cell; Docetaxel; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2002 |
[Radiation recall dermatitis after docetaxel and external beam radiotherapy. Report of two cases and review of the literature].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Lobular; Combined Modality Therapy; Docetaxel; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Paclitaxel; Radiodermatitis; Radiotherapy; Taxoids | 2002 |
Docetaxel-induced nail dystrophy.
Topics: Acute Disease; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Nail Diseases; Paclitaxel; Prostatic Neoplasms; Taxoids | 2002 |
Non-platinum gemcitabine combinations in non-small cell lung cancer.
Topics: Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival; Taxoids; Treatment Outcome | 2002 |
Overcoming multidrug resistance in taxane chemotherapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Bridged-Ring Compounds; Clinical Trials as Topic; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Models, Molecular; Paclitaxel; Taxoids | 2002 |
Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2002 |
The European experience with docetaxel in the treatment of early-stage breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Europe; Female; Genes, p53; Humans; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2002 |
HER2-positive breast cancer: update on Breast Cancer International Research Group trials.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Multicenter Studies as Topic; Paclitaxel; Platinum Compounds; Receptor, ErbB-2; Taxoids; Trastuzumab; Up-Regulation | 2002 |
Ongoing US cooperative group trials using taxanes in the adjuvant setting.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Risk Factors; Taxoids; Trastuzumab; United States | 2002 |
The search for enhanced therapeutic index in breast cancer: targeting the tumor and modulation of enzyme expression.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Design; Drug Synergism; Enzyme Induction; Epirubicin; Female; Fluorouracil; Humans; Irinotecan; Multicenter Studies as Topic; Neoplasm Proteins; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Thymidine Phosphorylase; Topoisomerase I Inhibitors; Treatment Outcome | 2002 |
[New neoadjuvant approaches using gemcitabine in non-small-cell lung cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Randomized Controlled Trials as Topic; Remission Induction; Taxoids; Treatment Outcome | 2002 |
[Combinations of platinum salts and gemcitabine in the treatment of non-small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Randomized Controlled Trials as Topic; Remission Induction; Reproducibility of Results; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
[Platinum-free gemcitabine-based combinations: an alternative to conventional chemotherapy of non-small-cell lung cancers?].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
[Gemcitabine-based combinations in inoperable pancreatic cancers].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Routes; Epirubicin; Fluorouracil; Gemcitabine; Humans; Irinotecan; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
[Gemcitabine and breast cancer].
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Immunotherapy; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Treatment for anthracycline-pretreated metastatic breast cancer.
Topics: Administration, Oral; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Economics, Pharmaceutical; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Combination versus sequential single-agent therapy in metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Quality of Life; Research Design; Taxoids; Trastuzumab | 2002 |
Taxanes for advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2002 |
Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estramustine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Fatal Outcome; Humans; Male; Paclitaxel; Prostatic Neoplasms; Radiography; Respiratory Insufficiency; Taxoids | 2002 |
Second line chemotherapy for NSCLC: establishing a gold standard.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Quality of Life; Taxoids; Treatment Outcome | 2002 |
First-line chemotherapy for NSCLC: an overview of relevant trials.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Disease Progression; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Survival; Taxoids; Treatment Outcome | 2002 |
Challenging the platinum combinations in the chemotherapy of NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Taxoids | 2002 |
Adjuvant and neoadjuvant treatments for NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Radiotherapy, Adjuvant; Survival; Taxoids | 2002 |
Meeting the chemotherapy needs of elderly and poor performance status patients with NSCLC.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Health Status; Humans; Lung Neoplasms; Paclitaxel; Palliative Care; Survival; Taxoids; Vinblastine; Vinorelbine | 2002 |
Weekly schedule of docetaxel in breast cancer: evaluation of response and toxicity.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Paclitaxel; Taxoids | 2003 |
Cutaneous reactions to chemotherapy drugs: the art of consultation.
Topics: Animals; Antineoplastic Agents; Bleomycin; Docetaxel; Doxorubicin; Drug Eruptions; Humans; Hydroxyurea; Paclitaxel; Skin; Taxoids; Thalidomide | 2003 |
Adjuvant use of taxanes for patients with breast cancer: we see the tip of the iceberg.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Mastectomy, Segmental; Neoplasm Staging; Paclitaxel; Patient Selection; Prognosis; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Survival Analysis; Taxoids; Treatment Outcome; United States | 2002 |
Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase II as Topic; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Neoplasm Staging; Paclitaxel; Remission Induction; Taxoids | 2003 |
Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Pancreatic Neoplasms; Signal Transduction; Taxoids; Transcription Factors; Treatment Failure | 2002 |
Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Hydroxamic Acids; Irinotecan; Organic Chemicals; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Phenylbutyrates; Quinolones; Randomized Controlled Trials as Topic; Taxoids | 2002 |
Adjuvant systemic therapy of early stage breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Enzyme Inhibitors; Female; Humans; Neoplasm Staging; Paclitaxel; Taxoids | 2003 |
[Chemotherapy for prostate cancers].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Estramustine; Etoposide; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids; Vinblastine | 2002 |
[Therapy for hormone-refractory prostate cancer].
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topic; Clodronic Acid; Cyclophosphamide; Dexamethasone; Docetaxel; Estramustine; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Strontium Radioisotopes; Taxoids; Tegafur; Treatment Outcome | 2002 |
Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Fluorouracil; Head and Neck Neoplasms; Humans; Paclitaxel; Prognosis; Radiotherapy, Adjuvant; Taxoids | 2003 |
Managing taxane toxicities.
Topics: Antineoplastic Agents, Phytogenic; Arthralgia; Bridged-Ring Compounds; Docetaxel; Drug Hypersensitivity; Humans; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Taxoids; Thrombocytopenia | 2003 |
[A new model of human prostate cancer, the PAC120 xenograft].
Topics: Adenocarcinoma; Animals; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Prostatic Neoplasms; Taxoids; Transplantation, Heterologous | 2003 |
Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Microtubules; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Palliative Care; Podophyllotoxin; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Docetaxel in non-small cell lung cancer: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Docetaxel; Drug Administration Schedule; Economics, Pharmaceutical; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2003 |
The solid state, solution and tubulin-bound conformations of agents that promote microtubule stabilization.
Topics: Antineoplastic Agents, Phytogenic; Binding Sites; Carbohydrate Conformation; Crystallography, X-Ray; Docetaxel; Drug Design; Magnetic Resonance Spectroscopy; Microtubules; Models, Molecular; Molecular Structure; Paclitaxel; Solutions; Taxoids; Tubulin | 2002 |
Role of gemcitabine in the treatment of advanced and metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Epirubicin; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vindesine; Vinorelbine | 2003 |
The role of taxanes as a component of neoadjuvant chemotherapy for breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Clinical Trials as Topic; Docetaxel; Humans; Neoadjuvant Therapy; Paclitaxel; Taxoids | 2003 |
Active chemotherapy for bone metastasis in sarcomatoid renal cell carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Carboplatin; Carcinoma, Renal Cell; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Kidney Neoplasms; Neoplasm Staging; Nephrectomy; Paclitaxel; Sarcoma; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Gemcitabine combined with docetaxel in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2003 |
[Gene therapy for breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Female; Genes, erbB-2; Genes, MDR; Genes, p53; Genes, Tumor Suppressor; Genetic Therapy; Genetic Vectors; Humans; Interleukins; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Retroviridae; Taxoids | 2003 |
Current status of taxane and platinum-based chemotherapy in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
The evolving role of capecitabine in breast cancer.
Topics: Age Factors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Controlled Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Paclitaxel; Prodrugs; Taxoids; Trastuzumab; Treatment Outcome; United States; Vinblastine; Vinorelbine | 2003 |
Signal transduction pathways of taxanes-induced apoptosis.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Apoptosis; Caspases; Docetaxel; Humans; Microtubules; Paclitaxel; Phosphorylation; Signal Transduction; Taxoids | 2003 |
Exudative hyponychial dermatitis associated with capecitabine and docetaxel combination chemotherapy for metastatic breast carcinoma: report of three cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Eruptions; Exudates and Transudates; Female; Fluorouracil; Humans; Middle Aged; Nail Diseases; Paclitaxel; Taxoids | 2003 |
Potential for combined modality therapy of cyclooxygenase inhibitors and radiation.
Topics: Angiogenesis Inhibitors; Animals; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Docetaxel; Humans; Isoenzymes; Lung Neoplasms; Membrane Proteins; Neoplasms; Paclitaxel; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Radiation-Sensitizing Agents; Taxoids | 2003 |
Docetaxel-based chemotherapy in the treatment of gastric cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Europe; Fluorouracil; Humans; Multicenter Studies as Topic; Paclitaxel; Research Design; Stomach Neoplasms; Taxoids; Treatment Outcome | 2003 |
Docetaxel (taxotere) in the treatment of prostate cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids | 2003 |
[Recent advances in chemotherapy for digestive cancers with special references to gastric and colonic cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Docetaxel; Drug Administration Schedule; Drug Combinations; Drug Delivery Systems; Fluorouracil; Humans; Irinotecan; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Taxoids; Tegafur | 2003 |
New principles in the treatment of prostate cancer--the oncologist's view.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Male; Mitoxantrone; Paclitaxel; Prostatic Neoplasms; Radiotherapy, High-Energy; Taxoids | 2003 |
Docetaxel-anthracycline combinations in metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2003 |
Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Trastuzumab | 2003 |
Neoadjuvant docetaxel in locally advanced breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Taxoids | 2003 |
The role of taxanes in the adjuvant treatment of early stage breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Female; Humans; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2003 |
Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Taxoids | 2003 |
Management of toxicities associated with the administration of taxanes.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 2003 |
Use and abuse of taxanes in the management of metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Bias; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Patient Selection; Randomized Controlled Trials as Topic; Substance-Related Disorders; Taxoids | 2003 |
[Role of the combination of trastuzumab and taxanes in the therapeutic management of cancer of the breast: from preclinical data to clinical application].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Docetaxel; Drug Screening Assays, Antitumor; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab | 2003 |
Optimizing primary chemotherapy in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Ovarian Neoplasms; Paclitaxel; Taxoids | 2003 |
Mode of action of docetaxel - a basis for combination with novel anticancer agents.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; Follow-Up Studies; Humans; Male; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Pharmacogenetics; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Advances in the use of taxanes in the adjuvant therapy of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2003 |
New perspectives in the management of pancreas cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Taxoids | 2003 |
Intraperitoneal taxanes.
Topics: Antineoplastic Agents, Phytogenic; Biological Availability; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Docetaxel; Dose-Response Relationship, Drug; Female; Gastrointestinal Neoplasms; Humans; Infusions, Parenteral; Male; Maximum Tolerated Dose; Paclitaxel; Risk Assessment; Sensitivity and Specificity; Taxoids | 2003 |
Antiblastic drug combinations with ifosfamide: an update.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Ifosfamide; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2003 |
The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents.
Topics: Animals; Breast Neoplasms; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Structure-Activity Relationship; Taxoids | 2003 |
[Chemotherapy for gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Meta-Analysis as Topic; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2003 |
The best use of chemotherapy in the adjuvant setting.
Topics: Anthracyclines; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2003 |
The taxanes: toxicity and quality of life considerations in advanced ovarian cancer.
Topics: Clinical Trials as Topic; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Quality of Life; Taxoids | 2003 |
[Current status and perspectives of chemotherapy for anthracycline-pretreated breast cancer].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Retreatment; Survival Rate; Taxoids; Treatment Outcome | 2003 |
Gemcitabine combination chemotherapy in metastatic breast cancer: phase II experience.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2003 |
[Docetaxel and ovarian cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids | 2004 |
Use of fluorine in the medicinal chemistry and chemical biology of bioactive compounds--a case study on fluorinated taxane anticancer agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Docetaxel; Fluorine; Humans; Models, Molecular; Molecular Conformation; Paclitaxel; Structure-Activity Relationship; Taxoids | 2004 |
Taxanes in elderly breast cancer patients.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Paclitaxel; Taxoids; Treatment Outcome | 2004 |
Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Paclitaxel; Taxoids; Treatment Outcome | 2004 |
Preclinical pharmacology of the taxanes: implications of the differences.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Humans; Maximum Tolerated Dose; Neoplasms; Paclitaxel; Prognosis; Survival Rate; Taxoids | 2004 |
The treatment of advanced gastric cancer: new findings on the activity of the taxanes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Risk Assessment; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Taxane-platinum combinations in advanced non-small cell lung cancer: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Current data and ongoing trials in patients with recurrent non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cytotoxins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Glutathione; Guanine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Prodrugs; Prognosis; Quinazolines; Taxoids | 2004 |
[Neurotoxic effects of medications: an update].
Topics: Anti-Retroviral Agents; Antineoplastic Agents; Carboplatin; Cisplatin; Colchicine; Docetaxel; Humans; Interferon-alpha; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Taxoids; Thalidomide | 2004 |
Chemotherapy in gastric cancer: a brief chronicle with emphasis on recent developments.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Docetaxel; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pyrimidines; Stomach Neoplasms; Taxoids | 2004 |
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Endosonography; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Irinotecan; Life Tables; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Preoperative Care; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Radiotherapy, Adjuvant; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
[Treatment of platinum-resistant ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; DNA Damage; Docetaxel; Drug Resistance, Neoplasm; Etoposide; Female; Gynecologic Surgical Procedures; Humans; Irinotecan; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2004 |
[Do combinations without cisplatin represent an alternative to conventional chemotherapy in non-small cell lung cancers?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2004 |
Recurrent ovarian cancer: how important is it to treat to disease progression?
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Recurrence; Risk; Taxoids; Time Factors; Topotecan | 2004 |
[Second-line chemotherapy for recurrent ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Platinum; Taxoids | 2005 |
[Association of taxanes and radiotherapy: preclinical and clinical studies].
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cells, Cultured; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Taxoids; Time Factors; Tumor Cells, Cultured | 2004 |
Development of docetaxel in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2004 |
Chemoresistance in non-small cell lung cancer.
Topics: Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Tubulin; Vinblastine; Vinorelbine | 2005 |
Taxanes in the treatment of head and neck cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Head and Neck Neoplasms; Humans; Medical Oncology; Paclitaxel; Taxoids | 2005 |
The current role of chemotherapy in metastatic hormone-refractory prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Paclitaxel; Prostatic Neoplasms; Taxoids | 2005 |
Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer: a systematic review of phase III trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Databases, Bibliographic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Platinum Compounds; Quality Control; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Taxoids | 2005 |
Therapy of breast cancer with molecular targeting agents.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclooxygenase 2; Docetaxel; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Paclitaxel; Prenylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2005 |
Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology.
Topics: Animals; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Receptor, ErbB-2; Tamoxifen; Taxoids; Trastuzumab | 2005 |
The role of taxanes in the treatment of breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemistry, Pharmaceutical; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Female; Humans; Lymphatic Metastasis; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Trastuzumab | 2005 |
Revisiting induction chemotherapy for head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Paclitaxel; Taxoids | 2005 |
[Chemotherapy for advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2005 |
Taxanes in adjuvant breast cancer setting: which standard in Europe?
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Europe; Female; Humans; Paclitaxel; Taxoids | 2005 |
Perspectives on salvage therapy for non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Lung Neoplasms; Meta-Analysis as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2005 |
Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Trastuzumab | 2005 |
Taxanes in the treatment of early breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Taxoids | 2005 |
[Activity of Taxanes for advanced and recurrent pancreatic cancer].
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Humans; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Taxoids | 2006 |
[Progress in therapy for testicular tumors].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Camptothecin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lymph Node Excision; Male; Paclitaxel; Taxoids; Testicular Neoplasms | 2006 |
Taxanes in paediatric oncology: and now?
Topics: Antineoplastic Agents, Phytogenic; Child; Clinical Trials as Topic; Docetaxel; Humans; Medical Oncology; Neoplasms; Paclitaxel; Pediatrics; Taxoids | 2006 |
Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2006 |
Optimizing adjuvant chemotherapy in early-stage breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2005 |
Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2005 |
Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Taxoids | 2006 |
Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 2006 |
Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
[Molecular-targeted agents in breast cancer].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Drug Delivery Systems; Female; Humans; Indoles; Lapatinib; Middle Aged; Paclitaxel; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sunitinib; Taxoids; Trastuzumab | 2006 |
Overview of gemcitabine activity in advanced breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Taxoids | 2006 |
Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2006 |
Gemcitabine and taxanes in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2006 |
Non-platinum combination of gemcitabine in NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Platinum Compounds; Taxoids; Vinblastine; Vinorelbine | 2006 |
State-of-the-art management of metastatic disease at initial presentation or recurrence.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Taxoids; Urinary Bladder Neoplasms | 2006 |
Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Epothilones; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 2007 |
Taxanes: perspectives for biotechnological production.
Topics: Bridged-Ring Compounds; Cell Culture Techniques; Docetaxel; Molecular Structure; Paclitaxel; Taxoids; Taxus | 2007 |
[Indications, contra-indications, expected results and choice of neoadjuvant chemotherapy for operable breast cancer].
Topics: Age Factors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Contraindications; Docetaxel; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
[Chemotherapy in advanced gastric cancer--to ensure timely and appropriate switch to subsequent treatment options].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Methotrexate; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2007 |
Pharmacogenetics and oncology treatment for breast cancer.
Topics: Aromatase Inhibitors; Biological Transport; Breast Neoplasms; Cytochrome P-450 CYP2D6; Docetaxel; Female; Gene Amplification; Genes, bcl-1; Glucuronosyltransferase; Humans; Paclitaxel; Pharmacogenetics; Tamoxifen; Taxoids | 2007 |
Improved biochemical strategies for targeted delivery of taxoids.
Topics: Animals; Antineoplastic Agents; Docetaxel; Drug Delivery Systems; Humans; Paclitaxel; Prodrugs; Taxoids | 2007 |
[Non-cisplatin based chemotherapy in advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2007 |
Gemcitabine in the management of metastatic breast cancer: a systematic review.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2008 |
Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Paclitaxel; Taxoids | 2007 |
Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Heart Diseases; Humans; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2007 |
[Recent advances in the biosynthesis of Taxol].
Topics: Antineoplastic Agents, Phytogenic; Arteriosclerosis; Docetaxel; Genes, Plant; Genetic Engineering; Neoplasms; Paclitaxel; Taxoids; Taxus | 2007 |
Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents.
Topics: Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epothilones; Humans; Microtubules; Neoplasms; Paclitaxel; Taxoids; Tubulin Modulators | 2007 |
[Breast conserving surgery after preoperative chemotherapy].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Evidence-Based Medicine; Female; Humans; Mastectomy, Segmental; Paclitaxel; Preoperative Care; Prognosis; Sentinel Lymph Node Biopsy; Taxoids; Trastuzumab | 2007 |
[Optimal chemotherapy for advanced and recurrent breast cancer patients].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Diphosphonates; Docetaxel; Female; Fluorouracil; Humans; Informed Consent; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Patient Care Team; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Silicates; Taxoids; Titanium; Trastuzumab | 2007 |
Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Models, Biological; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2007 |
Emerging therapeutic options for breast cancer chemotherapy during pregnancy.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Lapatinib; Oligohydramnios; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2008 |
Taxanes for adjuvant treatment of early breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2007 |
Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2008 |
Angiosarcomas and taxanes.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Doxorubicin; Hemangiosarcoma; Humans; Paclitaxel; Radiotherapy, Adjuvant; Taxoids | 2007 |
Microtubules: an overview.
Topics: Animals; Docetaxel; Epothilones; Eukaryotic Cells; Guanosine Triphosphate; Humans; Hydrolysis; Microtubules; Models, Molecular; Paclitaxel; Protein Structure, Tertiary; Structure-Activity Relationship; Taxoids; Tubulin | 2007 |
Strategies for the development of novel Taxol-like agents.
Topics: Alkanes; Antineoplastic Agents; Carbamates; Cell Line, Tumor; Docetaxel; Drug Design; Drug Resistance, Neoplasm; Epothilones; Humans; Lactones; Microtubules; Paclitaxel; Pyrones; Taxoids | 2007 |
Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2008 |
Quality-of-life issues in the management of epithelial ovarian cancer.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Disease Progression; Docetaxel; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Taxoids | 2007 |
Recent developments in taxane drug delivery.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Docetaxel; Drug Delivery Systems; Drug Design; Humans; Liposomes; Nanoparticles; Oligopeptides; Paclitaxel; Peptides, Cyclic; Polymers; Taxoids | 2008 |
Comparing methods for full versus single technology appraisal: a case study of docetaxel and paclitaxel for early breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Decision Making; Docetaxel; Early Diagnosis; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Technology Assessment, Biomedical; Uncertainty | 2008 |
The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
Topics: Angiogenesis Inhibitors; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Taxoids; Vascular Endothelial Growth Factor A | 2008 |
Treatment of metastatic breast cancer: looking towards the future.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Lapatinib; Medical Oncology; Neoplasm Metastasis; Paclitaxel; Quinazolines; Taxoids; Trastuzumab; Treatment Outcome | 2009 |
The taxane limbo: how low can we go?
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Meta-Analysis as Topic; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Prognosis; Receptor, ErbB-2; Retrospective Studies; Taxoids | 2008 |
Neurotoxic effects of antineoplastic drugs: the lesson of pre-clinical studies.
Topics: Animals; Antineoplastic Agents; Carboplatin; Docetaxel; Epothilones; Humans; Models, Animal; Neurotoxins; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Taxoids | 2008 |
Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Female; Genes, erbB-2; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab | 2008 |
Systemic nonhormonal management of advanced prostate cancer and its likely impact on patients' survival and quality of life.
Topics: Atrasentan; Cisplatin; Diphosphonates; Docetaxel; Humans; Male; Mitoxantrone; Paclitaxel; Prostatic Neoplasms; Pyrrolidines; Quality of Life; Receptors, Calcitriol; Taxoids | 2008 |
The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome | 2008 |
Taxanes in the elderly: can we gain as much and be less toxic?
Topics: Aged; Aged, 80 and over; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2009 |
Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Fatigue; Feasibility Studies; Female; Fluorouracil; Gastrointestinal Diseases; Germany; Hematologic Diseases; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2008 |
Paclitaxel and docetaxel in the treatment of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2008 |
Time to full publication of studies of anti-cancer medicines for breast cancer and the potential for publication bias: a short systematic review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Consensus Development Conferences as Topic; Databases, Bibliographic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lapatinib; Paclitaxel; Publication Bias; Publishing; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Technology Assessment, Biomedical; Time; Trastuzumab | 2008 |
The role of the taxanes in the treatment of older patients with advanced stage non-small cell lung cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Evidence-Based Medicine; Humans; Lung Neoplasms; Meta-Analysis as Topic; Neoplasm Staging; Paclitaxel; Palliative Care; Quality of Life; Randomized Controlled Trials as Topic; Severity of Illness Index; Taxoids; Treatment Outcome | 2009 |
Gefitinib in the treatment of advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Double-Blind Method; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Proteins; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Reasons for response differences seen in the V15-32, INTEREST and IPASS trials.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Docetaxel; ErbB Receptors; Europe; Female; Gefitinib; Humans; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Staging; North America; Paclitaxel; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Recurrence; South America; Survival Analysis; Taxoids; Tumor Burden | 2009 |
What is the role of novel taxanes in non-small-cell lung cancer?
Topics: Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cross-Linking Reagents; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2008 |
[Progress in chemotherapy for advanced gastric cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drug Combinations; Fluorouracil; Gefitinib; Humans; Irinotecan; Methotrexate; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Quinazolines; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Trastuzumab | 2009 |
Intravenous-to-oral switch in anticancer chemotherapy: a focus on docetaxel and paclitaxel.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Clinical Trials as Topic; Cytochrome P-450 CYP3A; Docetaxel; Humans; Infusions, Intravenous; Paclitaxel; Taxoids | 2010 |
Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis.
Topics: Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2010 |
Scheduling of taxanes: a review.
Topics: Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Docetaxel; Drug Administration Schedule; Humans; Neoplasms; Paclitaxel; Taxoids; Trastuzumab | 2010 |
Targeting Notch signaling pathway to overcome drug resistance for cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; MicroRNAs; Neoplasms; Paclitaxel; Receptors, Notch; Signal Transduction; Tamoxifen; Taxoids; Trastuzumab | 2010 |
The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Asparaginase; Carboplatin; Cisplatin; Cytostatic Agents; Desensitization, Immunologic; Docetaxel; Drug Hypersensitivity; Humans; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Procarbazine; Risk Factors; Taxoids; Teniposide | 2010 |
Controversies in the management of adjuvant breast cancer with taxanes: review of the current literature.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Paclitaxel; Practice Guidelines as Topic; Taxoids | 2011 |
Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Meta-Analysis as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Retrospective Studies; Taxoids | 2010 |
[Non-pegylated doxorubicin (Myocet®) as the less cardiotoxic alternative of free doxorubicin].
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Doxorubicin; Heart Diseases; Humans; Neoplasms; Paclitaxel; Taxoids; Trastuzumab | 2010 |
Malignant mixed Mullerian tumor of the ovary with two cases and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Disease Progression; Docetaxel; Female; Follow-Up Studies; Humans; Hysterectomy; Mixed Tumor, Mullerian; Neoplasm Staging; Omentum; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Palliative Care; Salpingectomy; Taxoids; Tomography, X-Ray Computed | 2011 |
[Subacute cutaneous lupus erythematosus and cancer: two cases and literature review].
Topics: Adenocarcinoma; Aged; Antibodies, Antinuclear; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Bevacizumab; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Lupus Erythematosus, Cutaneous; Mastectomy; Middle Aged; Paclitaxel; Paraneoplastic Syndromes; Ribonucleoproteins; Salvage Therapy; Tamoxifen; Taxoids; Trastuzumab | 2011 |
Albumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancers.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasms; Paclitaxel; Standard of Care; Taxoids | 2011 |
Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication.
Topics: Adverse Drug Reaction Reporting Systems; Anaphylaxis; Cohort Studies; Docetaxel; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Paclitaxel; Premedication; Taxoids; United States; United States Food and Drug Administration | 2011 |
Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids | 2011 |
Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Meta-Analysis as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Dexamethasone premedication for prophylaxis of taxane toxicities: can the doses be reduced when paclitaxel or docetaxel are given weekly?
Topics: Animals; Dexamethasone; Docetaxel; Drug Administration Schedule; Humans; Paclitaxel; Premedication; Taxoids | 2012 |
Chemotherapy-induced infiltrative pneumonitis cases in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Middle Aged; Paclitaxel; Taxoids | 2012 |
Sorafenib in locally advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Fluorouracil; Gemcitabine; Humans; Letrozole; Niacinamide; Nitriles; Paclitaxel; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sorafenib; Taxoids; Triazoles | 2012 |
Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Odds Ratio; Paclitaxel; Platinum Compounds; Publication Bias; Research Report; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
Maternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: case series and review of the literature.
Topics: Antineoplastic Agents; Birth Weight; Breast Neoplasms; Bridged-Ring Compounds; Cohort Studies; Docetaxel; Female; Gestational Age; Humans; Ovarian Neoplasms; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Retrospective Studies; Taxoids | 2012 |
Primary systemic therapy in HER2-amplified breast cancer: a clinical review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Celecoxib; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Lapatinib; Mastectomy, Segmental; Paclitaxel; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sulfonamides; Taxoids; Trastuzumab | 2012 |
Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity.
Topics: Breast Neoplasms; Docetaxel; Female; Humans; Multidrug Resistance-Associated Protein 2; Organic Anion Transporters, Sodium-Independent; Paclitaxel; Pharmacogenetics; Polymorphism, Single Nucleotide; Precision Medicine; Solute Carrier Organic Anion Transporter Family Member 1B3; Taxoids | 2012 |
Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2013 |
Update on taxane development: new analogs and new formulations.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Approval; Drug Design; Humans; Neoplasms; Paclitaxel; Taxoids; United States; United States Food and Drug Administration | 2012 |
Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Humans; Mitomycin; Paclitaxel; Taxoids; Thiotepa; Treatment Failure; Urinary Bladder Neoplasms | 2013 |
Adjuvant systemic therapies in breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Humans; Mastectomy; Paclitaxel; Practice Guidelines as Topic; Prognosis; Receptor, ErbB-2; Taxoids; Trastuzumab | 2013 |
[Impact of taxanes in the adjuvant setting of node-negative breast cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Methotrexate; Paclitaxel; Tamoxifen; Taxoids | 2013 |
Defining risks of taxane neuropathy: insights from randomized clinical trials.
Topics: Axons; Bridged-Ring Compounds; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Nanoparticles; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Randomized Controlled Trials as Topic; Taxoids | 2013 |
[Contemporary trends of the adjutant chemotherapy in non-small cell lung cancer].
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Evidence-Based Medicine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Prognosis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
Dosing considerations for obese patients receiving cancer chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Docetaxel; Humans; Neoplasms; Obesity; Paclitaxel; Taxoids; Vincristine | 2013 |
Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Microtubules; Molecular Structure; Paclitaxel; Taxoids; Tubulin Modulators | 2014 |
Chemotherapy plus estramustine for management of castration-resistant prostate cancer: meta-analysis of randomized controlled trials.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Combined Modality Therapy; Docetaxel; Epirubicin; Epothilones; Estramustine; Fatigue; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Orchiectomy; Paclitaxel; Peripheral Nervous System Diseases; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine | 2014 |
Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel--a review.
Topics: Administration, Metronomic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Interactions; Humans; Maximum Tolerated Dose; Neoplasms; Paclitaxel; Taxoids | 2014 |
In vivo imaging as a pharmacodynamic marker.
Topics: Antineoplastic Agents; Carbon Radioisotopes; Docetaxel; Fluorine Radioisotopes; Humans; Neoplasms; Paclitaxel; Positron-Emission Tomography; Taxoids; Tissue Distribution; Treatment Outcome | 2014 |
Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer.
Topics: Antineoplastic Agents; Camptothecin; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Deoxycytidine; Docetaxel; Enzyme Induction; Erlotinib Hydrochloride; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Nicotine; Paclitaxel; Polycyclic Aromatic Hydrocarbons; Quinazolines; Smoking; Taxoids | 2014 |
Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mass Screening; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Taxoids; Topotecan; Uterine Cervical Neoplasms | 2014 |
Systemic therapy for early-stage HER2-positive breast cancers: time for a less-is-more approach?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Trastuzumab; Treatment Outcome | 2015 |
Metabolism of the taxanes including nab-paclitaxel.
Topics: Albumins; Animals; Antineoplastic Agents; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Humans; Liver; Neoplasms; Paclitaxel; Taxoids | 2015 |
Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: sensitivity analysis of randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids | 2015 |
The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Nail Diseases; Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Tubulin Modulators | 2015 |
[Adjuvant treatment for esophagogastric junction cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Capecitabine; Carboplatin; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Digestive System Surgical Procedures; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Europe; Fluorouracil; Humans; Lymph Node Excision; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Taxoids; Tegafur | 2015 |
Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Docetaxel; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 2015 |
[CURRENT STATE OF ADJUVANT TREATMENT FOR GASTRIC CANCER AFTER RADICAL SURGERY WITH EXTENDED LYMPH NODE DISSECTION].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Drug Combinations; Fluorouracil; Gastrectomy; Humans; Leucovorin; Lymph Node Excision; Multicenter Studies as Topic; Oxaloacetates; Oxonic Acid; Paclitaxel; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Analysis; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2015 |
The role of taxanes in triple-negative breast cancer: literature review.
Topics: Albumins; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Chemotherapy-induced peripheral neuropathy: Current status and progress.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Models, Neurological; Neural Stem Cells; Neurons; Paclitaxel; Peripheral Nervous System Diseases; Taxoids | 2016 |
Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Docetaxel; Gastrointestinal Diseases; Hematologic Diseases; Humans; Neurotoxicity Syndromes; Paclitaxel; Pharmacogenetics; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Receptor, EphA5; Receptor, EphA6; Taxoids; Tubulin | 2015 |
Treatment regimens of classical and newer taxanes.
Topics: Albumins; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Liver; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome; Tubulin Modulators | 2016 |
Taxane anticancer agents: a patent perspective.
Topics: Animals; Antineoplastic Agents; Docetaxel; Drug Delivery Systems; Drug Design; Female; Humans; Male; Nanostructures; Neoplasms; Paclitaxel; Patents as Topic; Taxoids | 2016 |
Novel cytotoxic drugs in advanced nonsmall cell lung cancer.
Topics: Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Organoplatinum Compounds; Paclitaxel; Taxoids; Treatment Outcome | 2016 |
Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Discovery; Gemcitabine; History, 19th Century; History, 20th Century; History, 21st Century; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2016 |
Recent advances in design, synthesis and bioactivity of paclitaxel-mimics.
Topics: Animals; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Multiple; Humans; Mice; Molecular Structure; Neoplasms; Paclitaxel; Taxoids | 2016 |
Taxanes in the Treatment of Advanced Gastric Cancer.
Topics: Apoptosis; Cell Division; Cell Proliferation; Docetaxel; Humans; Neoplasm Staging; Paclitaxel; Stomach Neoplasms; Taxoids | 2016 |
Management of patients treated with pertuzumab in the Australian clinical practice setting.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Australia; Breast Neoplasms; Bridged-Ring Compounds; Disease Management; Disease Progression; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2016 |
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Taxoids; Ureteral Neoplasms | 2017 |
The Evolving and Future Role of Taxanes in Squamous Cell Carcinomas of the Head and Neck: A Review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chemoradiotherapy; Clinical Trials as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Immunotherapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy, Adjuvant; Taxoids | 2016 |
Dermatological adverse events with taxane chemotherapy.
Topics: Alopecia; Antineoplastic Agents; Docetaxel; Drug Eruptions; Edema; Humans; Lupus Erythematosus, Cutaneous; Nail Diseases; Paclitaxel; Pigmentation Disorders; Radiodermatitis; Taxoids | 2016 |
A network meta-analysis for toxicity of eight chemotherapy regimens in the treatment of metastatic/advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2016 |
EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Survival Analysis; Taxoids | 2016 |
Second-line chemotherapy for patients with advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Everolimus; Humans; Molecular Targeted Therapy; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Receptor, ErbB-2; STAT3 Transcription Factor; Stomach Neoplasms; Taxoids; Vascular Endothelial Growth Factor A | 2017 |
Impact of treatment regimen on acute care use during and after adjuvant chemotherapy for early-stage breast cancer.
Topics: Adult; Age Distribution; Aged; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Hospitalization; Humans; Insurance Claim Review; Middle Aged; Paclitaxel; Patient Care; Retrospective Studies; Taxoids; Young Adult | 2017 |
Pharmacogenetic and Pharmacokinetic Dose Individualization of the Taxane Chemotherapeutic Drugs Paclitaxel and Docetaxel.
Topics: Animals; Antineoplastic Agents; Docetaxel; Dose-Response Relationship, Drug; Humans; Neoplasms; Paclitaxel; Pharmacogenetics; Taxoids | 2017 |
Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Humans; Models, Economic; Paclitaxel; Quality-Adjusted Life Years; Ramucirumab; Stomach Neoplasms; Taxoids; Technology Assessment, Biomedical | 2017 |
Management of Hypersensitivity Reactions to Taxanes.
Topics: Allergens; Animals; Antineoplastic Agents; Bridged-Ring Compounds; Desensitization, Immunologic; Docetaxel; Drug Hypersensitivity; Humans; Paclitaxel; Skin Tests; Taxoids | 2017 |
The best platinum regimens for chemo-naive incurable non-small cell lung cancer: network meta-analysis.
Topics: Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Network Meta-Analysis; Paclitaxel; Platinum | 2017 |
Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review.
Topics: Aged; Albumins; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Cross Reactions; Docetaxel; Drug Hypersensitivity; Female; Humans; Paclitaxel; Taxoids | 2017 |
Any place left for induction chemotherapy for locally advanced head and neck squamous cell carcinoma?
Topics: Antineoplastic Agents, Phytogenic; Carboplatin; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Lymph Nodes; Lymphatic Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Survival Rate | 2018 |
Quest for Efficacious Next-Generation Taxoid Anticancer Agents and Their Tumor-Targeted Delivery.
Topics: Animals; Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Neoplasms; Paclitaxel; Taxoids | 2018 |
Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Docetaxel; Humans; Paclitaxel; Quality of Life; Taxoids; Urinary Bladder Neoplasms; Vinblastine | 2018 |
Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Physiological Phenomena; Cisplatin; Docetaxel; Female; Humans; Models, Biological; Ovarian Neoplasms; Paclitaxel | 2019 |
Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Neoadjuvant Therapy; Nervous System; Neutropenia; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2019 |
Combined strategies for tumor immunotherapy with nanoparticles.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Dendritic Cells; Docetaxel; Doxorubicin; Galectin 1; Gold; Humans; Immunity, Cellular; Immunity, Humoral; Immunotherapy; Killer Cells, Natural; Lymphocyte Activation; Macrophage Activation; Nanoparticles; Neoplasms; Organ Specificity; Paclitaxel; Receptors, Chimeric Antigen | 2019 |
Prophylactic management for taxane-induced nail toxicity: A systematic review and meta-analysis.
Topics: Cryotherapy; Docetaxel; Humans; Nail Diseases; Neoplasms; Oils, Volatile; Onycholysis; Paclitaxel; Paronychia; Pigmentation Disorders; Plant Oils; Taxoids; Waxes | 2019 |
Comparative Effectiveness of Taxane-Containing Regimens for Treatment of HER2-Negative Metastatic Breast Cancer: A Network Meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Network Meta-Analysis; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Rate | 2019 |
Chitosan-based advanced materials for docetaxel and paclitaxel delivery: Recent advances and future directions in cancer theranostics.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Chitosan; Docetaxel; Drug Carriers; Humans; Hydrogen-Ion Concentration; Molecular Targeted Therapy; Nanoparticles; Neoplasms; Oxidation-Reduction; Paclitaxel; Solubility; Static Electricity; Theranostic Nanomedicine | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Taxane-induced neurotoxicity: Pathophysiology and therapeutic perspectives.
Topics: Antineoplastic Agents; Bridged-Ring Compounds; Docetaxel; Humans; Paclitaxel; Taxoids | 2020 |
Current Development of Oral Taxane Formulations: A Review.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Drug Carriers; Drug Compounding; Drug Delivery Systems; Humans; Lipids; Micelles; Nanoparticles; Paclitaxel | 2020 |
Mitotic Poisons in Research and Medicine.
Topics: Animals; Antineoplastic Agents; Colchicine; Docetaxel; Humans; Mitosis; Paclitaxel | 2020 |
Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Humans; Immunotherapy; Irinotecan; Neoplasm Recurrence, Local; Paclitaxel; Placebos; Progression-Free Survival; Quality of Life; Randomized Controlled Trials as Topic; Salvage Therapy; Stomach Neoplasms | 2020 |
Role of TDM-based dose adjustments for taxane anticancer drugs.
Topics: Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2021 |
Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships.
Topics: Animals; Antineoplastic Agents; Biomarkers; Docetaxel; Dose-Response Relationship, Drug; Humans; Paclitaxel; Peripheral Nervous System Diseases; Pharmacogenetics; Precision Medicine | 2021 |
New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Neoplasms; Paclitaxel | 2021 |
Probing the new strategy for the oral formulations of taxanes: changing the method with the situation.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Compounding; Paclitaxel; Taxoids | 2021 |
Efficacy and safety of apatinib alone or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced non-small cell lung cancer: A meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Pyridines | 2021 |
FOXO3a and Its Regulators in Prostate Cancer.
Topics: Apoptosis; Cell Proliferation; Cisplatin; Docetaxel; Doxorubicin; Forkhead Box Protein O3; Gene Expression Regulation, Neoplastic; Humans; Male; Oxidative Stress; Paclitaxel; Prostatic Neoplasms | 2021 |
A Meta-Analysis of the Efficacy of Albumin Paclitaxel versus Docetaxel in the Treatment of Breast Cancer.
Topics: Albumins; Asian People; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel | 2021 |
Adverse Event Profile for Nanoparticle Albumin-Bound Paclitaxel Compared With Solvent-Based Taxanes in Solid-Organ Tumors: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Nanoparticles; Paclitaxel; Randomized Controlled Trials as Topic; Solvents; Taxoids | 2022 |
A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Etoposide; Humans; Irinotecan; Lung Neoplasms; Network Meta-Analysis; Paclitaxel; Pemetrexed; Vinorelbine | 2022 |
Drugs That Changed Society: Microtubule-Targeting Agents Belonging to Taxanoids, Macrolides and Non-Ribosomal Peptides.
Topics: Docetaxel; Female; Humans; Macrolides; Male; Microtubules; Ovarian Neoplasms; Paclitaxel; Peptides | 2022 |
Neurophysiopathological Aspects of Paclitaxel-induced Peripheral Neuropathy.
Topics: Antineoplastic Agents; Docetaxel; Humans; Microtubules; Neuralgia; Oxidative Stress; Paclitaxel | 2022 |
Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cisplatin; Docetaxel; Doxorubicin; Female; Humans; Paclitaxel; Polyphenols; Resveratrol; Stilbenes; Tumor Microenvironment; Water | 2022 |
Paclitaxel resistance related to nuclear envelope structural sturdiness.
Topics: Apoptosis; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Humans; Neoplasms; Nuclear Envelope; Paclitaxel; Taxoids | 2022 |
Effectiveness of taxanes following nivolumab in patients with advanced esophageal squamous cell carcinoma: a retrospective chart review of patients in ATTRACTION-3.
Topics: Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Nivolumab; Paclitaxel; Retrospective Studies; Taxoids | 2023 |
Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies.
Topics: Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids | 2023 |
652 trial(s) available for docetaxel anhydrous and paclitaxel
| Article | Year |
|---|---|
Phase I trial of Taxotere: five-day schedule.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Mouth Mucosa; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 1992 |
Laboratory and phase I studies of new cancer drugs.
Topics: Antineoplastic Agents; Bryostatins; Camptothecin; Docetaxel; Humans; Lactones; Macrolides; Neoplasms; Paclitaxel; Taxoids | 1992 |
Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Male; Middle Aged; Models, Biological; Paclitaxel; Taxoids | 1995 |
Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials. EORTC Early Clinical Trials Group and Clinical Screening Group, and the MD Anderson Cancer Center.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Taxoids | 1995 |
Docetaxel in stage III and IV non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids | 1995 |
Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Head and Neck Neoplasms; Humans; Melanoma; Middle Aged; Neoplasms; Paclitaxel; Sarcoma; Stomach Neoplasms; Taxoids | 1995 |
Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 1994 |
Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Hypersensitivity; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Taxoids | 1994 |
Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Renal Cell; Docetaxel; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 1994 |
Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Taxoids | 1995 |
[Late phase II trial of RP56976 (Docetaxel) in patients with non-small-cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alopecia; Anorexia; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Nausea; Paclitaxel; Taxoids; Vomiting | 1995 |
Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Therapy, Combination; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Prednisone; Premedication; Survival Rate; Taxoids | 1995 |
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Confidence Intervals; Docetaxel; Drug Tolerance; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Quality Control; Taxoids; Time Factors | 1995 |
Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Docetaxel; Drug Eruptions; Female; Humans; Male; Middle Aged; Paclitaxel; Prospective Studies; Taxoids | 1995 |
Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Hypersensitivity; Drug Resistance; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction; Survival Rate; Taxoids | 1995 |
[Taxotere: from yew's needles to clinical practice].
Topics: Animals; Antineoplastic Agents, Phytogenic; Docetaxel; Dogs; Drug Screening Assays, Antitumor; Humans; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Paclitaxel; Taxoids; Tubulin; Tumor Cells, Cultured | 1993 |
Docetaxel in advanced renal carcinoma. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Hypersensitivity; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 1994 |
Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 1994 |
Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Taxoids | 1994 |
Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis.
Topics: Adult; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 1994 |
Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Colorectal Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Paclitaxel; Taxoids | 1994 |
Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Male; Middle Aged; Paclitaxel; Stomach Neoplasms; Taxoids | 1994 |
Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 1994 |
Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Colorectal Neoplasms; Docetaxel; Drug Administration Schedule; Drug Eruptions; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1994 |
[Phase I clinical trial of RP 56976 (docetaxel) a new anticancer drug].
Topics: Adolescent; Adult; Aged; Alopecia; Anorexia; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Paclitaxel; Taxoids | 1994 |
A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Eruptions; Europe; Female; Humans; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 1994 |
Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Asthenia; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Europe; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 1994 |
Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Europe; Female; Humans; Leukopenia; Male; Middle Aged; Nervous System Diseases; Paclitaxel; Remission Induction; Sarcoma; Soft Tissue Neoplasms; Taxoids; Thrombocytopenia | 1994 |
[An early phase II clinical study of RP56976 (docetaxel) in patients with cancer of the gastrointestinal tract].
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Anorexia; Antineoplastic Agents, Phytogenic; Colonic Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Stomach Neoplasms; Taxoids | 1994 |
[An early phase II clinical study of RP56976 (docetaxel) in patients with breast cancer].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Nausea; Paclitaxel; Remission Induction; Taxoids | 1994 |
[Phase II clinical study of RP56976 (docetaxel) in patients with carcinoma ovarii or carcinoma colli uteri].
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cystadenocarcinoma, Serous; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Paclitaxel; Taxoids; Thrombocytopenia; Uterine Cervical Neoplasms | 1994 |
Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Carboplatin; Cisplatin; Docetaxel; Drug Resistance; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Analysis; Taxoids | 1994 |
[Early phase II clinical study of RP56976 (docetaxel) in patients with primary pulmonary cancer. Docetaxel Cooperative Study Group for Lung Cancer].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 1994 |
[Late phase II clinical study of RP56976 (docetaxel) in patients with non-small cell lung cancer].
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Asthenia; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Fever; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Taxoids; Treatment Outcome | 1994 |
[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent breast cancer].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Agents, Phytogenic; Asthenia; Bone Neoplasms; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Treatment Outcome | 1994 |
Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Taxoids | 1993 |
Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 1993 |
Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 1993 |
Coping with toxicities of docetaxel (Taxotere).
Topics: Antineoplastic Agents, Phytogenic; Cetirizine; Docetaxel; Drug Hypersensitivity; Edema; Humans; Ketotifen; Methylprednisolone; Paclitaxel; Skin Diseases; Taxoids | 1993 |
Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.
Topics: Adult; Aged; Anthracyclines; Anthraquinones; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Mitoxantrone; Paclitaxel; Taxoids | 1995 |
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1995 |
Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Skin Neoplasms; Taxoids | 1995 |
A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Carcinoma, Medullary; Carcinoma, Papillary; Docetaxel; Female; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Taxoids; Toxicity Tests | 1996 |
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cimetidine; Dexamethasone; Diphenhydramine; Docetaxel; Drug Administration Schedule; Drug Hypersensitivity; Edema; Female; Humans; Injections, Intravenous; Leukopenia; Middle Aged; Neoplasm Metastasis; Paclitaxel; Premedication; Taxoids | 1996 |
Docetaxel (Taxotere): an overview of first-line monotherapy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 1995 |
Docetaxel (Taxotere) in combination: a step forward.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Clinical Trials as Topic; Docetaxel; Female; Humans; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 1995 |
Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 1996 |
Docetaxel: an active drug for squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Treatment Outcome | 1996 |
Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Leukopenia; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 1996 |
Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Docetaxel; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Taxoids | 1996 |
[Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
Topics: Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Irinotecan; Loperamide; Male; Neoplasms; Neutropenia; Paclitaxel; Remission Induction; Taxoids; Topoisomerase I Inhibitors | 1996 |
Docetaxel: an interesting new drug for the treatment of head and neck cancers and soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Sarcoma; Taxoids | 1995 |
A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors | 1996 |
A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Confidence Intervals; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 1996 |
Phase II study of docetaxel (taxotere) in patients with previously untreated extensive small cell lung cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Docetaxel; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 1996 |
Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix.
Topics: Adult; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Uterine Cervical Neoplasms | 1996 |
First-line treatment of metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Europe; Female; Humans; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; North America; Paclitaxel; Taxoids | 1996 |
Treatment of patients resistant to anthracycline therapy.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 1996 |
Treatment of patients resistant to paclitaxel therapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Prospective Studies; Taxoids | 1996 |
Taxoids in combination chemotherapy for metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Humans; Paclitaxel; Taxoids | 1996 |
A population pharmacokinetic model for docetaxel (Taxotere): model building and validation.
Topics: Antineoplastic Agents, Phytogenic; Bayes Theorem; Docetaxel; Female; Humans; Male; Middle Aged; Models, Biological; Paclitaxel; Population; Prospective Studies; Sampling Studies; Taxoids | 1996 |
Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Docetaxel; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 1996 |
Phase II study of docetaxel in advanced soft tissue sarcomas.
Topics: Adult; Aged; Alopecia; Anorexia; Antiemetics; Antineoplastic Agents, Phytogenic; Cause of Death; Dexamethasone; Diarrhea; Diphenhydramine; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leiomyosarcoma; Leukopenia; Male; Middle Aged; Nausea; Paclitaxel; Patient Selection; Premedication; Remission Induction; Sarcoma; Taxoids; Uterine Neoplasms; Vomiting | 1996 |
A phase II trial of docetaxel in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 1996 |
Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Paclitaxel; Remission Induction; Stomach Neoplasms; Survival Rate; Taxoids | 1996 |
Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neutropenia; Paclitaxel; Taxoids | 1996 |
Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Nervous System Diseases; Paclitaxel; Paresthesia; Taxoids | 1997 |
Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 1997 |
Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Feasibility Studies; Female; Follow-Up Studies; Humans; Leukopenia; Male; Middle Aged; Nausea; Neoplasms; Paclitaxel; Taxoids; Vomiting | 1997 |
Effectiveness of cold cap in the prevention of docetaxel-induced alopecia.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Cryotherapy; Docetaxel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paclitaxel; Taxoids | 1997 |
Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Docetaxel; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Paclitaxel; Remission Induction; Survival Analysis; Taxoids; Urologic Neoplasms | 1997 |
Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Docetaxel; Drug Administration Schedule; Female; Humans; Incidence; Infant; Infusions, Intravenous; Male; Neoplasms; Neutropenia; Paclitaxel; Severity of Illness Index; Taxoids; Treatment Outcome | 1997 |
The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Edema; Female; Flavonoids; Humans; Infusions, Intravenous; Lymphatic System; Middle Aged; Neoplasm Invasiveness; Ovarian Neoplasms; Paclitaxel; Taxoids; Water-Electrolyte Balance | 1997 |
Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography.
Topics: Aged; Antineoplastic Agents, Phytogenic; Chromatography, High Pressure Liquid; Docetaxel; Female; Humans; Neoplasms; Paclitaxel; Reproducibility of Results; Sensitivity and Specificity; Taxoids | 1997 |
Docetaxel in combination with doxorubicin: a phase I dose-finding study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pilot Projects; Survival Rate; Taxoids | 1997 |
Docetaxel and cyclophosphamide in patients with advanced solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Humans; Neoplasms; Neutropenia; Paclitaxel; Taxoids | 1997 |
Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pilot Projects; Taxoids | 1997 |
Docetaxel combined with vinorelbine: phase I results and new study designs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Liver Neoplasms; Neoplasm Metastasis; Neutropenia; Paclitaxel; Research Design; Taxoids; Vinblastine; Vinorelbine | 1997 |
Docetaxel in combination with fluorouracil: study design and preliminary results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Taxoids | 1997 |
Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Body Fluids; Breast Neoplasms; Cetirizine; Docetaxel; Drug Administration Schedule; Drug Eruptions; Edema; Europe; Female; Histamine H1 Antagonists; Humans; Methylprednisolone; Middle Aged; Paclitaxel; Pleural Effusion; Severity of Illness Index; Skin; Taxoids; Treatment Outcome; Water-Electrolyte Imbalance | 1997 |
Docetaxel (Taxotere) and vinorelbine in the treatment of advanced non-small cell lung cancer: preliminary results of a phase I/II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1997 |
The development of docetaxel (Taxotere) in non-small cell lung cancer--docetaxel in new combinations and new schedules: an overview of ongoing and future developments.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1997 |
Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer: preliminary results.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 1997 |
Clinical studies of docetaxel (Taxotere) and concomitant chest therapy.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Radiation Dosage; Research Design; Taxoids; Thorax | 1997 |
The role of docetaxel (Taxotere) as a single agent or in combination before local treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1997 |
Phase II trial of docetaxel in non-Hodgkin's lymphomas: a study of the Cancer and Leukemia Group B.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 1997 |
Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Doxorubicin; Drug Administration Schedule; Estrogen Antagonists; Female; Fever; Humans; Infusions, Intravenous; Mastectomy, Modified Radical; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Remission Induction; Tamoxifen; Taxoids | 1997 |
Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bacterial Infections; Breast Neoplasms; Cause of Death; Disease Progression; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Fever; Heart Diseases; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Quality of Life; Remission Induction; Safety; Survival Rate; Taxoids; Thrombocytopenia | 1997 |
Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Constipation; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Middle Aged; Mitomycins; Neoplasm Metastasis; Paclitaxel; Quality of Life; Remission Induction; Safety; Survival Rate; Taxoids; Thrombocytopenia; Vinblastine | 1997 |
Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
Topics: Adenocarcinoma; Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Cyclophosphamide; Dexamethasone; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Premedication; Remission Induction; Sarcoma; Taxoids | 1997 |
Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fever; Heart Failure; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 1997 |
Phase I study of docetaxel with concomitant thoracic radiation therapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagitis; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Taxoids; Treatment Outcome | 1998 |
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Bayes Theorem; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Edema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Prospective Studies; Taxoids | 1998 |
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Feasibility Studies; Female; Follow-Up Studies; Humans; Ifosfamide; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Paclitaxel; Taxoids; Vomiting | 1998 |
[Taxotere: the first drug better than acrdiamycin, the most frequently used drug in the treatment of metastasized breast cancer. Phase III study shows a better response than standard treatment].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1997 |
Lhermitte's sign following chemotherapy with docetaxel.
Topics: Adult; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Infusions, Intravenous; Magnetic Resonance Imaging; Middle Aged; Neoplasms; Paclitaxel; Spinal Cord; Spinal Cord Diseases; Taxoids | 1998 |
Docetaxel alternating with epirubicin and cyclophosphamide: a feasibility study in breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Recombinant Proteins; Taxoids | 1997 |
Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Feasibility Studies; Female; Humans; Ifosfamide; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 1998 |
Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Middle Aged; Paclitaxel; Taxoids | 1998 |
Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 1998 |
First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Severity of Illness Index; Survival Rate; Taxoids; Treatment Outcome | 1998 |
Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Dexamethasone; Docetaxel; Drug Administration Schedule; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 1998 |
Phase II trial of docetaxel (Taxotere) for untreated advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Colorectal Neoplasms; Docetaxel; Female; Humans; Male; Middle Aged; Paclitaxel; Taxoids | 1998 |
A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 1998 |
Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Docetaxel; Female; Humans; Kidney Diseases; Male; Middle Aged; Paclitaxel; Taxoids | 1998 |
New chemotherapy combinations with docetaxel in the treatment of patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lenograstim; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Recombinant Proteins; Taxoids | 1998 |
Combined modality therapy in non-small cell lung and esophageal cancer: a phase I dose-escalation study of docetaxel with concurrent radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 1998 |
A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Edema; Female; Fever; Humans; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Taxoids | 1998 |
Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Paclitaxel; Taxoids; Urologic Neoplasms | 1998 |
Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Hypersensitivity; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy; Taxoids; Treatment Outcome | 1998 |
[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A)].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Fever; Humans; Leukopenia; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Paclitaxel; Stomach Neoplasms; Taxoids; Vomiting | 1998 |
Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Infusions, Intravenous; Likelihood Functions; Lung Neoplasms; Metabolic Clearance Rate; Neoplasms; Paclitaxel; Prospective Studies; Sampling Studies; Specimen Handling; Taxoids | 1997 |
Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Survival Rate; Taxoids | 1996 |
Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Disease Progression; Docetaxel; Drug Administration Schedule; Edema; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome; Urologic Neoplasms | 1998 |
First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Patient Compliance; Recombinant Proteins; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Docetaxel; Female; Glucocorticoids; Humans; Male; Middle Aged; Neoplasms; Nervous System Diseases; Paclitaxel; Prospective Studies; Taxoids | 1998 |
Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 1998 |
Combination chemotherapy with docetaxel, vinorelbine and cisplatin as first-line treatment of advanced non-small-cell lung cancer: a multicenter phase II study of the Greek Cooperative Group for Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Patient Compliance; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Mitomycin; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids; Vinblastine | 1998 |
Weekly schedules of docetaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 1998 |
Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Failure | 1998 |
Taxanes in combination with doxorubicin in the treatment of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1998 |
Taxoids in combination with epirubicin: the search for improved outcomes in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1998 |
Taxane-based three-drug combination in metastatic and adjuvant treatment of breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Taxoids | 1998 |
Induction combination chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Time Factors; Treatment Outcome | 1998 |
[Breast cancer: new therapeutic strategies].
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Resistance, Multiple; Female; Humans; Neoplasm Metastasis; Paclitaxel; Prognosis; Taxoids; Treatment Outcome | 1998 |
Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Recombinant Proteins; Survival Analysis; Taxoids | 1999 |
The venotonic drug hydroxyethylrutosiden does not prevent or reduce docetaxel-induced fluid retention: results of a comparative study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Ascites; Breast Neoplasms; Docetaxel; Edema; Humans; Hydroxyethylrutoside; Middle Aged; Paclitaxel; Pericardial Effusion; Pleural Effusion; Taxoids; Water-Electrolyte Imbalance | 1999 |
[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent head and neck cancer].
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 1999 |
Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Drug Administration Schedule; Feasibility Studies; Female; Glioblastoma; Humans; Lung Neoplasms; Lymphocytes; Lymphopenia; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Pelvic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy; Survival Analysis; Taxoids; Treatment Outcome | 1999 |
Phase II trial of docetaxel for cholangiocarcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Docetaxel; Female; Humans; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 1999 |
Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 1998 |
Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lymphocyte Count; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction; Taxoids; Ventricular Function, Left | 1999 |
Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Paclitaxel; Survival Analysis; Taxoids | 1999 |
Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Estramustine; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Middle Aged; Paclitaxel; Pain; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids | 1999 |
Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Estramustine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Prostatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 1999 |
Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Survival Rate; Taxoids; Treatment Outcome | 1999 |
Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Taxoids | 1999 |
A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 1999 |
[A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (group B)].
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Anorexia; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Paclitaxel; Stomach Neoplasms; Taxoids; Vomiting, Anticipatory | 1999 |
Mobilization of peripheral blood stem cells with docetaxel and cyclophosphamide (CY) in patients with metastatic breast cancer: a randomized trial of 3 vs 4 g/m2 of CY.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins; Taxoids | 1999 |
Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial.
Topics: Adolescent; Adult; Child; Child, Preschool; Docetaxel; Dose-Response Relationship, Drug; Drug Eruptions; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Infant; Male; Neoplasms; Neutropenia; Paclitaxel; Recombinant Proteins; Taxoids | 1999 |
Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Health Status; Humans; Middle Aged; Mitomycins; Neutropenia; Paclitaxel; Patient Compliance; Proportional Hazards Models; Prospective Studies; Survival Analysis; Taxoids; Thrombocytopenia; Vinblastine | 1999 |
[Evaluation of chemotherapy with docetaxel and cisplatin in advanced non-small cell lung cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Evaluation; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 1999 |
Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Ductal, Breast; Docetaxel; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Taxoids | 1999 |
[Docetaxel therapy against anthracycline resistant breast cancer].
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Taxoids | 1999 |
Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. The Greek Breast Cancer Cooperative Group (GBCCG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Ventricular Function, Left | 1999 |
Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Heart Failure; Humans; Middle Aged; Paclitaxel; Taxoids; Ventricular Function, Left | 1999 |
Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Docetaxel (Taxotere) in combination with vinorelbine in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 1999 |
Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 1999 |
A phase II study of the effectiveness of docetaxel (Taxotere) in women with advanced breast cancer previously treated with polychemotherapy. Hellenic Cooperative Interhospital Group in Oncology.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 1999 |
The use of docetaxel (Taxotere) in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Platinum Compounds; Quality of Life; Sickness Impact Profile; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 1999 |
Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids | 1999 |
Docetaxel (Taxotere) administered in weekly schedules.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 1999 |
Concurrent conventionally factionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Asthenia; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Esophagitis; Female; Humans; Lung Neoplasms; Lymphopenia; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy; Survival Analysis; Taxoids | 1999 |
Quantitative PCR analysis of c-erb B-2 (HER2/neu) gene amplification and comparison with p185(HER2/neu) protein expression in breast cancer drill biopsies.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; DNA, Neoplasm; Docetaxel; Doxorubicin; Gene Amplification; Genes, erbB-2; Humans; Immunohistochemistry; Neoadjuvant Therapy; Paclitaxel; Polymerase Chain Reaction; Receptor, ErbB-2; Reproducibility of Results; Taxoids | 1999 |
Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Pilot Projects; Taxoids; Treatment Outcome | 1999 |
A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Female; Head and Neck Neoplasms; Humans; Life Tables; Male; Metabolic Clearance Rate; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Tomography, X-Ray Computed | 1999 |
Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Dyspnea; Fatal Outcome; Gemcitabine; Humans; Lung; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Severity of Illness Index; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms | 1999 |
Docetaxel: standard recommended dose of 100 mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II single-center study.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Patient Compliance; Survival Rate; Taxoids; Treatment Outcome | 1999 |
Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Paclitaxel; Statistics, Nonparametric; Taxoids | 1999 |
Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Edema; Female; Humans; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Scotland; Survival Rate; Taxoids | 1999 |
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 1999 |
Docetaxel (Taxotere) in the neo-adjuvant setting in non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Taxoids; Treatment Outcome | 1999 |
[Docetaxel as a single agent in cases of advanced/recurrent breast cancer previously treated with anthracycline].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Taxoids | 1999 |
[Clinical phase II-evaluation of neoadjuvant, cytostatic combination chemotherapy with docetaxel and epidoxorubicin in female breast cancer patients (T1-4, N0-2, M0)].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome | 1999 |
Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 1999 |
A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Gene Expression; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids | 1999 |
Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids | 1999 |
A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Hydrocortisone; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids | 1999 |
Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Docetaxel; Estramustine; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.
Topics: Adult; Aged; Algorithms; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Over Studies; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Paclitaxel; Patient Compliance; Taxoids; Treatment Failure | 1999 |
A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia; Treatment Outcome | 2000 |
Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids | 2000 |
A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Severity of Illness Index; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome | 1999 |
Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Docetaxel; Female; Follow-Up Studies; Greece; Humans; Linear Models; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Remission Induction; Severity of Illness Index; Survival Rate; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium | 1999 |
Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neutropenia; Paclitaxel; Taxoids | 1999 |
Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Breast Neoplasms, Male; Chemical and Drug Induced Liver Injury; Docetaxel; Drug Resistance, Neoplasm; Female; Fever; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neutropenia; Paclitaxel; Prognosis; Risk Factors; Stomatitis; Taxoids; Treatment Outcome | 2000 |
A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Methylprednisolone; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Taxoids | 2000 |
Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion.
Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Alopecia; Antineoplastic Agents, Phytogenic; Area Under Curve; Aspartate Aminotransferases; Breast Neoplasms; Diarrhea; Docetaxel; Fatigue; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Mouth Mucosa; Neoplasms; Neutropenia; Paclitaxel; Stomatitis; Taxoids; Time Factors | 2000 |
Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Enterocolitis, Pseudomembranous; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2000 |
Phase I study of cisplatin and docetaxel plus mitomycin C in patients with metastatic non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hyponatremia; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neutropenia; Paclitaxel; Taxoids | 1999 |
Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Dexamethasone; Docetaxel; Drug Administration Schedule; Estramustine; Humans; Male; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2000 |
Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Humans; Infusions, Intravenous; Irinotecan; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Combined radiochemotherapy with docetaxel in patients with unresectable locally advanced head and neck tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Taxoids; Time Factors; Treatment Outcome | 2000 |
A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Europe; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Mexico; Middle Aged; Paclitaxel; Palliative Care; Quality of Life; Survival Analysis; Taxoids; United States | 2000 |
Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Recombinant Proteins; Taxoids; Vinblastine; Vinorelbine | 2000 |
Docetaxel administered on a weekly basis for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids | 2000 |
Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proto-Oncogene Mas; Recombinant Proteins; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2000 |
[Efficacy of docetaxel for recurrent breast cancer: evaluation based on chemosensitivity test and clinical response].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Drug Screening Assays, Antitumor; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 2000 |
Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Docetaxel; Epirubicin; Female; Humans; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Urinary Bladder Neoplasms | 2000 |
Intestinal side-effects of docetaxel/vinorelbine combination.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastroenteritis; Humans; Neutropenia; Paclitaxel; Risk Factors; Taxoids; Vinblastine; Vinorelbine | 2000 |
Reversion of primary hyperfibrinogenolysis in patients with hormone-refractory prostate cancer using docetaxel.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Neoplasm; Fibrinogen; Fibrinolysis; Hemorrhage; Humans; Male; Neoplasm Metastasis; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Urokinase-Type Plasminogen Activator | 2000 |
[Efficacy of docetaxel in non-small cell lung cancer patients previously treated with platinum-containing chemotherapy. French Group of Pneumo-Cancerology].
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diosmin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Prednisolone; Premedication; Taxoids; Time Factors | 2000 |
Phase II study of docetaxel alternating with cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
A sensitive docetaxel assay in plasma by solid-phase extraction and high performance liquid chromatography-UV detection: validation and suitability in phase I clinical trial pharmacokinetics.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Calibration; Chromatography, High Pressure Liquid; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Methotrexate; Paclitaxel; Reproducibility of Results; Solvents; Spectrophotometry, Ultraviolet; Taxoids | 1999 |
A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Confidence Intervals; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2000 |
Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Prognosis; Statistics, Nonparametric; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: a multicentre phase I study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 2000 |
Prevention of chemotherapy-induced alopecia using an effective scalp cooling system.
Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cryotherapy; Docetaxel; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Scalp; Taxoids | 2000 |
Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Feasibility Studies; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Recurrence; Taxoids | 2000 |
Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cohort Studies; Dexamethasone; Docetaxel; Drug Resistance, Neoplasm; Female; Glucocorticoids; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Prednisone; Taxoids | 2000 |
The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breath Tests; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Erythromycin; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Mixed Function Oxygenases; Orosomucoid; Paclitaxel; Sarcoma; Soft Tissue Neoplasms; Taxoids | 2000 |
The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzazepines; Docetaxel; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Male; Middle Aged; Mouth Mucosa; Neoplasms; Neutropenia; Paclitaxel; Quinolines; Stomatitis; Taxoids; Vomiting | 2000 |
[Phase II study of docetaxel in inoperable advanced non small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 2000 |
[Clinical efficacy of low-dose weekly docetaxel combined with oral 5'-deoxy-5-fluorouridine (5'-DFUR) in advanced or metastatic breast cancer: a pilot trial].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Floxuridine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Taxoids | 2000 |
Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Humans; Paclitaxel; Stomach Neoplasms; Survival Analysis; Taxoids | 2000 |
Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Taxoids; Treatment Failure; Vinblastine; Vinorelbine | 2000 |
Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and b
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cross-Over Studies; Disease Progression; Docetaxel; Doxorubicin; Female; Humans; Male; Paclitaxel; Sarcoma; Soft Tissue Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Palliative Care; Proportional Hazards Models; Prospective Studies; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Monotherapy with docetaxel in second- or third-line treatment of anthracycline-resistant metastatic breast cancer.
Topics: Adult; Anthracyclines; Antineoplastic Agents, Phytogenic; Austria; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
A phase I trial of docetaxel and gemcitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Phase II trial of docetaxel in Asian patients with inoperable stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Dexamethasone; Docetaxel; Female; Fever; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome; Water-Electrolyte Balance | 2000 |
Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Docetaxel; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasm, Residual; Neoplasms; Paclitaxel; Taxoids | 2000 |
Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Cyclophosphamide; Daunorubicin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Idarubicin; Maximum Tolerated Dose; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors | 2000 |
A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Biotransformation; Capecitabine; Carboxylic Ester Hydrolases; Deamination; Deoxycytidine; Dexamethasone; Docetaxel; Drug Administration Schedule; Female; Fever; Fluorouracil; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Liver; Male; Maximum Tolerated Dose; Methylprednisolone; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Paronychia; Prodrugs; Remission Induction; Taxoids; Treatment Outcome | 2000 |
A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Docetaxel; Female; France; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Statistics, Nonparametric; Survival Analysis; Taxoids | 2000 |
Preliminary results of multicenter phase II trial of docetaxel (Taxotere) in combination with doxorubicin as first line chemotherapy in Indonesian patients with advanced or metastatic breast cancer.
Topics: Adrenal Cortex Hormones; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Indonesia; Liver Neoplasms; Middle Aged; Paclitaxel; Remission Induction; Stroke Volume; Taxoids; Ventricular Function, Left | 2000 |
Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Intravenous; Middle Aged; Netherlands; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2000 |
Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma--a feasibility study.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Feasibility Studies; Female; Humans; Irinotecan; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Pleural Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2000 |
Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Neoplasm Metastasis; Paclitaxel; Quality of Life; Taxoids | 2000 |
A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease Progression; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Taxoids; Treatment Outcome | 2000 |
Phase II study of docetaxel in patients with liver metastases from breast cancer. UK study group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Docetaxel; Female; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Paclitaxel; Survival Analysis; Taxoids | 2000 |
Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Patient Compliance; Survival Rate; Taxoids | 2000 |
Treatment of patients with advanced nonsmall cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Taxoids | 2000 |
Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dexamethasone; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Disease-Free Survival; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Microtubules; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 2000 |
Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Chemotherapy, Adjuvant; Confidence Intervals; Disease Progression; Docetaxel; Female; Fever; Follow-Up Studies; Gastrectomy; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2000 |
Pharmacokinetics of ifosfamide are changed by combination with docetaxel: results of a phase I pharmacologic study.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chromatography, High Pressure Liquid; Confidence Intervals; Dexamethasone; Docetaxel; Drug Administration Schedule; Drug Interactions; Female; Gas Chromatography-Mass Spectrometry; Glucocorticoids; Half-Life; Humans; Ifosfamide; Infusions, Intravenous; Male; Metabolic Clearance Rate; Methylprednisolone; Middle Aged; Paclitaxel; Taxoids | 2000 |
Docetaxel in combination with 5-fluorouracil in patients with metastatic breast cancer previously treated with anthracycline-based chemotherapy: a phase I, dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 2000 |
Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Interactions; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Male; Middle Aged; Neoplasms; Paclitaxel; Platelet Count; Recombinant Proteins; Taxoids; Topotecan | 2000 |
Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routine daily practice.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Analysis; Taxoids | 2000 |
Successful rechallenge with taxanes following prophylactic ketotifen in patients who had developed severe hypersensitivity reactions.
Topics: Adult; Aged; Anti-Allergic Agents; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Hypersensitivity; Female; Humans; Ketotifen; Male; Middle Aged; Neoplasms; Paclitaxel; Pilot Projects; Taxoids | 2000 |
Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy, Needle; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Predictive Value of Tests; Sentinel Lymph Node Biopsy; Tamoxifen; Taxoids | 2000 |
Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2000 |
Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Chromatography, High Pressure Liquid; Cross-Over Studies; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Time Factors | 2000 |
[Intra-arterial infusion chemotherapy with docetaxel for locally advanced breast cancer and inflammatory breast cancer].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intra-Arterial; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Taxoids | 2000 |
Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diarrhea; Disease Progression; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lung Diseases, Interstitial; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Recombinant Proteins; Remission Induction; Stomatitis; Survival Analysis; Taxoids; Thiotepa; Thrombocytopenia; Transplantation Conditioning | 2000 |
Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Recombinant Proteins; Taxoids | 2000 |
A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Paclitaxel; Salvage Therapy; Stomach Neoplasms; Taxoids | 2000 |
Treatment of advanced, refractory breast cancer with alternating docetaxel and epirubicin/cyclophosphamide plus human granulocyte colony-stimulating factor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Taxoids | 2000 |
Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Disease-Free Survival; Docetaxel; Female; Humans; Ifosfamide; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Prospective Studies; Taxoids; Treatment Failure; Urologic Neoplasms | 2001 |
A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fever; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Salvage Therapy; Taxoids | 2000 |
Phase I study of docetaxel and topotecan in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Topotecan | 2000 |
A dose escalation study of weekly docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Fever; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Taxoids | 2000 |
Phase I study of carboplatin, docetaxel and irinotecan with recombinant human granulocyte colony stimulating factor support in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 2000 |
Phase I clinical trial of weekly combined paclitaxel plus docetaxel in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Erythema; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2000 |
Docetaxel in patients with anthracycline-resistant advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Middle Aged; Neutrophils; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Constipation; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Fatigue; Female; Hematologic Diseases; Humans; Middle Aged; Nausea; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vomiting | 2001 |
Mobilization of peripheral blood stem cells in high-risk breast cancer patients using G-CSF after standard dose docetaxel.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Breast Neoplasms; Cohort Studies; Docetaxel; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Middle Aged; Paclitaxel; Taxoids | 2000 |
Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hypocalcemia; Magnesium; Male; Middle Aged; Paclitaxel; Remission Induction; Taxoids | 2001 |
Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Cyclosporine; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2001 |
A phase II study of single-agent docetaxel chemotherapy for non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids | 2000 |
A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Therapy, Combination; Epirubicin; Fatigue; Female; Fluorouracil; Glutathione; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leucovorin; Male; Middle Aged; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Thrombocytopenia; Treatment Outcome | 2001 |
Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Remission Induction; Survival Analysis; Taxoids | 2001 |
Efficacy of docetaxel 60 mg/m2 in patients with metastatic breast cancer according to the status of anthracycline resistance.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids; Treatment Failure | 2001 |
Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Taxoids; Treatment Outcome | 2001 |
Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Docetaxel; Female; Humans; Leukopenia; Male; Middle Aged; Paclitaxel; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Docetaxel; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2000 |
Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Docetaxel; Drug Hypersensitivity; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2001 |
Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Female; Head and Neck Neoplasms; Humans; Italy; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Survival Rate; Taxoids; Treatment Outcome | 2001 |
High-dose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Epirubicin; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins; Survival Analysis; Taxoids | 2001 |
Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Recombinant Proteins; Salvage Therapy; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome | 2001 |
Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Hydrocortisone; Male; Paclitaxel; Prostatic Neoplasms; Survival Rate; Taxoids | 2001 |
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Incidence; Liver Neoplasms; Middle Aged; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Taxoids | 2001 |
Efficacy of monochemotherapy with docetaxel (taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Disease Progression; Docetaxel; Female; Humans; Hyperprolactinemia; Injections, Intravenous; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Prolactin; Remission Induction; Taxoids | 2001 |
Phase I studies of cisplatin and docetaxel administered by three consecutive weekly infusions for advanced non-small cell lung cancer in elderly and non-elderly patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids | 2001 |
[Effectiveness of doxorubicin-docetaxel or doxorubicin-cyclophosphamide combination in advanced breast cancer with distant metastasis].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life; Taxoids; Treatment Outcome | 2001 |
A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer.
Topics: Adult; Antigens, CD34; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Leukocyte Count; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Recombinant Proteins; Stem Cells; Taxoids | 2001 |
Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 2001 |
A Phase II study of docetaxel and carboplatin in the treatment of non-small cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids | 2001 |
Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Heart; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Taxoids | 2001 |
A phase I study of weekly docetaxel and cisplatin in advanced non-small cell lung cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Female; Fever; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia | 2001 |
[Efficacy of weekly docetaxel therapy for advanced or recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Tolerance; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pilot Projects; Taxoids; Treatment Outcome | 2001 |
The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Docetaxel; Drug Resistance, Neoplasm; Emotions; Estramustine; Feasibility Studies; Female; Health Status; Humans; Hydrocortisone; Infusions, Intravenous; Male; Mental Health; Middle Aged; Paclitaxel; Pain; Prostatic Neoplasms; Quality of Life; Sexual Behavior; Spouses; Taxoids | 2001 |
Phase III randomized trial of docetaxel in combination with cisplatin or carboplatin or vinorelbine plus cisplatin in advanced non--small cell lung cancer: interim analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2001 |
Phase II study of sequential administration of docetaxel followed by doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Survival Analysis; Taxoids | 2001 |
Epirubicin--docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids | 2001 |
[Evaluation of efficacy and toxicity of docetaxel (Taxotere) in patients with advanced mammary gland cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Survival Rate; Taxoids; Treatment Outcome | 2001 |
[A phase I study of docetaxel (TXT) and doxifluridine (5'-DFUR) combination therapy in patients with advanced and recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Floxuridine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 2001 |
Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Taxoids | 2001 |
Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Patient Compliance; Preoperative Care; Prospective Studies; Tamoxifen; Taxoids | 2001 |
Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Mitoxantrone; Nausea; Neutropenia; Paclitaxel; Sepsis; Survival Rate; Taxoids | 2001 |
Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
[Effect of weekly docetaxel in patients with recurrent breast cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pilot Projects; Taxoids | 2001 |
Effect of induction chemotherapy and tandem cycles of high-dose chemotherapy on outcomes in autologous stem cell transplant for metastatic breast cancer.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Paclitaxel; Remission Induction; Survival Analysis; Taxoids; Transplantation, Autologous; Treatment Outcome | 2001 |
Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2001 |
Phase I trial of weekly docetaxel combined with cisplatin in patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hyponatremia; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2001 |
First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Biliary Tract Neoplasms; Docetaxel; Female; Humans; Male; Middle Aged; Paclitaxel; Patient Compliance; Survival Rate; Taxoids; Treatment Outcome | 2001 |
Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Taxoids | 2001 |
Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Taxoids | 2001 |
Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Survival Analysis; Taxoids; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids | 2001 |
Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Estramustine; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Survival Analysis; Taxoids | 2001 |
Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Finasteride; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Paclitaxel; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Taxoids; Tosyl Compounds | 2001 |
Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2001 |
Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pilot Projects; Prostatectomy; Prostatic Neoplasms; Taxoids | 2001 |
Preliminary observations of single-agent docetaxel as neoadjuvant therapy for locally advanced prostate cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prostatectomy; Prostatic Neoplasms; Taxoids | 2001 |
Weekly high-dose calcitriol and docetaxel in advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Calcitriol; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Taxoids; Tumor Cells, Cultured | 2001 |
Docetaxel and exisulind in hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Docetaxel; Humans; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Sulindac; Survival Analysis; Taxoids | 2001 |
A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Taxoids; Thalidomide | 2001 |
Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Agents; Docetaxel; Genes, bcl-2; Humans; Male; Middle Aged; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Taxoids; Thionucleotides | 2001 |
Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Genes, erbB-2; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Taxoids; Trastuzumab | 2001 |
Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Analgesics; Antineoplastic Agents, Phytogenic; Disease Progression; Docetaxel; Drug Administration Schedule; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Pain; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2001 |
Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Sarcoma; Soft Tissue Neoplasms; Taxoids; Treatment Outcome | 2001 |
[Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Female; Germany; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Taxoids; Treatment Outcome | 2001 |
Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
A sequence-dependent combination of docetaxel and vinorelbine: pharmacokinetic interactions.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Interactions; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Metabolic Clearance Rate; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
Dose-finding phase I study of simultaneous weekly infusion with doxorubicin and docetaxel in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 2001 |
Docetaxel as neo-adjuvant therapy for radically treatable stage III non-small cell lung cancer: early results of an international phase III study.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Survival Analysis; Taxoids | 2001 |
Weekly docetaxel as II line therapy in non-small cell lung cancer: an interim analysis of a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Taxoids | 2001 |
Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Taxoids | 2001 |
Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma .
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Patient Selection; Prognosis; Risk Factors; Severity of Illness Index; Survival Analysis; Taxoids | 2001 |
Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids; Treatment Failure | 2001 |
Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fever; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Platinum; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Weekly docetaxel (Taxotere) in patients with metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in Stage III non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids | 2002 |
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids | 2002 |
Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neutropenia; Paclitaxel; Skin Neoplasms; Taxoids; Temozolomide; Thrombocytopenia | 2002 |
[Efficacy and toxicity of a taxotere/cisplatin combination in first line chemotherapy in patients with disseminated ovarian cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dermatitis; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia | 2001 |
Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Therapy, Combination; Female; Humans; Middle Aged; Neutrophils; Paclitaxel; Pilot Projects; Survival Rate; Taxoids; Vomiting | 2002 |
Phase II study of docetaxel and cisplatin administered as three consecutive weekly infusions for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome; World Health Organization | 2002 |
A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Taxoids | 2002 |
Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Delayed-Action Preparations; Docetaxel; Double-Blind Method; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Recombinant Proteins; Taxoids | 2002 |
Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Compliance; Taxoids | 2002 |
Phase I pharmacokinetic and sequence finding study of the combination of docetaxel and methotrexate in patients with solid tumours.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Synergism; Female; Humans; Male; Methotrexate; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2002 |
C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Receptor, ErbB-2; Taxoids | 2002 |
Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium | 2002 |
Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Taxoids; Urinary Bladder Neoplasms | 2002 |
Phase II study of weekly docetaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chi-Square Distribution; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Linear Models; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prednisolone; Taxoids; Treatment Outcome; Vincristine | 2002 |
Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+granulocyte colony stimulating factor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Menopause; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Palliative Care; Prospective Studies; Survival Rate; Taxoids | 2002 |
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Paclitaxel; Receptor, ErbB-2; Taxoids; Time Factors; Trastuzumab; Treatment Outcome; Up-Regulation | 2002 |
Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Estramustine; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2002 |
Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Male; Middle Aged; Paclitaxel; Taxoids | 2002 |
Docetaxel does not impair cardiac autonomic function in breast cancer patients previously treated with anthracyclines.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Circadian Rhythm; Docetaxel; Electrocardiography; Female; Heart Rate; Humans; Middle Aged; Paclitaxel; Taxoids | 2002 |
A dose-finding study of carboplatin-epirubicin-docetaxel in advanced epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Stomatitis; Taxoids | 2002 |
Malignant pleural mesothelioma: a phase II trial with docetaxel.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Docetaxel; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Mesothelioma; Middle Aged; Paclitaxel; Pleural Neoplasms; Survival Rate; Taxoids | 2002 |
Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2002 |
Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Fatigue; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Middle Aged; Nausea; Nervous System Diseases; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Docetaxel and carboplatin as second-line chemotherapy for metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pilot Projects; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma.
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Enzyme Inhibitors; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Uracil | 2002 |
Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Thymidine Phosphorylase | 2002 |
Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dexamethasone; Docetaxel; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Intubation; Lacrimal Apparatus; Lacrimal Duct Obstruction; Middle Aged; Paclitaxel; Retrospective Studies; Taxoids; Trastuzumab | 2002 |
Phase I study of carboplatin, irinotecan and docetaxel on a divided schedule with recombinant human granulocyte colony stimulating factor support in patients with stage IIIB or IV non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Recombinant Proteins; Taxoids | 2002 |
Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leiomyosarcoma; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia; Treatment Outcome; Uterine Neoplasms | 2002 |
Combined modality treatment of oral and oropharyngeal cancer including neoadjuvant intraarterial cisplatin and radical surgery followed by concurrent radiation and chemotherapy with weekly docetaxel - three year results of a pilot study.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Cranial Irradiation; Docetaxel; Dose Fractionation, Radiation; Drug Tolerance; Feasibility Studies; Female; Humans; Injections, Intra-Arterial; Lymph Node Excision; Male; Middle Aged; Mouth Neoplasms; Neck; Neoplasm Recurrence, Local; Neoplasm Staging; Oropharyngeal Neoplasms; Paclitaxel; Patient Compliance; Pilot Projects; Prognosis; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Survival Analysis; Taxoids | 2002 |
Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin-vinorelbine with a cisplatin-vinorelbine control group in patients with stage IV non-small-cell lung cancer: GFPC 97.01 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Evaluation Studies as Topic; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Probability; Reference Values; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Tumour microvessel density as predictor of chemotherapy response in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Neovascularization, Pathologic; Paclitaxel; Prognosis; Taxoids; Time Factors; Treatment Outcome | 2002 |
Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes.
Topics: Adult; Antibody Formation; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cytokines; Docetaxel; Enzyme-Linked Immunosorbent Assay; Female; Growth Substances; Humans; Immunity, Cellular; Killer Cells, Lymphokine-Activated; Middle Aged; Paclitaxel; Taxoids | 2002 |
Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Dexamethasone; Diphenhydramine; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Study shows 2-year survival advantage for docetaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Taxoids | 2001 |
Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Confidence Intervals; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Filgrastim; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Middle Aged; Neutropenia; Paclitaxel; Polyethylene Glycols; Probability; Recombinant Proteins; Reference Values; Taxoids; Treatment Outcome | 2002 |
A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: a Hoosier Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
A Phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Area Under Curve; Biotransformation; Chromatography, High Pressure Liquid; Deoxycytidine; Docetaxel; Drug Interactions; Female; Gemcitabine; Half-Life; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2002 |
Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Docetaxel; Drug Therapy, Combination; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiation-Protective Agents; Radiotherapy; Radiotherapy Dosage; Taxoids; Time Factors; Treatment Outcome | 2002 |
A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Case-Control Studies; Cyclophosphamide; Disease Progression; Docetaxel; Doxorubicin; ErbB Receptors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Remission Induction; Survival Rate; Taxoids | 2002 |
Isolated leptomeningeal carcinomatosis (carcinomatous meningitis) after taxane-induced major remission in patients with advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Combined Modality Therapy; Disease Progression; Docetaxel; Female; Humans; Incidence; Meningeal Neoplasms; Meningitis; Methotrexate; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Recurrence; Remission Induction; Survival Rate; Taxoids | 2002 |
Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas.
Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Docetaxel; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Survival Analysis; Taxoids | 2002 |
Docetaxel secretion in tears: association with lacrimal drainage obstruction.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chromatography, High Pressure Liquid; Docetaxel; Female; Gas Chromatography-Mass Spectrometry; Humans; Infusions, Intravenous; Lacrimal Duct Obstruction; Middle Aged; Paclitaxel; Pilot Projects; Prospective Studies; Taxoids; Tears | 2002 |
A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Paclitaxel; Taxoids | 2002 |
Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Head and Neck Neoplasms; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Palliative Care; Recurrence; Survival Rate; Taxoids; Time Factors | 2002 |
Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Docetaxel; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids | 2002 |
A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Thrombocytopenia; Treatment Outcome | 2002 |
Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost Control; Deoxycytidine; Disease Progression; Docetaxel; Drug Costs; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival; Taxoids; Treatment Outcome | 2002 |
Phase I study of docetaxel plus ifosfamide in patients with advanced cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Ifosfamide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2002 |
Combined anti-microtubule therapy: a phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Estramustine; Female; Humans; Microtubules; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival; Taxoids; Treatment Outcome; Venous Thrombosis | 2002 |
Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Incidence; Infusions, Intravenous; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Severity of Illness Index; Stomach Neoplasms; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2002 |
Docetaxel and cisplatin in patients with advanced or recurrent gastric cancer: a multicenter phase I/II study.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Incidence; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Severity of Illness Index; Stomach Neoplasms; Survival Analysis; Taxoids; Transferases (Other Substituted Phosphate Groups); Treatment Outcome | 2002 |
Doxorubicin-docetaxel sequential schedule: results of front-line treatment in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2002 |
A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids | 2002 |
Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Paclitaxel; Quality of Life; Salvage Therapy; Survival Analysis; Taxoids | 2002 |
Epirubicin/docetaxel regimen in progressive breast cancer-a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
A phase II study of dose-dense docetaxel and mitoxantrone in the treatment of patients with high-risk metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Paclitaxel; Taxoids | 2002 |
Phase I trial of weekly docetaxel in elderly patients with non-small cell lung cancer.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Diarrhea; Docetaxel; Drug Administration Schedule; Female; Humans; Infections; Lung Neoplasms; Male; Neutropenia; Paclitaxel; Taxoids | 2002 |
Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 2002 |
Docetaxel plus vinorelbine as salvage chemotherapy in advanced breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Salvage Therapy; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Liver; Liver Neoplasms; Paclitaxel; Taxoids; Tomography, Spiral Computed; Treatment Outcome | 2002 |
Docetaxel in combination with dacarbazine in patients with advanced melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Docetaxel; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Skin Neoplasms; Survival Analysis; Taxoids | 2002 |
Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Confidence Intervals; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Probability; Risk Assessment; Sensitivity and Specificity; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Double-Blind Method; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Interleukin-3; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Recombinant Fusion Proteins; Recombinant Proteins; Taxoids; Treatment Outcome | 2002 |
Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Remission Induction; Taxoids; Treatment Outcome | 2002 |
Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prednisolone; Scotland; Survival Analysis; Taxoids; Time Factors; Treatment Outcome; Vincristine | 2002 |
Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infections; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Palliative Care; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Phase II non-randomized study of three different sequences of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Drug Synergism; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
[Phase I study of gemcitabine (GEM) and docetaxel (TXT) combination chemotherapy for unresectable non-small-cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Taxoids | 2002 |
Weekly carboplatin and docetaxel for locally advanced primary and recurrent cervical cancer: a phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Uterine Cervical Neoplasms | 2002 |
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Delayed-Action Preparations; Docetaxel; Double-Blind Method; Doxorubicin; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Staging; Neutropenia; Neutrophils; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2003 |
Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Combined Modality Therapy; Disease Progression; Docetaxel; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Postoperative Period; Safety; Survival Rate; Taxoids; Treatment Outcome | 2003 |
Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
Weekly low-dose docetaxel in advanced non-small cell lung cancer previously treated with two chemotherapy regimens.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Salvage Therapy; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2003 |
Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids | 2003 |
[Comparison of effects of three chemotherapy regimens for advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Mitomycin; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Cause of Death; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Breast Neoplasms; Confidence Intervals; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Staging; Odds Ratio; Paclitaxel; Pilot Projects; Risk Assessment; Salvage Therapy; Soft Tissue Neoplasms; Survival Analysis; Taxoids | 2002 |
Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Time Factors | 2003 |
Docetaxel with epirubicin--investigations on cardiac safety.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular System; Confidence Intervals; Docetaxel; Epirubicin; Female; Follow-Up Studies; Heart Function Tests; Humans; Middle Aged; Paclitaxel; Taxoids | 2003 |
A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Estramustine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Remission Induction; Survival Analysis; Taxoids | 2003 |
Amelioration of docetaxel/cisplatin induced polyneuropathy by alpha-lipoic acid.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Cisplatin; Docetaxel; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Polyneuropathies; Taxoids; Thioctic Acid | 2003 |
Phase II study of concurrent administration of doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Failure; Treatment Outcome | 2003 |
Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2003 |
Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Menopause; Middle Aged; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Spain; Taxoids; Treatment Outcome | 2003 |
Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer: a pilot phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Gene Expression; Genes, erbB-2; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Taxoids; Trastuzumab | 2003 |
A phase I study of carboplatin and docetaxel for advanced non-small cell lung cancer using the continual reassessment method.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia | 2002 |
Bcl-2 and bax expression in advanced non-small cell lung cancer: lack of correlation with chemotherapy response or survival in patients treated with docetaxel plus vinorelbine.
Topics: Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Biomarkers, Tumor; Biopsy; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Docetaxel; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2003 |
Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small cell lung cancer: a dose finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2003 |
Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Ifosfamide; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids; Treatment Failure | 2003 |
A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2003 |
Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Darbepoetin alfa; Deoxycytidine; Docetaxel; Erythropoietin; Fatigue; Female; Gemcitabine; Humans; Injections, Subcutaneous; Male; Middle Aged; Neoplasms; Paclitaxel; Pilot Projects; Taxoids; Treatment Outcome | 2003 |
Sequential doxorubicin and docetaxel as first-line treatment in metastatic breast cancer: a GEICAM-9801 phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Palliative Care; Prospective Studies; Spain; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Phase I-II parallel study of docetaxel on a bimonthly schedule in refractory metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Recurrent gastric adenocarcinoma with unusual metastatic localization and excellent response to docetaxel and 5-FU continuous infusion.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cisplatin; Docetaxel; Epirubicin; Fluorouracil; Humans; Infusions, Intravenous; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Spleen; Splenic Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome | 2003 |
Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Orosomucoid; Paclitaxel; Prognosis; Proportional Hazards Models; Taxoids; Time Factors; Treatment Outcome | 2003 |
Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Health Status; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome; Ventricular Dysfunction, Left | 2003 |
Vinorelbine and docetaxel as first-line chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Evaluation; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2003 |
Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Recombinant Proteins; Salvage Therapy; Taxoids; Treatment Outcome | 2003 |
Docetaxel and vinorelbine: an effective regimen in recurrent squamous cell esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Drug Synergism; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
[Efficacy of docetaxel (TXT) combined with cisplatin (CDDP) in non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2003 |
Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Docetaxel; Estramustine; Feasibility Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Testosterone; Treatment Outcome | 2003 |
Docetaxel as second-line chemotherapy for advanced non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Palliative Care; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. A multicenter phase II trial.
Topics: Adult; Aged; Ambulatory Care; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Salvage Therapy; Survival Analysis; Taxoids; Treatment Failure; Treatment Outcome | 2003 |
A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumours.
Topics: Adult; Aged; Docetaxel; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2003 |
[Clinical research of taxotere in treatment of metastatic breast cancer].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Neoplasm Metastasis; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2003 |
Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Analysis; Taxoids | 2003 |
Biweekly docetaxel and vinorelbine in anthracycline-resistant metastatic breast cancer: a multicenter phase II study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2003 |
Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Survival; Taxoids; Treatment Outcome | 2003 |
Phase I study of docetaxel and cyclophosphamide in patients with advanced or recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Drug Therapy, Combination; Female; Hematologic Diseases; Humans; Incidence; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Taxoids | 2003 |
Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Taxoids; Treatment Outcome | 2003 |
Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; United States | 2003 |
Weekly low-dose docetaxel in advanced hormone-resistant prostate cancer patients previously exposed to chemotherapy.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Palliative Care; Prostatic Neoplasms; Quality of Life; Taxoids; Treatment Outcome | 2003 |
Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Taxoids; Urologic Neoplasms; Urothelium | 2003 |
Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids | 2003 |
Docetaxel and cisplatin in patients with advanced gastric cancer: results of Japanese phase I/II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Humans; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Stomach Neoplasms; Taxoids; Treatment Outcome | 2002 |
European experience of docetaxel and cisplatin in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Stomach Neoplasms; Taxoids | 2002 |
Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Budgets; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Neoplasm Metastasis; Ontario; Paclitaxel; Population Surveillance; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine; Women's Health | 2003 |
Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Blood Cell Count; Disease-Free Survival; Docetaxel; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Paclitaxel; Prognosis; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2003 |
Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate.
Topics: Antineoplastic Agents, Phytogenic; Blood Cell Count; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Methylprednisolone; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone; Recurrence; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
The effectiveness of scalp cooling in preventing alopecia for patients receiving epirubicin and docetaxel.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Hypothermia, Induced; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardia; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Hypotension; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Paclitaxel; Stomach Neoplasms; Taxoids; Treatment Outcome; Vomiting | 2002 |
Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pulmonary Fibrosis; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of müllerian origin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epithelial Cells; Female; Gemcitabine; Humans; Middle Aged; Mullerian Ducts; Ovarian Neoplasms; Paclitaxel; Taxoids | 2003 |
Combination chemotherapy with docetaxel and irinotecan in metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
The treatment of multiple myeloma with docetaxel (an ECOG study).
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Male; Middle Aged; Multiple Myeloma; Paclitaxel; Salvage Therapy; Survival Analysis; Survival Rate; Taxoids; Thrombocytopenia; Treatment Failure | 2003 |
Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Over Studies; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Paclitaxel; Prognosis; Quality of Life; Statistics as Topic; Survival Analysis; Taxoids | 2003 |
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Taxoids; Treatment Outcome | 2003 |
Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/ relapsed metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Drug Interactions; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
A multicenter phase II study of the efficacy and safety of docetaxel plus cisplatin in Asian chemonaïve patients with metastatic or locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2003 |
Neoadjuvant docetaxel in locally advanced breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Taxoids | 2003 |
Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Polyethylene Glycols; Taxoids; Treatment Outcome | 2003 |
A feasibility study on biweekly administration of docetaxel for patients with recurrent ovarian cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Taxoids | 2003 |
A phase I study of gemcitabine and docetaxel for advanced stage solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Patient Selection; Taxoids | 2003 |
Phase I study of weekly docetaxel infusion and concurrent radiation therapy for head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mouth Mucosa; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Stomatitis; Taxoids | 2003 |
Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2003 |
Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Radiation-Sensitizing Agents; Survival Rate; Taxoids | 2003 |
Intermittent chemotherapy in metastatic androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Calcitriol; Dexamethasone; Disease-Free Survival; Docetaxel; Humans; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids | 2003 |
Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Assessment of fatty acid metabolism in taxan-induced myocardial damage with iodine-123 BMIPP SPECT: comparative study with myocardial perfusion, left ventricular function, and histopathological findings.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Cardiomyopathies; Docetaxel; Fatty Acids; Female; Humans; Iodine Radioisotopes; Iodobenzenes; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radionuclide Imaging; Radiopharmaceuticals; Stroke Volume; Taxoids; Technetium Tc 99m Sestamibi | 2003 |
Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: a phase I and pharmacokinetic study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Humans; Ketoconazole; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2003 |
A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms | 2003 |
A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Stomatitis; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Weekly docetaxel for patients with platinum/paclitaxel/irinotecan-resistant relapsed ovarian cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Infusions, Intravenous; Irinotecan; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Doxorubicin; Drug Interactions; Female; Humans; Liposomes; Male; Middle Aged; Paclitaxel; Polyethylene Glycols; Taxoids | 2004 |
Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Feasibility Studies; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Lymph Nodes; Middle Aged; Paclitaxel; Pilot Projects; Risk Factors; Survival Rate; Taxoids | 2004 |
Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2004 |
Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Confidence Intervals; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neutropenia; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Proportional Hazards Models; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Epothilones; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Middle Aged; Nervous System; Paclitaxel; Taxoids; Treatment Outcome | 2005 |
Efficacy of platinum-based chemotherapy after cranial radiation in patients with brain metastasis from non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Preoperative second-line chemotherapy induces objective responses in primary breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Methotrexate; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Preoperative Care; Taxoids; Treatment Failure; Treatment Outcome | 2005 |
Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-Paclitaxel-refractory breast cancer patients.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Recombinant Proteins; Salvage Therapy; Taxoids | 2005 |
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chi-Square Distribution; Disease Progression; Docetaxel; Female; Humans; Infusions, Intravenous; Logistic Models; Middle Aged; Paclitaxel; Proportional Hazards Models; Quality of Life; Taxoids; Treatment Outcome | 2005 |
Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome | 2005 |
A randomized trial assessing the utility of a test-dose program with taxanes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Cost Control; Docetaxel; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2005 |
Breath alcohol concentrations in Japanese outpatients following paclitaxel and docetaxel infusion.
Topics: Adult; Aged; Alcoholic Intoxication; Antineoplastic Agents, Phytogenic; Asian People; Breast Neoplasms; Breath Tests; Carcinoma, Non-Small-Cell Lung; Docetaxel; Ethanol; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Outpatients; Ovarian Neoplasms; Paclitaxel; Taxoids | 2005 |
Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Quality of Life; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2006 |
Treatment with taxanes of refractory or life-threatening Kaposi sarcoma not associated with human immunodeficiency virus infection.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Docetaxel; Female; HIV Seronegativity; Humans; Male; Middle Aged; Paclitaxel; Sarcoma, Kaposi; Skin Neoplasms; Taxoids | 2006 |
A phase I clinical and pharmacokinetic study of paclitaxel and docetaxel given in combination in patients with solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2006 |
Gemcitabine and split-dose paclitaxel or docetaxel in metastatic breast cancer: a randomised phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Failure | 2006 |
Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment.
Topics: Acetylcarnitine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carnitine; Chromatography, High Pressure Liquid; Creatinine; Docetaxel; Female; Glucose; Humans; Infusions, Intravenous; Kidney; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Paclitaxel; Phosphates; Taxoids; Urea; Vinblastine; Vinorelbine | 2007 |
Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel--ANZGOG 02-01.
Topics: Antineoplastic Agents; Cohort Studies; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Taxoids | 2007 |
A phase II randomized study of two taxanes and cisplatin for metastatic breast cancer after anthracycline: a final analysis.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 2007 |
Albumin-bound paclitaxel improves response rate vs docetaxel in metastatic breast cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2007 |
A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Dietary Supplements; Docetaxel; Female; Folic Acid Antagonists; Homocysteine; Humans; Male; Methylmalonic Acid; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Vitamins | 2007 |
A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Japan; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Quality of Life; Survival Analysis; Taxoids | 2007 |
A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life; Taxoids | 2008 |
The use of an in vitro adenosine triphosphate-based chemotherapy response assay to predict chemotherapeutic response in breast cancer.
Topics: Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; bcl-X Protein; Biomarkers, Tumor; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Middle Aged; Paclitaxel; Predictive Value of Tests; Receptor, ErbB-2; Taxoids; Tumor Suppressor Protein p53 | 2008 |
Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers.
Topics: Antineoplastic Agents; Breast Neoplasms; DNA Methylation; Docetaxel; Drug Resistance, Neoplasm; Female; Genetic Markers; Glutathione S-Transferase pi; Humans; Immunohistochemistry; Paclitaxel; Taxoids | 2008 |
Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Carcinoma; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Humans; Middle Aged; Obesity; Ovarian Neoplasms; Overweight; Paclitaxel; Survival Analysis; Taxoids; Thinness | 2008 |
A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Epothilones; Female; Head and Neck Neoplasms; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Recurrence; Salvage Therapy; Survival Analysis; Taxoids | 2008 |
Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: a randomized, placebo-controlled, double-blind study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Double-Blind Method; Dysgeusia; Female; Glutamine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Risk Factors; Taste; Taxoids; Treatment Outcome | 2008 |
Weekly paclitaxel in the adjuvant treatment of breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Middle Aged; Paclitaxel; Receptors, Steroid; Taxoids | 2008 |
Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carrier Proteins; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Genes, erbB-2; Humans; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Trastuzumab; Treatment Failure; Treatment Outcome | 2008 |
Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Polyglutamic Acid; Quality of Life; Taxoids; Treatment Outcome | 2008 |
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab | 2009 |
Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer.
Topics: Adult; Age Factors; Amenorrhea; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cohort Studies; Cross-Over Studies; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Taxoids | 2009 |
[Randomized phase II study of carboplatin/paclitaxel followed by gemcitabine versus carboplatin/gemcitabine followed by docetaxel in patients with advanced nonsmall cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 2008 |
Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oligodeoxyribonucleotides; Paclitaxel; Taxoids; Toll-Like Receptor 9 | 2008 |
Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2008 |
Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Gemcitabine; Greece; Humans; Neoplasm Metastasis; Paclitaxel; Quality of Life; Quality-Adjusted Life Years; Survival Rate; Taxoids | 2009 |
Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Paclitaxel; Receptor, ErbB-2; Research Design; Taxoids; Trastuzumab | 2008 |
Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Smoking; Taxoids; Vinblastine; Vinorelbine | 2008 |
Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Taxoids; Treatment Outcome | 2009 |
Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
Topics: Adenocarcinoma; Aged; Breast Neoplasms; Confidence Intervals; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Probability; Risk Assessment; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2009 |
nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.
Topics: Albumins; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Delivery Systems; Female; Humans; Middle Aged; Nanoparticles; Paclitaxel; Taxoids | 2010 |
Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: a randomized phase-II study of the Belgian Society of Medical Oncology.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Frail Elderly; Humans; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids | 2010 |
Weekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel-pretreated patients with metastatic breast cancer: a randomized phase II study conducted by the Hellenic Co-Operative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 2009 |
Maintenance immunotherapy in recurrent ovarian cancer: long term follow-up of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Humans; Immunotherapy; Interleukin-2; Isotretinoin; Killer Cells, Natural; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; T-Lymphocytes, Regulatory; Taxoids; Vascular Endothelial Growth Factor A; Young Adult | 2010 |
Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Risk Factors; Taxoids; Treatment Outcome; Young Adult | 2009 |
A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Estradiol; Humans; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Paclitaxel; Polyglutamic Acid; Prostatic Neoplasms; Taxoids | 2010 |
Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Endometrial Neoplasms; Erythrocyte Transfusion; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hemoglobins; Humans; Middle Aged; Neoplasms, Multiple Primary; Ovarian Neoplasms; Paclitaxel; Taxoids; Young Adult | 2010 |
Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: a multi-center phase II study.
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Taxoids | 2010 |
Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Docetaxel; ErbB Receptors; Female; Gene Dosage; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC).
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Quality of Life; Survival Rate; Taxoids; Tegafur | 2010 |
High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Endonucleases; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Targeted therapies: Biomarkers in NSCLC for selecting cetuximab therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Disease Progression; Docetaxel; Drug Therapy, Combination; ErbB Receptors; Humans; Lung Neoplasms; Paclitaxel; Retrospective Studies; Taxoids; United States | 2010 |
Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Docetaxel; Endometrial Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2011 |
Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Endostatins; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Recombinant Proteins; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)].
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Health Status; Humans; Kaplan-Meier Estimate; Methotrexate; Paclitaxel; Prospective Studies; Quality of Life; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2011 |
The validity of neuropathy and neuropathic pain measures in patients with cancer receiving taxanes and platinums.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cisplatin; Comorbidity; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasms; Neuralgia; Nursing Assessment; Oncology Nursing; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pain Measurement; Reproducibility of Results; Risk Factors; Taxoids | 2011 |
First-line bevacizumab-containing therapy for breast cancer: results in patients aged≥70 years treated in the ATHENA study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Hypertension; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2012 |
Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Quality of Life; Recurrence; Taxoids | 2012 |
Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Paclitaxel; Pelvic Neoplasms; Taxoids; Treatment Outcome | 2011 |
Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Self-Assessment; Surveys and Questionnaires; Taxoids; Vinblastine; Vinorelbine | 2011 |
[Clinical comparative study of neoadjuvant chemotherapy outcome in locally advanced breast cancer: docetaxel versus paclitaxel plus pirarubicin hydrochloride and cyclophosphamide].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Young Adult | 2011 |
Chemotherapeutic effects of different paclitaxel plus poldine combination methods for treatment of ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzilates; Docetaxel; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2011 |
Randomized phase II study of primary systemic chemotherapy and trastuzumab for operable HER2 positive breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2012 |
Efficacy of weekly paclitaxel in patients with advanced gastric cancer refractory to docetaxel-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Paclitaxel; Stomach Neoplasms; Taxoids; Treatment Outcome | 2012 |
Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Intraductal, Noninfiltrating; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Subjective and objective assessment of edema during adjuvant chemotherapy for breast cancer using taxane-containing regimens in a randomized controlled trial: The National Surgical Adjuvant Study of Breast Cancer 02.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Edema; Female; Humans; Middle Aged; Paclitaxel; Prognosis; Prospective Studies; Quality of Life; Taxoids | 2012 |
Circadian rhythms, symptoms, physical functioning, and body mass index in breast cancer survivors.
Topics: Activities of Daily Living; Adult; Affective Symptoms; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Body Mass Index; Breast Neoplasms; Circadian Rhythm; Cyclophosphamide; Depression; Docetaxel; Doxorubicin; Fatigue; Female; Humans; Middle Aged; Paclitaxel; Quality of Life; Sleep; Survivors; Taxoids | 2012 |
Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Middle Aged; Neurotoxicity Syndromes; Paclitaxel; Paresthesia; Peripheral Nervous System Diseases; Quality of Life; Surveys and Questionnaires; Taxoids | 2012 |
[Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France].
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Docetaxel; Female; Hemorrhage; Humans; Hypertension; Middle Aged; Neutropenia; Paclitaxel; Proteinuria; Taxoids; Thromboembolism; Young Adult | 2012 |
Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Taxoids | 2012 |
Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Maximum Tolerated Dose; Middle Aged; Niacinamide; Oligonucleotides; Paclitaxel; Proto-Oncogene Proteins c-kit; Receptors, Platelet-Derived Growth Factor; Taxoids; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2012 |
Cisplatin-based therapy for the treatment of elderly patients with non-small-cell lung cancer: a retrospective analysis of a single institution.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2012 |
A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2012 |
Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Imidazoles; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Taxoids; Treatment Outcome | 2012 |
Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Drug Hypersensitivity; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2013 |
Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Medical Futility; Middle Aged; Neoplasm Metastasis; Paclitaxel; Patient Compliance; Taxoids; Treatment Outcome | 2013 |
Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Nanoparticles; Paclitaxel; Prognosis; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Paclitaxel; Taxoids; Treatment Failure; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Neoplasms, Squamous Cell; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
Predictive factors determining neoadjuvant chemotherapy outcomes in breast cancer - a single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; DNA Topoisomerases, Type II; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2013 |
A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Febrile Neutropenia; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Multivariate Analysis; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Taxoids | 2013 |
A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study).
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Japan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Taxoids | 2013 |
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Prognosis; Survival Rate; Taxoids | 2013 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pyrroles; Sunitinib; Survival Rate; Taxoids; Thrombocytopenia; Triple Negative Breast Neoplasms | 2013 |
Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2014 |
A phase III concurrent chemoradiotherapy trial with cisplatin and paclitaxel or docetaxel or gemcitabine in unresectable non-small cell lung cancer: KASLC 0401.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiation Injuries; Radiotherapy, Conformal; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Carboplatin plus either docetaxel or paclitaxel for Japanese patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Paclitaxel; Taxoids; Treatment Outcome | 2013 |
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Exanthema; Fatigue; Febrile Neutropenia; Female; Heterocyclic Compounds, 3-Ring; Humans; Male; Middle Aged; Nausea; Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-akt; Quinazolines; Stomatitis; Taxoids; Tinnitus; Treatment Outcome; Young Adult | 2014 |
Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prospective Studies; Salvage Therapy; Taxoids | 2014 |
Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine; Young Adult | 2014 |
Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced non-small cell lung cancer: north japan lung cancer group trial 0801.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Japan; Lung Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2014 |
Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Docetaxel; Epothilones; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Proportional Hazards Models; Protein Isoforms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
A phase 1/2 of a combination of cetuximab and taxane for "triple negative" breast cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cetuximab; Docetaxel; ErbB Receptors; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Skin Neoplasms; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
O02.03 Value of adding erlotinib to thoracic radiation therapy with chemotherapy for stage III non-small cell lung cancer: a prospective phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Docetaxel; Erlotinib Hydrochloride; Esophagitis; Genes, erbB-1; Humans; Lung Neoplasms; Paclitaxel; Prospective Studies; Quinazolines; Radiation Injuries; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Analysis; Taxoids | 2014 |
Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Drug Interactions; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Serine; Taxoids; Young Adult | 2014 |
Prognostic impact of circulating monocytes and lymphocyte-to-monocyte ratio on previously untreated metastatic non-small cell lung cancer patients receiving platinum-based doublet.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Monocytes; Paclitaxel; Pemetrexed; Prognosis; Proportional Hazards Models; Taxoids; Treatment Outcome | 2014 |
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Broadly Neutralizing Antibodies; Carboplatin; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Polyethylene Glycols; Taxoids | 2015 |
Nuclear survivin expression: a prognostic factor for the response to taxane-platinum chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Nucleus; Cell Proliferation; Cisplatin; Docetaxel; Female; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Predictive Value of Tests; Prognosis; Survivin; Taxoids; Treatment Outcome | 2014 |
Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Female; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2014 |
Neurotoxicity in ovarian cancer patients on Gynecologic Oncology Group (GOG) protocol 218: characteristics associated with toxicity and the effect of substitution with docetaxel: an NRG Oncology/Gynecologic Oncology Group study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Docetaxel; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life; Taxoids | 2015 |
Nab-paclitaxel-based compared to docetaxel-based induction chemotherapy regimens for locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cause of Death; Disease-Free Survival; Docetaxel; Female; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Taxoids; Treatment Outcome | 2015 |
Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Middle Aged; Nanoparticles; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Radiopharmaceuticals; Taxoids; Treatment Outcome | 2015 |
Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Longitudinal Studies; Middle Aged; Neoplasm Staging; Obesity; Paclitaxel; Taxoids | 2015 |
4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Cytochrome P-450 CYP3A; Docetaxel; Female; Humans; Hydroxycholesterols; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Young Adult | 2015 |
[Study on therapy of metastasized or locally advanced urothelial cancer: A phase III randomized clinical trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel or vinflunine in subjects with recurrent or progressive metastatic urothelial cancer (Ke
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Docetaxel; Europe; Germany; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Treatment Outcome; United States; Vinblastine | 2015 |
Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; China; Cisplatin; Confidence Intervals; Disease-Free Survival; Docetaxel; Esophagitis; Female; Humans; Karnofsky Performance Status; Leukopenia; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Pemetrexed; Prospective Studies; Radiation Pneumonitis; Radiotherapy; Survival Rate; Taxoids; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2015 |
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug Combinations; Edema; Fatigue; Female; Follow-Up Studies; Health Status; Humans; Liver Neoplasms; Middle Aged; Neutropenia; Oxonic Acid; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Tegafur | 2016 |
Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quality of Life; Survival Rate; Taxoids | 2016 |
The role of postoperative adjuvant chemotherapy for lymph node-positive esophageal squamous cell carcinoma: a propensity score matching analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Postoperative Period; Propensity Score; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
A multicenter randomized controlled open-label trial to assess the efficacy of compound kushen injection in combination with single-agent chemotherapy in treatment of elderly patients with advanced non-small cell lung cancer: study protocol for a randomiz
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Drugs, Chinese Herbal; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Lung Neoplasms; Male; Paclitaxel; Proportional Hazards Models; Quality of Life; Research Design; Taxoids; Time Factors; Treatment Outcome | 2016 |
High Efficacy and Low Toxicity of the Modified Docetaxel and Carboplatin Protocol in Patients with Recurrent Ovarian Cancer-A Phase 2 Cohort Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Cohort Studies; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Taxoids | 2016 |
Effects of paclitaxel liposome and capecitabine in the treatment of advanced gastric cancer by clinical observation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Liposomes; Male; Middle Aged; Paclitaxel; Remission Induction; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2016 |
Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Taxoids; Tissue Array Analysis; Transcriptome; Trastuzumab; Treatment Outcome; Young Adult | 2016 |
HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Diarrhea; Docetaxel; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Proanthocyanidins; Prognosis; Quality of Life; Taxoids; Trastuzumab; Young Adult | 2017 |
Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Quality of Life; Receptor, ErbB-2; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2017 |
Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nivolumab; Paclitaxel; Pemetrexed; Taxoids | 2016 |
Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast Neoplasms; Disease Progression; Docetaxel; Double-Blind Method; Female; Humans; Intention to Treat Analysis; Middle Aged; Paclitaxel; Receptor, ErbB-2; Remission Induction; Survival Analysis; Taxoids; Therapeutic Equipoise; Time Factors; Trastuzumab | 2017 |
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Platinum Compounds; Programmed Cell Death 1 Receptor; Survival Analysis; Taxoids; Urologic Neoplasms; Urothelium; Vinblastine | 2017 |
Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Cost-Benefit Analysis; Disease Progression; Docetaxel; Female; Health Resources; Humans; Kaplan-Meier Estimate; Netherlands; Paclitaxel; Quality-Adjusted Life Years; Receptor, ErbB-2; Taxoids | 2017 |
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Albumins; Anorexia; Antineoplastic Agents; Body Image; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Cancer Pain; Deoxycytidine; Docetaxel; Dyspnea; Epothilones; Fatigue; Female; Furans; Gemcitabine; Health Status; Heterocyclic Compounds, 4 or More Rings; Humans; Ketones; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nausea; Paclitaxel; Polyethylene Glycols; Quality of Life; Reproductive Health; Sleep Initiation and Maintenance Disorders; Taxoids; Vinblastine; Vinorelbine; Vomiting | 2017 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
Registry study to assess hair loss prevention with the Penguin Cold Cap in breast cancer patients receiving chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Animals; Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Hypothermia, Induced; Induction Chemotherapy; Middle Aged; Paclitaxel; Quality of Life; Scalp; Taxoids; Trastuzumab | 2018 |
Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Disease-Free Survival; Docetaxel; Female; Heterozygote; Humans; Middle Aged; Mutation; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2018 |
Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715).
Topics: Acetylcarnitine; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Dietary Supplements; Docetaxel; Double-Blind Method; Female; Humans; Middle Aged; Neurotoxicity Syndromes; Paclitaxel; Placebos; Taxoids; Treatment Outcome | 2018 |
Utilization of an Alternative Docetaxel-based Intraperitoneal Chemotherapy Regimen in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma: A Continued Need for Ovarian Cancer Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2019 |
Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Docetaxel; Doxorubicin; Endpoint Determination; Epirubicin; Feasibility Studies; Female; Fluorouracil; Guideline Adherence; Humans; Middle Aged; Paclitaxel; Pilot Projects; Random Allocation; Surveys and Questionnaires; Triple Negative Breast Neoplasms | 2018 |
Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2018 |
Role of Skin Tests in the Diagnosis of Immediate Hypersensitivity Reactions to Taxanes: Results of a Multicenter Study.
Topics: Adult; Aged; Antineoplastic Agents; Docetaxel; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Skin Tests | 2019 |
Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Genes, erbB-2; Heart Diseases; Humans; Injections, Subcutaneous; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Stroke Volume; Trastuzumab | 2018 |
Dynamics of blood neutrophil-related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non-small cell lung cancer: A hypothesis-generating study.
Topics: Adenocarcinoma; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Nivolumab; Oxonic Acid; Paclitaxel; Prognosis; Ramucirumab; Retrospective Studies; Salvage Therapy; Survival Rate; Tegafur | 2019 |
Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Papillomaviridae; Papillomavirus Infections; Progression-Free Survival; Squamous Cell Carcinoma of Head and Neck | 2019 |
Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.
Topics: Ado-Trastuzumab Emtansine; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Docetaxel; Esophagogastric Junction; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paclitaxel; Polymorphism, Genetic; Prognosis; Receptor, ErbB-2; Stomach Neoplasms; Survival Rate; Young Adult | 2019 |
Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cyclopentanes; Cytochrome P-450 CYP3A Inhibitors; Docetaxel; Drug Interactions; Enzyme Inhibitors; Female; Fluconazole; Humans; Itraconazole; Male; Middle Aged; Neoplasms; Paclitaxel; Pyrimidines | 2019 |
Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bridged-Ring Compounds; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Paclitaxel; Prospective Studies; Stomach Neoplasms; Taxoids | 2019 |
Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE).
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Non-Randomized Controlled Trials as Topic; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Trastuzumab | 2019 |
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Follow-Up Studies; Humans; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Response Evaluation Criteria in Solid Tumors; Survival Rate; Urologic Neoplasms; Vinblastine | 2019 |
Somatosensory predictors of response to pregabalin in painful chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled, crossover study.
Topics: Aged; Analgesics; Antineoplastic Agents; Cross-Over Studies; Docetaxel; Double-Blind Method; Female; Humans; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pain Threshold; Peripheral Vascular Diseases; Predictive Value of Tests; Pregabalin | 2019 |
Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Docetaxel; Etoposide; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Progression-Free Survival; Proportional Hazards Models; Survival Rate; Treatment Outcome; Young Adult | 2019 |
Effect of Exercise on Taxane Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer: A Randomized Controlled Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Exercise Therapy; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Prognosis; Quality of Life; Survival Rate | 2019 |
Analysis of the relapse patterns and risk factors of endometrial cancer following postoperative adjuvant chemotherapy in a phase III randomized clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Doxorubicin; Endometrial Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Postoperative Care; Recurrence; Risk Factors; Young Adult | 2019 |
Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Docetaxel; Female; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 2020 |
Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Microwaves; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Paclitaxel; Pemetrexed; Progression-Free Survival; Prospective Studies; Radiofrequency Ablation; Treatment Outcome; Vinorelbine | 2020 |
Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Paclitaxel; Pemetrexed; Progression-Free Survival; Treatment Outcome | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Platinum; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2020 |
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Irinotecan; Male; Middle Aged; Paclitaxel; Progression-Free Survival; Survival Rate; Young Adult | 2020 |
Efficacy and safety of ramucirumab plus paclitaxel therapy for advanced gastric cancer patients treated previously with docetaxel-containing chemotherapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Paclitaxel; Ramucirumab; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2021 |
Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Disease Progression; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Functional Status; Humans; Immune Checkpoint Inhibitors; Irinotecan; Paclitaxel; Quality of Life; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2022 |
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Can
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Neoplasms, Second Primary; Paclitaxel; Ramucirumab; Stomach Neoplasms | 2022 |
HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Docetaxel; Female; Humans; Paclitaxel; Quality of Life; Receptor, ErbB-2; Taxoids; Trastuzumab | 2022 |
Minimal added value of wetting hair before scalp cooling to prevent chemotherapy-induced alopecia in cancer patients - results from the Dutch Scalp Cooling Registry.
Topics: Alopecia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Hair; Humans; Hypothermia, Induced; Neoplasms; Paclitaxel; Registries; Scalp | 2023 |
Quality of life with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: quality of life analysis of TORG 0503.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Taxoids | 2023 |
1270 other study(ies) available for docetaxel anhydrous and paclitaxel
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Neoplasms; Noscapine | 2015 |
An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer.
Topics: Animals; Antineoplastic Agents; Caco-2 Cells; Cell Proliferation; Drug Screening Assays, Antitumor; Head and Neck Neoplasms; Heterografts; Humans; Indoles; Male; Mice; Mice, Nude; Microtubules; Neoplasm Transplantation; Structure-Activity Relationship; Tubulin; Tubulin Modulators | 2015 |
New MKLP-2 inhibitors in the paprotrain series: Design, synthesis and biological evaluations.
Topics: Acrylonitrile; Animals; Antimitotic Agents; Brain Chemistry; Cell Line, Tumor; Cytokinesis; Drug Design; Epithelial Cells; Gene Expression; Humans; Indoles; Kinesins; Microtubules; Sheep; Structure-Activity Relationship | 2016 |
Some Anticancer Agents Act on Human Serum Paraoxonase-1 to Reduce Its Activity.
Topics: Antineoplastic Agents; Aryldialkylphosphatase; Electrophoresis, Polyacrylamide Gel; Humans | 2016 |
Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors.
Topics: | 2016 |
Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Microtubules; Molecular Docking Simulation; Molecular Structure; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Structure-Activity Relationship | 2017 |
Antagonizing NOD2 Signaling with Conjugates of Paclitaxel and Muramyl Dipeptide Derivatives Sensitizes Paclitaxel Therapy and Significantly Prevents Tumor Metastasis.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Lewis Lung; Drug Synergism; Mice; Neoplasm Metastasis; Nod2 Signaling Adaptor Protein; Paclitaxel; Signal Transduction | 2017 |
A Series of Enthalpically Optimized Docetaxel Analogues Exhibiting Enhanced Antitumor Activity and Water Solubility.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Female; Mice; Mice, Inbred BALB C; Mice, Nude; Microtubules; Ovarian Neoplasms; Paclitaxel; Solubility; Tubulin; Water | 2018 |
Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy.
Topics: Animals; Apoptosis; Binding Sites; Colchicine; Crystallography, X-Ray; Drug Design; Drug Resistance, Multiple; Heterografts; Humans; Male; Melanoma; Polymerization; Prostatic Neoplasms; Pyrimidines; Tubulin | 2018 |
Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of β-Tubulin and the Multidrug Resistance Associated P-Glycoprotein.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Microtubules; Ovarian Neoplasms; Paclitaxel; Taxoids; Tubulin; Tumor Cells, Cultured; Verapamil; Vinblastine | 2018 |
Synthesis and biological evaluation of novel larotaxel analogues.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry Techniques, Synthetic; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Mice, SCID; Molecular Docking Simulation; Neoplasms; Structure-Activity Relationship; Taxoids | 2018 |
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
Topics: Anti-Bacterial Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Quinolines; Receptor, Bradykinin B2 | 2021 |
Chemists vie to make a better taxol.
Topics: Alkaloids; Docetaxel; Drug Design; Neoplasms; Paclitaxel; Taxoids | 1992 |
Agreement to develop Taxotere expected in April.
Topics: Alkaloids; Antineoplastic Agents; Docetaxel; Drug Evaluation; Humans; Paclitaxel; Taxoids | 1992 |
Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Cell Division; Docetaxel; Female; Humans; Neoplasms, Experimental; Paclitaxel; Taxoids; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1992 |
Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
Topics: Antineoplastic Agents, Phytogenic; Cell Death; Cisplatin; Docetaxel; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Ovarian Neoplasms; Paclitaxel; Rhodamines; Taxoids; Tumor Cells, Cultured | 1992 |
Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method.
Topics: Antineoplastic Agents, Phytogenic; Chromatography, High Pressure Liquid; Docetaxel; Humans; Paclitaxel; Taxoids | 1992 |
[Anticancer substances of vegetable origin. Spindle poisons: vincaleukoblastine, leurocristine and navelbine; taxol and taxotere].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; In Vitro Techniques; Paclitaxel; Plant Extracts; Spindle Apparatus; Taxoids; Vinblastine; Vincristine; Vinorelbine | 1992 |
Effects of Taxotere on murine and human tumor cell lines.
Topics: Alkaloids; Animals; Cell Division; DNA; Docetaxel; Drug Resistance; Humans; Leukemia P388; Mice; Molecular Structure; Neoplasms; Paclitaxel; Protein Biosynthesis; RNA; Taxoids; Tumor Cells, Cultured | 1992 |
[Recent advances in ovarian cancer chemotherapy].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Etoposide; Female; Humans; Infusions, Parenteral; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Paclitaxel; Taxoids | 1992 |
Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol.
Topics: Alkaloids; Animals; Cell Survival; Cells, Cultured; Cricetinae; Cricetulus; Docetaxel; Guanosine Triphosphate; Leukemia, Lymphoid; Microtubules; Paclitaxel; Structure-Activity Relationship; Taxoids; Tumor Cells, Cultured | 1991 |
Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.
Topics: Adenocarcinoma; Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Intraductal, Noninfiltrating; Colonic Neoplasms; Docetaxel; Female; Leukemia, Experimental; Lung Neoplasms; Male; Mammary Neoplasms, Experimental; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasm Transplantation; Neoplasms, Experimental; Osteosarcoma; Paclitaxel; Pancreatic Neoplasms; Sarcoma, Experimental; Taxoids | 1991 |
Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere).
Topics: Animals; Antineoplastic Agents, Phytogenic; Colonic Neoplasms; Docetaxel; Drugs, Investigational; Female; Humans; Lung Neoplasms; Mammary Neoplasms, Experimental; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Taxoids; Transplantation, Heterologous | 1995 |
[Cancer of the ovary. New therapeutic approaches].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon-gamma; Ovarian Neoplasms; Paclitaxel; Taxoids | 1994 |
Novel cytotoxic 3'-(tert-butyl) 3'-dephenyl analogs of paclitaxel and docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Melanoma, Experimental; Microtubules; Molecular Structure; Paclitaxel; Solubility; Taxoids; Tumor Cells, Cultured | 1995 |
Paclitaxel in doxorubicin-resistant metastatic breast cancer patients.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Resistance; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1995 |
Cytotoxicity of paclitaxel and docetaxel in human neuroblastoma cell lines.
Topics: Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Neuroblastoma; Paclitaxel; Taxoids; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1995 |
An overview of phase II studies of docetaxel in patients with metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1995 |
Simultaneous combination of microtubule depolymerizing and stabilizing agents acts at low doses.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cell Division; Colchicine; Demecolcine; Docetaxel; Humans; KB Cells; Microscopy, Fluorescence; Microscopy, Immunoelectron; Microtubule Proteins; Microtubules; Paclitaxel; Pyrazines; Pyridines; Taxoids; Tubulin | 1995 |
Effect of microtubule network disturbance by nocodazole and docetaxel (Taxotere) on protein secretion in rat extraorbital lacrimal and parotid glands.
Topics: Animals; Bucladesine; Calcimycin; Carbachol; Docetaxel; Dose-Response Relationship, Drug; Epinephrine; Fluorescent Antibody Technique; Galactose; Glycoproteins; Isoproterenol; Lacrimal Apparatus; Male; Microtubules; Nocodazole; Paclitaxel; Parotid Gland; Phorbol 12,13-Dibutyrate; Rats; Rats, Sprague-Dawley; Taxoids | 1995 |
Docetaxel-induced alopecia can be prevented.
Topics: Alopecia; Antineoplastic Agents, Phytogenic; Bandages; Cold Temperature; Docetaxel; Head; Humans; Paclitaxel; Taxoids | 1995 |
Crystal and molecular structure of paclitaxel (taxol).
Topics: Crystallography, X-Ray; Docetaxel; Hydrogen Bonding; Models, Molecular; Molecular Conformation; Molecular Structure; Paclitaxel; Structure-Activity Relationship; Taxoids | 1995 |
Taxoids.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids | 1995 |
In the clinic: where paclitaxel and docetaxel stand.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1995 |
Docetaxel and radiation-recall severe mucositis.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Docetaxel; Humans; Lung Neoplasms; Male; Mouth Mucosa; Paclitaxel; Radiation Injuries; Radiotherapy; Stomatitis; Taxoids | 1994 |
[Effect of the association of antimitotic agents on cell lines of human adenocarcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Colonic Neoplasms; Docetaxel; Humans; Paclitaxel; Pyrazines; Pyridines; Skin Neoplasms; Taxoids; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine | 1994 |
Docetaxel (Taxotere): a highly active taxoid with manageable toxicity.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Paclitaxel; Taxoids | 1995 |
In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cisplatin; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Female; Humans; Lethal Dose 50; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome; Tumor Cells, Cultured | 1995 |
S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells.
Topics: Antineoplastic Agents, Phytogenic; Biological Transport; Cell Cycle; Cell Division; Cell Survival; Docetaxel; HeLa Cells; Humans; Kinetics; Paclitaxel; S Phase; Taxoids; Time Factors; Tritium; Tumor Stem Cell Assay | 1995 |
Effects of the microtubule-disturbing agents docetaxel (Taxotere), vinblastine and vincristine on epidermal growth factor-receptor binding of human breast cancer cell lines in vitro.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Kinetics; Neoplasm Proteins; Paclitaxel; Taxoids; Tumor Cells, Cultured; Vinblastine; Vincristine | 1994 |
Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; CHO Cells; Cricetinae; DNA Topoisomerases, Type II; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance; Drug Screening Assays, Antitumor; Humans; Paclitaxel; Taxoids; Tumor Cells, Cultured; Verapamil | 1994 |
Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents.
Topics: Antineoplastic Agents; Cell Division; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Paclitaxel; Taxoids; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1993 |
[Effect of a new anticancer drug, docetaxel (RP56976), on human leukemia cell lines].
Topics: Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Division; DNA Topoisomerases, Type I; Docetaxel; Doxorubicin; Drug Resistance; Humans; Leukemia, Myeloid; Paclitaxel; Taxoids; Tumor Cells, Cultured; Vincristine | 1994 |
In vitro cytotoxic activity of Taxol and Taxotere on primary cultures and established cell lines of human ovarian cancer.
Topics: Carcinoma; Cell Death; Cisplatin; Docetaxel; Drug Resistance; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1993 |
[Testing chemosensitivity of cancer cell lines and gynecologic tumors with the ATP assay].
Topics: Adenosine Triphosphate; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell Line; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Genital Neoplasms, Female; Humans; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1993 |
Prevention of docetaxel-induced erythrodysesthesia with local hypothermia.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Erythema; Female; Humans; Hypothermia, Induced; Paclitaxel; Paresthesia; Taxoids | 1994 |
Taxol and taxotere in bladder cancer: in vitro activity and urine stability.
Topics: Antineoplastic Agents, Phytogenic; Cell Division; Chromatography, High Pressure Liquid; Docetaxel; Humans; Paclitaxel; Taxoids; Tumor Cells, Cultured; Tumor Stem Cell Assay; Urinary Bladder Neoplasms | 1994 |
Analysis of microtubule rigidity using hydrodynamic flow and thermal fluctuations.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biomechanical Phenomena; Docetaxel; Guanosine Triphosphate; Hot Temperature; Hydrolysis; Microtubules; Paclitaxel; Rheology; Swine; Taxoids | 1994 |
Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Survival; Docetaxel; Drug Resistance; Drug Screening Assays, Antitumor; Female; Genital Neoplasms, Female; Humans; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1994 |
Predominant labeling of beta- over alpha-tubulin from porcine brain by a photoactivatable taxoid derivative.
Topics: Affinity Labels; Animals; Antineoplastic Agents, Phytogenic; Azides; Brain Chemistry; Docetaxel; Microtubules; Paclitaxel; Photochemistry; Swine; Taxoids; Tritium; Tubulin | 1994 |
The growth inhibiting effect of docetaxel (Taxotere) in head and neck squamous cell carcinoma xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Line; Cisplatin; Docetaxel; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Taxoids | 1994 |
Structure-activity relationships of Taxol and Taxotere analogues.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Molecular Conformation; Paclitaxel; Structure-Activity Relationship; Taxoids; Tubulin | 1993 |
Comparative effects of taxol and Taxotere on two different human carcinoma cell lines.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Flow Cytometry; Fluorescent Antibody Technique; Humans; KB Cells; Microtubules; Mitosis; Paclitaxel; Taxoids; Tubulin; Tumor Cells, Cultured | 1994 |
Docetaxel (Taxotere): a new anti-cancer drug with promising potential?
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1994 |
Synthesis and structure-activity relationships of new antitumor taxoids. Effects of cyclohexyl substitution at the C-3' and/or C-2 of taxotere (docetaxel).
Topics: Animals; Antineoplastic Agents, Phytogenic; Docetaxel; Doxorubicin; Drug Resistance; Leukemia P388; Melanoma, Experimental; Mice; Microtubules; Molecular Structure; Paclitaxel; Structure-Activity Relationship; Taxoids | 1994 |
Structure-activity studies of antitumor taxanes: synthesis of novel C-13 side chain homologated taxol and taxotere analogs.
Topics: Docetaxel; In Vitro Techniques; Molecular Conformation; Paclitaxel; Structure-Activity Relationship; Taxoids; Tubulin | 1994 |
Interactions between docetaxel (Taxotere) and Plasmodium falciparum-infected erythrocytes.
Topics: Animals; Docetaxel; Erythrocytes; In Vitro Techniques; Malaria, Falciparum; Microtubules; Paclitaxel; Plasmodium falciparum; Taxoids | 1994 |
Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Ascites; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids; Transplantation, Heterologous | 1994 |
The effect of the aromatic rings of taxol on biological activity and solution conformation: synthesis and evaluation of saturated taxol and taxotere analogues.
Topics: Antineoplastic Agents; Cell Survival; Chloroform; Dimethyl Sulfoxide; Docetaxel; Melanoma, Experimental; Microtubules; Molecular Conformation; Molecular Structure; Paclitaxel; Solutions; Structure-Activity Relationship; Taxoids | 1994 |
Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Cell Line; Docetaxel; Epithelium; Humans; Immunoblotting; Intestinal Mucosa; Paclitaxel; Taxoids; Vinblastine | 1994 |
Comparative studies of taxol and taxotere on tumor growth and lymphocyte functions.
Topics: Antineoplastic Agents, Phytogenic; Cell Division; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Killer Cells, Natural; Leukemia, Erythroblastic, Acute; Lymphocyte Activation; Lymphocytes; Ovarian Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1994 |
Solution structure of Taxotere-induced microtubules to 3-nm resolution. The change in protofilament number is linked to the binding of the taxol side chain.
Topics: Docetaxel; Guanosine Triphosphate; In Vitro Techniques; Microscopy, Electron; Microtubules; Models, Molecular; Paclitaxel; Protein Binding; Scattering, Radiation; Solutions; Synchrotrons; Taxoids; Tubulin; X-Rays | 1994 |
4-Deacetyltaxol and 10-acetyl-4-deacetyltaxotere: synthesis and biological evaluation.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Microtubules; Molecular Conformation; Paclitaxel; Taxoids | 1994 |
Taxotere shows significant antitumor activity in anthracycline-resistant breast cancer patients.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Drug Resistance; Female; Humans; Paclitaxel; Taxoids; Treatment Outcome | 1994 |
Taxotere inhibits in-vitro growth of human colonic cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Cell Cycle; Colonic Neoplasms; DNA, Neoplasm; Docetaxel; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Paclitaxel; Taxoids; Time Factors; Tumor Cells, Cultured | 1994 |
Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition.
Topics: Animals; Antineoplastic Agents, Phytogenic; Binding, Competitive; Brain; Cattle; Docetaxel; Guanosine Diphosphate; Guanosine Triphosphate; Kinetics; Ligands; Mathematics; Microscopy, Electron; Microtubules; Paclitaxel; Taxoids; Tubulin | 1993 |
Antitumor activity of taxotere (RP 56976, NSC 628503), a new taxol analog, in experimental ovarian cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Division; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Taxoids; Transplantation, Heterologous | 1993 |
Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Colforsin; Docetaxel; Epithelium; Humans; Intestinal Absorption; Intestinal Mucosa; Membrane Glycoproteins; Nifedipine; Paclitaxel; Taxoids; Tumor Cells, Cultured; Verapamil; Vinblastine | 1993 |
Lipopolysaccharide antagonists block taxol-induced signaling in murine macrophages.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cells, Cultured; Docetaxel; Gene Expression; Lipid A; Macrophages; Mice; Mice, Inbred C3H; Microtubules; Paclitaxel; Phosphorylation; Signal Transduction; Taxoids; Tumor Necrosis Factor-alpha; Tyrosine | 1993 |
Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Erythema; Female; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Paclitaxel; Paresthesia; Pyridoxine; Taxoids | 1993 |
Thermodynamics of ligand-induced assembly of tubulin.
Topics: Antineoplastic Agents, Phytogenic; Calorimetry, Differential Scanning; Dimethyl Sulfoxide; Docetaxel; Guanosine Diphosphate; Guanosine Triphosphate; Hydrogen-Ion Concentration; Kinetics; Ligands; Macromolecular Substances; Magnesium; Mathematics; Microtubules; Models, Structural; Models, Theoretical; Paclitaxel; Taxoids; Thermodynamics; Tubulin | 1993 |
Clinical trials referral resource. Clinical trials with Docetaxel (Taxotere).
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1993 |
Docetaxel: current status and future prospects.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Forecasting; Humans; Lung Neoplasms; Neoplasms; Paclitaxel; Taxoids | 1995 |
Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro.
Topics: Adenocarcinoma; Aminopterin; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Synergism; Humans; Paclitaxel; Prospective Studies; Taxoids; Tumor Cells, Cultured | 1996 |
Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs.
Topics: Antineoplastic Agents, Phytogenic; Cytochrome P-450 Enzyme System; Docetaxel; Female; Humans; Isoenzymes; Liver; Microsomes, Liver; Paclitaxel; Pregnancy; Taxoids | 1996 |
Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cisplatin; DNA Adducts; DNA, Neoplasm; Docetaxel; Humans; Leukocytes; Paclitaxel; Taxoids | 1996 |
Peripheral neurotoxicity induced by docetaxel.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Taxoids | 1996 |
Peripheral neuropathy secondary to docetaxel (Taxotere)
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Electromyography; Humans; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Taxoids | 1996 |
Docetaxel neuropathy.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Nervous System Diseases; Paclitaxel; Taxoids | 1996 |
Fluorescent and biotinylated analogues of docetaxel: synthesis and biological evaluation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Avidin; Biotin; Brain Chemistry; Cattle; Cells, Cultured; Docetaxel; Fluorescent Dyes; Macropodidae; Magnetic Resonance Spectroscopy; Microtubules; Paclitaxel; Taxoids; Tubulin | 1995 |
Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neoplasms; Docetaxel; Female; Humans; Leukemia P388; Male; Mammary Neoplasms, Experimental; Melanoma, Experimental; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Paclitaxel; Taxoids | 1995 |
Association of acquired Pelger-Huet anomaly with taxoid therapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Cell Count; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Pelger-Huet Anomaly; Taxoids; Time Factors | 1996 |
Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells.
Topics: Antineoplastic Agents, Phytogenic; Cell Division; Cell Survival; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Gamma Rays; HeLa Cells; Humans; Paclitaxel; Radiation-Sensitizing Agents; Taxoids; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1996 |
Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities. A report of three cases.
Topics: Aged; Alopecia; Antineoplastic Agents, Phytogenic; Docetaxel; Edema; Female; Humans; Leg; Leiomyosarcoma; Lung Neoplasms; Male; Melanoma; Middle Aged; Paclitaxel; Scleroderma, Localized; Taxoids | 1995 |
Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Cytochrome P-450 CYP2E1; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Docetaxel; Dogs; Drug Interactions; Humans; Male; Mice; Microsomes, Liver; Mixed Function Oxygenases; Oxygenases; Paclitaxel; Rats; Species Specificity; Substrate Specificity; Taxoids | 1996 |
Taxoids: new weapons against cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Microtubules; Molecular Structure; Neoplasms; Ovarian Neoplasms; Paclitaxel; Phytotherapy; Taxoids; Trees | 1996 |
Evaluation of antitumour effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Stomach Neoplasms; Taxoids; Transplantation, Heterologous; Tumor Cells, Cultured | 1996 |
Response to dexamethasone in patients with fluid retention after docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Docetaxel; Edema; Female; Glucocorticoids; Humans; Paclitaxel; Taxoids | 1996 |
Typhlitis associated with docetaxel treatment.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cecal Diseases; Docetaxel; Enterocolitis, Pseudomembranous; Fatal Outcome; Humans; Ileal Diseases; Lung Neoplasms; Male; Middle Aged; Necrosis; Paclitaxel; Taxoids | 1996 |
NMR and molecular modeling study of the conformations of taxol 2'-acetate in chloroform and aqueous dimethyl sulfoxide solutions.
Topics: Acetates; Alkaloids; Chloroform; Deuterium; Dimethyl Sulfoxide; Docetaxel; Hydrogen Bonding; Magnetic Resonance Spectroscopy; Microtubules; Models, Molecular; Molecular Conformation; Molecular Structure; Paclitaxel; Taxoids | 1996 |
[Ovarian cancer. The new chemotherapeutic agents].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids; Topotecan | 1995 |
[Taxans in the treatment of ovarian cancer].
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids | 1996 |
Motor neuropathy due to docetaxel and paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Electromyography; Humans; Middle Aged; Motor Neuron Disease; Paclitaxel; Taxoids | 1996 |
Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Docetaxel; Drug Carriers; Female; Humans; Liposomes; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Taxoids | 1995 |
Docetaxel neuropathy.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Nervous System Diseases; Paclitaxel; Taxoids | 1996 |
Isolation, purification and biological activity of major docetaxel metabolites from human feces.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Feces; Female; Humans; Paclitaxel; Taxoids | 1996 |
Use caution when managing paclitaxel and taxotere infiltrations.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Drug Eruptions; Humans; Infusions, Intravenous; Neoplasms; Nursing Assessment; Paclitaxel; Taxoids | 1996 |
Influence of microtubule-associated proteins on the differential effects of paclitaxel and docetaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain; Calcium; Docetaxel; Microscopy, Electron; Microtubule-Associated Proteins; Microtubules; Nephelometry and Turbidimetry; Paclitaxel; Rats; tau Proteins; Taxoids; Temperature; Tubulin | 1996 |
Docetaxel said to be highly effective and well tolerated in advanced head and neck cancer.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase III as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Paclitaxel; Taxoids; Treatment Outcome | 1996 |
Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Docetaxel; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Irinotecan; Leukemia, Experimental; Male; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Paclitaxel; Sensitivity and Specificity; Taxoids; Vincristine | 1996 |
Docetaxel and gemcitabine released for cancer chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Approval; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Taxoids; United States; United States Food and Drug Administration | 1996 |
Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Melanoma, Experimental; Mice; Mice, Nude; Molecular Structure; Ovarian Neoplasms; Paclitaxel; Structure-Activity Relationship; Taxoids; Tumor Cells, Cultured | 1996 |
In vitro and in vivo inhibition of erythrocytic development of malarial parasites by docetaxel.
Topics: Animals; Antimalarials; Cell Division; Docetaxel; Dose-Response Relationship, Drug; Erythrocytes; Female; In Vitro Techniques; Malaria; Male; Mice; Microbial Sensitivity Tests; Paclitaxel; Parasitemia; Plasmodium; Plasmodium falciparum; Taxoids | 1996 |
Cancer treatments rationed by authority.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Drug Costs; England; Health Care Rationing; Humans; Neoplasms; Paclitaxel; Taxoids | 1996 |
Determination of paclitaxel in biological fluids by micellar electrokinetic chromatography.
Topics: Acetonitriles; Antineoplastic Agents, Phytogenic; Docetaxel; Electrophoresis, Capillary; Humans; Linear Models; Micelles; Paclitaxel; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Sodium Dodecyl Sulfate; Taxoids | 1996 |
Management of advanced breast cancer: patient needs, challenges and new treatment options. Introduction.
Topics: Aging; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Humans; Paclitaxel; Research; Taxoids | 1996 |
Conclusion: the place of docetaxel (Taxotere) in future therapy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Humans; Paclitaxel; Taxoids | 1996 |
Phase II data on paclitaxel and docetaxel in gastrointestinal malignancies.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase II as Topic; Docetaxel; Gastrointestinal Neoplasms; Humans; Paclitaxel; Taxoids | 1996 |
Association of docetaxel/paclitaxel with irradiation in ovarian carcinoma cell lines in bidimensional (sulforhodamine B assay) and tridimensional (spheroids) cultures.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Screening Assays, Antitumor; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1996 |
Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein.
Topics: Antineoplastic Agents, Phytogenic; Blood Proteins; Cells, Cultured; Docetaxel; Erythrocytes; Humans; Kinetics; Orosomucoid; Paclitaxel; Protein Binding; Taxoids | 1996 |
CA 125: a misleading tumor marker?
Topics: Antineoplastic Agents, Phytogenic; CA-125 Antigen; Cystadenocarcinoma, Mucinous; Docetaxel; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 1996 |
Bcl2 is the guardian of microtubule integrity.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Chronic Disease; Docetaxel; G2 Phase; Humans; Leukemia; Lymphoma, B-Cell; Male; Microtubules; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tumor Cells, Cultured | 1997 |
Syntheses and structure-activity relationships of taxoids derived from 14 beta-hydroxy-10-deacetylbaccatin III.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Magnetic Resonance Spectroscopy; Molecular Conformation; Molecular Structure; Paclitaxel; Structure-Activity Relationship; Taxoids; Tumor Cells, Cultured | 1997 |
Synthesis and structure-activity relationships of nonaromatic taxoids: effects of alkyl and alkenyl ester groups on cytotoxicity.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Esters; Female; Humans; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Structure; Ovarian Neoplasms; Paclitaxel; Structure-Activity Relationship; Taxoids; Tumor Cells, Cultured | 1997 |
[What has been done for international harmonization and what remains to be solved?].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Industry; Health Policy; International Cooperation; Japan; Paclitaxel; Taxoids | 1997 |
In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Glutathione; Humans; Lung Neoplasms; Neoplasm Proteins; Paclitaxel; Taxoids; Topotecan; Tumor Cells, Cultured | 1997 |
Synergistic antiproliferative activity of tamoxifen and docetaxel on three oestrogen receptor-negative cancer cell lines is mediated by the induction of apoptosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; DNA Fragmentation; DNA, Neoplasm; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; G2 Phase; Humans; Paclitaxel; Receptors, Estrogen; Tamoxifen; Taxoids; Tumor Cells, Cultured | 1997 |
Compatibility of docetaxel and paclitaxel in intravenous solutions with polyvinyl chloride infusion materials.
Topics: Antineoplastic Agents, Phytogenic; Chromatography, High Pressure Liquid; Docetaxel; Drug Incompatibility; Drug Storage; Injections, Intravenous; Paclitaxel; Polyvinyl Chloride; Solutions; Taxoids | 1997 |
Pretreatment by tubulin agents decreases C-MYC induction in human colon carcinoma cell line HT29-D4.
Topics: Antineoplastic Agents, Phytogenic; Cell Line; Docetaxel; Gene Expression Regulation, Neoplastic; Genes, myc; HT29 Cells; Humans; Microtubules; Nocodazole; Paclitaxel; Precipitin Tests; Protein Binding; Proto-Oncogene Proteins c-myc; RNA, Messenger; RNA, Neoplasm; Taxoids; Tubulin | 1997 |
Activity and toxicity of docetaxel (Taxotere) in women with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Ascites; Breast Neoplasms; Docetaxel; Edema; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pleural Effusion; Taxoids; Treatment Failure; Treatment Outcome | 1997 |
Successful docetaxel rechallenge with cromoglycate after major sensitivity reactions.
Topics: Administration, Oral; Anti-Asthmatic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cromolyn Sodium; Docetaxel; Drug Hypersensitivity; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 1996 |
[3H](azidophenyl)ureido taxoid photolabels peptide amino acids 281-304 of alpha-tubulin.
Topics: Affinity Labels; Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Azides; Binding Sites; Brain; Chromatography, Gel; Chromatography, High Pressure Liquid; Chromatography, Ion Exchange; Docetaxel; Electrophoresis, Polyacrylamide Gel; Microtubules; Molecular Sequence Data; Molecular Structure; Paclitaxel; Peptide Fragments; Sequence Analysis; Swine; Taxoids; Trypsin; Tubulin | 1997 |
Dutch agree budget for expensive anticancer drugs.
Topics: Antineoplastic Agents; Docetaxel; Drug Costs; Health Expenditures; Humans; Netherlands; Paclitaxel; Taxoids | 1997 |
Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere).
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Taxoids | 1997 |
Docetaxel and interstitial pulmonary injury.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Paclitaxel; Taxoids; Tomography, X-Ray Computed; X-Rays | 1997 |
Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Polysorbates; Surface-Active Agents; Taxoids | 1997 |
Structural intermediates in the assembly of taxoid-induced microtubules and GDP-tubulin double rings: time-resolved X-ray scattering.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain; Cattle; Docetaxel; Guanosine Diphosphate; Guanosine Triphosphate; Kinetics; Microtubules; Models, Structural; Paclitaxel; Taxoids; Time Factors; Tubulin; X-Ray Diffraction | 1996 |
Skin ulceration potential of paclitaxel in a mouse skin model in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Docetaxel; Extravasation of Diagnostic and Therapeutic Materials; Humans; Hyaluronoglucosaminidase; Male; Mice; Paclitaxel; Skin Ulcer; Taxoids | 1997 |
Recent advances in managing non-small-cell lung cancer: 4. Chemotherapy of metastatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Palliative Care; Taxoids; Topoisomerase I Inhibitors | 1997 |
[Advance through research].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy; Humans; Neutropenia; Paclitaxel; Research; Taxoids | 1994 |
Images in clinical medicine. Nail changes after chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Middle Aged; Nails; Paclitaxel; Taxoids | 1997 |
[Docetaxel in lymphangiosis carcinomatosa].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Paclitaxel; Taxoids; Tomography, X-Ray Computed | 1997 |
Docetaxel-induced subungual hemorrhage.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Breast Neoplasms, Male; Docetaxel; Female; Hemorrhage; Humans; Male; Middle Aged; Nail Diseases; Paclitaxel; Taxoids | 1997 |
Radiation-recall dermatitis with docetaxel: establishment of a requisite radiation threshold.
Topics: Abdominal Muscles; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Eruptions; Female; Humans; Middle Aged; Paclitaxel; Radiodermatitis; Radiotherapy Dosage; Taxoids | 1997 |
Paclitaxel- and docetaxel-dependent activation of CA-125 expression in human ovarian carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; CA-125 Antigen; Cell Division; Cytosol; Docetaxel; Female; Humans; Neoplasm Proteins; Ovarian Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1997 |
Bio-analysis of docetaxel and hydroxylated metabolites in human plasma by high-performance liquid chromatography and automated solid-phase extraction.
Topics: Antineoplastic Agents, Phytogenic; Chromatography, High Pressure Liquid; Circadian Rhythm; Docetaxel; Female; Humans; Hydroxylation; Linear Models; Methanol; Middle Aged; Osmolar Concentration; Paclitaxel; Reproducibility of Results; Spectrophotometry, Ultraviolet; Taxoids | 1997 |
Anti-proliferative activity of a new class of taxanes (14beta-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Division; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Female; Humans; Leukemia; Mitosis; Paclitaxel; Structure-Activity Relationship; Taxoids; Triterpenes; Tumor Cells, Cultured | 1997 |
Ataxia following docetaxel infusion.
Topics: Antineoplastic Agents, Phytogenic; Ataxia; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 1997 |
Introduction: taxoids and the management of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 1997 |
The development of docetaxel (Taxotere) in non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1997 |
Combination treatment with docetaxel (Taxotere) and platinum compounds for non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1997 |
Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1997 |
[Docetaxel symposium].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 1997 |
Docetaxel: today's results and tomorrow's promises.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cisplatin; Clinical Trials as Topic; Docetaxel; Female; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1997 |
Docetaxel chemotherapy induces transverse superficial loss of the nail plate.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Nail Diseases; Paclitaxel; Taxoids | 1997 |
Synthesis and structure-activity relationships of novel 2',2'-difluoro analogues of docetaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Coloring Agents; Crystallography, X-Ray; Docetaxel; Humans; Mass Spectrometry; Mice; Microtubules; Paclitaxel; Structure-Activity Relationship; Swine; Taxoids; Tetrazolium Salts; Thiazoles; Tubulin; Tumor Cells, Cultured | 1997 |
Oncology update: activity of docetaxel in single-agent and combination chemotherapy regimens. Proceedings of a symposium. Denver, Colorado.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Paclitaxel; Taxoids | 1997 |
Pulse treatment of interphasic HeLa cells with nanomolar doses of docetaxel affects centrosome organization and leads to catastrophic exit of mitosis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Division; Centrosome; Docetaxel; Dose-Response Relationship, Drug; Female; G2 Phase; HeLa Cells; Humans; Interphase; Mitosis; Paclitaxel; Parthenogenesis; Spindle Apparatus; Taxoids; Xenopus laevis | 1997 |
Assessment of microtubule stabilizers by semiautomated in vitro microtubule protein polymerization and mitotic block assays.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Biological Assay; Cattle; Cells, Cultured; Dimethyl Sulfoxide; Docetaxel; Drug Screening Assays, Antitumor; In Vitro Techniques; Melanoma; Mice; Microtubule-Associated Proteins; Mitosis; Paclitaxel; Taxoids | 1997 |
Differential effects of paclitaxel and derivatives on guinea pig isolated heart and papillary muscle.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Coronary Circulation; Docetaxel; Guinea Pigs; Heart; Heart Rate; In Vitro Techniques; Membrane Potentials; Paclitaxel; Papillary Muscles; Taxoids; Vasodilation | 1998 |
Another taxane takes center stage in San Antonio.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Estrogen Antagonists; Female; Genes, BRCA1; Humans; Mutation; Paclitaxel; Taxoids | 1998 |
Differences in docetaxel and paclitaxel activity in resistant tumor cells which express MRP: need of comparative clinical trials in resistant patients.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP-Binding Cassette Transporters; Docetaxel; Gene Expression Regulation, Neoplastic; Mice; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasms, Experimental; Paclitaxel; Taxoids | 1997 |
Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP)
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP-Binding Cassette Transporters; Docetaxel; Fibrosarcoma; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Paclitaxel; Sarcoma, Experimental; Taxoids; Transplantation, Heterologous; Tumor Cells, Cultured; Up-Regulation | 1997 |
Docetaxel treatment of HT-29 colon carcinoma cells reinforces the adhesion and immunocytotoxicity of peripheral blood lymphocytes in vitro.
Topics: Antibodies, Monoclonal; Antigens, Surface; Antineoplastic Agents, Phytogenic; Cell Adhesion; Cell Adhesion Molecules; Cytokines; Cytotoxicity, Immunologic; Docetaxel; HT29 Cells; Humans; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Paclitaxel; T-Lymphocytes; Taxoids | 1998 |
In vitro cytotoxicity of docetaxel in childhood acute leukemias.
Topics: Acute Disease; Adolescent; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Survival; Child; Child, Preschool; Docetaxel; Drug Screening Assays, Antitumor; Drug Synergism; Flow Cytometry; Humans; Infant; Karyotyping; Leukemia, Myeloid; Paclitaxel; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Taxoids; Tumor Cells, Cultured; Vincristine | 1998 |
Necessity of interleukin-1beta converting enzyme cascade in taxotere-initiated death signaling.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 1; Coloring Agents; Cysteine Endopeptidases; Docetaxel; L Cells; Mice; Necrosis; Paclitaxel; Taxoids | 1998 |
Onycholysis in patients treated with docetaxel.
Topics: Aged; Antineoplastic Agents, Phytogenic; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Nail Diseases; Paclitaxel; Taxoids | 1998 |
Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidine; Docetaxel; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Induction; Female; Fluorouracil; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Taxoids; Thymidine Phosphorylase; Transplantation, Heterologous; Tumor Necrosis Factor-alpha; Up-Regulation | 1998 |
[Breast cancer with liver metastasis responsive to docetaxel: case report].
Topics: Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Leukopenia; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 1998 |
Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Paclitaxel; Receptor, ErbB-2; Taxoids; Tumor Cells, Cultured | 1998 |
Lack of CNS penetration of docetaxel in a patient with leptomeningeal carcinomatosis.
Topics: Adult; Antineoplastic Agents, Phytogenic; Arachnoid; Blood-Brain Barrier; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Docetaxel; Female; Humans; Meningeal Neoplasms; Paclitaxel; Taxoids | 1998 |
[Acute diffuse interstitial pneumopathy following docetaxel (Taxotère). Apropos of 2 cases].
Topics: Aged; Alveolitis, Extrinsic Allergic; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Hypersensitivity; Glucocorticoids; Humans; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Male; Paclitaxel; Prednisolone; Pulmonary Edema; Taxoids | 1998 |
Effect of microtubule disruption on cell adhesion and spreading.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Adhesion; Cell Size; Docetaxel; Dose-Response Relationship, Drug; Humans; Integrins; Microtubules; Neoplasm Metastasis; Nocodazole; Paclitaxel; Taxoids; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 1998 |
Synthesis and evaluation of water-soluble non-prodrug analogs of docetaxel bearing sec-aminoethyl group at the C-10 position.
Topics: Animals; Antineoplastic Agents, Phytogenic; Chemical Phenomena; Chemistry, Physical; Docetaxel; Drug Screening Assays, Antitumor; Humans; Microtubules; Paclitaxel; Solubility; Swine; Taxoids; Tubulin | 1998 |
[Taxoids in ovarian and breast carcinoma: the role of the medical profession and the government].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Costs; Drug Utilization; Female; Guidelines as Topic; Humans; Paclitaxel; Physician's Role; Policy Making; Public Policy; Taxoids | 1998 |
[Provision of taxoids in 1996: inequality of care].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Budgets; Clinical Trials as Topic; Docetaxel; Drug Costs; Drug Utilization; Female; Health Care Rationing; Hospitals; Humans; Netherlands; Ovarian Neoplasms; Paclitaxel; Population Surveillance; Surveys and Questionnaires; Taxoids | 1998 |
In vitro modulation of doxorubicin and docetaxel antitumoral activity by methyl-beta-cyclodextrin.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; beta-Cyclodextrins; Breast Neoplasms; Cisplatin; Cyclodextrins; Docetaxel; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Ovarian Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1998 |
The effect of combining antitubulin agents on differentiated and undifferentiated human colon cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Cell Differentiation; Cell Division; Cell Survival; Colonic Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Humans; Paclitaxel; Taxoids; Time Factors; Tubulin; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 1998 |
Potential interactions between antitubulin agents and temperature: implications for modulation of multidrug resistance.
Topics: Antineoplastic Agents, Phytogenic; Biological Transport; Cell Division; Cell Survival; Docetaxel; Drug Resistance, Multiple; Humans; Hyperthermia, Induced; Leukemia, Erythroblastic, Acute; Paclitaxel; Sarcoma; Taxoids; Temperature; Tumor Cells, Cultured; Vinblastine | 1998 |
Microtubules and intracellular traffic of secretory proteins in rat extraorbital lacrimal glands.
Topics: Animals; Anti-Bacterial Agents; Brefeldin A; Carbon Radioisotopes; Cyclopentanes; Docetaxel; Eye Proteins; Galactose; Glycoproteins; Golgi Apparatus; In Vitro Techniques; Kinetics; Lacrimal Apparatus; Leucine; Macrolides; Male; Microtubules; Nocodazole; Paclitaxel; Rats; Rats, Sprague-Dawley; Taxoids; Time Factors; Tritium | 1998 |
Paclitaxel hypersensitivity reactions: a role for docetaxel substitution.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Hypersensitivity; Female; Glycerol; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 1998 |
Evaluation of the linearity of docetaxel pharmacokinetics.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase I as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1998 |
Taxanes propagate apoptosis via two cell populations with distinctive cytological and molecular traits.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Calcium-Calmodulin-Dependent Protein Kinases; Caspase 3; Caspases; CDC2 Protein Kinase; Cell Cycle; Cyclin B; Cyclin B1; DNA Fragmentation; Docetaxel; Enzyme Activation; Flow Cytometry; Humans; Jurkat Cells; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Microtubules; Mitogen-Activated Protein Kinase 1; Nocodazole; Paclitaxel; Phosphorylation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-raf; Taxoids; ZAP-70 Protein-Tyrosine Kinase | 1998 |
Docetaxel chronopharmacology in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Bone Marrow; Circadian Rhythm; Docetaxel; Drug Administration Schedule; Male; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Taxoids | 1998 |
Nail bed dyschromia secondary to docetaxel therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Nail Diseases; Paclitaxel; Pigmentation Disorders; Taxoids | 1998 |
Tau expression in model adenocarcinomas correlates with docetaxel sensitivity in tumour-bearing mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Immunoblotting; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Nude; Microtubule-Associated Proteins; Neoplasm Proteins; Paclitaxel; Pancreatic Neoplasms; Polymerase Chain Reaction; RNA, Messenger; tau Proteins; Taxoids; Tubulin | 1998 |
[Yellow nails].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Eruptions; Female; Hand Dermatoses; Humans; Middle Aged; Nail Diseases; Paclitaxel; Pigmentation Disorders; Taxoids | 1998 |
Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment.
Topics: Adult; Antineoplastic Agents, Phytogenic; Body Weight; Capillary Leak Syndrome; Capillary Permeability; Carcinoma, Non-Small-Cell Lung; Docetaxel; Edema; Female; Hemodynamics; Humans; Lung Neoplasms; Male; Paclitaxel; Prospective Studies; Taxoids | 1998 |
In vitro effect of amifostine on haematopoietic progenitors exposed to carboplatin and non-alkylating antineoplastic drugs: haematoprotection acts as a drug-specific progenitor rescue.
Topics: Amifostine; Antigens, CD34; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Cell Cycle; Cell Division; Cells, Cultured; Docetaxel; Doxorubicin; Etoposide; Hematopoietic Stem Cells; Humans; Leukocytes, Mononuclear; Paclitaxel; Taxoids; Time Factors | 1998 |
Docetaxel is a potent cytotoxic drug in the treatment of advanced breast cancer.
Topics: Adult; Aged; Anthraquinones; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Division; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Microtubules; Middle Aged; Mitosis; Neoplasm Staging; Neutropenia; Paclitaxel; Remission Induction; Survival Rate; Taxoids; Tubulin | 1998 |
Docetaxel: response in patients who have received at least two prior chemotherapy regimens for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome | 1998 |
A rapid reversed phase high performance liquid chromatographic method for the determination of docetaxel (Taxotere) in human plasma using a column switching technique.
Topics: Antineoplastic Agents, Phytogenic; Chromatography, High Pressure Liquid; Docetaxel; Humans; Infusions, Intravenous; Paclitaxel; Taxoids | 1998 |
Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Biological Transport; Cell Size; Centrosome; CHO Cells; Cricetinae; Docetaxel; Dyneins; Endoplasmic Reticulum; Gene Expression; Intermediate Filament Proteins; Kinesins; Microinjections; Mitochondria; Nocodazole; Paclitaxel; tau Proteins; Taxoids; Transferrin; Tumor Cells, Cultured | 1998 |
Docetaxel enhances tumor radioresponse in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Survival; Combined Modality Therapy; Docetaxel; Female; Intestinal Mucosa; Jejunum; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Paclitaxel; Radiotherapy Dosage; Taxoids; Transplantation, Isogeneic; Whole-Body Irradiation | 1997 |
Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Humans; Kinetics; Liver; Microsomes, Liver; Middle Aged; Mixed Function Oxygenases; Oxidation-Reduction; Paclitaxel; Recombinant Proteins; Substrate Specificity; Taxoids | 1998 |
[Recurrent squamous-cell lung cancer treated with bronchial-arterial infusion of docetaxel--case report].
Topics: Aged; Antineoplastic Agents, Phytogenic; Bronchial Arteries; Carcinoma, Squamous Cell; Docetaxel; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Male; Paclitaxel; Taxoids; Tracheal Neoplasms | 1998 |
Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Neoplasms; Paclitaxel; Taxoids | 1998 |
Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Interactions; Epirubicin; Female; Humans; Mice; Paclitaxel; Taxoids | 1998 |
Is there a place for "dose-dense" weekly schedules of the taxoids?
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Humans; Paclitaxel; Palliative Care; Taxoids | 1998 |
Synthesis and cytotoxic activity of novel 10-alkylated docetaxel analogs.
Topics: Alkylation; Antineoplastic Agents, Phytogenic; Docetaxel; Models, Molecular; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1998 |
Docetaxel and cyclophosphamide induced remission in platinum and paclitaxel refractory ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma; Cyclophosphamide; Cystadenocarcinoma, Papillary; Docetaxel; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Taxoids | 1998 |
Effect of taxol and taxotere on gene expression in macrophages: induction of the prostaglandin H synthase-2 isoenzyme.
Topics: Animals; Cell Line; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Docetaxel; Drug Synergism; Enzyme Activation; Enzyme Induction; Gene Expression Regulation; Humans; Interferon-gamma; Isoenzymes; Macrophages; Membrane Proteins; Mice; Monocytes; Nitric Oxide Synthase; Paclitaxel; Prostaglandin-Endoperoxide Synthases; Ribonucleases; RNA, Messenger; Taxoids | 1999 |
Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Costs and Cost Analysis; Disease Progression; Docetaxel; Female; Humans; Markov Chains; Models, Economic; Paclitaxel; Quality-Adjusted Life Years; Taxoids; Western World | 1998 |
Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Docetaxel; Genes, p53; Mice; Mice, Inbred Strains; Mitosis; Mutation; Neoplasms, Experimental; Paclitaxel; Specific Pathogen-Free Organisms; Taxoids | 1999 |
Docetaxel in the community setting: an analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. UK Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Paclitaxel; Taxoids | 1999 |
Paclitaxel and docetaxel. Innovation, but at what cost?
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Costs and Cost Analysis; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 1995 |
Cost utility in second-line metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cost-Benefit Analysis; Docetaxel; Female; Humans; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1997 |
A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine.
Topics: Antineoplastic Agents; Breast Neoplasms; Cost-Benefit Analysis; Docetaxel; Female; Humans; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1996 |
In vitro antagonistic cytotoxic interactions between platinum drugs and taxanes on bone marrow progenitor cell CFU-GM.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Carboplatin; Cells, Cultured; Cisplatin; Docetaxel; Drug Antagonism; Granulocytes; Hematopoietic Stem Cells; Humans; Inhibitory Concentration 50; Monocytes; Paclitaxel; Polysorbates; Taxoids | 1999 |
Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Cell Division; Cetuximab; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Female; Flow Cytometry; Humans; Oligonucleotides; Oligonucleotides, Antisense; Oligoribonucleotides, Antisense; Paclitaxel; Taxoids; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1999 |
The common marmoset as a target preclinical primate model for cytokine and gene therapy studies.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow Cells; Callithrix; Cells, Cultured; Cytokines; Disease Models, Animal; DNA, Viral; Docetaxel; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Granulocyte Colony-Stimulating Factor; Granulocytes; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Lymphocytes; Paclitaxel; Polymerase Chain Reaction; Retroviridae; Stromal Cells; Taxoids; Transplantation, Autologous | 1999 |
The coral-derived natural products eleutherobin and sarcodictyins A and B: effects on the assembly of purified tubulin with and without microtubule-associated proteins and binding at the polymer taxoid site.
Topics: Alkaloids; Animals; Antineoplastic Agents; Binding, Competitive; Cnidaria; Diterpenes; Docetaxel; Epothilones; Epoxy Compounds; Growth Inhibitors; Guanosine Triphosphate; Humans; Microtubule-Associated Proteins; Paclitaxel; Polymers; Protein Binding; Protein Processing, Post-Translational; Taxoids; Thiazoles; Tubulin; Tumor Cells, Cultured | 1999 |
Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Docetaxel; Doxorubicin; Drug Interactions; Injections, Intravenous; Kidney; Liver; Lung; Male; Mice; Mice, Inbred Strains; Myocardium; Paclitaxel; Pharmaceutical Vehicles; Reference Values; Spleen; Taxoids; Time Factors; Tissue Distribution | 1999 |
Nail changes secondary to docetaxel (Taxotere).
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Nail Diseases; Paclitaxel; Taxoids | 1999 |
[Low-dose weekly administration of docetaxel for metastatic breast cancer].
Topics: Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 1999 |
Synthesis of taxoids 5. Synthesis and evaluation of novel water-soluble prodrugs of a 3'-desphenyl-3'-cyclopropyl analogue of docetaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Docetaxel; Drug Screening Assays, Antitumor; Humans; Melanoma, Experimental; Mice; Neoplasm Transplantation; Paclitaxel; Prodrugs; Solubility; Structure-Activity Relationship; Taxoids; Transplantation, Heterologous; Tumor Cells, Cultured; Water | 1999 |
The role of taxanes in the management of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Evidence-Based Medicine; Humans; Medical Oncology; Paclitaxel; Taxoids | 1999 |
Effect of docetaxel (Taxotere) on expression of radiation-induced lethal mutations in human cell lines.
Topics: bcl-2-Associated X Protein; Docetaxel; Dose-Response Relationship, Radiation; Humans; Mutation; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Radiation-Sensitizing Agents; Taxoids; Tumor Cells, Cultured | 1999 |
Radiobiological effects of docetaxel (Taxotere): a potential radiation sensitizer.
Topics: Apoptosis; Cell Survival; Docetaxel; Genes, p53; Humans; Paclitaxel; Radiation-Sensitizing Agents; Taxoids; Tumor Cells, Cultured | 1999 |
Continual reassessment methods in phase I trials of the combination of two drugs in oncology.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Camptothecin; Clinical Trials, Phase I as Topic; Computer Simulation; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Humans; Irinotecan; Likelihood Functions; Neoplasms; Neutropenia; Paclitaxel; Retrospective Studies; Taxoids | 1999 |
Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Heart; Humans; Middle Aged; Paclitaxel; Taxoids | 1999 |
Physico-chemical stability of docetaxel premix solution and docetaxel infusion solutions in PVC bags and polyolefine containers.
Topics: Antineoplastic Agents, Phytogenic; Chemical Phenomena; Chemistry, Physical; Chromatography, High Pressure Liquid; Docetaxel; Drug Packaging; Drug Stability; Glass; Infusions, Intravenous; Paclitaxel; Pharmaceutical Solutions; Plastics; Polyenes; Taxoids | 1999 |
Docetaxel (Taxotere) in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Chemotherapy combination shows efficacy in hormone-refractory prostate cancer.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Routes; Estramustine; Follow-Up Studies; Humans; Hydrocortisone; Male; Paclitaxel; Prostatic Neoplasms; Taxoids; Treatment Outcome | 1999 |
Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blood Vessels; Brain Neoplasms; Docetaxel; Female; Glioblastoma; Humans; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Paclitaxel; Pressure; Sarcoma, Experimental; Specific Pathogen-Free Organisms; Taxoids; Tumor Cells, Cultured | 1999 |
Telomerase enzyme activity and RNA expression in adriamycin-resistant human breast carcinoma MCF-7 cells.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Breast Neoplasms; Carcinoma; Cell Count; Cell Division; Cell Survival; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Electrophoresis, Agar Gel; Female; Fluorouracil; Gene Expression; Humans; Paclitaxel; Polymerase Chain Reaction; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Taxoids; Telomerase; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1999 |
Docetaxel (Taxotere) in the treatment of non-small cell lung cancer: recent results and future developments.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Use of gabapentin to treat taxane-induced myalgias.
Topics: Acetates; Amines; Analgesics; Antineoplastic Agents, Phytogenic; Cyclohexanecarboxylic Acids; Docetaxel; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Middle Aged; Muscular Diseases; Paclitaxel; Pain; Taxoids | 1999 |
The effect of pretreatment with docetaxel (taxotere; RP 56976) on irradiated subcutaneous MA 16/C murine tumors.
Topics: Animals; Chemotherapy, Adjuvant; Docetaxel; Female; Injections, Intravenous; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Paclitaxel; Premedication; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Skin Neoplasms; Taxoids | 1999 |
Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Diphosphonates; Docetaxel; Drug Synergism; Humans; Ibandronic Acid; Neoplasm Invasiveness; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1999 |
[Inhibition of tumor neo-angiogenesis and induction of apoptosis as properties of docetaxel (taxotere)].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Capillaries; Carcinoma, Squamous Cell; Docetaxel; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Skin Neoplasms; Taxoids; Tumor Cells, Cultured | 1999 |
[Multi-drug resistant breast cancer responding to chemotherapy with docetaxel (taxotere: TXT)].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Quality of Life; Taxoids | 1999 |
[A breast cancer patient with docetaxel-resistant pleural recurrence with remarkable response to doxifluridine and cyclophosphamide].
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cranial Irradiation; Cyclophosphamide; Docetaxel; Drug Resistance, Neoplasm; Female; Floxuridine; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pleural Neoplasms; Quality of Life; Taxoids | 1999 |
Activation and the interaction of proapoptotic genes in modulating sensitivity to anticancer drugs in gastric cancer cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Cisplatin; DNA Fragmentation; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Humans; Inhibitory Concentration 50; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Signal Transduction; Stomach Neoplasms; Taxoids; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Up-Regulation | 1999 |
Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Paclitaxel; Sensitivity and Specificity; Taxoids; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1999 |
[Pharmacological study of weekly docetaxel in patients with metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 1999 |
[Effective alendronate therapy against a bone metastasis occurring during docetaxel therapy for breast cancer--a case report].
Topics: Aged; Alendronate; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 1999 |
[A case of recurrent breast cancer successfully treated with docetaxel].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids | 1999 |
Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cost-Benefit Analysis; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Health Care Costs; Humans; Middle Aged; Paclitaxel; Quality-Adjusted Life Years; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 1999 |
Taxane-induced glaucoma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Fatal Outcome; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Paclitaxel; Recurrence; Taxoids | 1999 |
Efficacy of docetaxel in the second-line treatment of locally advanced or metastatic soft tissue sarcoma after failure of chemotherapy with anthracycline or ifosfamide.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Male; Paclitaxel; Salvage Therapy; Sarcoma; Soft Tissue Neoplasms; Taxoids | 1999 |
[Taxotere and methylnitrosourea: experimental appraisal of combination chemotherapy].
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Synergism; Leukemia P388; Male; Methylnitrosourea; Mice; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 1999 |
Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Chromatography, High Pressure Liquid; Docetaxel; Esterases; Female; Mice; Paclitaxel; Pharmaceutical Vehicles; Polysorbates; Taxoids | 1999 |
[Experimental chemotherapy of xenotransplanted oral squamous epithelial carcinoma: effectiveness of docetaxel (taxotere) in the nude mouse model].
Topics: Aged; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Docetaxel; Humans; Male; Mice; Mice, Nude; Mouth Mucosa; Mouth Neoplasms; Neoplasm Transplantation; Paclitaxel; Taxoids; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
The pharmacokinetics of epirubicin and docetaxel in combination in rats.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Epirubicin; Male; Metabolic Clearance Rate; Models, Biological; Paclitaxel; Rats; Rats, Sprague-Dawley; Software; Taxoids | 1999 |
[A case of multiple liver metastases from breast cancer successfully treated with intra-arterial administration of docetaxel].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Lymph Node Excision; Middle Aged; Paclitaxel; Taxoids | 1999 |
[A case report: effective trans-arterial neoadjuvant chemotherapy with docetaxel for a local advanced breast cancer patient].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Infusions, Intra-Arterial; Mastectomy, Radical; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Taxoids | 1999 |
[A case of hepatic arterial infusion chemotherapy with docetaxel for liver metastasis from breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids | 1999 |
Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Area Under Curve; Biotransformation; Breast Neoplasms; Chromatography, High Pressure Liquid; Docetaxel; Drug Synergism; Epirubicin; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 1999 |
Tubulin polyglutamylase: isozymic variants and regulation during the cell cycle in HeLa cells.
Topics: Animals; Brain; Cell Cycle; Cell Division; Centrioles; Docetaxel; G2 Phase; Gene Expression Regulation, Enzymologic; Genetic Variation; HeLa Cells; Humans; Hydroxyurea; Isoenzymes; Mice; Nocodazole; Paclitaxel; Peptide Synthases; Polyglutamic Acid; Spindle Apparatus; Taxoids; Tubulin | 1999 |
Carboplatin-paclitaxel- and carboplatin-docetaxel-induced cytotoxic effect in epithelial ovarian carcinoma in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Colony-Forming Units Assay; Docetaxel; Female; Humans; Linear Models; Ovarian Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1999 |
Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Survival; Deoxycytidine; Docetaxel; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1999 |
[Administration of docetaxel in cases of recurrent breast carcinoma with malignant pleural effusion controlled by intrapleural administration of OK-432].
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Picibanil; Pleura; Pleural Effusion, Malignant; Taxoids | 1999 |
Taxing the taxanes: overused or undersold?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Synergism; Estramustine; Female; Humans; Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids | 1999 |
Docetaxel neuropathy: a distal axonopathy.
Topics: Antineoplastic Agents, Phytogenic; Axons; Docetaxel; Humans; Male; Middle Aged; Nerve Fibers, Myelinated; Paclitaxel; Peripheral Nervous System Diseases; Taxoids | 1999 |
Docetaxel (Taxotere) in hormone-refractory prostate cancer: a new addition to the physicians' toolbag.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Paclitaxel; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 1999 |
Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides.
Topics: Androgens; Animals; Antineoplastic Agents, Phytogenic; Blotting, Northern; Blotting, Western; Disease Progression; DNA Primers; DNA, Neoplasm; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gene Targeting; Genes, bcl-2; Male; Mice; Oligodeoxyribonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Taxoids | 1999 |
Docetaxel (Taxotere): a new option for the treatment of hormone-refractory prostate cancer. Proceedings of a symposium. Chicago, Illinois, USA. April 23, 1999.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Docetaxel (Taxotere): effectiveness against Plasmodium falciparum in vitro and Plasmodium yoelii nigeriensis in vivo.
Topics: Animals; Antimalarials; Docetaxel; Mice; Paclitaxel; Plasmodium falciparum; Plasmodium yoelii; Taxoids | 1998 |
Liquid chromatographic analysis and preliminary pharmacokinetics of methotrexate in cancer patients co-treated with docetaxel.
Topics: Acetone; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemical Precipitation; Chromatography, High Pressure Liquid; Docetaxel; Humans; Hydroxylation; Kinetics; Methanol; Methotrexate; Neoplasms; Paclitaxel; Rats; Rats, Wistar; Sensitivity and Specificity; Taxoids | 1999 |
Cytomegalovirus colitis after administration of docetaxel-5-fluorouracil-cisplatin chemotherapy for locally advanced hypopharyngeal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Colitis; Cytomegalovirus Infections; Docetaxel; Fatal Outcome; Fluorouracil; Ganciclovir; Humans; Hypopharyngeal Neoplasms; Immune Tolerance; Male; Middle Aged; Paclitaxel; Taxoids | 1999 |
Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Division; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Growth Inhibitors; Intestinal Mucosa; Jejunum; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Paclitaxel; Radiation-Sensitizing Agents; Taxoids | 1999 |
Docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Drug Interactions; Drug Therapy; Humans; Paclitaxel; Patient Care Planning; Patient Education as Topic; Taxoids | 1999 |
[A case of synchronous bilateral double primary lung cancer successfully treated by Nd-YAG laser therapy and chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Situ; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Humans; Laser Therapy; Lung Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Paclitaxel; Taxoids | 1999 |
Docetaxel chemotherapy for pancreatic cancer: Do results support certainty? Italian Group for the Study of Gastrointestinal Tract Carcinomas.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Granulocyte Colony-Stimulating Factor; Humans; Karnofsky Performance Status; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Reproducibility of Results; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Docetaxel and epirubicin plus G-CSF mobilize hematopoietic progenitors in breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Paclitaxel; Taxoids | 1999 |
Enhancement of radiation effects by combined docetaxel and carboplatin treatment in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Administration Schedule; Drug Interactions; Flow Cytometry; Humans; Lung Neoplasms; Paclitaxel; Radiation Dosage; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Taxoids; Tumor Cells, Cultured | 1999 |
A comparative study of the generation of dendritic cells from mobilized peripheral blood progenitor cells of patients undergoing high-dose chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cells, Cultured; Culture Media, Serum-Free; Cyclophosphamide; Dendritic Cells; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Interleukin-4; Leukapheresis; Leukocyte Count; Lymphocyte Culture Test, Mixed; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neutropenia; Paclitaxel; Taxoids | 1999 |
Possible metabolic interaction between docetaxel and ifosfamide.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Humans; Ifosfamide; Liver; Microsomes; Neoplasms; Paclitaxel; Taxoids | 2000 |
In vitro efficacy of a novel chemoradiopotentiator--taxoltere metro.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Hypoxia; Cell Survival; CHO Cells; Colonic Neoplasms; Cricetinae; Docetaxel; Drug Resistance, Neoplasm; Humans; Paclitaxel; Radiation-Sensitizing Agents; Taxoids; Tumor Cells, Cultured | 2000 |
[A case of squamous cell lung cancer in a nonsmoking female, successfully treated with docetaxel and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Smoking; Taxoids | 2000 |
[A trial for neoadjuvant chemotherapy of transarterial infusion of docetaxel in locally advanced breast cancer].
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intra-Arterial; Neoadjuvant Therapy; Paclitaxel; Taxoids | 2000 |
Anti-tumour activity of a panel of taxanes toward a cellular model of human cervical cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Bridged-Ring Compounds; Cell Cycle; DNA, Neoplasm; Docetaxel; Drug Screening Assays, Antitumor; Female; Flow Cytometry; Humans; Mice; Mice, Nude; Paclitaxel; Taxoids; Transplantation, Heterologous; Tubulin; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2000 |
Interaction of docetaxel ("Taxotere") with human P-glycoprotein.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Cell Line; DNA, Complementary; Docetaxel; Drug Resistance, Multiple; Humans; Intracellular Fluid; Kidney; Paclitaxel; Swine; Taxoids; Transfection | 1999 |
Clinical efficacy of micronized purified flavonoid fraction (MPFF) in edema.
Topics: Anthropometry; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capillary Permeability; Carcinoma; Docetaxel; Double-Blind Method; Edema; Electronics, Medical; Female; Flavonoids; Humans; Leg; Lymphedema; Mastectomy; Optics and Photonics; Ovarian Neoplasms; Paclitaxel; Placebos; Randomized Controlled Trials as Topic; Taxoids; Venous Insufficiency; Weight Loss | 2000 |
Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Palliative Care; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 1999 |
A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells.
Topics: Alkaloids; Antineoplastic Agents; Bridged-Ring Compounds; Diterpenes; Docetaxel; Drug Resistance, Neoplasm; Epothilones; Epoxy Compounds; Humans; Inhibitory Concentration 50; Models, Chemical; Models, Molecular; Mutation; Paclitaxel; Protein Conformation; Structure-Activity Relationship; Taxoids; Thiazoles; Tubulin; Tumor Cells, Cultured | 2000 |
Complete regression of choroidal metastases from breast cancer after docetaxel-based systemic chemotherapy.
Topics: Adjuvants, Immunologic; Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Choroid Neoplasms; Docetaxel; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Lung Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Paclitaxel; Recombinant Proteins; Skin Neoplasms; Taxoids; Treatment Outcome | 2000 |
Preclinical evaluation of the cardiotoxicity of taxane-anthracycline combinations using the model of isolated perfused rat heart.
Topics: Animals; Anthracyclines; Bridged-Ring Compounds; Chemotherapy, Cancer, Regional Perfusion; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Combinations; Drug Synergism; Epirubicin; Heart; Liver; Male; Paclitaxel; Rats; Rats, Sprague-Dawley; Taxoids | 2000 |
Can HER2 status predict response to cancer therapy?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Predictive Value of Tests; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Taxoids; Trastuzumab | 2000 |
Cutaneous fibrosis induced by docetaxel: a case report.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Eruptions; Female; Fibrosis; Humans; Paclitaxel; Skin; Taxoids | 2000 |
Late apoptotic effects of taxanes on K562 erythroleukemia cells: apoptosis is delayed upstream of caspase-3 activation.
Topics: Apoptosis; Caspase 3; Caspases; Cell Survival; Dactinomycin; Docetaxel; Dose-Response Relationship, Drug; Enzyme Activation; HL-60 Cells; Humans; K562 Cells; Kinetics; Paclitaxel; Taxoids; Time Factors | 2000 |
Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A.
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Carboplatin; Cell Division; Cell Line; Cell Line, Transformed; Cell Survival; Cisplatin; Cyclic AMP-Dependent Protein Kinase Type II; Cyclic AMP-Dependent Protein Kinases; Docetaxel; Doxorubicin; Epithelial Cells; Etoposide; Female; Genes, erbB-2; Humans; Oligodeoxyribonucleotides, Antisense; Paclitaxel; Receptor, ErbB-2; Taxoids; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 2000 |
[Taxane-induced ungual anomalies].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Male; Nail Diseases; Paclitaxel; Taxoids; Time Factors | 2000 |
Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Division; Cisplatin; Cyclophosphamide; Docetaxel; Female; Fluorouracil; Folic Acid Antagonists; Glutamates; Guanine; Humans; Injections, Intraperitoneal; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pemetrexed; Taxoids; Transplantation, Heterologous; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Weight Loss | 2000 |
Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Paclitaxel; Prednisolone; Radiopharmaceuticals; Sensitivity and Specificity; Taxoids; Tomography, Emission-Computed; Vincristine | 2000 |
Cytochrome P-450 and other determinants of pharmacokinetics, toxicity, and efficacy in humans.
Topics: Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Breath Tests; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Erythromycin; Humans; Neoplasms; Oxidoreductases, N-Demethylating; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Docetaxel-induced mobilization of hematopoietic stem cells in a murine model: kinetics, dose titration, and toxicity.
Topics: Animals; Cell Count; Cell Division; Colony-Forming Units Assay; Docetaxel; Dose-Response Relationship, Drug; Female; Flow Cytometry; Hematopoietic Stem Cell Mobilization; Leukocyte Count; Leukocytes, Mononuclear; Mice; Mice, Inbred C57BL; Paclitaxel; Spleen; Taxoids | 2000 |
In vitro sensitivity of normal human mesothelial and malignant mesothelioma cell lines to four new chemotherapeutic agents.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Transformed; Cell Survival; Comet Assay; Deoxycytidine; DNA Damage; Docetaxel; Epithelial Cells; Gemcitabine; Humans; Irinotecan; Mesothelioma; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2000 |
[A case of epithelial cancer of the alveoli which responded favorably to the additional administration of UFT for refractory cancer after administration of carboplatin and docetaxel].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms, Glandular and Epithelial; Paclitaxel; Pulmonary Alveoli; Taxoids; Tegafur; Uracil | 2000 |
[A case of recurrent breast cancer with carcinoma erysipeloides responding to sequential therapy with docetaxel (TXT) and doxifluridine (5'-DFUR) accompanied by leucovorin (LV)].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Floxuridine; Fluorouracil; Humans; Injections, Intra-Arterial; Leucovorin; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Skin Neoplasms; Taxoids | 2000 |
Supravenous discoloration of the skin due to docetaxel treatment.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Humans; Hyperpigmentation; Male; Middle Aged; Paclitaxel; Taxoids | 2000 |
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carboplatin; Cell Division; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Quinazolines; Survival Rate; Taxoids; Thiophenes; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 2000 |
Molecular recognition of taxol by microtubules. Kinetics and thermodynamics of binding of fluorescent taxol derivatives to an exposed site.
Topics: Animals; Binding Sites; Cattle; Docetaxel; Fluorescent Dyes; Kinetics; Microtubules; Models, Molecular; Paclitaxel; Scattering, Radiation; Spectrometry, Fluorescence; Taxoids; Thermodynamics; Tubulin; X-Rays | 2000 |
Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Docetaxel; Female; Humans; Hydrocortisone; Least-Squares Analysis; Linear Models; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 2000 |
Colitis associated with docetaxel-based chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Colitis; Docetaxel; Humans; Paclitaxel; Taxoids | 2000 |
Taxane-based therapy for breast cancer: combination or sequential therapy?
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Paclitaxel; Taxoids | 2000 |
Integration of taxanes into primary chemotherapy for squamous cell carcinoma of the head and neck: promise fulfilled?
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Paclitaxel; Radiation-Sensitizing Agents; Taxoids | 2000 |
[Tumor therapy. New concepts for advanced cases].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Neoplasm Metastasis; Paclitaxel; Survival Rate; Taxoids | 2000 |
Cytotoxic effects toward human hematopoietic progenitor cells and tumor cell lines of paclitaxel, docetaxel, and newly developed analogues IDN5109, IDN5111, and IDN5127.
Topics: Antigens, CD34; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Cell Cycle; Cell Division; Docetaxel; Drug Resistance, Multiple; Flow Cytometry; Hematopoietic Stem Cells; Humans; Inhibitory Concentration 50; Leukocytes, Mononuclear; Paclitaxel; Taxoids; Time Factors; Tumor Cells, Cultured | 1999 |
Successful conservative treatment of neutropenic enterocolitis complicating taxane-based chemotherapy: a report of five cases.
Topics: Acute Disease; Aged; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Squamous Cell; Docetaxel; Enterocolitis; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Recombinant Proteins; Taxoids; Tomography, X-Ray Computed | 2000 |
Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Cell Cycle; Cell Survival; Docetaxel; Drug Interactions; Enzyme Inhibitors; Humans; Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 2000 |
Rapid in vivo monitoring of chemotherapeutic response using weighted sodium magnetic resonance imaging.
Topics: Animals; Annexin A5; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Nucleus; Docetaxel; Etoposide; Flow Cytometry; Fluorescent Antibody Technique; Fluorescent Dyes; Humans; Magnetic Resonance Imaging; Male; Mice; Neoplasm Transplantation; Paclitaxel; Phantoms, Imaging; Prostatic Neoplasms; Sodium; Sodium Chloride; Taxoids; Time Factors; Treatment Outcome; Tumor Cells, Cultured | 2000 |
Colitis and docetaxel-based chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Colitis; Diarrhea; Docetaxel; Estramustine; Female; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids; Vinblastine; Vinorelbine | 2000 |
Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzazepines; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Daunorubicin; Docetaxel; Drug Resistance, Multiple; Feces; Half-Life; Humans; Intestinal Mucosa; Metabolic Clearance Rate; Mixed Function Oxygenases; Neoplasms; Paclitaxel; Quinolines; Taxoids; Tumor Cells, Cultured | 2000 |
[Recent advances in surgical treatment for primary lung cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Docetaxel; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Pneumonectomy; Taxoids; Thoracic Surgery, Video-Assisted | 2000 |
[Preoperative bronchial arterial infusion of docetaxel for squamous cell carcinoma of the lung--clinical evaluation and correlation between anti-tumor effect and apoptosis].
Topics: Aged; Antineoplastic Agents, Phytogenic; Apoptosis; Bronchial Arteries; Carcinoma, Squamous Cell; Docetaxel; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Male; Paclitaxel; Taxoids | 2000 |
[A case of advanced breast cancer associated with humoral hypercalcemia that responded to medroxyprogesterone acetate and docetaxel].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Hypercalcemia; Lymph Nodes; Lymphatic Metastasis; Medroxyprogesterone Acetate; Neoplasm Invasiveness; Paclitaxel; Taxoids | 2000 |
[A case of head metastases of breast cancer successfully treated with radiation therapy and docetaxel].
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Female; Humans; Mastectomy, Radical; Meningeal Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Skin Neoplasms; Skull Neoplasms; Taxoids | 2000 |
Docetaxel extravasation causing significant delayed tissue injury.
Topics: Aged; Antineoplastic Agents, Phytogenic; Blister; Docetaxel; Edema; Erythema; Extravasation of Diagnostic and Therapeutic Materials; Female; Hand Dermatoses; Humans; Paclitaxel; Taxoids | 2000 |
Proteolysis of microtubule associated protein 2 and sensitivity of pancreatic tumours to docetaxel.
Topics: Amino Acid Sequence; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Blotting, Western; Brain; Carcinoma, Ductal, Breast; Cathepsin D; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Immunohistochemistry; Kinetics; Mice; Mice, Inbred C57BL; Microscopy, Electron; Microtubule-Associated Proteins; Microtubules; Molecular Sequence Data; Paclitaxel; Pancreatic Neoplasms; Peptide Hydrolases; Peptides; Rats; Taxoids; Tubulin; Tumor Cells, Cultured | 2000 |
Subungual abscess: a new ungual side-effect related to docetaxel therapy.
Topics: Abscess; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Eruptions; Female; Humans; Middle Aged; Nail Diseases; Paclitaxel; Taxoids | 2000 |
Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Estramustine; Humans; Inhibitory Concentration 50; Male; Microtubules; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Rats; Taxoids; Tumor Cells, Cultured | 2000 |
Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
Topics: Adolescent; Adult; Aged; Antigens, Nuclear; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Docetaxel; Female; Fluorouracil; Humans; Immunohistochemistry; Ki-67 Antigen; Methotrexate; Middle Aged; Multicenter Studies as Topic; Neoplasm Proteins; Nuclear Proteins; Paclitaxel; Paraffin Embedding; Predictive Value of Tests; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Randomized Controlled Trials as Topic; Taxoids; Tumor Suppressor Protein p53 | 2000 |
Mesenteric venous thrombosis attributed to docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Female; Humans; Lung Neoplasms; Mesenteric Vascular Occlusion; Mesenteric Veins; Middle Aged; Osteolysis; Paclitaxel; Sternum; Taxoids; Venous Thrombosis | 2000 |
Comparison of 2-methoxyestradiol-induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species.
Topics: 2-Methoxyestradiol; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Survival; DNA Fragmentation; Docetaxel; Estradiol; Flow Cytometry; Humans; Liver Neoplasms; Microtubules; Paclitaxel; Reactive Oxygen Species; Taxoids; Tumor Cells, Cultured | 2000 |
[Effective chemotherapy with docetaxel in a patient with breast cancer who had progressed after high-dose chemotherapy with autologous peripheral blood stem cell transplantation (APBSCT)].
Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Paclitaxel; Salvage Therapy; Taxoids | 2000 |
Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Retrospective Studies; Taxoids | 2000 |
Syntheses and biological activity of C-3'-difluoromethyl-taxoids.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Division; DNA Fragmentation; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Inhibitory Concentration 50; Paclitaxel; Structure-Activity Relationship; Taxoids; Tumor Cells, Cultured | 2000 |
In vitro evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; DNA Fragmentation; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Interactions; Female; Humans; Mitosis; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-raf; Taxoids; Tumor Cells, Cultured | 2000 |
Differential impact of Raf-1 kinase activity on tumor cell resistance to paclitaxel and docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-raf; Taxoids; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2000 |
Docetaxel-induced lymphopenia in patients with solid tumors: a prospective phenotypic analysis.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Female; Humans; Immunophenotyping; Infections; Lymphocyte Count; Lymphocyte Subsets; Lymphocytes; Lymphopenia; Male; Middle Aged; Neoplasms; Neutropenia; Neutrophils; Paclitaxel; Prospective Studies; Taxoids | 2000 |
Docetaxel-induced radiation recall dermatitis and successful rechallenge without recurrence.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Radiodermatitis; Recurrence; Taxoids | 2000 |
[A case of effective chemotherapy using CAF followed by docetaxel for advanced breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Taxoids | 2000 |
Docetaxel effectively mobilizes peripheral blood CD34+ cells.
Topics: Adult; Antigens, CD34; Antineoplastic Agents, Phytogenic; Blood Component Removal; Breast Neoplasms; Cell Count; Docetaxel; Drug Evaluation; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Middle Aged; Paclitaxel; Prospective Studies; Taxoids; Time Factors | 2000 |
Docetaxel in the management of breast and non-small-cell lung cancers. ASCO 2000, 22nd annual San Antonio Breast Cancer Symposium, and ECCO 10. Abstracts.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2000 |
Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity.
Topics: Adult; Antineoplastic Agents, Phytogenic; Carcinoma; Cimetidine; Cystadenocarcinoma; Dexamethasone; Diphenhydramine; Docetaxel; Drug Administration Schedule; Drug Hypersensitivity; Drug Therapy, Combination; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Taxoids | 2000 |
Paclitaxel-induced remission in docetaxel-refractory anthracycline-pretreated metastatic breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Lymphatic Metastasis; Paclitaxel; Remission Induction; Salvage Therapy; Taxoids | 2000 |
Docetaxel (taxotere) extravasation: a report of five cases with treatment recommendations.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Edema; Erythema; Extravasation of Diagnostic and Therapeutic Materials; Hand; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Taxoids | 2000 |
Cellular immune profile of patients with advanced cancer before and after taxane treatment.
Topics: Aged; Antineoplastic Agents, Phytogenic; Cytokines; Cytotoxicity, Immunologic; Docetaxel; Female; Humans; Immunity, Cellular; Immunophenotyping; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Lymphocyte Activation; Lymphocyte Subsets; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2000 |
Docetaxel as second-line chemotherapy for non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2000 |
[Antitumor activity of UFT and docetaxel on human breast carcinoma xenografts].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Paclitaxel; Succinate Dehydrogenase; Taxoids; Tegafur; Transplantation, Heterologous; Uracil; Xenograft Model Antitumor Assays | 2000 |
[A case of docetaxel-resistant lung cancer effectively treated with chemotherapy of gemcitabine and vinorelbine].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2000 |
Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracyclines and paclitaxel: partial cross-resistance between paclitaxel and docetaxel.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Dexamethasone; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Survival Rate; Taxoids | 2000 |
[A case of locally advanced breast cancer successfully resected after selective intra-arterial chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Paclitaxel; Taxoids | 2000 |
Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine.
Topics: Antineoplastic Agents, Phytogenic; Chromatography, High Pressure Liquid; Docetaxel; Humans; Paclitaxel; Reproducibility of Results; Spectrophotometry, Ultraviolet; Taxoids | 2000 |
Cytotoxicity of cyclophosphamide, paclitaxel, and docetaxel for tumor cell lines in vitro: effects of concentration, time and cytochrome P450-catalyzed metabolism.
Topics: Animals; Ascorbic Acid; Catalysis; Cyclophosphamide; Cytochrome P-450 Enzyme System; Dimethyl Sulfoxide; Docetaxel; Dose-Response Relationship, Drug; Lipid Peroxidation; Male; Microscopy, Fluorescence; Paclitaxel; Rats; Rats, Wistar; Taxoids; Time Factors; Tumor Cells, Cultured | 2000 |
[Effectiveness of docetaxel plus cisplatin in large cell lung cancer showing little response to prior chemotherapy with MVP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Paclitaxel; Taxoids; Treatment Failure; Vindesine | 2000 |
Activity of docetaxel in chemoresistant gestational choriocarcinoma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Choriocarcinoma; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Pregnancy; Taxoids; Uterine Neoplasms | 2000 |
Efficacy of docetaxel in disseminated classical Kaposi's sarcoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Paclitaxel; Sarcoma, Kaposi; Taxoids | 2000 |
Chemotherapy-induced noncardiogenic pulmonary edema related to gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor support.
Topics: Adrenal Cortex Hormones; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Liver Neoplasms; Lymphatic Metastasis; Paclitaxel; Pulmonary Edema; Radiography; Taxoids | 2000 |
The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents, Phytogenic; Cell Division; Docetaxel; Drug Synergism; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Male; Mice; Mice, Nude; Mice, Transgenic; Paclitaxel; Piperidines; Pyridines; Taxoids; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2000 |
Taxanes: the genetic toxicity of paclitaxel and docetaxel in somatic cells of Drosophila melanogaster.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Bridged-Ring Compounds; Docetaxel; Drosophila melanogaster; Female; Genetic Markers; Larva; Male; Mutagenicity Tests; Paclitaxel; Radiation-Sensitizing Agents; Taxoids | 2001 |
Mobilization of hematopoietic progenitor cells with a combination of docetaxel, adriamycin, 5-fluorouracil and filgrastim in breast cancer patients.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Paclitaxel; Recombinant Proteins; Taxoids | 2001 |
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Topics: Aminopterin; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carboplatin; Cell Division; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Prostatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Time Factors; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Vulvar Neoplasms | 2000 |
Enhancement of antitumor effect by intratumoral administration of bax gene in combination with anticancer drugs in gastric cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Cation Exchange Resins; Cisplatin; Combined Modality Therapy; Docetaxel; Fluorouracil; Genetic Therapy; Humans; Indicators and Reagents; Lipids; Mice; Mice, Nude; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Stomach Neoplasms; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Enhancement of tumor radioresponse by docetaxel: Involvement of immune system.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Survival; Combined Modality Therapy; Docetaxel; Immune System; Immune Tolerance; Immunocompetence; Killer Cells, Natural; Lymphocytes, Tumor-Infiltrating; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Muscle Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; T-Lymphocytes, Helper-Inducer; Taxoids; Whole-Body Irradiation | 2001 |
Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Computer Simulation; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Models, Biological; Multicenter Studies as Topic; Orosomucoid; Paclitaxel; Prognosis; Proportional Hazards Models; Regression Analysis; Reproducibility of Results; Survival Analysis; Taxoids | 2000 |
Different docetaxel-induced apoptotic pathways are present in prostate cancer cell lines LNCaP and PC-3.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Caspases; Clusterin; Docetaxel; Glycoproteins; Humans; Inhibitor of Apoptosis Proteins; Male; Microtubule-Associated Proteins; Molecular Chaperones; Neoplasm Proteins; Paclitaxel; Prostatic Neoplasms; Proteins; Survivin; Taxoids; Tumor Cells, Cultured | 2001 |
Changes in findings of mammography, ultrasonography and contrast-enhanced computed tomography of three histological complete responders with primary breast cancer before and after neoadjuvant chemotherapy: case reports.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Mammography; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Postmenopause; Taxoids; Tomography, X-Ray Computed; Ultrasonography, Mammary | 2000 |
[Refractory non-small-cell lung cancer responding to combination chemotherapy with docetaxel, gemcitabine and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 2001 |
Combined effect of docetaxel and cisplatin for non-small cell lung cancer cell lines in vitro.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle; Cell Division; Cisplatin; Docetaxel; Drug Interactions; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 2000 |
Docetaxel and cisplatin in head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diuretics; Docetaxel; Head and Neck Neoplasms; Humans; Kidney Tubules; Magnesium; Magnesium Deficiency; Paclitaxel; Taxoids | 2000 |
Carboplatin pharmacokinetics in patients receiving carboplatin and paclitaxel/docetaxel for advanced lung cancers: impact of age and renal function on area under the curve.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Carboplatin; Docetaxel; Female; Humans; Kidney; Kinetics; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Regression Analysis; Spectrophotometry, Atomic; Taxoids; Time Factors | 2001 |
Severe syndrome of inappropriate antidiuretic hormone secretion with docetaxel treatment in metastatic breast cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Inappropriate ADH Syndrome; Paclitaxel; Taxoids | 2000 |
Selective drug resistant human osteosarcoma cell lines.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Docetaxel; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Immunohistochemistry; Osteosarcoma; Paclitaxel; Taxoids; Tumor Cells, Cultured | 2001 |
Orally active docetaxel analogue: synthesis of 10-deoxy-10-C-morpholinoethyl docetaxel analogues.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Cell Division; Combinatorial Chemistry Techniques; Docetaxel; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Morpholines; Paclitaxel; Solubility; Structure-Activity Relationship; Survival Rate; Taxoids; Tumor Cells, Cultured | 2001 |
Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.
Topics: Adenoviridae; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Survival; DNA, Viral; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Humans; Immunoblotting; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Virus Replication; Xenograft Model Antitumor Assays | 2001 |
Potentiation of docetaxel antitumor activity by batimastat against mouse forestomach carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Male; Mice; Paclitaxel; Phenylalanine; Stomach Neoplasms; Taxoids; Thiophenes | 2000 |
Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a multicenter, community-based feasibility trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Child; Child, Preschool; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 2001 |
Accuracy of contrast-enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Female; Humans; Mammography; Middle Aged; Paclitaxel; Reproducibility of Results; Taxoids; Tomography, Emission-Computed | 2001 |
[Two cases of advanced and metastatic breast cancers treated by docetaxel in combination with intra-arterial infusion of adriamycin].
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 2001 |
[A case of breast cancer 5 cm in diameter treated with a breast preserving approach after preoperative intra-arterial chemotherapy].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Injections, Intra-Arterial; Middle Aged; Paclitaxel; Taxoids | 2001 |
[A case of recurrent breast cancer successfully treated with docetaxel].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
Effects of docetaxel in combination with radiation on human head and neck cancer cells (ZMK-1) and cervical squamous cell carcinoma cells (CaSki ).
Topics: Carcinoma, Squamous Cell; Cell Cycle; Cell Survival; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Female; Flow Cytometry; Head and Neck Neoplasms; Humans; Paclitaxel; Radiation Tolerance; Radiation-Sensitizing Agents; Radiotherapy; Taxoids; Time Factors; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2001 |
Experimental chronotherapy of mouse mammary adenocarcinoma MA13/C with docetaxel and doxorubicin as single agents and in combination.
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Circadian Rhythm; Docetaxel; Doxorubicin; Drug Administration Schedule; Heart; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Microscopy, Electron; Myocardium; Paclitaxel; Taxoids | 2001 |
Docetaxel (Taxotere) in the treatment of non-small cell lung cancer: an international update.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Taxoids | 2001 |
Clinical picture: nail changes secondary to docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Nail Diseases; Paclitaxel; Taxoids | 2001 |
Docetaxel extravasation.
Topics: Aged; Analgesics, Non-Narcotic; Antineoplastic Agents, Phytogenic; Cryotherapy; Dimethyl Sulfoxide; Docetaxel; Extravasation of Diagnostic and Therapeutic Materials; Female; Humans; Ice; Paclitaxel; Sodium Chloride; Taxoids | 2001 |
The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors.
Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Division; Docetaxel; Drug Synergism; Endothelial Growth Factors; Endothelium, Vascular; Estradiol; Fibroblast Growth Factor 2; Humans; Lymphokines; Mice; Mice, Nude; Neovascularization, Physiologic; Paclitaxel; Taxoids; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Models, Animal; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Floxuridine; Fluorouracil; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Paclitaxel; Taxoids; Thymidine Phosphorylase; Tumor Cells, Cultured; Up-Regulation; Xenograft Model Antitumor Assays | 2001 |
The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density.
Topics: Binding Sites; Crystallography; Docetaxel; Drug Resistance, Neoplasm; Microscopy, Electron; Models, Molecular; Molecular Conformation; Paclitaxel; Photoaffinity Labels; Structure-Activity Relationship; Taxoids; Tubulin | 2001 |
Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect.
Topics: Adult; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Fibrosis; Humans; Lacrimal Apparatus; Lacrimal Apparatus Diseases; Lacrimal Duct Obstruction; Middle Aged; Paclitaxel; Taxoids; Tears | 2001 |
The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux.
Topics: Animals; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Cytochrome P-450 Enzyme System; Dioxoles; Docetaxel; Gene Expression Regulation; Humans; Isoquinolines; Paclitaxel; Pregnane X Receptor; Receptors, Steroid; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Taxoids; Tetrahydroisoquinolines; Trabectedin | 2001 |
[A case of docetaxel-resistant breast cancer responsive to paclitaxel therapy].
Topics: Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2001 |
Metastatic eccrine porocarcinoma: response to docetaxel (Taxotere) chemotherapy.
Topics: Acrospiroma; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Sweat Gland Neoplasms; Taxoids; Thorax; Tomography, X-Ray Computed | 2001 |
[Fulminant hepatocellular necrosis following administration of docetaxel].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Liver Failure; Middle Aged; Necrosis; Paclitaxel; Taxoids | 2001 |
Novel d-seco paclitaxel analogues: synthesis, biological evaluation, and model testing.
Topics: Antineoplastic Agents, Phytogenic; Binding Sites; Docetaxel; Humans; Models, Molecular; Molecular Conformation; Nuclear Magnetic Resonance, Biomolecular; Paclitaxel; Protein Binding; Structure-Activity Relationship; Taxoids; Tubulin Modulators; Tumor Cells, Cultured | 2001 |
A preclinical model for experimental chemotherapy of human head and neck cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Body Weight; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Disease Models, Animal; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Ifosfamide; Methotrexate; Mice; Mice, Nude; Paclitaxel; Survival Rate; Taxoids | 2001 |
Highlights of the Eighth European Cancer Conference.
Topics: Amifostine; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Docetaxel; Head and Neck Neoplasms; Humans; Irinotecan; Neoplasms; Paclitaxel; Radiation Injuries; Radiation-Protective Agents; Taxoids; Vinblastine; Vinorelbine | 1995 |
Hypertrophic osteoarthropathy associated with docetaxel treatment.
Topics: Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Diagnosis, Differential; Docetaxel; Female; Humans; Lung Neoplasms; Mastectomy; Middle Aged; Osteoarthropathy, Secondary Hypertrophic; Paclitaxel; Taxoids | 2001 |
[Efficacy of docetaxel for anthracycline-resistant metastatic breast cancer].
Topics: Alopecia; Anthracyclines; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids | 2001 |
Modulation of docetaxel-induced apoptosis and cell cycle arrest by all- trans retinoic acid in prostate cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cyclin D1; Docetaxel; Down-Regulation; Drug Interactions; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids; Tretinoin; Tumor Cells, Cultured | 2001 |
Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance.
Topics: Animals; Antineoplastic Agents; Aryl Hydrocarbon Hydroxylases; Cell Survival; CHO Cells; Cricetinae; Cytochrome P-450 CYP1B1; Cytochrome P-450 Enzyme System; Docetaxel; Drug Resistance, Neoplasm; Humans; Paclitaxel; Taxoids; Transfection | 2001 |
Overexpression of Bcl-2 regulates sodium butyrate- and/or docetaxel-induced apoptosis in human bladder cancer cells both in vitro and in vivo.
Topics: Amides; Animals; Antineoplastic Agents; Apoptosis; Butyrates; Cell Division; Docetaxel; Female; Genes, bcl-2; Humans; Mice; Mice, Nude; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Taxoids; Transfection; Transplantation, Heterologous; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2001 |
Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Chi-Square Distribution; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Middle Aged; Neoplasm Proteins; Paclitaxel; Polymerase Chain Reaction; Predictive Value of Tests; RNA, Neoplasm; Taxoids; Transcription Factors | 2001 |
Docetaxel and liver dysfunction: is it absolutely contraindicated?
Topics: Antineoplastic Agents, Phytogenic; Contraindications; Docetaxel; Female; Humans; Liver Diseases; Middle Aged; Paclitaxel; Taxoids | 2001 |
Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Survival Rate; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2001 |
Clinical significance of plasma nucleosome levels in cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Docetaxel; Enzyme-Linked Immunosorbent Assay; Female; Humans; Leukocyte Count; Male; Mastectomy; Middle Aged; Neoplasms; Nucleosomes; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2001 |
Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Heart; Humans; Myocardium; Paclitaxel; Taxoids; Tubulin; Vinblastine; Vinorelbine | 2001 |
Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bone Marrow Cells; Breast Neoplasms; Cell Survival; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Flow Cytometry; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Immunohistochemistry; Immunomagnetic Separation; Keratins; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Risk Factors; Stem Cells; Taxoids; Time Factors; Tumor Cells, Cultured | 2001 |
[Effect of G-CSF (nartograstim) on neutropenia (leukopenia) induced by taxane in metastatic breast cancer--time-course changes in neutrophil and leukocyte counts].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Neutropenia; Neutrophils; Paclitaxel; Retrospective Studies; Taxoids | 2001 |
[A case of adrenal metastasis of lung cancer treated by carboplatin and docetaxel].
Topics: Adrenal Gland Neoplasms; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Male; Paclitaxel; Taxoids | 2001 |
Microtubule structure at improved resolution.
Topics: Actin Cytoskeleton; Alkaloids; Amino Acid Sequence; Animals; Dimerization; Diterpenes; Docetaxel; Epothilones; Epoxy Compounds; Excipients; Guanosine Triphosphate; Microtubules; Molecular Sequence Data; Paclitaxel; Protein Conformation; Surface Properties; Swine; Taxoids; Thiazoles; Tubulin | 2001 |
Evaluating new treatments for advanced cancer.
Topics: Antineoplastic Agents; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
Neoadjuvant chemotherapy with docetaxel in non--small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Male; Neoadjuvant Therapy; Paclitaxel; Survival Rate; Taxoids | 2001 |
Docetaxel induced cardiotoxicity.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Skin Neoplasms; Taxoids; Ventricular Dysfunction, Left | 2001 |
Semisynthesis of D-ring modified taxoids: novel thia derivatives of docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Indicators and Reagents; KB Cells; Microtubules; Paclitaxel; Plant Leaves; Plants, Medicinal; Taxoids | 2001 |
Mechanisms of taxotere-related drug resistance in pancreatic carcinoma.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Calcium Channel Blockers; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorescent Dyes; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Indomethacin; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Paclitaxel; Pancreatic Neoplasms; Rhodamine 123; RNA, Messenger; Taxoids; Tubulin; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles; Verapamil | 2001 |
Resistance to topoisomerase poisons due to loss of DNA mismatch repair.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Base Pair Mismatch; Breast Neoplasms; Carrier Proteins; Colorectal Neoplasms; Deoxycytidine; DNA Repair; DNA-Binding Proteins; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Enzyme Inhibitors; Epirubicin; Female; Gemcitabine; Humans; Intercalating Agents; Mitoxantrone; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins; Taxoids; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2001 |
Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Colonic Neoplasms; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Immunotoxins; Inhibitory Concentration 50; Lewis Blood Group Antigens; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
[Combination chemotherapy of carboplatin and docetaxel for advanced non-small cell lung cancer (NSCLC)].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2001 |
Induction of cytochrome P450 3A4 by docetaxel in peripheral mononuclear cells and its expression in lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Female; Humans; Leukocytes, Mononuclear; Lung Neoplasms; Male; Middle Aged; Mixed Function Oxygenases; Paclitaxel; Taxoids | 2001 |
The integration of docetaxel into first-line chemotherapy for ovarian cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cisplatin; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2001 |
Combination therapy in hormone-refractory prostate cancer.
Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Docetaxel; Estramustine; Humans; Hydrocortisone; Male; Paclitaxel; Prostatic Neoplasms; Taxoids | 2001 |
Rapid high-performance liquid chromatographic determination of docetaxel (Taxotere) in plasma using liquid-liquid extraction.
Topics: Antineoplastic Agents, Phytogenic; Chromatography, High Pressure Liquid; Docetaxel; Humans; Paclitaxel; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Taxoids | 2001 |
Docetaxel/carboplatin combination produces impressive response in ovarian cancer patients.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
Sustained complete remission in a patient with platinum-resistant ovarian yolk sac tumor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Endodermal Sinus Tumor; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids; Thalidomide | 2001 |
Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Area Under Curve; Cyclosporine; Docetaxel; Drug Interactions; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2001 |
Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Cell Division; Combined Modality Therapy; Docetaxel; Female; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Radiotherapy; Taxoids; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2001 |
Increased activity of CYP3A enzyme in primary cultures of rat hepatocytes treated with docetaxel: comparative evaluation with paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexamethasone; Docetaxel; Dose-Response Relationship, Drug; Enzyme Induction; Glucocorticoids; Hepatocytes; Immunoblotting; Male; Oxidoreductases, N-Demethylating; Paclitaxel; Rats; Rats, Sprague-Dawley; Taxoids | 2001 |
Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Paclitaxel; Retrospective Studies; Salvage Therapy; Survival Analysis; Taxoids | 2001 |
Combination chemotherapy with docetaxel plus vinorelbine in metastatic breast cancer patients with prior exposure to anthracyclines.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Confidence Intervals; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Humans; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Docetaxel alone or orally combined with 5-fluorouracil and its derivatives: effects on mouse mammary tumor cell line MM2 in vitro and in vivo.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Docetaxel; Drug Synergism; Female; Floxuridine; Fluorouracil; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Paclitaxel; Prodrugs; Taxoids; Thymidine Phosphorylase; Tumor Cells, Cultured; Up-Regulation | 2001 |
Two special types of breast cancer presenting as progressive disease after neoadjuvant chemotherapy with docetaxel plus doxorubicin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Squamous Cell; Disease Progression; Docetaxel; Doxorubicin; Female; Humans; Lymphatic Metastasis; Mammography; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Sternum; Taxoids | 2001 |
Chemotherapy for non-small-cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Prognosis; Taxoids | 2001 |
A preliminary pharmacokinetic study of docetaxel, carboplatin and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Agents; Area Under Curve; Carboplatin; Carcinoma, Squamous Cell; Chromatography, High Pressure Liquid; Combined Modality Therapy; Docetaxel; Half-Life; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Paclitaxel; Taxoids | 2001 |
[Outpatient chemotherapy for advanced lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2001 |
[Treatment outcomes with vinorelbine for metastatic breast cancer patients previously treated with both doxorubicin and docetaxel].
Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
[A patient with recurrent breast cancer whose liver metastasis regressed following combined use of weekly docetaxel and MPA.5'-DFUR].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Floxuridine; Humans; Liver Neoplasms; Medroxyprogesterone Acetate; Paclitaxel; Taxoids | 2001 |
From the Food and Drug Administration.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Diethylhexyl Phthalate; Docetaxel; Female; Financing, Government; Fluorouracil; Heart Failure; Humans; Male; Orphan Drug Production; Pacemaker, Artificial; Paclitaxel; Spermatogenesis; Taxoids; Testis; United States; United States Food and Drug Administration | 2001 |
Commercial taxane formulations induce stomatocytosis and increase blood viscosity.
Topics: Aged; Antineoplastic Agents, Phytogenic; Blood Viscosity; Bridged-Ring Compounds; Cardiovascular System; Docetaxel; Dose-Response Relationship, Drug; Erythrocytes; Female; Humans; Male; Middle Aged; Paclitaxel; Rheology; Surface-Active Agents; Taxoids; Time Factors | 2001 |
Cutaneous drug reaction case reports: from the world literature.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Aged; Amlodipine; Anti-Bacterial Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Anticonvulsants; Antihypertensive Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Antirheumatic Agents; BCG Vaccine; Cefotetan; Cephamycins; Contrast Media; Cysteine; Dapsone; Diltiazem; Dipyrone; Docetaxel; Drug Eruptions; Echinacea; Enoxaparin; Female; Fructose; Glucans; Glucose; Gold Sodium Thiomalate; Humans; Ibuprofen; Icodextrin; Ioxaglic Acid; Male; Middle Aged; Minocycline; Paclitaxel; Pregnancy; Solvents; Taxoids; Topiramate; Triamcinolone; Trichloroethylene | 2001 |
Metastatic breast cancer with resistance to both anthracycline and docetaxel successfully treated with weekly paclitaxel.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Liver Neoplasms; Paclitaxel; Salvage Therapy; Taxoids | 2001 |
[Therapeutic effect of multimodal therapy, such as cryosurgery, locoregional immunotherapy and systemic chemotherapy against far advanced breast cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Cisplatin; Combined Modality Therapy; Cryosurgery; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Immunotherapy; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Picibanil; Taxoids | 2001 |
[Docetaxel was effective as neoadjuvant chemotherapy for patients after failure of trans-arterial neoadjuvant chemotherapy with CEF in 2 cases of advanced breast cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Taxoids; Treatment Failure | 2001 |
[A case of locally advanced breast cancer successfully treated with wide resection and reconstruction of chest wall with A-O metallic plates].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Mastectomy; Middle Aged; Paclitaxel; Plastic Surgery Procedures; Quality of Life; Surgical Mesh; Survivors; Taxoids | 2001 |
[Local therapy for stage IV advanced breast cancer with brain metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Female; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Quality of Life; Radiosurgery; Tamoxifen; Taxoids | 2001 |
[Taxane-based palliative chemotherapy for metastatic breast cancer: matched pair analysis to compare the efficacy and safety of docetaxel and paclitaxel].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Disease-Free Survival; Docetaxel; Female; Humans; Matched-Pair Analysis; Middle Aged; Paclitaxel; Palliative Care; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Combined effects of docetaxel and fluoropyrimidines on tumor growth and expression of interleukin-6 and thymidine phosphorylase in breast cancer xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cachexia; Docetaxel; Drug Interactions; Female; Floxuridine; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Paclitaxel; Taxoids; Tegafur; Thymidine Phosphorylase; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |
[Cardiac conduction abnormalities after neoadjuvant chemotherapy with doxorubicin and docetaxel for primary breast carcinoma: a case report].
Topics: Aged; Anesthesia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Female; Heart Block; Humans; Intraoperative Complications; Mastectomy, Segmental; Paclitaxel; Postoperative Complications; Taxoids | 2001 |
Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv.
Topics: Animals; Antineoplastic Agents, Phytogenic; DNA Primers; Docetaxel; Enzyme-Linked Immunosorbent Assay; Female; Gene Targeting; Genetic Therapy; Genetic Vectors; Humans; Liposomes; Male; Mice; Mice, Nude; Neoplasms; Paclitaxel; Polymerase Chain Reaction; Receptors, Transferrin; Taxoids; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
Technology evaluation: G-3139.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Dacarbazine; Docetaxel; Female; Genes, bcl-2; Genetic Therapy; Humans; Male; Mice; Mice, Inbred BALB C; National Institutes of Health (U.S.); Neoplasm Proteins; Neoplasms; Paclitaxel; Patents as Topic; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Neoplasm; Safety; Structure-Activity Relationship; Taxoids; Thionucleotides; Treatment Outcome; United States | 1999 |
Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere).
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cross Infection; Docetaxel; Female; Humans; Hydrocortisone; Immunosuppressive Agents; Lung Neoplasms; Male; Methylprednisolone; Paclitaxel; Pneumonia; Pneumothorax; Respiration, Artificial; Taxoids | 2001 |
Efficient synthesis of the 3'-phenolic metabolite of paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Paclitaxel; Phenols; Taxoids | 2001 |
[Hepatic infusion of docetaxel using PEIT for a patient with stage IV breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Ethanol; Fadrozole; Female; Floxuridine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Injections, Intralesional; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids | 2001 |
[A case of breast cancer with multiple metastases effectively treated with long-term administration of docetaxel, aclarubicin and UFT].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Taxoids; Tegafur; Uracil | 2001 |
Surgical treatment of canalicular stenosis in patients receiving docetaxel weekly.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dacryocystorhinostomy; Docetaxel; Drug Administration Schedule; Female; Glass; Humans; Infusions, Intravenous; Intubation; Lacrimal Duct Obstruction; Middle Aged; Nasolacrimal Duct; Paclitaxel; Silicone Elastomers; Taxoids; Tears | 2001 |
Enhanced transgene expression in androgen independent prostate cancer gene therapy by taxane chemotherapeutic agents.
Topics: Adenoviridae; Antineoplastic Agents, Phytogenic; Docetaxel; Gene Expression; Genetic Therapy; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids; Transgenes; Tumor Cells, Cultured | 2002 |
Cost-minimisation analysis of three regimens of chemotherapy (docetaxel-cisplatin, paclitaxel-cisplatin, paclitaxel-carboplatin) for advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Docetaxel; Drug Costs; Economics, Pharmaceutical; Humans; Infusions, Intravenous; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Sensitivity and Specificity; Survival Rate; Taxoids | 2002 |
Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6.
Topics: Animals; Combined Modality Therapy; Docetaxel; Heterocyclic Compounds; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Oligopeptides; Paclitaxel; Prostatic Neoplasms; Radiation-Sensitizing Agents; Radioimmunotherapy; Taxoids; Transplantation, Heterologous; Yttrium | 2002 |
Japanese experience with second-line chemotherapy with low-dose (60 mg/M2) docetaxel in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2001 |
Taxanes in the adjuvant treatment of breast cancer: why not yet?
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Follow-Up Studies; Humans; Meta-Analysis as Topic; Paclitaxel; Patient Selection; Randomized Controlled Trials as Topic; Taxoids | 2001 |
Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Breast Neoplasms; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; DNA Primers; Docetaxel; Female; Humans; Middle Aged; Mixed Function Oxygenases; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Taxoids | 2002 |
[Clinical observation of taxotere in the treatment of advanced non-small-cell lung cancer and breast cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
[The mechanism of docetaxel-induced apoptosis in human lung cancer cells].
Topics: Annexin A5; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; DNA, Neoplasm; Docetaxel; Flow Cytometry; Humans; Lung Neoplasms; Paclitaxel; Proteins; Taxoids; Tumor Cells, Cultured | 2000 |
Docetaxel combination produces 2-year survival advantage in NSCLC patients.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
High-dose chemotherapy and CD34-selected peripheral blood progenitor cell transplantation for patients with breast cancer metastatic to bone and/or bone marrow.
Topics: Adult; Anthracyclines; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Bone Neoplasms; Breast Neoplasms; Cell Separation; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunohistochemistry; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy.
Topics: Adult; Aged; Ambulatory Care; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Drug Therapy, Combination; Female; Fever; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Infection Control; Infections; Inflammation; Melphalan; Middle Aged; Mitoxantrone; Mucous Membrane; Multivariate Analysis; Neutropenia; Paclitaxel; Patient Selection; Retrospective Studies; Risk; Taxoids; Thiotepa; Transplantation Conditioning | 2001 |
[Docitaxol-induction apoptosis of osteosarcoma].
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Division; Docetaxel; Humans; Osteosarcoma; Paclitaxel; Taxoids; Tumor Cells, Cultured | 2001 |
Cellular sensitivity determinants to docetaxel in human gastrointestinal cancers.
Topics: bcl-X Protein; Cell Division; Docetaxel; Ethacrynic Acid; Flow Cytometry; Gastrointestinal Neoplasms; Gene Expression Regulation, Neoplastic; Genes, p53; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Inhibitory Concentration 50; Isoenzymes; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Time Factors; Transfection; Tubulin; Tumor Cells, Cultured | 2002 |
'Rings' of F-actin form around the nucleus in cultured human MCF7 adenocarcinoma cells upon exposure to both taxol and taxotere.
Topics: Actins; Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Nucleus; Cell Survival; Cytoskeleton; Docetaxel; Female; Humans; Immunohistochemistry; Microfilament Proteins; Microtubules; Paclitaxel; Taxoids; Tumor Cells, Cultured | 2000 |
Electrochemical monitoring of anticancer compounds on the human ovarian carcinoma cell line A2780 and its adriamycin- and Cisplatin-resistant variants.
Topics: Antineoplastic Agents; Cell Adhesion; Cell Survival; Cisplatin; Docetaxel; Doxorubicin; Drug Monitoring; Drug Resistance, Neoplasm; Electrochemistry; Female; Humans; Microscopy, Electron, Scanning; Ovarian Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured; Vinblastine | 2002 |
Successful treatment of metastatic hormone-refractory prostate cancer with malignant pericardial tamponade using docetaxel.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cardiac Tamponade; Cisplatin; Combined Modality Therapy; Docetaxel; Humans; Male; Methylprednisolone; Middle Aged; Paclitaxel; Pericardial Effusion; Pericardiocentesis; Pleural Effusion; Prostatic Neoplasms; Taxoids | 2002 |
Biological basis for chemo-radiotherapy interactions.
Topics: Antineoplastic Agents; Apoptosis; Cell Transformation, Neoplastic; Cisplatin; Combined Modality Therapy; Deoxycytidine; DNA Adducts; DNA Repair; Docetaxel; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Paclitaxel; Radiotherapy; Taxoids | 2002 |
Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids | 2001 |
Effects of Taxotere on invasive potential and multidrug resistance phenotype in pancreatic carcinoma cell line SUIT-2.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biocompatible Materials; Carcinoma; Collagen; Docetaxel; Drug Combinations; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorescent Dyes; Humans; In Vitro Techniques; Laminin; Neoplasm Invasiveness; Paclitaxel; Pancreatic Neoplasms; Phenotype; Proteoglycans; Rhodamine 123; RNA, Neoplasm; Taxoids; Tumor Cells, Cultured | 2001 |
Challenges in oncology. Case 2. Radiation recall associated with docetaxel.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Female; Humans; Paclitaxel; Radiation Injuries; Radiotherapy; Skin; Taxoids | 2002 |
[Combination of taxotere and doxorubicin in chemotherapy of disseminated breast cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors | 2001 |
New tools for prevention of restenosis could decrease the "oculo-stento" reflex.
Topics: Angioplasty, Balloon, Coronary; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Coronary Restenosis; Coronary Stenosis; Docetaxel; Drug Implants; Humans; Injections, Intra-Arterial; Models, Animal; Paclitaxel; Rabbits; Rats; Sirolimus; Stents; Taxoids | 2002 |
Local delivery of low-dose docetaxel, a novel microtubule polymerizing agent, reduces neointimal hyperplasia in a balloon-injured rabbit iliac artery model.
Topics: Administration, Topical; Analysis of Variance; Animals; Antineoplastic Agents; Catheterization; Docetaxel; Drug Delivery Systems; Hyperplasia; Iliac Artery; Image Processing, Computer-Assisted; Leukocyte Count; Paclitaxel; Rabbits; Taxoids; Tunica Intima | 2002 |
Metastatic breast cancer in pregnancy: first case of chemotherapy with docetaxel.
Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Administration Schedule; Female; Humans; Magnetic Resonance Imaging; Neoplasm Staging; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy Trimester, First; Taxoids; Treatment Outcome | 2000 |
Docetaxel induced durable response in advanced extramammary Paget's disease: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; Epirubicin; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Paclitaxel; Paget Disease, Extramammary; Radiography; Scrotum; Skin Neoplasms; Taxoids; Vincristine | 2002 |
MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Cycle; Cell Division; Cell Line; Docetaxel; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Inhibitory Concentration 50; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mitosis; Models, Chemical; Neoplasm Transplantation; Paclitaxel; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Time Factors; Tumor Cells, Cultured | 2002 |
Future treatment options with capecitabine in solid tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fluorouracil; Forecasting; Humans; Irinotecan; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Taxoids | 2002 |
Docetaxel versus paclitaxel for antiangiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Division; Chemotaxis; Chick Embryo; Docetaxel; Dose-Response Relationship, Drug; Endothelium, Vascular; Humans; Matrix Metalloproteinases; Neovascularization, Physiologic; Paclitaxel; Taxoids; Umbilical Veins; Urokinase-Type Plasminogen Activator | 2002 |
Taxotere resistance in SUIT Taxotere resistance in pancreatic carcinoma cell line SUIT 2 and its sublines.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Docetaxel; Drug Resistance, Neoplasm; Humans; Paclitaxel; Pancreatic Neoplasms; Taxoids; Tumor Cells, Cultured | 2001 |
Severe interstitial pneumonitis associated with docetaxel administration.
Topics: Adrenal Cortex Hormones; Aged; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Fatal Outcome; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Paclitaxel; Prognosis; Prostatic Neoplasms; Respiration, Artificial; Taxoids; Uterine Neoplasms | 2002 |
Massive cavitation of solid pulmonary metastatic lesions in a breast cancer patient: a case report.
Topics: Adult; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Lung; Lung Neoplasms; Paclitaxel; Taxoids | 2002 |
[A case of advanced hypopharyngeal carcinoma successfully treated with superselective intra-arterial infusion of docetaxel].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Fluorouracil; Humans; Hypopharyngeal Neoplasms; Infusions, Intra-Arterial; Male; Paclitaxel; Taxoids | 2002 |
Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Canada; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Costs and Cost Analysis; Docetaxel; Hospitalization; Humans; Lung Neoplasms; Paclitaxel; Palliative Care; Radiotherapy; Retrospective Studies; Sensitivity and Specificity; Taxoids | 2002 |
[Certified study protocols for patients with endometrial carcinoma].
Topics: Clinical Trials as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Germany; Humans; Multicenter Studies as Topic; Paclitaxel; Taxoids; Uterine Neoplasms | 2002 |
Neoadjuvant treatment with docetaxel and the effects of irradiation for human ovarian adenocarcinoma and cervical squamous cell carcinoma in vitro.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; DNA, Single-Stranded; Docetaxel; Female; Humans; In Vitro Techniques; Neoplastic Stem Cells; Ovarian Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Taxoids; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2002 |
Src tyrosine kinase augments taxotere-induced apoptosis through enhanced expression and phosphorylation of Bcl-2.
Topics: Adenocarcinoma; Androstadienes; Apoptosis; Benzoquinones; Biological Transport; Docetaxel; Enzyme Inhibitors; Humans; Lactams, Macrocyclic; Nucleosomes; Paclitaxel; Phosphorylation; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Quinones; Rifabutin; src-Family Kinases; Taxoids; Tumor Cells, Cultured; Wortmannin | 2002 |
Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Lacrimal Apparatus Diseases; Lacrimal Duct Obstruction; Middle Aged; Paclitaxel; Taxoids | 2002 |
Influence of alternate sequences of epirubicin and docetaxel on the pharmacokinetic behaviour of both drugs in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Paclitaxel; Taxoids | 2002 |
Second-line treatment with docetaxel after failure of a platinum-based chemotherapy in squamous-cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Head and Neck Neoplasms; Humans; Middle Aged; Paclitaxel; Taxoids; Treatment Failure | 2002 |
Clinical trials of new anticancer agents in recent years in China.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; China; Clinical Trials as Topic; Colorectal Neoplasms; Docetaxel; Female; Humans; Lung Neoplasms; Male; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2002 |
Cyclooxygenase-2 induction by paclitaxel, docetaxel, and taxane analogues in human monocytes and murine macrophages: structure-activity relationships and their implications.
Topics: Animals; Antineoplastic Agents, Phytogenic; Binding, Competitive; Bridged-Ring Compounds; Cells, Cultured; Cyclooxygenase 2; Docetaxel; Enzyme Induction; Humans; Immunoenzyme Techniques; Isoenzymes; Macrophages; Membrane Proteins; Mice; Microtubules; Molecular Structure; Monocytes; Paclitaxel; Prostaglandin-Endoperoxide Synthases; Receptors, Cell Surface; Structure-Activity Relationship; Taxoids; Tubulin | 2002 |
Anticancer activity of docetaxel in murine salivary gland carcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Communication; Cell Cycle; Cell Division; Connexin 43; Docetaxel; fas Receptor; Female; Flow Cytometry; Fluorescent Antibody Technique; Gap Junctions; Immunoenzyme Techniques; Keratins; Mice; Mice, Inbred BALB C; Mice, SCID; Paclitaxel; Precipitin Tests; Proliferating Cell Nuclear Antigen; S100 Proteins; Salivary Gland Neoplasms; Taxoids; Tumor Cells, Cultured | 2002 |
Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Docetaxel; Drug Administration Schedule; Female; Humans; In Situ Nick-End Labeling; Lung Neoplasms; Mediastinal Neoplasms; Neoplasms, Experimental; Paclitaxel; Rats; Rats, Nude; Sulindac; Survival Rate; Taxoids; Tetrazolium Salts; Thiazoles | 2002 |
Assessment of response by breast helical computed tomography to neoadjuvant chemotherapy in large inflammatory breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Drug Monitoring; Epirubicin; Female; Fluorouracil; Humans; Mammography; Mastectomy; Middle Aged; Mitoxantrone; Neoadjuvant Therapy; Paclitaxel; Physical Examination; Taxoids; Tomography, X-Ray Computed; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship.
Topics: Alkaloids; Animals; Aryl Hydrocarbon Hydroxylases; Biotransformation; COS Cells; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Humans; Hydroxylation; Microsomes, Liver; Mixed Function Oxygenases; Paclitaxel; Recombinant Proteins; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Structure-Activity Relationship; Substrate Specificity; Taxoids; Triterpenes | 2002 |
Brachial plexopathy affecting the development of Beau's lines unilaterally.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Middle Aged; Nails, Malformed; Paclitaxel; Taxoids | 2001 |
Gastrointestinal pneumatosis after docetaxel chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Emphysema; Female; Humans; Middle Aged; Paclitaxel; Pneumatosis Cystoides Intestinalis; Stomach Diseases; Taxoids; Tomography, X-Ray Computed | 2002 |
New highly active taxoids from 9 beta-dihydrobaccatin-9,10-acetals.
Topics: Acetals; Antineoplastic Agents; Docetaxel; Drug Screening Assays, Antitumor; Humans; Neoplasms; Paclitaxel; Structure-Activity Relationship; Taxoids; Tumor Cells, Cultured | 2002 |
Enhanced oral bioavailability of docetaxel by coadministration of cyclosporine: quantitation and role of P-glycoprotein.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Cyclosporine; Docetaxel; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Paclitaxel; Taxoids | 2002 |
Prediction of chemotherapeutic response by collagen gel droplet embedded culture-drug sensitivity test in human breast cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Collagen; Cyclophosphamide; Docetaxel; Drug Screening Assays, Antitumor; Epirubicin; Female; Gels; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Taxoids | 2002 |
[Phase III clinical trials concerning non-small-cell lung carcinoma (NSCLC) presented at the ASCO 2001].
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2001 |
[An autopsy case of pulmonary and central nervous system metastatic osteosarcoma treated with thirty-six courses of chemotherapy over four years].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carboplatin; Cisplatin; Dacarbazine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Methotrexate; Osteosarcoma; Paclitaxel; Spinal Cord Neoplasms; Survivors; Taxoids; Vincristine; Vindesine | 2002 |
Squamous syringometaplasia associated with docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Humans; Male; Metaplasia; Middle Aged; Necrosis; Paclitaxel; Sweat Gland Neoplasms; Sweat Glands; Taxoids | 2002 |
Responses to docetaxel plus vinorelbine in metastatic breast cancer patients failing high-dose chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2002 |
The effect of stathmin phosphorylation on microtubule assembly depends on tubulin critical concentration.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain; Cattle; Chromatography, Gel; Docetaxel; Dose-Response Relationship, Drug; Hydrogen-Ion Concentration; Microtubule Proteins; Microtubules; Models, Chemical; Paclitaxel; Phosphoproteins; Phosphorylation; Protein Binding; Stathmin; Taxoids; Tubulin | 2002 |
Local erythematous dermatitis after intravenous docetaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Eruptions; Erythema Multiforme; Female; Firearms; Humans; Infusions, Intravenous; Ovarian Neoplasms; Paclitaxel; Taxoids | 2002 |
Docetaxel (taxotere) in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Taxoids | 2002 |
Nail changes due to docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Drug Eruptions; Female; Humans; Male; Middle Aged; Nail Diseases; Paclitaxel; Taxoids | 2002 |
Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Deoxycytidine; Docetaxel; Gels; Gemcitabine; Half-Life; Humans; Liposomes; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Phospholipids; Sarcoma; Taxoids; Tissue Distribution; Transplantation, Heterologous; Urinary Bladder Neoplasms; Vindesine | 2002 |
Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Caspases; Cell Cycle; Docetaxel; Enzyme Activation; Female; Humans; Kinetics; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinase 9; Mitogen-Activated Protein Kinases; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tumor Cells, Cultured | 2002 |
Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Biological Availability; Cohort Studies; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Quinolines; Taxoids | 2002 |
Second-line chemotherapy for non-small cell lung cancer: is more better or just simply more?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2002 |
Monotherapy with paclitaxel as third-line chemotherapy against anthracycline-pretreated and docetaxel-refractory metastatic breast cancer.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Resistance, Multiple; Female; Follow-Up Studies; Humans; Lung Neoplasms; Mastectomy, Modified Radical; Neoplasm Staging; Paclitaxel; Risk Assessment; Taxoids; Treatment Failure; Treatment Outcome | 2002 |
Synthesis and cytotoxicity of 2alpha-amido docetaxel analogues.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Neoplasm; Inhibitory Concentration 50; Paclitaxel; Structure-Activity Relationship; Taxoids; Tumor Cells, Cultured | 2002 |
Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry.
Topics: Antineoplastic Agents, Phytogenic; Calibration; Docetaxel; Humans; Neoplasms; Paclitaxel; Pharmaceutical Vehicles; Polysorbates; Reproducibility of Results; Sensitivity and Specificity; Taxoids | 2002 |
Hypersensitivity reaction (HSR) to docetaxel after a previous HSR to paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Drug Hypersensitivity; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 2002 |
[A case report of both CAF and docetaxel-resistant breast cancer responding to paclitaxel weekly therapy].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Taxoids | 2002 |
[A case of adenocarcinoma of the lung with superior vena cava syndrome (SVCS), effectively treated with implantation of intravascular stent and chemotherapy of single agent of docetaxel].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Stents; Superior Vena Cava Syndrome; Taxoids | 2002 |
Salvage chemotherapy with the gemcitabine/docetaxel combination in non-small cell lung cancer: an overview of recent phase II studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Taxoids | 2002 |
A mouse model for the study of factors affecting angiogenesis.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Docetaxel; Endothelium, Vascular; Female; Fibroblast Growth Factor 2; Humans; Ifosfamide; Injections, Subcutaneous; Mice; Neovascularization, Pathologic; Paclitaxel; Prostheses and Implants; Surgical Sponges; Taxoids | 2002 |
Treatment side effects. Case 2. Toxic, epidermal, necrolysis-like reaction associated with docetaxel chemotherapy.
Topics: Adult; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Eruptions; Female; Humans; Lymphoma, Non-Hodgkin; Neutropenia; Paclitaxel; Salvage Therapy; Taxoids; Treatment Outcome | 2002 |
[A case of large-cell lung cancer successfully treated with docetaxel in combination with carboplatin and radiotherapy].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonectomy; Taxoids | 2002 |
Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel.
Topics: Adenovirus E1B Proteins; Adenoviruses, Human; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Combined Modality Therapy; Cytopathogenic Effect, Viral; Docetaxel; Drug Synergism; Gene Deletion; Genes, Regulator; Humans; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Promoter Regions, Genetic; Taxoids; Urinary Bladder Neoplasms; Uroplakin II; Virus Replication; Xenograft Model Antitumor Assays | 2002 |
Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model.
Topics: Absorption; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Docetaxel; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Injections, Intravenous; Male; Models, Animal; Neoplasms; Paclitaxel; Rats; Rats, Sprague-Dawley; Taxoids; Tissue Distribution | 2002 |
The current status of docetaxel in solid tumors. An M. D. Anderson Cancer Center Review.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoadjuvant Therapy; Neoplasms; Paclitaxel; Taxoids | 2002 |
Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Camptothecin; Carboplatin; Clinical Trials, Phase I as Topic; Computer Simulation; Dexamethasone; Diphosphonates; Docetaxel; Dose-Response Relationship, Drug; Humans; Imidazoles; Maximum Tolerated Dose; Monte Carlo Method; Paclitaxel; Taxoids; Zoledronic Acid | 2002 |
Docetaxel improves survival and reduces risk of relapse in node-positive early-stage breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Neoplasm Staging; Paclitaxel; Postoperative Care; Secondary Prevention; Survival Rate; Taxoids | 2002 |
Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents.
Topics: Adenocarcinoma; Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Division; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; In Vitro Techniques; Isoenzymes; Lung Neoplasms; Membrane Proteins; Mice; Mice, Nude; Neoplasm Transplantation; Oxazoles; Paclitaxel; Prostaglandin-Endoperoxide Synthases; Taxoids; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2002 |
Gastrointestinal toxicity associated with weekly docetaxel treatment.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Digestive System; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Enterocolitis; Fatal Outcome; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Multiple Organ Failure; Neoplasm Staging; Paclitaxel; Risk Assessment; Taxoids | 2002 |
Fixed erythrodysaesthesia plaque due to gemcitabine and epirubicin treatment.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Eruptions; Epirubicin; Erythema; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Paresthesia; Skin; Taxoids | 2002 |
[Therapeutic strategy for a patient suffering from a peripheral pulmonary tumor in the right upper lobe and an endotracheal tumor in the carina].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Humans; Laser Therapy; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Neoplasms, Multiple Primary; Paclitaxel; Pneumonectomy; Taxoids; Tracheal Neoplasms | 2002 |
[One case of locally advanced breast cancer in which multidisciplinary treatment, chiefly, therapy with preoperative intraarterial infusion of docetaxel (TXT), was successful].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Docetaxel; Female; Floxuridine; Humans; Infusions, Intra-Arterial; Medroxyprogesterone Acetate; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Taxoids | 2002 |
In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disulfiram; Docetaxel; Drug Interactions; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Epirubicin; Female; Humans; Paclitaxel; Razoxane; Taxoids; Tretinoin; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2002 |
Docetaxel-induced nail changes--a neurogenic mechanism: a case report.
Topics: Afferent Pathways; Arm; Brachial Plexus; Breast Neoplasms; Docetaxel; Efferent Pathways; Female; Humans; Middle Aged; Motor Neurons; Nail Diseases; Neoplasm Invasiveness; Neural Conduction; Neurologic Examination; Neurons, Afferent; Paclitaxel; Paralysis; Parasympathetic Nervous System; Sensory Thresholds; Skin; Sympathetic Nervous System; Taxoids; Vibration | 2002 |
Concordance in pathological response to neoadjuvant chemotherapy between invasive and noninvasive components of primary breast carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Carcinoma, Squamous Cell; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Editorial: the coming revolution in the treatment of prostate cancer patients.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Forecasting; Humans; Male; Neoadjuvant Therapy; Paclitaxel; Prostatic Neoplasms; Taxoids; Vinblastine | 2002 |
Docetaxel/platinum combination provides quality-of-life advantage over vinorelbine/cisplatin in advanced lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Taxoids; Vinblastine; Vinorelbine | 2002 |
Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Ethnicity; Female; Genes, MDR; Genotype; Humans; Linear Models; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Multivariate Analysis; Oxidoreductases, N-Demethylating; Paclitaxel; Phenotype; Polymorphism, Genetic; Taxoids | 2002 |
[A case of multiple skin metastases from gastric cancer successfully treated with docetaxel combined with doxifluridine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Floxuridine; Gastrectomy; Humans; Male; Paclitaxel; Skin Neoplasms; Splenectomy; Stomach Neoplasms; Taxoids | 2002 |
Which dosing scheme is suitable for the taxanes? An in vitro model.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Division; Cell Survival; Docetaxel; Female; Humans; Indicators and Reagents; Paclitaxel; Taxoids; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 2002 |
Nonneutropenic febrile episodes associated with docetaxel-based chemotherapy in patients with solid tumors.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Candidiasis; Cytomegalovirus Infections; Docetaxel; Fever; Herpesviridae Infections; Humans; Infections; Lung Diseases; Lymphopenia; Neoplasms; Paclitaxel; Pneumonia, Pneumocystis; Prospective Studies; T-Lymphocytopenia, Idiopathic CD4-Positive; Taxoids | 2002 |
Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-X Protein; Cell Division; Cell Survival; Clone Cells; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Giant Cells; Humans; Kinetics; Male; Paclitaxel; Phenotype; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tubulin; Tumor Cells, Cultured | 2002 |
Growth-inhibiting effects of intralesional docetaxel and paclitaxel on an experimental model of malignant neuroectodermal tumor.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Division; Docetaxel; Ethylnitrosourea; Immunoenzyme Techniques; Injections, Intralesional; Models, Animal; Neoplasms, Experimental; Neuroectodermal Tumors; Paclitaxel; Rats; Rats, Wistar; Taxoids; Time Factors | 2002 |
Prompt resolution of acute disseminated intravascular coagulation with docetaxel and cisplatin in hormone refractory prostate cancer.
Topics: Acute Disease; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Disseminated Intravascular Coagulation; Docetaxel; Humans; Male; Paclitaxel; Platelet Count; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2002 |
[A case of recurrent breast cancer with chronic renal failure treated on an outpatient basis].
Topics: Ambulatory Care; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Kidney Failure, Chronic; Lung Neoplasms; Middle Aged; Paclitaxel; Radiotherapy Dosage; Renal Dialysis; Taxoids; Thoracic Neoplasms | 2002 |
[Patient with bone metastasis of breast cancer who were improved by weekly DXR/TXT therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Mastectomy, Segmental; Middle Aged; Paclitaxel; Taxoids | 2002 |
[A case of recurrent gastric cancer that responded dramatically to docetaxel and 5'-DFUR combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; Floxuridine; Fluorouracil; Gastrectomy; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pancreatic Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome | 2002 |
Meeting highlights 38th annual meeting of the American Society of Clinical Oncology. Advances in adjuvant chemotherapy for management of breast cancer: the emerging role of docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Medical Oncology; Middle Aged; Paclitaxel; Taxoids | 2002 |
Mobilization of dendritic cells in cancer patients treated with granulocyte colony-stimulating factor and chemotherapy.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Dendritic Cells; Docetaxel; Epirubicin; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Leukapheresis; Leukocyte Count; Leukocytes, Mononuclear; Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 2002 |
Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Chromosomal Proteins, Non-Histone; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; In Situ Nick-End Labeling; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Mutation; Neoplasm Proteins; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Phosphorylation; Phosphotransferases; Survivin; Taxoids; Transfection; Tumor Cells, Cultured | 2002 |
Improved survival in advanced breast cancer with docetaxel and capecitabine in combination: biological synergy or an artefact of trial design?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
New study expands look at effects of high-dose vitamin D with docetaxel for advanced prostate cancer patients.
Topics: Docetaxel; Humans; Male; Multicenter Studies as Topic; Paclitaxel; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Vitamin D | 2002 |
Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cadherins; Cell Division; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Fibroblast Growth Factor 2; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Nude; Neoplasm Metastasis; Paclitaxel; Polyethylene Glycols; Prostatic Neoplasms; Random Allocation; Recombinant Proteins; Taxoids; Xenograft Model Antitumor Assays | 2002 |
Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme.
Topics: Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Benzoflavones; Catalysis; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1B1; Docetaxel; Estradiol; Humans; In Vitro Techniques; Kinetics; Microsomes, Liver; Paclitaxel; Recombinant Proteins; Spectrometry, Fluorescence; Taxoids | 2002 |
Neo-adjuvant therapy with dose-dense docetaxel plus short-term filgrastim rescue for locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Recombinant Proteins; Taxoids | 2002 |
[Pharmacologic study of intraperitoneal docetaxel in gastric cancer patients with peritoneal dissemination].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Mitomycin; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Taxoids; Vindesine | 2002 |
[A case of hypopharyngeal carcinoma in which a complete response to chemotherapy was achieved with docetaxel, cisplatin, 5-FU and levofolinate].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Fluorouracil; Humans; Hypopharyngeal Neoplasms; Leucovorin; Male; Paclitaxel; Remission Induction; Taxoids | 2002 |
Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Biological Availability; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Drug Synergism; Female; Humans; Mice; Mice, Knockout; Paclitaxel; Ritonavir; Taxoids | 2002 |
Radiation recall dermatitis from docetaxel.
Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Female; Humans; Paclitaxel; Radiodermatitis; Radiotherapy, Adjuvant; Recurrence; Taxoids | 2002 |
In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Flow Cytometry; Gene Expression Regulation; Genes, erbB-2; Humans; Immunohistochemistry; Paclitaxel; Probability; Sensitivity and Specificity; Statistics, Nonparametric; Taxoids; Trastuzumab; Tumor Cells, Cultured | 2002 |
[Localization of primary small cell carcinoma with liver metastasis: a rare combination of colonic adenocarcinoma and undifferentiated small cell carcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Colectomy; Colon; Colonic Neoplasms; Docetaxel; Doxorubicin; Etoposide; Female; Humans; Immunohistochemistry; Liver; Liver Neoplasms; Neoplasms, Multiple Primary; Neoplasms, Unknown Primary; Paclitaxel; Taxoids; Time Factors; Vincristine | 2002 |
Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels.
Topics: Animals; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Folic Acid; Genes, erbB-2; Genetic Therapy; Genetic Vectors; Humans; Liposomes; Mammary Neoplasms, Experimental; Mice; Oligonucleotides, Antisense; Paclitaxel; Taxoids | 2002 |
[Updates on gemcitabine at the American Society of Clinical Oncology congress (ASCO, 2002) ].
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Female; Gemcitabine; Glutamates; Guanine; Humans; Immunotherapy; Lung Neoplasms; Mitomycins; Multicenter Studies as Topic; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Radiotherapy; Remission Induction; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine | 2002 |
Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma.
Topics: Antineoplastic Agents, Phytogenic; Chromatography, High Pressure Liquid; Docetaxel; Humans; Paclitaxel; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Taxoids | 2003 |
Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot.
Topics: Annexin A5; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; DNA Primers; Docetaxel; Endothelial Growth Factors; fas Receptor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Taxoids; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Drug Eruptions; Erythema; Female; Foot; Hand; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Skin Diseases; Sweat Gland Diseases; Syndrome; Taxoids | 2002 |
High incidence of central nervous system involvement in patients with breast cancer treated with epirubicin and docetaxel.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Central Nervous System Neoplasms; Combined Modality Therapy; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Paclitaxel; Taxoids | 2002 |
Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Movement; Cells, Cultured; Centrosome; Collagen; Docetaxel; Drug Combinations; Endothelium, Vascular; Fibroblast Growth Factor 2; Humans; In Vitro Techniques; Laminin; Mice; Mice, Inbred C57BL; Microtubules; Neoplasms, Experimental; Neovascularization, Pathologic; Paclitaxel; Proteoglycans; Rats; Taxoids; Tumor Cells, Cultured; Umbilical Veins; Xenograft Model Antitumor Assays | 2002 |
Microangiopathic hemolysis refractory to plasmapheresis responding to docetaxel and cisplatin: a case report.
Topics: Adenocarcinoma; Anemia, Hemolytic; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Docetaxel; Female; Hemolysis; Humans; Methylprednisolone; Middle Aged; Paclitaxel; Plasmapheresis; Taxoids | 2002 |
Advances in breast oncology: the 2002 ASCO meeting.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclooxygenase Inhibitors; Docetaxel; Evidence-Based Medicine; Female; Humans; Nitriles; Paclitaxel; Sentinel Lymph Node Biopsy; Tamoxifen; Taxoids; Technology Assessment, Biomedical; Triazoles | 2002 |
Pegfilgrastim: the promise of pegylation fulfilled.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Neutropenia; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2003 |
Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.
Topics: Antineoplastic Agents; Bone Marrow; Camptothecin; Deoxycytidine; Docetaxel; Etoposide; Humans; Irinotecan; Leukocytes; Models, Biological; Neutrophils; Paclitaxel; Taxoids; Vinblastine | 2002 |
Effectiveness of doxifluridine (5'-DFUR)/docetaxel against advanced/recurrent gastric cancer showing resistance to various anticancer drug regimens.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Fatal Outcome; Floxuridine; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Stomach Neoplasms; Taxoids | 2002 |
Synthesis of C-3' methyl taxotere (docetaxel).
Topics: Combinatorial Chemistry Techniques; Docetaxel; Esterification; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Paclitaxel; Stereoisomerism; Structure-Activity Relationship; Taxoids | 2002 |
A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Retrospective Studies; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2003 |
A third-generation matrix metalloproteinase (MMP) inhibitor (ONO-4817) combined with docetaxel suppresses progression of lung micrometastasis of MMP-expressing tumor cells in nude mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Drug Therapy, Combination; Humans; In Vitro Techniques; Injections, Intravenous; Lung Neoplasms; Matrix Metalloproteinase Inhibitors; Mice; Mice, Nude; Paclitaxel; Phenyl Ethers; Survival Rate; Taxoids | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Dose Fractionation, Radiation; Fluorouracil; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Leucovorin; Paclitaxel; Radiotherapy, Adjuvant; Survival Analysis; Taxoids; Treatment Failure; Treatment Outcome | 2003 |
[Comparative pharmaco-economic analysis of docetaxel with cisplatin and cyclophosphamide with cisplatin in first-line chemotherapy of advanced ovarian cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost-Benefit Analysis; Cyclophosphamide; Docetaxel; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Russia; Taxoids; Treatment Outcome | 2002 |
Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere).
Topics: Angiogenesis Inhibitors; Animals; Aorta; Apoptosis; Capillaries; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Division; Cells, Cultured; Chemotaxis; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Endothelium, Vascular; Fibrosarcoma; Glioblastoma; Humans; Lung Neoplasms; Male; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Rats; Taxoids; Tumor Cells, Cultured; Umbilical Veins; Xenograft Model Antitumor Assays | 2003 |
Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy, Needle; Bone Neoplasms; Breast Neoplasms; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Immunohistochemistry; Microtubules; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pilot Projects; Predictive Value of Tests; Prognosis; Sensitivity and Specificity; Soft Tissue Neoplasms; Survival Analysis; tau Proteins; Taxoids; Treatment Outcome; Tubulin | 2002 |
[Therapeutic strategies in advanced non-small cell bronchial cancers: combinations without platin drugs].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Patient Selection; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
[Two patients with distant metastases from head and neck squamous cell carcinomas successfully treated with docetaxel and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Paclitaxel; Remission Induction; Taxoids | 2003 |
[Two cases of complete response to combination chemotherapy of gemcitabine and docetaxel for recurrent ovarian cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pelvic Neoplasms; Taxoids | 2003 |
Taxane-induced nail changes: incidence, clinical presentation and outcome.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Incidence; Male; Middle Aged; Nail Diseases; Paclitaxel; Taxoids | 2003 |
Fatal herpes simplex virus hepatitis complicating chemotherapy with weekly docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Fatal Outcome; Female; Hepatitis, Viral, Human; Herpes Simplex; Humans; Liver Failure; Middle Aged; Paclitaxel; Taxoids | 2003 |
Docetaxel-related skin, nail, and vascular toxicity.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Female; Forearm; Humans; Infusions, Intravenous; Middle Aged; Nail Diseases; Paclitaxel; Phlebitis; Skin Diseases; Taxoids; Toes | 2003 |
Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Carcinoma; Combined Modality Therapy; Docetaxel; Female; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Intraoperative Care; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids; Tissue Distribution | 2003 |
Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Carcinoma, Transitional Cell; Cyclohexanes; Docetaxel; Drug Synergism; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Paclitaxel; Sesquiterpenes; Taxoids; Time Factors; Transplantation, Heterologous; Urinary Bladder Neoplasms | 2003 |
In vitro schedule-dependent interaction between docetaxel and gemcitabine in human gastric cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Survival; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Paclitaxel; Stomach Neoplasms; Taxoids; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2003 |
Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Division; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression; Genes, erbB-2; Humans; Paclitaxel; Taxoids; Transfection; Tumor Cells, Cultured | 2003 |
Unknown primary carcinoma: a feasibility assessment of combination chemotherapy with cisplatin and docetaxel.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Diarrhea; Docetaxel; Drug Hypersensitivity; Feasibility Studies; Female; Humans; Male; Middle Aged; Nausea; Neoplasms, Unknown Primary; Neutropenia; Paclitaxel; Patient Compliance; Prospective Studies; Severity of Illness Index; Taxoids; Treatment Outcome; Vomiting | 2003 |
Docetaxel and carboplatin combination chemotherapy for recurrent endometrial cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Taxoids; Tomography, X-Ray Computed | 2003 |
[Histoculture drug response assay (HDRA) guided induction concurrent chemoradiotherapy for mediastinal node-positive non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Pneumonectomy; Taxoids; Tumor Cells, Cultured | 2003 |
[A case of advanced recurrent breast cancer responding to treatment with weekly docetaxel combined with doxorubicin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Floxuridine; Humans; Lung Neoplasms; Lymphatic Metastasis; Mastectomy, Modified Radical; Medroxyprogesterone Acetate; Middle Aged; Paclitaxel; Skin Neoplasms; Taxoids | 2003 |
Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle Proteins; Chemotherapy, Adjuvant; Cyclin D3; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Cyclophosphamide; Docetaxel; Enzyme Inhibitors; Epirubicin; Female; Fluorouracil; Gene Expression; Genes, p53; Genes, Tumor Suppressor; Humans; Ki-67 Antigen; Methotrexate; Middle Aged; Paclitaxel; Preoperative Care; Receptors, Steroid; Taxoids; Transcription Factors; Treatment Outcome; Tumor Suppressor Proteins | 2003 |
Measurement of volumetric and vascular changes with dynamic contrast enhanced MRI for cancer therapy monitoring.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Contrast Media; Docetaxel; Female; Gadolinium; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Paclitaxel; Radiography; Rats; Rats, Inbred F344; Taxoids; Time Factors; Treatment Outcome | 2002 |
The use of putative placebo in active control trials: two applications in a regulatory setting.
Topics: Angina, Unstable; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase III as Topic; Confidence Intervals; Data Interpretation, Statistical; Docetaxel; Doxorubicin; Enoxaparin; Female; Fibrinolytic Agents; Humans; Myocardial Infarction; Odds Ratio; Paclitaxel; Placebos; Randomized Controlled Trials as Topic; Taxoids; Therapeutic Equivalency | 2003 |
Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Taxoids; Thalidomide; Venous Thrombosis | 2003 |
Semi-synthesis of an O-glycosylated docetaxel analogue.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Brain Chemistry; Breast Neoplasms; Cattle; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Glycosylation; Humans; In Vitro Techniques; Indicators and Reagents; Paclitaxel; Taxoids; Tubulin; Tumor Cells, Cultured | 2003 |
Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response.
Topics: Apoptosis; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; DNA Fragmentation; Docetaxel; Doxorubicin; Female; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Neoplasm Transplantation; Paclitaxel; Taxoids; Time Factors; Tumor Cells, Cultured | 2003 |
Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Division; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Humans; Inhibitory Concentration 50; Mitomycin; Oligonucleotides; Oligonucleotides, Antisense; Paclitaxel; Prognosis; Proto-Oncogene Proteins c-bcl-2; Receptor, ErbB-2; Signal Transduction; Taxoids; Time Factors | 2003 |
Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Docetaxel; Double-Blind Method; Doxorubicin; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Middle Aged; Multicenter Studies as Topic; Narcotics; Neoplasm Metastasis; Paclitaxel; Pain; Pain Measurement; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Taxoids | 2003 |
Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer?
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2003 |
Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Protein-Tyrosine Kinases; Quinazolines; Salvage Therapy; Taxoids; Treatment Outcome | 2003 |
Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation Pneumonitis; Radiotherapy; Survival Rate; Taxoids | 2003 |
Two strategies may enhance breast cancer treatment.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Genetic Testing; Humans; Immunotherapy; Mice; Paclitaxel; Taxoids | 2003 |
Docetaxel inhibits SMMC-7721 human hepatocellular carcinoma cells growth and induces apoptosis.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Hepatocellular; Cell Division; Docetaxel; Glutathione; Humans; Liver Neoplasms; Paclitaxel; Reactive Oxygen Species; Taxoids; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2003 |
[Regression of an uveal metastatic tumor from breast cancer during chemotherapy--a case report].
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Choroid Neoplasms; Combined Modality Therapy; Diphosphonates; Docetaxel; Doxorubicin; Female; Fluorescein Angiography; Follow-Up Studies; Humans; Paclitaxel; Pamidronate; Tamoxifen; Taxoids; Time Factors; Ultrasonography; Visual Acuity | 2003 |
Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.
Topics: Androgens; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Mice; Mice, Nude; Middle Aged; Mitoxantrone; Neoplasm Transplantation; Paclitaxel; Prostatic Neoplasms; Taxoids | 2003 |
PSK-mediated NF-kappaB inhibition augments docetaxel-induced apoptosis in human pancreatic cancer cells NOR-P1.
Topics: Apoptosis; Cell Division; Docetaxel; Humans; NF-kappa B; Paclitaxel; Pancreatic Neoplasms; Proteoglycans; Taxoids; Tumor Cells, Cultured | 2003 |
Cystic maculopathy with normal capillary permeability secondary to docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capillary Permeability; Docetaxel; Fatal Outcome; Female; Fluorescein Angiography; Humans; Macular Edema; Middle Aged; Paclitaxel; Retinal Vessels; Taxoids; Visual Acuity | 2003 |
Erosive conjunctivitis and punctal stenosis secondary to docetaxel (taxotere).
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Conjunctivitis; Docetaxel; Female; Humans; Lacrimal Duct Obstruction; Middle Aged; Paclitaxel; Taxoids | 2003 |
[Cylindroma of the trachea, a rate tumor with unusual evolution].
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Carcinoma, Adenoid Cystic; Cisplatin; Combined Modality Therapy; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Radiography, Thoracic; Radiotherapy Dosage; Taxoids; Tracheal Neoplasms; Treatment Outcome | 2003 |
Calcitriol and alopecia--is it the hair apparent?
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Docetaxel; Humans; Male; Neoplasm Metastasis; Paclitaxel; Prostatic Neoplasms; Taxoids | 2003 |
Additive effects of radiation and docetaxel on murine SCCVII tumors in vivo: special reference to changes in the cell cycle.
Topics: Animals; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Ki-67 Antigen; Male; Mice; Mice, Inbred C3H; Mitosis; Paclitaxel; Taxoids | 2003 |
Sensitivity of non-small-cell lung cancer cell lines established from patients treated with prolonged infusions of Paclitaxel.
Topics: Adult; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Immunohistochemistry; Inhibitory Concentration 50; Lung Neoplasms; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Paclitaxel; Phenotype; Polymerase Chain Reaction; Receptor, ErbB-2; Taxoids; Tumor Cells, Cultured | 2003 |
Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Chromatography, Liquid; Docetaxel; Half-Life; Humans; Infusions, Intravenous; Mass Spectrometry; Models, Biological; Neoplasms; Paclitaxel; Reproducibility of Results; Specimen Handling; Taxoids; Time Factors | 2003 |
NICE recommends new treatment for breast and bowel cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Paclitaxel; Practice Guidelines as Topic; Taxoids; Tegafur; Uracil | 2003 |
Successful treatment of thrombocytopenia due to marrow metastases of breast cancer with weekly docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Bone Marrow Neoplasms; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Taxoids; Thrombocytopenia; Treatment Outcome | 2003 |
[Effect of chemotherapy on cytosol proteins of ovarian tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytosol; Docetaxel; Electrophoresis, Gel, Two-Dimensional; Female; Humans; Neoplasm Proteins; Ovarian Neoplasms; Paclitaxel; Taxoids | 2003 |
Reversible life-threatening encephalopathy in the absence of hepatic failure following conventional doses of docetaxel.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Breast Neoplasms; Docetaxel; Female; Humans; Liver Failure; Paclitaxel; Taxoids | 2003 |
DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Survival; Colony-Forming Units Assay; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; In Vitro Techniques; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Neoplasms, Experimental; Paclitaxel; Taxoids; Tumor Cells, Cultured | 2003 |
A rapid and sensitive liquid chromatography/tandem mass spectrometry method for determination of docetaxel in human plasma.
Topics: Antineoplastic Agents, Phytogenic; Calibration; Chromatography, High Pressure Liquid; Docetaxel; Humans; Indicators and Reagents; Mass Spectrometry; Paclitaxel; Reference Standards; Reproducibility of Results; Taxoids | 2003 |
Docetaxel-induced histologic changes in the lacrimal sac and the nasal mucosa.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dacryocystorhinostomy; Docetaxel; Female; Humans; Intubation; Lacrimal Apparatus; Lacrimal Duct Obstruction; Middle Aged; Nasal Mucosa; Paclitaxel; Silicone Elastomers; Taxoids | 2003 |
Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Squamous Cell; Dacryocystorhinostomy; Docetaxel; Drainage; Esophageal Neoplasms; Female; Humans; Intubation; Lacrimal Duct Obstruction; Lung Neoplasms; Male; Middle Aged; Nasolacrimal Duct; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Taxoids; Texas | 2003 |
Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Division; Cell Line; Cisplatin; Deoxycytidine; DNA, Neoplasm; Docetaxel; Drug Screening Assays, Antitumor; Fenretinide; Flow Cytometry; Gemcitabine; Humans; Irinotecan; Mesothelioma; Paclitaxel; Taxoids; Topotecan | 2003 |
[A case of postoperative recurrent breast cancer with multiple lung metastases that completely responded to combination therapy of docetaxel (TXT) and medroxyprogesterone acetate (MPA)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Mastectomy, Modified Radical; Medroxyprogesterone Acetate; Middle Aged; Paclitaxel; Postoperative Period; Remission Induction; Taxoids | 2003 |
Synthesis of novel macrocyclic docetaxel analogues. Influence of their macrocyclic ring size on tubulin activity.
Topics: Antineoplastic Agents; Docetaxel; Drug Screening Assays, Antitumor; Humans; KB Cells; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Paclitaxel; Solutions; Structure-Activity Relationship; Taxoids; Tubulin | 2003 |
Predictive cancer genomics--what do we need?
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Screening Assays, Antitumor; Female; Gene Expression Regulation, Neoplastic; Genomics; Humans; Neoadjuvant Therapy; Neoplasms; Oligonucleotide Array Sequence Analysis; Paclitaxel; Sequence Analysis, DNA; Taxoids | 2003 |
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Biopsy, Needle; Breast; Breast Neoplasms; Docetaxel; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Neoadjuvant Therapy; Oligonucleotide Array Sequence Analysis; Paclitaxel; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Treatment Outcome | 2003 |
Extraorbital sebaceous carcinoma with rapidly developing visceral metastases.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Fatal Outcome; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Orbit; Paclitaxel; Sebaceous Gland Neoplasms; Taxoids; Viscera | 2003 |
Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Caspases; Docetaxel; Drug Resistance; Humans; Lung Neoplasms; Microtubules; Mitosis; Nocodazole; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Spindle Apparatus; Taxoids; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2003 |
[A case of posterior wall cancer of the hypopharynx treated with docetaxel followed by radiation].
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Female; Humans; Hypopharyngeal Neoplasms; Paclitaxel; Taxoids | 2003 |
[A case of uterine endometrial cancer with lung metastases improved by various treatments including taxane].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Endometrial Neoplasms; Female; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2003 |
Pharmacokinetics and tissue distribution of intraperitoneal docetaxel with different carrier solutions.
Topics: Animals; Antineoplastic Agents, Phytogenic; Ascitic Fluid; Colon; Docetaxel; Infusions, Parenteral; Male; Models, Animal; Paclitaxel; Pharmaceutical Solutions; Rats; Rats, Sprague-Dawley; Stomach; Taxoids | 2003 |
Nail toxicity related to taxanes.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Lung Neoplasms; Nail Diseases; Nails; Paclitaxel; Taxoids | 2003 |
Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? A population-based study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Docetaxel; Female; Humans; Middle Aged; Mixed Tumor, Mullerian; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Practice Guidelines as Topic; Prospective Studies; Radiotherapy Dosage; Survival Rate; Taxoids | 2003 |
Osteonecrosis of the jaws associated with cancer chemotherapy.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Jaw Diseases; Middle Aged; Osteonecrosis; Paclitaxel; Taxoids | 2003 |
Inhibitory effects of docetaxel on expression of VEGF, bFGF and MMPs of LS174T cell.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Docetaxel; Endothelial Growth Factors; Fibroblast Growth Factor 2; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells.
Topics: Apoptosis; bcl-X Protein; Butadienes; Docetaxel; Drug Synergism; Enzyme Inhibitors; Flavonoids; Humans; Male; Mitogen-Activated Protein Kinases; Neoplasms, Hormone-Dependent; Nitriles; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2003 |
Epiphora induced by intermittent docetaxel (taxotere) in patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lacrimal Apparatus Diseases; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 2003 |
Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Blood Proteins; Chemistry, Pharmaceutical; Docetaxel; Excipients; Female; Humans; Infusions, Intravenous; Linear Models; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Orosomucoid; Paclitaxel; Polysorbates; Taxoids | 2003 |
Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Taxoids | 2003 |
MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Cell Division; Docetaxel; Female; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Microtubules; Neoplasms, Experimental; Paclitaxel; Taxoids; Tubulin; Tumor Cells, Cultured | 2003 |
[The platelet-sparing effect of carboplatin and docetaxel combination chemotherapy for lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Platelet Count; Taxoids; Thrombopoietin | 2003 |
[Two cases of recurrent breast cancer successfully treated with paclitaxel weekly therapy].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Paclitaxel; Taxoids | 2003 |
Improvement of paclitaxel-induced neuropathy by substitution of docetaxel for paclitaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Taxoids | 2003 |
Activity of docetaxel in paclitaxel-resistant ovarian cancer cells.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Cycle; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Taxoids; Tubulin | 2004 |
[Cryoimmunological therapy with local injection of OK-432 against advance or recurrent breast cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined Modality Therapy; Cryosurgery; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Injections, Intralesional; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Picibanil; Taxoids | 2003 |
Diastereoselective 14beta-hydroxylation of baccatin III derivatives.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Docetaxel; Hydroxylation; Molecular Structure; Oxidation-Reduction; Paclitaxel; Stereoisomerism; Taxoids | 2003 |
Highlights from the 10th World Conference on Lung Cancer. Vancouver, British Columbia, Canada, August 10-14, 2003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Taxoids | 2003 |
Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carboplatin; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2003 |
Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer.
Topics: Acetylation; Antineoplastic Agents, Phytogenic; Cell Cycle Proteins; Cell Line, Tumor; DNA Methylation; DNA Mutational Analysis; Docetaxel; Gene Expression Regulation, Neoplastic; Gene Silencing; Histones; Humans; Microtubules; Mitosis; Neoplasm Proteins; Paclitaxel; Poly-ADP-Ribose Binding Proteins; Stomach Neoplasms; Taxoids; Ubiquitin-Protein Ligases | 2003 |
[New: gemzar plus taxan in metastatic breast carcinoma. Optimal combination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2003 |
Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Taxoids; Treatment Outcome | 2004 |
Experience with the management of neutropenia in gynecologic cancer patients receiving carboplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Female; Fever; Genital Neoplasms, Female; Humans; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Taxoids | 2004 |
Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins.
Topics: Angiogenesis Inhibitors; Animals; Aorta, Thoracic; Blood Proteins; Cell Division; Chemistry, Pharmaceutical; Docetaxel; Drug Interactions; Endothelium, Vascular; Excipients; Glycerol; Humans; In Vitro Techniques; Male; Neovascularization, Pathologic; Paclitaxel; Pharmaceutical Vehicles; Polysorbates; Protein Binding; Rats; Rats, Sprague-Dawley; Taxoids | 2004 |
Synthesis, modeling, and anti-tubulin activity of a D-seco paclitaxel analogue.
Topics: Antineoplastic Agents, Phytogenic; Binding Sites; Docetaxel; Humans; Models, Molecular; Molecular Conformation; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Paclitaxel; Protein Binding; Structure-Activity Relationship; Taxoids; Tubulin Modulators | 2004 |
Effects of the taxanes paclitaxel and docetaxel on edema formation and interstitial fluid pressure.
Topics: Animals; Blood Vessels; Body Water; Capillary Permeability; Docetaxel; Dose-Response Relationship, Drug; Edema; Extracellular Fluid; Female; Hindlimb; Microtubules; Paclitaxel; Pressure; Punctures; Rats; Rats, Wistar; Serum Albumin; Skin Physiological Phenomena; Taxoids | 2004 |
Weekly taxanes--a leap forward or a minute progress?
Topics: Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Life Tables; Lymphatic Metastasis; Methotrexate; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Paclitaxel; Prednisone; Prognosis; Receptors, Progesterone; Risk; Survival Analysis; Tamoxifen; Taxoids; Transcription Factors; Vincristine | 2004 |
Measuring treatment preferences and willingness to pay for docetaxel in advanced ovarian cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Canada; Cost-Benefit Analysis; Docetaxel; Economics, Pharmaceutical; Female; Humans; Income; Middle Aged; Ovarian Neoplasms; Paclitaxel; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Severity of Illness Index; Taxoids | 2004 |
[Structure-activity relationship analysis].
Topics: Antineoplastic Agents; Benzamides; Camptothecin; Docetaxel; Drug Screening Assays, Antitumor; Epothilones; Gefitinib; Imatinib Mesylate; Irinotecan; Macrolides; Oligopeptides; Paclitaxel; Piperazines; Pyrimidines; Quinazolines; Structure-Activity Relationship; Taxoids; Topotecan; Vinblastine | 2004 |
Use of gabapentin in the prevention of taxane-induced arthralgias and myalgias.
Topics: Acetates; Amines; Analgesics; Antineoplastic Agents, Phytogenic; Arthralgia; Cyclohexanecarboxylic Acids; Docetaxel; Gabapentin; gamma-Aminobutyric Acid; Humans; Muscle, Skeletal; Muscular Diseases; Paclitaxel; Retrospective Studies; Taxoids | 2004 |
Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Ascites; Docetaxel; Erythrocytes; Excipients; Female; Glycerol; In Vitro Techniques; Injections, Intraperitoneal; Paclitaxel; Permeability; Pharmaceutical Vehicles; Polysorbates; Rats; Surface-Active Agents; Taxoids; Time Factors; Tissue Distribution | 2004 |
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Deoxycytidine; Disease Models, Animal; DNA, Neoplasm; Docetaxel; Doxorubicin; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Floxuridine; Gemcitabine; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Paclitaxel; Proto-Oncogene Proteins; Receptor, ErbB-2; Taxoids; Transplantation, Heterologous; Trastuzumab; Tumor Stem Cell Assay; Up-Regulation; Vinblastine; Vinorelbine | 2004 |
Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs, and minipigs.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Phytogenic; Cytochrome P-450 Enzyme System; Docetaxel; Enzyme Inhibitors; Flavonoids; Flavonols; Humans; In Vitro Techniques; Isoenzymes; Kinetics; Male; Microsomes, Liver; Paclitaxel; Rats; Rats, Wistar; Species Specificity; Swine; Swine, Miniature; Taxoids; Troleandomycin | 2004 |
[Retrospective analysis on efficacy and toxicity of paclitaxel-containing treatments in patients with advanced or recurrent breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Middle Aged; Nausea; Neoplasm Recurrence, Local; Paclitaxel; Peripheral Nervous System Diseases; Proportional Hazards Models; Retrospective Studies; Survival Rate; Taxoids; Trastuzumab; Vomiting, Anticipatory | 2004 |
Differences in the induction of cytochrome P450 3A4 by taxane anticancer drugs, docetaxel and paclitaxel, assessed employing primary human hepatocytes.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Northern; Blotting, Western; Cell Culture Techniques; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Drug Interactions; Enzyme Induction; Hepatocytes; Liver; Paclitaxel; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Taxoids | 2004 |
Non-allergic nature of docetaxel-induced acute hypersensitivity reactions.
Topics: Administration, Oral; Adult; Blood Pressure; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drug Hypersensitivity; Female; Gemcitabine; Histamine; Histamine Antagonists; Humans; Hypersensitivity, Immediate; Infusions, Intravenous; Male; Methylprednisolone; Middle Aged; Paclitaxel; Premedication; Serine Endopeptidases; Tachycardia; Taxoids; Time Factors; Tryptases | 2004 |
Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Female; Gene Amplification; Genes, erbB-2; Humans; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2004 |
Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Cell Line; Docetaxel; Drug Resistance, Neoplasm; Humans; Multidrug Resistance-Associated Proteins; Paclitaxel; Taxoids; Transfection | 2004 |
Enhanced method performance due to a shorter chromatographic run-time in a liquid chromatography-tandem mass spectrometry assay for paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Atmospheric Pressure; Chromatography, High Pressure Liquid; Docetaxel; Humans; Mass Spectrometry; Paclitaxel; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Taxoids | 2004 |
[Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA-Binding Proteins; Docetaxel; Drug Screening Assays, Antitumor; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Phenotype; Polymorphism, Single Nucleotide; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1 | 2004 |
Optimizing saccharide-directed molecular delivery to biological receptors: design, synthesis, and biological evaluation of glycodendrimer-cyclodextrin conjugates.
Topics: beta-Cyclodextrins; Concanavalin A; Cyclodextrins; Docetaxel; Drug Carriers; Humans; Lectins; Lectins, C-Type; Macrophages; Mannose Receptor; Mannose-Binding Lectins; Models, Molecular; Nuclear Magnetic Resonance, Biomolecular; Oligosaccharides; Paclitaxel; Receptors, Cell Surface; Taxoids | 2004 |
Effects of paclitaxel and docetaxel on EGFR-expressing human carcinoma cells under normoxic versus hypoxic conditions in vitro.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Hypoxia; Male; Neoplasms; Paclitaxel; Probability; Reference Values; Sensitivity and Specificity; Taxoids; Tumor Cells, Cultured | 2004 |
[Adjuvant chemotherapy with taxoid-containing drugs in breast cancer: soon to be expected in the Netherlands].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2004 |
Stability of palonosetron hydrochloride with paclitaxel and docetaxel during simulated Y-site administration.
Topics: Antineoplastic Agents, Phytogenic; Chromatography, High Pressure Liquid; Docetaxel; Drug Combinations; Drug Stability; Injections, Intravenous; Isoquinolines; Paclitaxel; Palonosetron; Quinuclidines; Serotonin Antagonists; Taxoids | 2004 |
Colitis in patients with breast carcinoma treated with taxane-based chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Colitis; Colonoscopy; Docetaxel; Female; Humans; Paclitaxel; Radiography; Taxoids | 2004 |
Should we be using cimetidine to premedicate patients receiving docetaxel or paclitaxel?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cimetidine; Cisplatin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Drug Synergism; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids | 2004 |
Advances in taxane therapy for metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Bone Marrow; Breast Neoplasms; Chemistry, Pharmaceutical; Docetaxel; Drug Hypersensitivity; Heart Diseases; Humans; Nausea; Paclitaxel; Taxoids; Treatment Outcome; Vomiting; Water-Electrolyte Imbalance | 2004 |
Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cyclophosphamide; Diphosphonates; Docetaxel; Drug Synergism; Epirubicin; Female; Fluorouracil; Humans; Ibandronic Acid; Imidazoles; In Vitro Techniques; Methotrexate; Middle Aged; Neoplasm Invasiveness; Neoplasms, Ductal, Lobular, and Medullary; Paclitaxel; Taxoids; Zoledronic Acid | 2004 |
Peripheral benzodiazepine receptor ligands induce apoptosis and cell cycle arrest in human hepatocellular carcinoma cells and enhance chemosensitivity to paclitaxel, docetaxel, doxorubicin and the Bcl-2 inhibitor HA14-1.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Benzopyrans; Carcinoma, Hepatocellular; Cell Cycle; Cell Division; Cell Line, Tumor; Docetaxel; Doxorubicin; Drug Synergism; Enzyme Inhibitors; Humans; Isoquinolines; Ligands; Liver Neoplasms; Nitriles; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Receptors, GABA-A; RNA, Messenger; Taxoids; Tritium | 2004 |
Successful combination therapy with trastuzumab and Paclitaxel for adriamycin- and docetaxel-resistant inflammatory breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Doxorubicin; Female; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Paclitaxel; Pleural Effusion, Malignant; Taxoids; Trastuzumab; Treatment Outcome | 2004 |
[Experimental study for a combination chemo-immunotherapy using dendritic cells].
Topics: Adult; Antineoplastic Agents, Phytogenic; Apoptosis; Dendritic Cells; Docetaxel; Humans; Immunotherapy; In Vitro Techniques; Leukocytes, Mononuclear; Lymphocyte Activation; Membrane Glycoproteins; Paclitaxel; Receptors, Cell Surface; Stomach Neoplasms; T-Lymphocytes, Cytotoxic; Taxoids; Toll-Like Receptor 4; Toll-Like Receptors; Tumor Cells, Cultured | 2004 |
Is the combination with 2-methoxyestradiol able to reduce the dosages of chemotherapeutices in the treatment of human ovarian cancer? Preliminary in vitro investigations.
Topics: 2-Methoxyestradiol; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Epirubicin; Estradiol; Female; Fluorouracil; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2004 |
[Role of taxanes in treatment of breast cancer].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Data Interpretation, Statistical; Disease Progression; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Taxoids; Time Factors; Trastuzumab | 2004 |
[Status report on the chemotherapy of ovarian cancer at special cancer centers in Hungary (2002-2003)].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Docetaxel; Doxorubicin; Female; Humans; Hungary; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Retrospective Studies; Taxoids; Topotecan; Treatment Outcome | 2004 |
Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Erythropoietin; Female; Humans; Incidence; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Skin Diseases; Taxoids | 2005 |
Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Desensitization, Immunologic; Docetaxel; Drug Hypersensitivity; Female; Genital Neoplasms, Female; Humans; Middle Aged; Paclitaxel; Taxoids | 2005 |
Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bone Marrow Cells; Caspase 3; Caspases; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Proliferation; Cisplatin; Clinical Trials as Topic; Cytochromes c; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Enzyme Activation; Farnesyltranstransferase; Flow Cytometry; Fluorouracil; G2 Phase; Gemcitabine; Homozygote; Humans; In Situ Nick-End Labeling; Inhibitory Concentration 50; Mice; Mice, SCID; Mitosis; Multiple Myeloma; Paclitaxel; Quinolones; Taxoids; Tetrazolium Salts; Thiazoles | 2005 |
Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Paclitaxel; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome | 2005 |
Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Hormones; Humans; Male; Middle Aged; Paclitaxel; Pilot Projects; Prostatic Neoplasms; Taxoids; Treatment Failure | 2005 |
Potential antagonism of tubulin-binding anticancer agents in combination therapies.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion; Cell Line; Cell Line, Tumor; Cell Proliferation; Cisplatin; Colchicine; Cytoskeleton; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Endothelial Cells; Female; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Microscopy, Fluorescence; Necrosis; Organophosphorus Compounds; Paclitaxel; Protein Binding; Taxoids; Tubulin; Umbilical Veins; Vincristine; Xenograft Model Antitumor Assays | 2005 |
NHS76/PEP2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Capillary Permeability; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Fluorouracil; Humans; Injections, Intravenous; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Paclitaxel; Peptide Fragments; Taxoids; Time Factors; Tissue Distribution; Treatment Outcome; Vinblastine; Xenograft Model Antitumor Assays | 2005 |
A molecular model to explain paclitaxel and docetaxel sensitivity changes through adduct formation with primary amines in electrospray ionization mass spectrometry.
Topics: Amines; Chromatography, Liquid; Docetaxel; Models, Chemical; Models, Molecular; Molecular Structure; Paclitaxel; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Taxoids | 2005 |
MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Transport; Cell Line; Docetaxel; Dogs; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Paclitaxel; Probenecid; Taxoids; Vinblastine | 2005 |
The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Docetaxel; Etoposide; Female; Humans; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Sex Cord-Gonadal Stromal Tumors; Taxoids | 2005 |
The administration of chemotherapy in a patient with Charcot-Marie-Tooth and ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Charcot-Marie-Tooth Disease; Docetaxel; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Taxoids | 2005 |
Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Chemistry, Pharmaceutical; Chitosan; Clusterin; Delayed-Action Preparations; Docetaxel; Drug Therapy, Combination; Glycoproteins; Humans; Injections, Intralesional; Male; Mice; Mice, Inbred BALB C; Molecular Chaperones; Neoplasm Transplantation; Ointments; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Taxoids; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2005 |
Exogenous supplementation with omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Down-Regulation; Fatty Acids, Omega-3; Female; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Receptor, ErbB-2; Taxoids; Tumor Cells, Cultured | 2005 |
Pre-chemotherapy hemoglobin levels and survival in patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen: results of a multicenter retrospective Italian study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Epithelial Cells; Female; Hemoglobins; Humans; Ifosfamide; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Taxoids | 2005 |
Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Microtubules; Nerve Fibers, Myelinated; Nerve Growth Factor; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Wistar; Taxoids | 2005 |
[An autopsied case of metastatic endocrine carcinoma of the pancreas with primary site difficult to identify].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Docetaxel; Head and Neck Neoplasms; Humans; Magnetic Resonance Imaging; Male; Neoplasm Metastasis; Neoplasms, Unknown Primary; Paclitaxel; Pancreatic Neoplasms; Taxoids | 2005 |
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cetuximab; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; ErbB Receptors; Esophageal Neoplasms; Gefitinib; Humans; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Piperidines; Quinazolines; Taxoids | 2005 |
Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Etoposide; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Paclitaxel; Pemetrexed; Survival Rate; Taxoids | 2005 |
An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Humans; Inhibitory Concentration 50; Ovarian Neoplasms; Paclitaxel; Taxoids | 2005 |
A pilot study of weekly docetaxel therapy for recurrent ovarian cancer, tubal cancer, and primary peritoneal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; CA-125 Antigen; Docetaxel; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Platinum Compounds; Taxoids; Treatment Outcome | 2005 |
Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of docetaxel and paclitaxel in human plasma and oral fluid.
Topics: Antineoplastic Agents; Chromatography, Liquid; Docetaxel; Drug Stability; Humans; Molecular Structure; Paclitaxel; Reproducibility of Results; Saliva; Sensitivity and Specificity; Tandem Mass Spectrometry; Taxoids | 2005 |
Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bromodeoxyuridine; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; Drug Synergism; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Paclitaxel; Suramin; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2005 |
[Cut-off level of docetaxel, paclitaxel and gemcitabine in histoculture drug response assay for non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Tumor Cells, Cultured | 2005 |
Transport and cytotoxicity of paclitaxel, docetaxel, and novel taxanes in human breast cancer cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Inhibitory Concentration 50; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Paclitaxel; RNA, Messenger; Taxoids; Time Factors; Verapamil | 2005 |
Small interfering RNA-induced CHFR silencing sensitizes oral squamous cell cancer cells to microtubule inhibitors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle Proteins; Cell Division; Docetaxel; Drug Resistance, Neoplasm; Female; G2 Phase; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Male; Microtubules; Middle Aged; Mouth Neoplasms; Neoplasm Proteins; Neoplasms, Squamous Cell; Paclitaxel; Poly-ADP-Ribose Binding Proteins; RNA, Small Interfering; Taxoids; Ubiquitin-Protein Ligases | 2005 |
Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells.
Topics: Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Bisbenzimidazole; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Fluorouracil; Humans; Immunoblotting; Inhibitor of Apoptosis Proteins; Male; Microtubule-Associated Proteins; Neoplasm Proteins; Neuronal Apoptosis-Inhibitory Protein; Paclitaxel; Phenotype; Prostatic Neoplasms; Survivin; Taxoids; Tetrazolium Salts; Time Factors; Ubiquitin-Protein Ligases; X-Linked Inhibitor of Apoptosis Protein | 2005 |
[Neutropenia induced by taxoids and its control with granulocyte colony-stimulating factor].
Topics: Antineoplastic Agents; Docetaxel; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Neutropenia; Paclitaxel; Recombinant Proteins; Retrospective Studies; Taxoids | 2005 |
Ins and outs of taxanes.
Topics: Biological Transport; Cell Membrane; Docetaxel; Hepatocytes; Humans; Liver-Specific Organic Anion Transporter 1; Models, Biological; Organic Anion Transporters, Sodium-Independent; Paclitaxel; Solute Carrier Organic Anion Transporter Family Member 1B3; Taxoids | 2005 |
Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Hypersensitivity; Female; Genital Neoplasms, Female; Humans; Paclitaxel; Retrospective Studies; Taxoids | 2006 |
The effect of alkylamine additives on the sensitivity of detection for paclitaxel and docetaxel and analysis in plasma of paclitaxel by liquid chromatography-tandem mass spectrometry.
Topics: Amines; Chromatography, Liquid; Docetaxel; Mass Spectrometry; Paclitaxel; Reproducibility of Results; Sensitivity and Specificity; Taxoids | 2006 |
[Antitumor effect of docetaxel against human endometrial tumor cell lines].
Topics: Animals; Antineoplastic Agents, Phytogenic; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Endometrial Neoplasms; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Taxoids; Tumor Cells, Cultured | 2005 |
Taxanes and breast cancer: shifting priorities.
Topics: Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2005 |
[A case of advanced gastric cancer with liver and lung metastases markedly responded to TS-1-based sequential chemotherapy].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic Antigen; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Combinations; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mitomycin; Oxonic Acid; Paclitaxel; Pyridines; Remission Induction; Taxoids; Tegafur | 2005 |
High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Docetaxel; Humans; Paclitaxel; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Taxoids | 2006 |
[Central diabetes insipidus caused by pituitary metastasis of lung cancer].
Topics: Adenocarcinoma; Aged; Antidiuretic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deamino Arginine Vasopressin; Diabetes Insipidus, Neurogenic; Docetaxel; Humans; Lung Neoplasms; Male; Paclitaxel; Pituitary Neoplasms; Radiosurgery; Taxoids | 2005 |
Ultrasonographic guidance for spinal extracranial radiosurgery: technique and application for metastatic spinal lesions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Feasibility Studies; Humans; Imaging, Three-Dimensional; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Phantoms, Imaging; Radiosurgery; Spinal Neoplasms; Taxoids; Tomography, X-Ray Computed; Ultrasonography, Interventional | 2001 |
Determination of unbound docetaxel and paclitaxel in plasma by ultrafiltration and liquid chromatography-tandem mass spectrometry.
Topics: Antineoplastic Agents, Phytogenic; Chromatography, High Pressure Liquid; Docetaxel; Humans; Mass Spectrometry; Paclitaxel; Taxoids; Ultrafiltration | 2006 |
Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents, Phytogenic; Aspartic Acid; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Epothilones; Glutamic Acid; Humans; Mice; Mice, Nude; Microtubules; Paclitaxel; Point Mutation; Protein Conformation; Taxoids; Tubulin; Verapamil | 2006 |
Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Combined Modality Therapy; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Taxoids | 2006 |
[Antitumor effect of docetaxel against human esophagus tumor cell lines and tumor xenografts in nude mice].
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Humans; In Vitro Techniques; Inhibitory Concentration 50; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Taxoids; Transplantation, Heterologous | 2006 |
The T-Taxol conformation.
Topics: Binding Sites; Crystallography; Docetaxel; Ligands; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Paclitaxel; Protein Structure, Tertiary; Stereoisomerism; Structure-Activity Relationship; Taxoids; Tubulin | 2006 |
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies.
Topics: Aged; Allosteric Regulation; Antineoplastic Agents; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; In Vitro Techniques; Male; Middle Aged; Myocardium; Paclitaxel; Taxoids | 2006 |
Determination of docetaxel and Paclitaxel in human plasma by high-performance liquid chromatography: validation and application to clinical pharmacokinetic studies.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Breast Neoplasms; Chromatography, High Pressure Liquid; Docetaxel; Drug Stability; Female; Half-Life; Humans; Paclitaxel; Quality Control; Reproducibility of Results; Spectrophotometry, Ultraviolet; Taxoids; Temperature | 2006 |
Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Costs and Cost Analysis; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; National Health Programs; Paclitaxel; Portugal; Taxoids | 2006 |
Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Blotting, Western; Clusterin; Docetaxel; Flow Cytometry; Genes, bcl-2; Humans; Male; Mitoxantrone; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Tumor Cells, Cultured | 2006 |
Prolonged mitosis versus tetraploid checkpoint: how p53 measures the duration of mitosis.
Topics: Antineoplastic Agents; Docetaxel; Gene Expression Regulation; Humans; Mitosis; Paclitaxel; Phosphorylation; Polyploidy; Taxoids; Tumor Suppressor Protein p53; Vinca Alkaloids | 2006 |
[Promising targeted molecular therapies for the future years in non-small-cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Forecasting; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Prognosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Randomized Controlled Trials as Topic; Research; Signal Transduction; Taxoids; Vascular Endothelial Growth Factor A | 2006 |
Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Binding Sites; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; In Situ Hybridization, Fluorescence; Injections, Intravenous; Mice; Mice, Nude; Molecular Conformation; Paclitaxel; Stereoisomerism; Taxoids; Tubulin; Xenograft Model Antitumor Assays | 2006 |
Taxane-containing chemotherapy in the treatment of early breast cancer patients.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 2006 |
Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Mitoxantrone; Paclitaxel; Prostatic Neoplasms; Retrospective Studies; Taxoids | 2006 |
Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Disease Progression; Docetaxel; Female; Fibrin Fibrinogen Degradation Products; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Predictive Value of Tests; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine | 2006 |
ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Carboplatin; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Female; Gene Frequency; Genetic Variation; Genotype; Humans; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Taxoids; Treatment Outcome | 2006 |
Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colony-Stimulating Factors; Docetaxel; Epirubicin; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Middle Aged; Neutropenia; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2006 |
[Lung cancer with bone metastasis].
Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Administration Schedule; Etoposide; Fractures, Bone; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Pain, Intractable; Prognosis; Quinazolines; Radiotherapy Dosage; Taxoids | 2006 |
Effects of paclitaxel, docetaxel and their combinations on subcutaneous lymphomas in inbred Sprague-Dawley/Cub rats.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Body Weight; Cell Line, Tumor; Docetaxel; Drug Therapy, Combination; Gene Expression Regulation; Humans; Intestinal Mucosa; Lymphoma, T-Cell; Mice; Microsomes, Liver; Paclitaxel; Rats; Rats, Sprague-Dawley; Subcutaneous Tissue; Taxoids | 2006 |
Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Drug Interactions; Etoposide; Female; Humans; Liver; Male; Middle Aged; Models, Theoretical; Neutropenia; Neutrophils; Paclitaxel; Sex Characteristics; Taxoids; Topotecan | 2006 |
Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies.
Topics: Aged; Antineoplastic Agents; Cytosol; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorenes; Heart; Humans; Hydantoins; Hydrogen Peroxide; Male; Middle Aged; Myocardium; Paclitaxel; Reactive Oxygen Species; Taxoids | 2007 |
Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cisplatin; Decitabine; DNA Methylation; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Proteins; Paclitaxel; Poly-ADP-Ribose Binding Proteins; Promoter Regions, Genetic; Taxoids; Ubiquitin-Protein Ligases | 2007 |
Vaginal evisceration during intraperitoneal chemotherapy for advanced ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Humans; Infusions, Parenteral; Middle Aged; Ovarian Neoplasms; Paclitaxel; Taxoids; Vaginal Diseases | 2007 |
[HER-2 and ER expression in prediction of chemo-sensitivity of taxane for advanced breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Immunohistochemistry; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Remission Induction; Retrospective Studies; Taxoids | 2006 |
Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites.
Topics: Alkanes; Amino Acid Sequence; Asparagine; Binding Sites; Binding, Competitive; Carbamates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Epothilones; Humans; Inhibitory Concentration 50; Lactones; Mass Spectrometry; Microtubules; Models, Chemical; Models, Molecular; Molecular Sequence Data; Paclitaxel; Polycyclic Compounds; Protein Binding; Pyrones; Taxoids; Threonine; Tubulin; Tubulin Modulators | 2007 |
[Two cases of radiofrequency ablation (RFA) therapy for control of liver metastases from breast cancer].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Catheter Ablation; Docetaxel; Fatal Outcome; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Lymphatic Metastasis; Mastectomy; Middle Aged; Paclitaxel; Taxoids; Trastuzumab | 2006 |
[A patient with advanced breast cancer refractory to chemotherapy accompanied by carcinomatous pleurisy and multiple bone metastasis that responded to combination therapy with high-dose toremifene and docetaxel].
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Paclitaxel; Pleural Effusion, Malignant; Pleural Neoplasms; Quality of Life; Remission Induction; Taxoids; Toremifene | 2007 |
[A case report of advanced gastric cancer with carcinomatous ascites successfully treated by outpatient chemotherapy].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Ascites; Ascitic Fluid; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Quality of Life; Stomach Neoplasms; Taxoids; Tegafur | 2007 |
Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Taxoids | 2007 |
In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway- and microtubule-targeting inhibitors.
Topics: 3T3 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Cell Transformation, Neoplastic; Colonic Neoplasms; Docetaxel; Drug Synergism; Enzyme Inhibitors; Humans; In Vitro Techniques; Lung Neoplasms; Male; Mice; Mice, Nude; Mice, SCID; Microtubules; Mitogen-Activated Protein Kinases; Paclitaxel; Proto-Oncogene Proteins c-raf; Proto-Oncogene Proteins p21(ras); Signal Transduction; Taxoids; Transcriptional Activation; Tumor Cells, Cultured; Vincristine; Xenograft Model Antitumor Assays | 2007 |
Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Salvage Therapy; Statistics, Nonparametric; Survival Analysis; Taiwan; Taxoids; Treatment Outcome | 2006 |
Isolated lung perfusion with Paclitaxel and docetaxel: comparison of the early effects on pulmonary physiology.
Topics: Animals; Antineoplastic Agents, Phytogenic; Chemotherapy, Cancer, Regional Perfusion; Docetaxel; Lung; Lung Neoplasms; Male; Paclitaxel; Rats; Rats, Sprague-Dawley; Taxoids | 2007 |
[Outpatient chemotherapy for lung cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gefitinib; Gemcitabine; Humans; Informed Consent; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Quality of Life; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2007 |
Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Mice; Mice, Inbred Strains; Neoplasms; Paclitaxel; S Phase; Taxoids; Xenograft Model Antitumor Assays | 2007 |
EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; ErbB Receptors; Female; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2007 |
Extreme drug resistance is common after prior exposure to paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cisplatin; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Taxoids | 2007 |
[Surgery for advanced breast cancer from the viewpoint of medical oncologist].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy, Adjuvant; Taxoids | 2007 |
Melanoma-associated antigen-A1 expression predicts resistance to docetaxel and paclitaxel in advanced and recurrent gastric cancer.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; DNA Methylation; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Melanoma-Specific Antigens; Neoplasm Proteins; Neoplasm Recurrence, Local; Paclitaxel; Polymerase Chain Reaction; Predictive Value of Tests; Prognosis; Stomach Neoplasms; Taxoids; Transfection | 2007 |
Developmental chemotherapy and management of recurrent ovarian cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drugs, Investigational; Enzyme Inhibitors; Etoposide; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Recurrence; Research Design; Taxoids; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2003 |
Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Docetaxel; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2007 |
Effects of patupilone (epothilone B; EPO906), a novel chemotherapeutic agent, in hepatocellular carcinoma: an in vitro study.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Hepatocellular; Cell Line, Tumor; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Epothilones; Humans; Liver Neoplasms; Paclitaxel; Taxoids | 2006 |
Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Cell Proliferation; Docetaxel; Doxorubicin; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Ki-67 Antigen; Models, Biological; Paclitaxel; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Spheroids, Cellular; Tamoxifen; Taxoids; Tissue Distribution; Tumor Burden; Tumor Cells, Cultured | 2007 |
[Lung cancer treatment in elderly patients].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2007 |
Toxic effects differ in combination treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colony-Stimulating Factors; Docetaxel; Doxorubicin; Drug Therapy, Combination; Female; Hematologic Diseases; Humans; Paclitaxel; Peripheral Nervous System Diseases; Taxoids | 2007 |
[Dose dense chemotherapy in the postoperative adjuvant treatment for breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lymphatic Metastasis; Mastectomy; Middle Aged; Nausea; Neutropenia; Paclitaxel; Postoperative Period; Retrospective Studies; Taxoids | 2007 |
Wild-type class I beta-tubulin sensitizes Taxol-resistant breast adenocarcinoma cells harboring a beta-tubulin mutation.
Topics: Adenocarcinoma; Alkanes; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carbamates; Cell Line, Tumor; Cell Survival; Dimerization; Docetaxel; Drug Resistance, Neoplasm; Epothilones; Fluorescent Antibody Technique, Indirect; Glutamic Acid; Glycine; Humans; Lactones; Models, Molecular; Mutation, Missense; Paclitaxel; Protein Structure, Quaternary; Pyrones; Taxoids; Transfection; Tubulin; Tubulin Modulators | 2007 |
Paclitaxel binding to the fatty acid-induced conformation of human serum albumin--automated docking studies.
Topics: Antineoplastic Agents; Binding Sites; Computer Simulation; Docetaxel; Fatty Acids; Humans; Hydrogen Bonding; Ligands; Models, Molecular; Molecular Structure; Paclitaxel; Protein Binding; Protein Conformation; Serum Albumin; Taxoids | 2007 |
Progression of disease despite good endoscopic local control of upper tract urothelial carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Electrocoagulation; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Nephrectomy; Paclitaxel; Taxoids; Ureteroscopy | 2007 |
Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Salvage Therapy; Survival Analysis; Taxoids; Time Factors | 2007 |
[Two cases of advanced gastric cancer in which paclitaxel proved effective after resistance to docetaxel].
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Salvage Therapy; Stomach Neoplasms; Taxoids | 2007 |
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Body Mass Index; Body Size; Body Surface Area; Body Weight; Camptothecin; Carboplatin; Cisplatin; Cytosine; Dioxolanes; Docetaxel; Doxorubicin; Humans; Irinotecan; Metabolic Clearance Rate; Obesity; Paclitaxel; Taxoids; Topotecan | 2007 |
The effect of core composition in biodegradable oligomeric micelles as taxane formulations.
Topics: Animals; Chemistry, Pharmaceutical; Colonic Neoplasms; Docetaxel; Drug Stability; Magnetic Resonance Spectroscopy; Mice; Micelles; Paclitaxel; Particle Size; Taxoids | 2008 |
Enhanced efficiency of thermally targeted taxanes delivery in a human xenograft model of gastric cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Lethal Dose 50; Mice; Micelles; Neoplasm Transplantation; Paclitaxel; Stomach Neoplasms; Taxoids | 2008 |
Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: a population-based evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; British Columbia; Cost-Benefit Analysis; Docetaxel; Drug Costs; Female; Humans; Middle Aged; Paclitaxel; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Expression and activity of taxane-metabolizing enzymes in ovarian tumors.
Topics: Antineoplastic Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Female; Gene Expression; Humans; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 2008 |
Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes.
Topics: Antineoplastic Agents; Camptothecin; Chenodeoxycholic Acid; Dactinomycin; Docetaxel; Fluorescent Dyes; Humans; Irinotecan; Kinetics; Lysine; Mitoxantrone; Organic Anion Transporters, Sodium-Independent; Paclitaxel; Signal Processing, Computer-Assisted; Solute Carrier Organic Anion Transporter Family Member 1B3; Spectrometry, Fluorescence; Taxoids; Transfection | 2008 |
The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Predictive Value of Tests; Prognosis; Retrospective Studies; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2008 |
Taxane analogues against breast cancer: a quantitative structure-activity relationship study.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Doxorubicin; Female; Humans; Paclitaxel; Quantitative Structure-Activity Relationship; Taxoids; Thermodynamics | 2008 |
TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Tumor Suppressor Protein p53 | 2008 |
Measuring the cost of chemotherapy is important, but it is not enough.
Topics: Antineoplastic Agents; Breast Neoplasms; Complementary Therapies; Cost of Illness; Cost-Benefit Analysis; Docetaxel; Drug Costs; Humans; Neutropenia; Paclitaxel; Quality of Life; Quality-Adjusted Life Years; Survival Analysis; Taxoids; Therapies, Investigational | 2008 |
Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Cell Line, Tumor; Docetaxel; Down-Regulation; Drug Synergism; Humans; Immunoblotting; Inhibitor of Apoptosis Proteins; Male; Mice; Microtubule-Associated Proteins; Neoplasm Proteins; Organoselenium Compounds; Paclitaxel; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Survivin; Taxoids; Xenograft Model Antitumor Assays | 2008 |
Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Monitoring; Estrogens; Female; Fluorouracil; Follow-Up Studies; Humans; Japan; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Paclitaxel; Progesterone; Prognosis; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome | 2009 |
Modeling resistance index of taxoids to MCF-7 cell lines using ANN together with electrotopological state descriptors.
Topics: Algorithms; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Resistance, Multiple; Female; Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Structure; Neural Networks, Computer; Paclitaxel; Predictive Value of Tests; Principal Component Analysis; Quantitative Structure-Activity Relationship; Reproducibility of Results; Software; Taxoids | 2008 |
Gastrointestinal tract epithelial changes associated with taxanes: marker of drug toxicity versus effect.
Topics: Adult; Aged; Aged, 80 and over; Colchicine; Docetaxel; Epithelium; Esophagus; Female; Gastric Mucosa; Humans; Intestinal Mucosa; Male; Middle Aged; Mitosis; Paclitaxel; Taxoids | 2008 |
Prolonged neutropenia after dose-dense chemotherapy with pegfilgrastim.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Japan; Mastectomy; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2008 |
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Genotype; Humans; Middle Aged; Paclitaxel; Polymorphism, Genetic; Receptor, ErbB-2; Receptors, IgG; Signal Transduction; Taxoids; Trastuzumab; Treatment Outcome | 2008 |
Influence of previous chemotherapy on the efficacy of subsequent docetaxel therapy in advanced non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids | 2008 |
[Collagen gel droplet-embedded culture drug sensitivity test in human breast cancer].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Collagen; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Female; Fluorouracil; Gels; Humans; Male; Paclitaxel; Taxoids | 2008 |
Single agent gemcitabine in the second-line treatment of advanced non-small cell lung cancer after treatment with taxane + platinum regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Retrospective Studies; Taxoids | 2008 |
Proteomic investigation of taxol and taxotere resistance and invasiveness in a squamous lung carcinoma cell line.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Humans; Lung Neoplasms; Neoplasm Invasiveness; Neoplasm Proteins; Paclitaxel; Proteomics; Reactive Oxygen Species; Taxoids | 2008 |
[Adjuvant chemotherapy for breast cancer and targeted therapies].
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Proportional Hazards Models; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Analysis; Taxoids; Trastuzumab | 2008 |
Highly efficient stereocontrolled synthesis of Danishefsky's taxol CD ring key intermediate.
Topics: Docetaxel; Molecular Structure; Paclitaxel; Propanols; Stereoisomerism; Taxoids | 2008 |
Mandating prospectively defined endpoints for ovarian cancer phase 2 trials: a strategy to improve the quality of gynecologic cancer clinical research.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Docetaxel; Endpoint Determination; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids | 2008 |
Sentinel lymph node biopsy after neoadjuvant chemotherapy in a patient with operable breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Axilla; Biopsy, Needle; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; False Negative Reactions; Feasibility Studies; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Sentinel Lymph Node Biopsy; Taxoids | 2008 |
ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Endonucleases; Etoposide; Female; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Taxoids; Topotecan | 2008 |
Weekly paclitaxel in the adjuvant treatment of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Paclitaxel; Proportional Hazards Models; Taxoids | 2008 |
Weekly paclitaxel in the adjuvant treatment of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Humans; Paclitaxel; Taxoids | 2008 |
Synthesis and biological evaluation of novel 3'-N-tert-butylsulfonyl analogues of docetaxel.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Screening Assays, Antitumor; HeLa Cells; Humans; KB Cells; Paclitaxel; Sulfonic Acids; Taxoids | 2008 |
Docetaxel as second line therapy in advanced non-small cell lung cancer-the dose and combination may matter!
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Salvage Therapy; Taxoids; Treatment Outcome | 2008 |
ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Polymorphism, Single Nucleotide; Taxoids | 2008 |
Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Docetaxel; Female; Humans; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Nanoparticles; Osteonectin; Paclitaxel; Polysorbates; Receptor, ErbB-2; Taxoids; Xenograft Model Antitumor Assays | 2008 |
CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Taxoids | 2008 |
The interaction between taxoids and serine/threonine protein phosphatase activities during taxan-induced apoptosis of HL 60 leukemic cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Differentiation; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HL-60 Cells; Humans; Inhibitory Concentration 50; Microscopy, Fluorescence; Paclitaxel; Phosphoprotein Phosphatases; Taxoids | 2008 |
hTERT gene expression levels and telomerase activity in drug resistant MCF-7 cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Proliferation; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Enzymologic; Humans; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Taxoids; Telomerase; Tumor Cells, Cultured; Vincristine | 2008 |
A genomic approach to identify molecular pathways associated with chemotherapy resistance.
Topics: Blotting, Western; Cell Death; Cell Line, Tumor; Chromones; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Genes, Neoplasm; Genomics; Humans; Indoles; Lung Neoplasms; Morpholines; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Sulfonamides; Taxoids | 2008 |
TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Carboplatin; Cell Line, Tumor; Cisplatin; Docetaxel; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tumor Suppressor Protein p53; Young Adult | 2009 |
Taxanes inhibit human TLR4 signaling by binding to MD-2.
Topics: Antineoplastic Agents; Cell Line; Docetaxel; Humans; Lipopolysaccharides; Lymphocyte Antigen 96; Paclitaxel; Signal Transduction; Taxoids; Toll-Like Receptor 4 | 2008 |
Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance.
Topics: Analysis of Variance; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cyclosporine; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Humans; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Paclitaxel; Statistics, Nonparametric; Taxoids; Vault Ribonucleoprotein Particles | 2008 |
Differences in paclitaxel and docetaxel interactions with tubulin detected by mutagenesis of yeast tubulin.
Topics: Antineoplastic Agents; Docetaxel; Inhibitory Concentration 50; Models, Molecular; Mutagenesis, Site-Directed; Paclitaxel; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Taxoids; Tubulin; Tubulin Modulators | 2008 |
The role of palliative chemotherapy for advanced pulmonary pleomorphic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Palliative Care; Taxoids | 2009 |
Determination of a hydrophilic paclitaxel derivative, 7-xylosyl-10-deacetylpaclitaxel in rat plasma by LC-MS/MS.
Topics: Animals; Chromatography, High Pressure Liquid; Docetaxel; Female; Paclitaxel; Rats; Rats, Wistar; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Taxoids; Time Factors | 2009 |
Decreased orotate phosphoribosyltransferase activity produces 5-fluorouracil resistance in a human gastric cancer cell line.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Orotate Phosphoribosyltransferase; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Stomach Neoplasms; Taxoids; Tetrazolium Salts; Thiazoles | 2008 |
Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer.
Topics: Adult; Albumins; Antineoplastic Agents; Attitude of Health Personnel; Breast Neoplasms; Canada; Cost-Benefit Analysis; Docetaxel; Drug Costs; Female; Humans; Meta-Analysis as Topic; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2009 |
Docetaxel inhibits bone resorption through suppression of osteoclast formation and function in different manners.
Topics: Actins; Animals; Antineoplastic Agents; Bone and Bones; Bone Marrow Cells; Bone Resorption; Calcitriol; Cell Survival; Cells, Cultured; Coculture Techniques; Dinoprostone; Docetaxel; Glutamic Acid; Humans; Macrophages; Male; Mice; Osteoblasts; Osteoclasts; Paclitaxel; RANK Ligand; Taxoids | 2009 |
[Differential gene expression of the inhibitor of apoptosis proteins in docetaxel-resistant gastric cancer cells].
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Stomach Neoplasms; Survivin; Taxoids; X-Linked Inhibitor of Apoptosis Protein | 2008 |
The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Administration Schedule; Female; Filgrastim; Genital Neoplasms, Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Taxoids; Young Adult | 2009 |
Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Hospitalization; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life; Retrospective Studies; Taxoids; Treatment Outcome | 2009 |
Chemotherapeutic sensitization by endoplasmic reticulum stress: increasing the efficacy of taxane against prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Death; Cell Line, Tumor; Docetaxel; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Enzyme-Linked Immunosorbent Assay; Formazans; Heat-Shock Proteins; Humans; Male; Molecular Chaperones; Organoselenium Compounds; Paclitaxel; Prostatic Neoplasms; RNA, Small Interfering; Taxoids; Tetrazolium Salts; Thapsigargin; Time Factors; Transcription Factor CHOP; Transfection | 2009 |
Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Polymorphism, Genetic; Taxoids; Young Adult | 2009 |
Yin yang 1 modulates taxane response in epithelial ovarian cancer.
Topics: Antineoplastic Agents, Phytogenic; Binding Sites; Cell Movement; Cell Proliferation; Cisplatin; Comparative Genomic Hybridization; Docetaxel; E2F Transcription Factors; Epigenesis, Genetic; Female; Gene Expression Profiling; Humans; Immunoenzyme Techniques; Neoplasms, Glandular and Epithelial; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Survival Rate; Taxoids; Wound Healing; YY1 Transcription Factor | 2009 |
Irreversible and severe alopecia following docetaxel or paclitaxel cytotoxic therapy for breast cancer.
Topics: Alopecia; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 2009 |
MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy.
Topics: Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Linear Models; MicroRNAs; Ovarian Neoplasms; Paclitaxel; RNA, Messenger; Taxoids; Topotecan | 2009 |
Local control and survival following concomitant chemoradiotherapy in inoperable stage I non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Docetaxel; Dose Fractionation, Radiation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Conformal; Regression Analysis; Retrospective Studies; Survival Rate; Taxoids | 2009 |
Detection and quantification of the evolution dynamics of apoptosis using the PET voltage sensor 18F-fluorobenzyl triphenyl phosphonium.
Topics: Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Caspase 3; Cell Line, Tumor; Cytochromes c; Docetaxel; Genes, bcl-2; Humans; Membrane Potential, Mitochondrial; Organophosphorus Compounds; Paclitaxel; Positron-Emission Tomography; Radiopharmaceuticals; Taxoids; Tubulin Modulators | 2009 |
Unilateral taxane-induced onychopathy in a patient with a brain metastasis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carboplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Fluorouracil; Hand; Humans; Lapatinib; Middle Aged; Onycholysis; Paclitaxel; Paresis; Peripheral Nervous System Diseases; Quinazolines; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2009 |
Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2009 |
XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Gemcitabine; Gene Frequency; Genotype; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Paclitaxel; Polymorphism, Single Nucleotide; Taxoids; Transcription Factors; Treatment Outcome; Vinblastine; Vinorelbine; Xeroderma Pigmentosum Group A Protein | 2009 |
Inhibition of NF-kappaB by ginsenoside Rg3 enhances the susceptibility of colon cancer cells to docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Cell Cycle Proteins; Cell Proliferation; Cisplatin; Colonic Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Ginsenosides; HCT116 Cells; Humans; Inhibitory Concentration 50; NF-kappa B; Paclitaxel; Taxoids | 2009 |
Gene expression analysis of drug-resistant MCF-7 cells: implications for relation to extracellular matrix proteins.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cluster Analysis; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Extracellular Matrix Proteins; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Oligonucleotide Array Sequence Analysis; Paclitaxel; Taxoids; Vincristine | 2010 |
Surfactants influence the distribution of taxanes in peritoneal dissemination tumor-bearing rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Ascites; Biological Transport; Carcinoma, Hepatocellular; Cell Line, Tumor; Docetaxel; Female; Glycerol; Injections, Intraperitoneal; Liver Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polysorbates; Rats; Surface-Active Agents; Taxoids; Tissue Distribution | 2010 |
[Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Signet Ring Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Remission Induction; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Vomiting; Young Adult | 2009 |
[A case of nonresected gastric cancer with peritoneal dissemination effectively treated by S-1/DOC and PTX/ CDDP combination chemotherapy with good QOL].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneum; Quality of Life; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2009 |
Evaluation of spatially fractionated radiotherapy (GRID) and definitive chemoradiotherapy with curative intent for locally advanced squamous cell carcinoma of the head and neck: initial response rates and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Middle Aged; Paclitaxel; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Taxoids; Tumor Burden | 2010 |
The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Count; Cell Enlargement; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Etoposide; Fluorouracil; Humans; Models, Biological; Myelopoiesis; Neoplasms; Neutrophils; Observation; Paclitaxel; Precision Medicine; Taxoids; Topotecan | 2010 |
Effect of low-dose Paclitaxel and docetaxel on endothelial progenitor cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma 256, Walker; Cell Line; Cell Migration Inhibition; Cell Proliferation; Docetaxel; Endothelial Cells; Female; Humans; Neovascularization, Pathologic; Paclitaxel; Rats; Rats, Wistar; Stem Cells; Taxoids | 2009 |
FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell Line; Cell Line, Tumor; Cytarabine; Docetaxel; Drug Therapy; Humans; Kidney; Neoplasms; Nuclear Proteins; Paclitaxel; Pancreatic Neoplasms; Phosphoprotein Phosphatases; Proto-Oncogene Proteins c-akt; Tacrolimus Binding Proteins; Taxoids | 2009 |
Effects of taxane-based chemotherapy on inhibin B and gonadotropins as biomarkers of spermatogenesis.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carboplatin; Deoxycytidine; Docetaxel; Fertility; Follicle Stimulating Hormone; Gemcitabine; Humans; Infertility, Male; Inhibins; Luteinizing Hormone; Male; Middle Aged; Neoplasms; Paclitaxel; Spermatogenesis; Taxoids; Testis; Ultrasonography; Young Adult | 2010 |
Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Bacterial Toxins; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Escherichia coli Proteins; Female; Genes, Transgenic, Suicide; Genetic Therapy; Genetic Vectors; Humans; Membrane Proteins; Paclitaxel; Spheroids, Cellular; Taxoids; Transfection | 2010 |
C-7 configuration as one of determinants in taxanes metabolism by human cytochrome P450 enzymes.
Topics: Bridged-Ring Compounds; Chromatography, Liquid; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Docetaxel; Enzyme Inhibitors; Female; Humans; Hydroxylation; Isoenzymes; Kinetics; Male; Microsomes, Liver; Molecular Conformation; Paclitaxel; Recombinant Proteins; Taxoids | 2009 |
An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Markov Chains; Models, Economic; Neoplasm Metastasis; Paclitaxel; Quality-Adjusted Life Years; Taxoids; United Kingdom | 2009 |
Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystadenocarcinoma, Serous; Docetaxel; Drug Administration Schedule; Female; Humans; Injections, Intraperitoneal; Middle Aged; Outpatients; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Retrospective Studies; Taxoids; Treatment Outcome | 2009 |
Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.
Topics: Androgen Receptor Antagonists; Androgens; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Chromatin Immunoprecipitation; Chromones; Docetaxel; Enzyme Inhibitors; Forkhead Box Protein O1; Forkhead Transcription Factors; Humans; Immunoblotting; Immunoenzyme Techniques; Luciferases; Male; Mice; Mice, Inbred NOD; Mice, SCID; Morpholines; Orchiectomy; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Prostate-Specific Antigen; Prostatic Neoplasms; PTEN Phosphohydrolase; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Taxoids | 2009 |
Successful treatment of metastatic pancreatic adenocarcinoma with combination chemotherapy regimens.
Topics: Adenocarcinoma, Mucinous; Adult; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy, Fine-Needle; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay.
Topics: Aged; Antineoplastic Agents; Carboplatin; Carcinosarcoma; Cisplatin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Survival Rate; Taxoids; Uterine Neoplasms | 2010 |
Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Cisplatin; Docetaxel; Female; Humans; Infusions, Parenteral; Middle Aged; Ovarian Neoplasms; Paclitaxel; Taxoids | 2010 |
Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Reversal of P-gp-mediated multidrug resistance by Bromotetrandrine in vivo is associated with enhanced accumulation of chemotherapeutical drug in tumor tissue.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzylisoquinolines; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Flow Cytometry; Humans; KB Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Taxoids; Vincristine; Xenograft Model Antitumor Assays | 2009 |
[Estimation of preoperative induction chemoradiotherapy effectiveness for non small-cell lung cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2009 |
Second and third line treatment in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Paclitaxel; Pemetrexed; Taxoids | 2009 |
[Effect of neoadjuvant chemotherapy on histologic grade and expression of biological markers in breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Epirubicin; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids | 2009 |
[Analysis of responses and prognostic factors in different chemotherapy regimens for metastatic nasopharyngeal carcinoma: a report of 171 cases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nasopharyngeal Neoplasms; Paclitaxel; Proportional Hazards Models; Remission Induction; Retrospective Studies; Survival Rate; Taxoids; Young Adult | 2009 |
Primary chemotherapy patterns for ovarian cancer treatment in Japan.
Topics: Adult; Age Factors; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Cyclophosphamide; Databases, Factual; Docetaxel; Evidence-Based Medicine; Female; Humans; International Classification of Diseases; Japan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Patient Selection; Practice Patterns, Physicians'; Taxoids; Treatment Outcome | 2009 |
Weekly paclitaxel/ docetaxel combined with a platinum in the treatment of advanced non-small cell lung cancer: a study on efficacy, safety and pre-medication.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Premedication; Taxoids; Treatment Outcome | 2009 |
Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Docetaxel; Drug Administration Schedule; Estramustine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2010 |
Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Endothelium, Vascular; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Paclitaxel; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Severe interstitial pneumonitis associated with the administration of taxanes.
Topics: Adrenal Cortex Hormones; Aged; Breast Neoplasms; Docetaxel; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Paclitaxel; Stomach Neoplasms; Taxoids; Tomography, X-Ray Computed | 2010 |
Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Diphosphonates; Docetaxel; Double-Blind Method; Drug Synergism; Female; Genes, erbB-2; Humans; Incidence; Jaw Diseases; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Oral Hygiene; Osteonecrosis; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2010 |
Drug resistant breast cancer cells overexpress ETS1 gene.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Matrix Metalloproteinase 1; Oncogenes; Paclitaxel; Proto-Oncogene Protein c-ets-1; Taxoids; Vincristine | 2010 |
Simultaneous determination of anthracyclines and taxanes in human serum using online sample extraction coupled to high performance liquid chromatography with UV detection.
Topics: Anthracyclines; Antineoplastic Agents; Blood Proteins; Calibration; Chemistry, Pharmaceutical; Chromatography; Chromatography, High Pressure Liquid; Daunorubicin; Docetaxel; Doxorubicin; Epirubicin; Humans; Paclitaxel; Sensitivity and Specificity; Taxoids | 2010 |
GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Endoplasmic Reticulum Chaperone BiP; Female; Heat-Shock Proteins; Humans; Lymphatic Metastasis; Menopause; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Taxoids; Treatment Outcome | 2011 |
HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Docetaxel; Hydrogen-Ion Concentration; Lymphoma, T-Cell; Male; Methacrylates; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Paclitaxel; Polymers; Taxoids | 2010 |
nab-paclitaxel: a novel formulation of taxane for treatment of breast cancer.
Topics: Albumins; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cytotoxins; Docetaxel; Drug Therapy, Combination; Female; Humans; Paclitaxel; Radiation-Sensitizing Agents; Taxoids; Treatment Outcome | 2010 |
Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients.
Topics: Aged; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Breast Neoplasms, Male; Chemotherapy, Adjuvant; Chi-Square Distribution; Cytochrome P-450 CYP1B1; Cytochrome P-450 CYP2C8; Cytochrome P-450 Enzyme System; Docetaxel; Drug Hypersensitivity; Female; Gene Frequency; Genetic Predisposition to Disease; Humans; Italy; Logistic Models; Male; Middle Aged; Neoadjuvant Therapy; Odds Ratio; Paclitaxel; Phenotype; Polymorphism, Single Nucleotide; Retrospective Studies; Risk Assessment; Risk Factors; Taxoids; Treatment Outcome | 2010 |
Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2011 |
Beta-casein nanoparticles as an oral delivery system for chemotherapeutic drugs: impact of drug structure and properties on co-assembly.
Topics: Administration, Oral; Antineoplastic Agents; Camptothecin; Caseins; Colloids; Docetaxel; Drug Carriers; Drug Compounding; Drug Stability; Hydrogen-Ion Concentration; Irinotecan; Molecular Structure; Nanoparticles; Paclitaxel; Particle Size; Structure-Activity Relationship; Taxoids; Vinblastine | 2010 |
Neoadjuvant treatment in young women with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Mastectomy; Methotrexate; Molecular Targeted Therapy; Neoadjuvant Therapy; Paclitaxel; Prognosis; Radiotherapy, Adjuvant; Sentinel Lymph Node Biopsy; Taxoids; Treatment Outcome | 2010 |
Development and validation of a nylon6 nanofibers mat-based SPE coupled with HPLC method for the determination of docetaxel in rabbit plasma and its application to the relative bioavailability study.
Topics: Animals; Area Under Curve; Biological Availability; Caprolactam; Chromatography, High Pressure Liquid; Docetaxel; Drug Stability; Female; Least-Squares Analysis; Male; Nanofibers; Paclitaxel; Polymers; Rabbits; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Taxoids | 2010 |
Competitive mass spectrometry binding assay for characterization of three binding sites of tubulin.
Topics: Animals; Binding Sites; Binding, Competitive; Cattle; Chromatography, Liquid; Colchicine; Docetaxel; Guanosine Triphosphate; Linear Models; Paclitaxel; Podophyllotoxin; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Taxoids; Thiazoles; Tubulin; Tubulin Modulators; Vinblastine; Vincristine | 2010 |
Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cisplatin; Cohort Studies; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Genotype; Humans; Irinotecan; Male; Middle Aged; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Retrospective Studies; Risk Factors; Salvage Therapy; Stomach Neoplasms; Survival Rate; Taxoids | 2010 |
CYP3A4*16 and CYP3A4*18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs.
Topics: Alleles; Animals; Asia, Eastern; Atorvastatin; Biocatalysis; Camptothecin; Carbamazepine; Cytochrome P-450 CYP3A; Docetaxel; Heptanoic Acids; Humans; Irinotecan; Midazolam; Models, Molecular; Paclitaxel; Pyrroles; Spodoptera; Substrate Specificity; Taxoids; Terfenadine | 2010 |
The effect of age on the tolerability of intraperitoneal chemotherapy, complication rate, and survival in patients with ovarian cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Taxoids | 2010 |
Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Brachytherapy; Brain Neoplasms; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Combined Modality Therapy; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Risk Factors; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Advanced inoperable type B3 thymoma: monitoring of a novel therapeutic approach with radio-chemotherapy and sorafenib by FDG-PET and CT.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Image Processing, Computer-Assisted; Middle Aged; Paclitaxel; Radiation-Sensitizing Agents; Radiography; Radionuclide Imaging; Taxoids; Thymoma; Thymus Neoplasms; Treatment Outcome | 2010 |
Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain.
Topics: Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Disease Progression; Docetaxel; Female; Humans; Markov Chains; Paclitaxel; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Salvage Therapy; Spain; Taxoids | 2010 |
Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Stomach Neoplasms; Taxoids; Treatment Outcome | 2010 |
A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Piperidines; Quinazolines; Retrospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
The uptake of paclitaxel and docetaxel into ex vivo porcine bladder tissue from polymeric micelle formulations.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Biological Transport; Docetaxel; Drug Carriers; Drug Compounding; Glycerol; In Vitro Techniques; Male; Micelles; Nanoparticles; Paclitaxel; Pharmaceutical Vehicles; Polyesters; Polyethylene Glycols; Polysorbates; Swine; Taxoids; Tissue Distribution; Urinary Bladder; Urinary Bladder Neoplasms | 2011 |
[Cost-effectiveness analysis comparing carboplatin and weekly paclitaxel with cisplatin and docetaxel in the treatment of advanced non-small cell lung carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2010 |
Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; China; Deoxycytidine; Docetaxel; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Paclitaxel; Pharmacogenetics; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-akt; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2011 |
Development and in vitro characterization of paclitaxel and docetaxel loaded into hydrophobically derivatized hyperbranched polyglycerols.
Topics: Antineoplastic Agents; Biological Transport; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemistry, Pharmaceutical; Delayed-Action Preparations; Docetaxel; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Stability; Glycerol; Humans; Hydrophobic and Hydrophilic Interactions; Kinetics; Molecular Structure; Nanotechnology; Paclitaxel; Particle Size; Polymers; Solubility; Taxoids; Technology, Pharmaceutical | 2011 |
Targeting the oncogenic protein beta-catenin to enhance chemotherapy outcome against solid human cancers.
Topics: Antineoplastic Agents; beta Catenin; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; Neoplasms; Organoplatinum Compounds; Organoselenium Compounds; Oxaliplatin; Paclitaxel; RNA Interference; Taxoids; Topotecan | 2010 |
Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Therapy, Computer-Assisted; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Methotrexate; Middle Aged; Paclitaxel; Survival Analysis; Taxoids | 2010 |
Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Drugs, Chinese Herbal; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Medicine, Chinese Traditional; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Organoplatinum Compounds; Outpatients; Paclitaxel; Platinum Compounds; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
[A long-term survival case of local recurrence of breast cancer treated with combined modality therapy].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Docetaxel; Female; Humans; Lymph Node Excision; Mastectomy; Neoplasm Recurrence, Local; Paclitaxel; Tamoxifen; Taxoids; Tegafur; Trastuzumab; Uracil | 2010 |
Feasibility, toxicity, and efficacy of short induction chemotherapy of docetaxel plus cisplatin or carboplatin (TP) followed by concurrent chemoradio-therapy for organ preservation in advanced cancer of the hypopharynx, larynx, and base of tongue. Early r
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease Progression; Docetaxel; Feasibility Studies; Female; Follow-Up Studies; Humans; Hypopharyngeal Neoplasms; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Kaplan-Meier Estimate; Laryngeal Neoplasms; Leukopenia; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Neoplasm Staging; Opportunistic Infections; Paclitaxel; Positron-Emission Tomography; Radiodermatitis; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Salvage Therapy; Taxoids; Thrombocytopenia; Tomography, X-Ray Computed; Tongue Neoplasms; Treatment Outcome | 2011 |
Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biological Transport; Carboplatin; Docetaxel; Female; Gestational Age; Maternal-Fetal Exchange; Models, Animal; Paclitaxel; Papio; Placenta; Pregnancy; Pregnancy, Animal; Taxoids; Trastuzumab | 2010 |
Falls in persons with chemotherapy-induced peripheral neuropathy.
Topics: Accidental Falls; Antineoplastic Combined Chemotherapy Protocols; Causality; Comorbidity; Docetaxel; Female; Humans; Logistic Models; Male; Middle Aged; Muscle Weakness; Neoplasm Staging; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Population Surveillance; Postural Balance; Prospective Studies; Risk Factors; Sensation Disorders; Severity of Illness Index; Surveys and Questionnaires; Taxoids | 2012 |
Second-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
Efficient purification of paclitaxel from yews using high-performance displacement chromatography technique.
Topics: Acetic Acid; Antineoplastic Agents, Phytogenic; Chromatography, High Pressure Liquid; Docetaxel; Hydrophobic and Hydrophilic Interactions; Methanol; Paclitaxel; Plant Leaves; Taxoids; Taxus; Water | 2011 |
Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer.
Topics: Adenosine Triphosphate; Adult; Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Cell Line, Tumor; Cluster Analysis; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Profiling; HEK293 Cells; Humans; Kinesins; Middle Aged; Neoplasm Staging; Paclitaxel; Protein Binding; Taxoids; Vincristine | 2012 |
Paclitaxel-resistant recurrent gastric cancer responsive to docetaxel: a case report.
Topics: Antineoplastic Agents; Carcinoembryonic Antigen; Clinical Trials, Phase III as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Recurrence; Salvage Therapy; Stomach Neoplasms; Taxoids | 2011 |
Dermatopathologic effects of taxane therapy.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Biopsy; Breast Neoplasms; Bridged-Ring Compounds; Cell Cycle; Docetaxel; Female; Humans; Leiomyosarcoma; Male; Mitosis; Paclitaxel; Skin; Skin Diseases; Taxoids | 2011 |
Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Proto-Oncogene Proteins c-bcl-2; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Serum levels of MMP-11 correlate with clinical outcome in Chinese patients with advanced gastric adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; China; Disease Progression; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Humans; Male; Matrix Metalloproteinase 11; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Stomach Neoplasms; Taxoids; Treatment Outcome | 2011 |
Insights into the interaction of discodermolide and docetaxel with tubulin. Mapping the binding sites of microtubule-stabilizing agents by using an integrated NMR and computational approach.
Topics: Alkanes; Antineoplastic Agents; Binding Sites; Carbamates; Computer Simulation; Docetaxel; Humans; Lactones; Microtubules; Models, Molecular; Molecular Conformation; Nuclear Magnetic Resonance, Biomolecular; Paclitaxel; Protein Multimerization; Pyrones; Taxoids; Tubulin; Tubulin Modulators | 2011 |
Second-line chemotherapy in patients with primary unknown cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Failure; Treatment Outcome | 2011 |
Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-/-) mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow; Cytarabine; Docetaxel; Drug Resistance, Neoplasm; Female; Fibroblasts; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Multidrug Resistance-Associated Proteins; Paclitaxel; Taxoids; Vincristine | 2011 |
Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Codon; Deoxycytidine; DNA-Binding Proteins; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Survival Rate; Taxoids; Treatment Outcome; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2011 |
Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Risk Factors; Taxoids; Young Adult | 2011 |
Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Computer Simulation; Docetaxel; Drug Resistance, Neoplasm; Epothilones; Female; Gene Expression Profiling; Genetic Association Studies; Humans; Inhibitory Concentration 50; Middle Aged; Models, Biological; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Phenotype; Receptor, ErbB-2; Receptors, Estrogen; Taxoids; Tubulin Modulators | 2012 |
Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fluorouracil; Fulvestrant; Humans; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Paclitaxel; Random Allocation; Tamoxifen; Taxoids; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2011 |
Conversional synthesis and cytotoxic evaluation of novel taxoid analogs.
Topics: Alkaloids; Antineoplastic Agents; Diterpenes; Docetaxel; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Paclitaxel; Taxoids | 2011 |
Precise evaluation of chemotherapy-induced peripheral neuropathy using the visual analogue scale: a quantitative and comparative analysis of neuropathy occurring with paclitaxel-carboplatin and docetaxel-carboplatin therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Pain Measurement; Peripheral Nervous System Diseases; Surveys and Questionnaires; Taxoids | 2012 |
WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report.
Topics: Adjuvants, Immunologic; Biomarkers, Tumor; CA-125 Antigen; Cancer Vaccines; Carboplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cystadenocarcinoma, Serous; Docetaxel; Female; HLA-A Antigens; HLA-A24 Antigen; Humans; Immunotherapy, Active; Membrane Proteins; Middle Aged; Omentum; Ovarian Neoplasms; Paclitaxel; Peptide Fragments; Peritoneal Neoplasms; Taxoids; Tumor Burden; Vaccines, Subunit; WT1 Proteins | 2011 |
A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Docetaxel; Humans; Neoplasms; Paclitaxel; Ritonavir; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Taxoids | 2011 |
Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Humans; Intestinal Fistula; Intestinal Perforation; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Rectovaginal Fistula; Retrospective Studies; Taxoids; Treatment Outcome; Urinary Bladder Fistula; Vascular Endothelial Growth Factor A; Vinblastine; Vinorelbine | 2011 |
Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Taxoids; Trastuzumab | 2012 |
LC-ESI-MS/MS determination of paclitaxel on dried blood spots.
Topics: Animals; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Docetaxel; Dried Blood Spot Testing; Drug Stability; Limit of Detection; Linear Models; Paclitaxel; Rats; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Taxoids | 2012 |
Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20.
Topics: Antineoplastic Agents; Complement Activation; Docetaxel; Glycerol; Humans; Paclitaxel; Polysorbates; Surface-Active Agents; Taxoids | 2012 |
Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Asparaginase; Bayes Theorem; Data Mining; Docetaxel; Drug Hypersensitivity; Etoposide; Humans; Paclitaxel; Pharmacovigilance; Procarbazine; Prognosis; Taxoids; Teniposide; United States; United States Food and Drug Administration | 2011 |
The clinical utility of HER2-targeted therapy in the neoadjuvant setting: recent results from the San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Texas; Trastuzumab; Treatment Outcome | 2011 |
70-Gene classifier for differentiation between paclitaxel- and docetaxel-sensitive breast cancers.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Gene Expression Profiling; Humans; Ki-67 Antigen; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2012 |
Second-line chemotherapy for carboplatin/paclitaxel-refractory ovarian cancer: are multi-agent chemotherapies of little value truly?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2011 |
Short-term serum deprivation confers sensitivity to taxanes in platinum-resistant human ovarian cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Culture Media, Serum-Free; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Membrane Potential, Mitochondrial; Microscopy, Confocal; Microscopy, Electron; Ovarian Neoplasms; Paclitaxel; Taxoids | 2011 |
A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Retrospective Studies; Taxoids | 2011 |
Cross-sensitivity between taxanes in patients with breast cancer.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dexamethasone; Docetaxel; Drug Hypersensitivity; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Premedication; Retrospective Studies; Taxoids; Treatment Outcome | 2011 |
Taxane-based mono- or combination therapy for managing metastatic breast cancer (MBC) in routine practice: a multinational prospective observational study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Regression Analysis; Taxoids; Trastuzumab | 2012 |
Posttherapy nodal status, not graded histologic response, predicts survival after neoadjuvant chemotherapy for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Follow-Up Studies; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Time Factors | 2012 |
The cytotoxic effect of combined hyperthermia and taxane chemotherapy on ovarian cancer cells: results of an in vitro study.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cold Temperature; Combined Modality Therapy; Cystadenocarcinoma, Serous; Docetaxel; Female; Humans; Lethal Dose 50; Middle Aged; Ovarian Neoplasms; Paclitaxel; Taxoids | 2012 |
Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: a study in isogenic resistant tumor cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Survival; Cycloheximide; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; MCF-7 Cells; NF-kappa B; Ovarian Neoplasms; Paclitaxel; Protein Synthesis Inhibitors; Proteolysis; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Signal Transduction; Taxoids; Transcriptional Activation; Tumor Necrosis Factor-alpha | 2012 |
Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Combinations; Female; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, SCID; Paclitaxel; Taxoids; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Pennsylvania; Peripheral Nervous System Diseases; Self Care; Taxoids; Young Adult | 2012 |
[The role of nanotechnology in creating novel antitumor agents].
Topics: Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Design; Female; Humans; Liposomes; Nanoparticles; Nanostructures; Nanotechnology; Neoplasms; Paclitaxel; Tamoxifen; Taxoids | 2011 |
Salinomycin sensitizes antimitotic drugs-treated cancer cells by increasing apoptosis via the prevention of G2 arrest.
Topics: Antimitotic Agents; Apoptosis; Cell Line, Tumor; Colchicine; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; Docetaxel; Drug Resistance, Neoplasm; G2 Phase Cell Cycle Checkpoints; Humans; Paclitaxel; Pyrans; Taxoids; Vinblastine | 2012 |
The role of chemoradiotherapy in patients with unresectable T4 breast tumors.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemoradiotherapy; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Remission Induction; Survival Rate; Taxoids | 2013 |
The longitudinal relationship between fatigue and sleep in breast cancer patients undergoing chemotherapy.
Topics: Actigraphy; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Sectional Studies; Cyclophosphamide; Docetaxel; Doxorubicin; Fatigue; Female; Fluorouracil; Humans; Longitudinal Studies; Middle Aged; Paclitaxel; Prospective Studies; Sleep; Sleep Wake Disorders; Taxoids | 2012 |
Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cohort Studies; Costs and Cost Analysis; Cyclophosphamide; Databases, Factual; Docetaxel; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Health Care Costs; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Retrospective Studies; Risk Factors; Taxoids | 2012 |
Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Electromyography; Evoked Potentials, Motor; Female; Genital Neoplasms, Female; Humans; Longitudinal Studies; Middle Aged; Neural Conduction; Neurologic Examination; Paclitaxel; Peripheral Nerves; Peripheral Nervous System Diseases; Taxoids; Time Factors | 2012 |
Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Postoperative Care; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2012 |
[Support of hematological homeostasis during chemotherapy with taxanes].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caproates; Docetaxel; Female; Fever; Follow-Up Studies; Homeostasis; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Protective Agents; Severity of Illness Index; Stomach Neoplasms; Taxoids; Tongue Neoplasms | 2011 |
Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy.
Topics: Aged; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Human papillomavirus 16; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oropharyngeal Neoplasms; Paclitaxel; Panitumumab; Papillomavirus Infections; Proportional Hazards Models; Radiation Tolerance; Radiotherapy, Intensity-Modulated; Retrospective Studies; Taxoids; Treatment Failure | 2012 |
Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Mastectomy; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Predictive Value of Tests; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Vinblastine; Vinorelbine | 2012 |
Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer: results of a Moroccan observational institutional study.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Meta-Analysis as Topic; Middle Aged; Morocco; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids | 2012 |
Dual approach utilizing self microemulsifying technique and novel P-gp inhibitor for effective delivery of taxanes.
Topics: Acridines; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Docetaxel; Drug Delivery Systems; Drug Screening Assays, Antitumor; Humans; Paclitaxel; Solubility; Taxoids; Tetrahydroisoquinolines | 2012 |
Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclobutanes; Docetaxel; Drug Synergism; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Organoplatinum Compounds; Paclitaxel; Taxoids; Tubulin Modulators; Tumor Burden; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2012 |
Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Costs; Female; Humans; Markov Chains; Ovarian Neoplasms; Paclitaxel; Quality of Life; Taxoids; United States | 2012 |
Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Taxoids; Treatment Outcome; Young Adult | 2012 |
The impact of cross-resistance between paclitaxel and docetaxel for metastatic gastric cancer.
Topics: Aged; Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Japan; Male; Paclitaxel; Prevalence; Risk Assessment; Risk Factors; Stomach Neoplasms; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Novel hydrophilic taxane analogues inhibit growth of cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Cycle; Cell Proliferation; Docetaxel; Female; Flow Cytometry; Humans; Hydrophobic and Hydrophilic Interactions; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 2012 |
Isolation, identification, semi-synthesis of aziditaxel derivatives and their biological evaluation.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Paclitaxel; Taxoids | 2012 |
Telomere and microtubule targeting in treatment-sensitive and treatment-resistant human prostate cancer cells.
Topics: Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Male; Microtubules; Paclitaxel; Prostatic Neoplasms; Taxoids; Telomere; Treatment Outcome | 2012 |
Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Paclitaxel; Retrospective Studies; Smoking; Taxoids; Young Adult | 2012 |
Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Binding Sites; Biological Availability; Caco-2 Cells; Cell Line, Tumor; Colchicine; Docetaxel; Dogs; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Indoles; Male; Mice; Mice, Inbred ICR; Mice, Nude; Neoplasms; Paclitaxel; Polymerization; Rats; Rats, Sprague-Dawley; Taxoids; Tubulin; Tubulin Modulators | 2012 |
Polymeric nanoparticles containing taxanes enhance chemoradiotherapeutic efficacy in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chemoradiotherapy; Docetaxel; Drug Synergism; Endocytosis; Feasibility Studies; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Electron, Scanning; Nanoconjugates; Paclitaxel; Polymers; Radiation-Sensitizing Agents; Random Allocation; Taxoids; Xenograft Model Antitumor Assays | 2012 |
Platinum-based combination chemotherapy for the treatment of advanced-stage squamous cell carcinoma of the vulva.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; HIV; HIV Infections; Humans; Middle Aged; Paclitaxel; Remission Induction; Taxoids; Vulvar Neoplasms | 2012 |
Taste alteration in breast cancer patients treated with taxane chemotherapy: experience, effect, and coping strategies.
Topics: Adaptation, Psychological; Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Dysgeusia; Feeding and Eating Disorders; Female; Flavoring Agents; Humans; Interviews as Topic; Middle Aged; Paclitaxel; Qualitative Research; Spices; Taste; Taxoids; Young Adult | 2013 |
Normal serum CA125 half-life and normal serum nadir CA125 level in patients with ovarian cancers.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Etoposide; Female; Half-Life; Humans; Irinotecan; Linear Models; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Reference Values; Remission Induction; Taxoids | 2012 |
Self-assembled micelles of monosialogangliosides as nanodelivery vehicles for taxanes.
Topics: Antineoplastic Agents; Blood Platelets; Cells, Cultured; Docetaxel; Drug Carriers; Drug Stability; Erythrocytes; Gangliosides; Hemolysis; Humans; Micelles; Nanostructures; Paclitaxel; Platelet Aggregation; Solubility; Taxoids | 2012 |
Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Phosphatidylinositol 3-Kinases; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Stomach Neoplasms; Survival Rate; Taxoids; TOR Serine-Threonine Kinases; Vinblastine; Vinorelbine | 2012 |
ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Metastasis; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Receptor, ErbB-2; Receptors, IgG; Survival Rate; Taxoids; Trastuzumab | 2012 |
Comparative pharmacokinetic study of paclitaxel and docetaxel in streptozotocin-induced diabetic rats.
Topics: Administration, Intravenous; Administration, Oral; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Cytochrome P-450 CYP3A; Diabetes Mellitus, Experimental; Docetaxel; Intestinal Mucosa; Isoenzymes; Liver; Male; Paclitaxel; Rats; Rats, Sprague-Dawley; RNA, Messenger; Taxoids | 2012 |
[Sensitivity to chemotherapeutic drugs of polyploid tumor cells induced by a spindle poison nocodazole].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Fluorouracil; Gene Knockdown Techniques; Humans; Inhibitory Concentration 50; Nocodazole; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Polyploidy; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Small Interfering; Taxoids; Vincristine | 2012 |
A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Antineoplastic Agents; Carboxymethylcellulose Sodium; Cell Line, Tumor; Delayed-Action Preparations; Docetaxel; Female; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, SCID; Nanoparticles; Neoplasms; Paclitaxel; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Role of taxanes in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Radiotherapy; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
Cognitive function in women with breast cancer receiving adjuvant chemotherapy and healthy controls.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Cognition; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Neuropsychological Tests; Paclitaxel; Prognosis; Stress, Psychological; Taxoids | 2014 |
Association between polymorphisms of XRCC1 and ADPRT genes and ovarian cancer survival with platinum-based chemotherapy in Chinese population.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; China; Cisplatin; DNA-Binding Proteins; Docetaxel; Female; Genetic Association Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Mutation, Missense; Ovarian Neoplasms; Paclitaxel; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Polymorphism, Genetic; Prospective Studies; Risk; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1 | 2013 |
Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; HMGB1 Protein; Humans; Mucin-1; Neoadjuvant Therapy; Paclitaxel; Prognosis; Receptor for Advanced Glycation End Products; Taxoids; Trastuzumab | 2013 |
Characterization of the low pH/low nutrient-resistant LNCaP cell subline LNCaP-F10.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line, Tumor; Cell Proliferation; Death-Associated Protein Kinases; DNA Fragmentation; Docetaxel; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Hydrogen-Ion Concentration; Inhibitor of Apoptosis Proteins; Male; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Survivin; Taxoids; Transplantation, Heterologous | 2012 |
Efficacy of docetaxel in patients with paclitaxel-resistant advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Stomach Neoplasms; Taxoids | 2012 |
P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Docetaxel; Enzyme Inhibitors; Humans; Infusions, Intravenous; Intestinal Absorption; Male; Mice; Mice, Knockout; Paclitaxel; Ritonavir; Taxoids | 2013 |
Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Protein Structure, Tertiary; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Protein Array Analysis; Proteomics; Taxoids | 2013 |
Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Taxoids | 2013 |
Prognostic significance of GSTP1, XRCC1 and XRCC3 polymorphisms in non-small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Female; Gemcitabine; Genotype; Glutathione S-Transferase pi; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Prospective Studies; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1 | 2012 |
Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Cause of Death; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Female; Fever; Fluorouracil; Humans; Malaysia; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Risk Factors; Taxoids | 2012 |
Comparative transplacental transfer of taxanes using the human perfused cotyledon placental model.
Topics: Adult; Antineoplastic Agents; Docetaxel; Female; Humans; Maternal-Fetal Exchange; Neoplasms; Paclitaxel; Placenta; Pregnancy; Taxoids | 2012 |
Diagnostic validity of CT gastrography versus gastroscopy for primary lesions in gastric cancer: evaluating the response to chemotherapy, a retrospective analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Gastroscopy; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Prognosis; Retrospective Studies; Stomach Neoplasms; Taxoids; Tegafur; Tomography, X-Ray Computed; Validation Studies as Topic | 2013 |
Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy.
Topics: Analysis of Variance; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Contrast Media; Cyclophosphamide; Diastole; Docetaxel; Doxorubicin; Echocardiography; Echocardiography, Three-Dimensional; Female; Heart Ventricles; Humans; Middle Aged; Paclitaxel; Prospective Studies; Reproducibility of Results; Stroke Volume; Systole; Taxoids; Trastuzumab; Ventricular Function, Left | 2013 |
[A case report of liver metastasis of breast cancer successfully treated by hepatic arterial infusion of docetaxel and systemic administration of nab-paclitaxel].
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids | 2012 |
Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Blood Proteins; Carcinoma, Ovarian Epithelial; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Regulatory Networks; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Principal Component Analysis; ROC Curve; Taxoids; Transcriptome | 2012 |
Dynamic cost-effectiveness of oncology drugs.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cost-Benefit Analysis; Docetaxel; Humans; Medicare; Models, Statistical; Paclitaxel; Taxoids; United States | 2012 |
Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Follow-Up Studies; Humans; Keratin-19; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplastic Cells, Circulating; Paclitaxel; Prognosis; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Taxoids | 2013 |
Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Taxoids; Topotecan | 2013 |
Drug-initiated ring-opening polymerization of O-carboxyanhydrides for the preparation of anticancer drug-poly(O-carboxyanhydride) nanoconjugates.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Camptothecin; Docetaxel; Doxorubicin; Drug Delivery Systems; Female; Humans; Kinetics; MCF-7 Cells; Mice; Mice, Nude; Nanoconjugates; Paclitaxel; Particle Size; Polyesters; Polymerization; Serum Albumin; Taxoids | 2013 |
β-Elemene and taxanes synergistically induce cytotoxicity and inhibit proliferation in ovarian cancer and other tumor cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Synergism; Female; Humans; Ovarian Neoplasms; Paclitaxel; Sesquiterpenes; Taxoids | 2013 |
Breast-conserving surgery after tumor downstaging by neoadjuvant chemotherapy is oncologically safe for stage III breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Lymphatic Metastasis; Mastectomy, Segmental; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Survival Rate; Taxoids | 2013 |
Taxane-sensitivity of ovarian carcinomas previously treated with paclitaxel and carboplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Taxoids | 2013 |
Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Receptors, Calcitriol; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2013 |
Bioimaging real-time PXR-dependent mdr1a gene regulation in mdr1a.fLUC reporter mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Constitutive Androstane Receptor; Docetaxel; Fatty Acids, Monounsaturated; Gene Expression; Genes, Reporter; Humans; Image Processing, Computer-Assisted; Intestinal Mucosa; Ligands; Luciferases; Luminescent Proteins; Mice; Mice, Knockout; Paclitaxel; Pregnane X Receptor; Pyridines; Quaternary Ammonium Compounds; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Taxoids; Xenobiotics | 2013 |
Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Confidence Intervals; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Female; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Paclitaxel; Polymorphism, Single Nucleotide; Proportional Hazards Models; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2013 |
Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Docetaxel; Drug Monitoring; Female; Humans; Neoplasms; Paclitaxel; Pharmacogenetics; Precision Medicine; Taxoids | 2013 |
Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Survival; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2013 |
Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; SEER Program; Survival Analysis; Taxoids; Treatment Outcome; United States | 2013 |
Acute oesophageal toxicity related to paclitaxel-based concurrent chemoradiotherapy for non-small cell lung cancer.
Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Comorbidity; Deoxycytidine; Docetaxel; Esophageal Diseases; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Taxoids | 2013 |
New advances in taxane therapy: the next generation.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Humans; Paclitaxel; Polyglutamic Acid; Taxoids | 2004 |
[Analysis of drug therapy of lung cancer in Hungary].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Etoposide; Gemcitabine; Glutamates; Guanine; Humans; Hungary; Inpatients; Insurance, Health; Lung Neoplasms; Paclitaxel; Pemetrexed; Prescription Drugs; Quinazolines; Retrospective Studies; Taxoids; Topotecan | 2013 |
Development and characterization of stabilized double loaded mPEG-PDLLA micelles for simultaneous delivery of paclitaxel and docetaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Carriers; Drug Compounding; Drug Design; Drug Liberation; Drug Stability; Magnetic Resonance Spectroscopy; Micelles; Microscopy, Electron, Transmission; Paclitaxel; Particle Size; Polyesters; Polyethylene Glycols; Solubility; Surface Properties; Taxoids | 2014 |
Oxidative stress induced in rat liver by anticancer drugs doxorubicin, paclitaxel and docetaxel.
Topics: Animals; Antineoplastic Agents; Antioxidants; Body Weight; Catalase; Docetaxel; Doxorubicin; Liver; Male; Molecular Weight; Oxidative Stress; Paclitaxel; Rats; Rats, Wistar; Sulfhydryl Compounds; Superoxide Dismutase; Taxoids; Thiobarbituric Acid Reactive Substances | 2013 |
Predictive effect of XPA and XPD polymorphisms on survival of advanced NSCLC patients treated with platinum-based chemotherapy: a three-dimensional (3-D), polyacrylamide gel-based DNA microarray method.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prognosis; Survival Rate; Taxoids; Vinblastine; Vinorelbine; Xeroderma Pigmentosum Group A Protein; Xeroderma Pigmentosum Group D Protein | 2013 |
Hand-foot syndrome caused by docetaxel with no recurrence after switch to paclitaxel, a different taxane.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Female; Hand-Foot Syndrome; Humans; Middle Aged; Paclitaxel; Secondary Prevention; Taxoids | 2014 |
Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Cyclophosphamide; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Topotecan | 2013 |
Synthesis and biological evaluation of new paclitaxel analogs and discovery of potent antitumor agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Screening Assays, Antitumor; Halogenation; Humans; Models, Molecular; Neoplasms; Paclitaxel; Structure-Activity Relationship; Taxoids; Taxus | 2013 |
Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Middle Aged; Paclitaxel; Skin Diseases; Survival Rate; Taxoids | 2013 |
[Successful treatment with docetaxel and prednisolone for paxlitaxel and carboplatin-resistant prostate cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Paclitaxel; Prednisolone; Prostatic Neoplasms; Taxoids | 2013 |
Establishing the optimal nebulization system for paclitaxel, docetaxel, cisplatin, carboplatin and gemcitabine: back to drawing the residual cup.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Equipment Design; Gemcitabine; Nebulizers and Vaporizers; Paclitaxel; Taxoids | 2013 |
A patient with scirrhous stomach cancer treated with combination of hyperthermotherapy and 5-aminolevulinic acid (ALA).
Topics: Adenocarcinoma, Scirrhous; Adult; Aminolevulinic Acid; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Cisplatin; Combined Modality Therapy; Dichloroacetic Acid; Docetaxel; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hyperthermia, Induced; Irinotecan; Ovarian Neoplasms; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Photosensitizing Agents; Prognosis; Silicates; Stomach Neoplasms; Taxoids; Tegafur; Titanium | 2013 |
Mitochondrial-targeted prodrug cancer therapy using a rhodamine B labeled fluorinated docetaxel.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Hepatocellular; Docetaxel; Drug Delivery Systems; Fluorine; Hep G2 Cells; Humans; Liver Neoplasms; Microscopy, Fluorescence; Mitochondria; Optical Imaging; Paclitaxel; Prodrugs; Rhodamines; Taxoids; Time Factors | 2013 |
Differential effects of paclitaxel and docetaxel on gap junctions affects their cytotoxicities in transfected HeLa cells.
Topics: Antineoplastic Agents, Phytogenic; Cell Survival; Connexins; Docetaxel; Dose-Response Relationship, Drug; Gap Junction beta-1 Protein; Gap Junctions; Gene Expression; HeLa Cells; Humans; Paclitaxel; Taxoids; Transfection | 2013 |
Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Docetaxel; Female; Gemcitabine; Humans; Inhibitory Concentration 50; Neoplasms, Experimental; Paclitaxel; Pancreatic Neoplasms; Stathmin; Stromal Cells; Taxoids; Tubulin; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
New therapeutic strategies in the second line setting of advanced or metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Docetaxel; Erlotinib Hydrochloride; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Taxoids; Treatment Outcome | 2013 |
Caffeic acid phenethyl ester synergistically enhances docetaxel and paclitaxel cytotoxicity in prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Caffeic Acids; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Synergism; Estrogen Receptor alpha; Estrogen Receptor beta; Forkhead Box Protein O1; Forkhead Transcription Factors; Humans; Inhibitory Concentration 50; Male; Paclitaxel; Phenylethyl Alcohol; Prostatic Neoplasms; Taxoids | 2013 |
Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Databases, Factual; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oncology Nursing; Paclitaxel; Platinum Compounds; Randomized Controlled Trials as Topic; Southwestern United States; Taxoids; Tubulin Modulators; Vinblastine; Vinorelbine | 2013 |
DNA microarray reveals different pathways responding to paclitaxel and docetaxel in non-small cell lung cancer cell line.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Gene Expression; Humans; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Paclitaxel; Real-Time Polymerase Chain Reaction; Signal Transduction; Taxoids | 2013 |
Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Paclitaxel; Pennsylvania; Peripheral Nervous System Diseases; Retrospective Studies; Taxoids | 2013 |
Synthesis and anti-HBV activity of novel 3'-N-phenylsulfonyl docetaxel analogs.
Topics: Antiviral Agents; Docetaxel; Drug Evaluation, Preclinical; Hep G2 Cells; Hepatitis B virus; Humans; Paclitaxel; Structure-Activity Relationship; Sulfones; Taxoids | 2013 |
Cost comparison and economic implications of commonly used originator and generic chemotherapy drugs in India.
Topics: Camptothecin; Cost Savings; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Drugs, Generic; Gemcitabine; Humans; India; Irinotecan; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Poverty; Taxoids | 2013 |
Combined quantification of paclitaxel, docetaxel and ritonavir in human feces and urine using LC-MS/MS.
Topics: Chromatography, High Pressure Liquid; Docetaxel; Drug Stability; Feces; Humans; Paclitaxel; Reproducibility of Results; Ritonavir; Tandem Mass Spectrometry; Taxoids | 2014 |
Targeted therapies for locally advanced or metastatic squamous cell carcinoma of the lung.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Deoxycytidine; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; SOXB1 Transcription Factors; Survival Analysis; Taxoids; Treatment Outcome; Tumor Suppressor Protein p53 | 2013 |
Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cisplatin; Disulfiram; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Neoplastic Stem Cells; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2013 |
Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Recurrence; Survival Analysis; Taxoids | 2013 |
Treatment of agarose-agarose RENCA macrobeads with docetaxel selects for OCT4(+) cells with tumor-initiating capability.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Kidney Neoplasms; Mice, Inbred BALB C; Neoplastic Stem Cells; Octamer Transcription Factor-3; Paclitaxel; Sepharose; Taxoids | 2013 |
Comparison of carboplatin-paclitaxel to docetaxel-cisplatin-5-flurouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Retrospective Studies; Taxoids | 2014 |
Microtubule-stabilizing agents delay the onset of EAE through inhibition of migration.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Bridged Bicyclo Compounds, Heterocyclic; Cell Movement; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Disease Progression; Docetaxel; Drug Synergism; Encephalomyelitis, Autoimmune, Experimental; Epothilones; Growth Inhibitors; Humans; Lactones; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microtubules; Multiple Sclerosis; Paclitaxel; Taxoids | 2013 |
ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Ifosfamide; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2013 |
First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimization analysis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Drug Costs; Female; France; Hospital Costs; Hospitals, Private; Hospitals, University; Humans; Kaplan-Meier Estimate; Middle Aged; National Health Programs; Neoplasm Metastasis; Paclitaxel; Public Sector; Retrospective Studies; Taxoids; Time Factors; Transportation; Trastuzumab; Treatment Outcome | 2014 |
Sequential chemotherapies for advanced gastric cancer: a retrospective analysis of 111 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Germany; Hospitals, University; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Taxoids; Treatment Outcome | 2013 |
Design, synthesis and cytotoxicity of novel 3'-N-alkoxycarbonyl docetaxel analogs.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Design; Humans; Paclitaxel; Stereoisomerism; Structure-Activity Relationship; Taxoids | 2013 |
Rapid and sensitive liquid chromatography coupled with electrospray ionization tandem mass spectrometry method for the analysis of paclitaxel, docetaxel, vinblastine, and vinorelbine in human plasma.
Topics: Antineoplastic Agents; Calibration; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Docetaxel; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Taxoids; Vinblastine; Vinorelbine | 2014 |
Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Giant Cell Tumors; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Sarcoma; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2013 |
[A case of paclitaxel-resistant recurrent gastric cancer responsive to S-1 plus docetaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Recurrence; Stomach Neoplasms; Taxoids; Tegafur | 2013 |
Biological evaluation of new antitumor taxoids: alteration of substitution at the C-7 and C-10 of docetaxel.
Topics: Antineoplastic Agents; Biological Assay; Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; Molecular Conformation; Molecular Structure; Paclitaxel; Taxoids | 2014 |
Direct glycosylation of bioactive small molecules with glycosyl iodide and strained olefin as acid scavenger.
Topics: Alkenes; Benzimidazoles; Docetaxel; Glycosides; Glycosylation; Iodides; Paclitaxel; Stereoisomerism; Taxoids | 2014 |
Development of taxane-containing chemotherapy of doxorubicin-resistant diffuse large B-cell lymphoma.
Topics: Antineoplastic Agents; Apoptosis; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Humans; Lymphoma, Large B-Cell, Diffuse; Paclitaxel; Taxoids; Tumor Cells, Cultured | 2014 |
Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Folic Acid; HeLa Cells; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Nude; Neoplasms; Neoplasms, Experimental; Paclitaxel; Taxoids; Topotecan; Treatment Outcome; Vinca Alkaloids; Xenograft Model Antitumor Assays | 2014 |
Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; M Phase Cell Cycle Checkpoints; MCF-7 Cells; Microtubules; Paclitaxel; Protein Isoforms; Taxoids; Time Factors; Tubulin; Tubulin Modulators | 2014 |
Efficacy and safety of Trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients.
Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Letrozole; Meta-Analysis as Topic; Nitriles; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab; Triazoles | 2013 |
Individual xenograft as a personalized therapeutic resort for women with metastatic triple-negative breast carcinoma.
Topics: Adult; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Mammary Neoplasms, Animal; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Paclitaxel; Taxoids; Transplantation, Heterologous; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
Genomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Genotype; Humans; Leukocytes, Mononuclear; Lung Neoplasms; Male; Middle Aged; Nucleoside Transport Proteins; Paclitaxel; Polymorphism, Single Nucleotide; Proportional Hazards Models; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2014 |
[Salvage therapy for castration-refractory prostate cancer resistant to docetaxel].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Drug Combinations; Drug Resistance, Neoplasm; Etoposide; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Prostatic Neoplasms, Castration-Resistant; Salvage Therapy; Streptonigrin; Taxoids; Tegafur; Uracil | 2013 |
Silicate esters of paclitaxel and docetaxel: synthesis, hydrophobicity, hydrolytic stability, cytotoxicity, and prodrug potential.
Topics: Antineoplastic Agents, Phytogenic; Cell Line; Cell Survival; Coloring Agents; Docetaxel; Drug Delivery Systems; Drug Design; Humans; Hydrolysis; Hydrophobic and Hydrophilic Interactions; Indicators and Reagents; Kinetics; Models, Molecular; Molecular Conformation; Nanoparticles; Paclitaxel; Prodrugs; Silicates; Taxoids; Tetrazolium Salts; Thiazoles | 2014 |
microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Docetaxel; Down-Regulation; Doxorubicin; Epirubicin; ErbB Receptors; Female; Fluorouracil; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Keratin-5; Keratin-6; Methotrexate; MicroRNAs; Middle Aged; Oligonucleotide Array Sequence Analysis; Paclitaxel; Prognosis; Risk Assessment; Survival Rate; Taxoids; Triple Negative Breast Neoplasms; Up-Regulation | 2014 |
Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Hospitalization; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Registries; Retrospective Studies; Survival Rate; Taxoids; United States; United States Department of Veterans Affairs; Vinblastine; Vinorelbine | 2014 |
[Fragmentation behaviors of taxanes drugs using electrospray ionization with quadrupole time-of-flight mass spectrometry].
Topics: Docetaxel; Paclitaxel; Peptide Fragments; Spectrometry, Mass, Electrospray Ionization; Taxoids | 2013 |
Introduction: why a supplement on taxanes?
Topics: Antineoplastic Agents; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 2014 |
Ecological momentary assessment of sleep, symptoms, and mood during chemotherapy for breast cancer.
Topics: Adult; Affect; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Breast Neoplasms; Cohort Studies; Computers, Handheld; Cyclophosphamide; Data Collection; Depression; Docetaxel; Doxorubicin; Fatigue; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Sleep; Taxoids | 2014 |
Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel.
Topics: Adult; Docetaxel; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Humans; Neoplasms; Paclitaxel; Pregnancy; Taxoids | 2014 |
Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; DNA Glycosylases; DNA-(Apurinic or Apyrimidinic Site) Lyase; DNA-Binding Proteins; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Survival Rate; Taxoids; X-ray Repair Cross Complementing Protein 1 | 2014 |
Influence of drug formulation on OATP1B-mediated transport of paclitaxel.
Topics: Animals; Antineoplastic Agents; Biological Transport; Bridged-Ring Compounds; Cell Line; Chemistry, Pharmaceutical; CHO Cells; Cricetulus; Docetaxel; Drug Interactions; HEK293 Cells; Humans; Liver; Liver-Specific Organic Anion Transporter 1; Mice; Mice, Inbred DBA; Mice, Knockout; Oocytes; Organic Anion Transporters; Paclitaxel; Taxoids; Tissue Distribution; Xenopus laevis | 2014 |
Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation.
Topics: Acridines; Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain; Docetaxel; Humans; Male; Mice; Mice, Knockout; Paclitaxel; Ritonavir; Taxoids; Tetrahydroisoquinolines; Tissue Distribution | 2014 |
In vitro chemoresponse assay based on the intrinsic subtypes in breast cancer.
Topics: Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; In Vitro Techniques; Ki-67 Antigen; Mastectomy; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2014 |
Evaluation of the Semmes-Weinstein filaments and a questionnaire to assess chemotherapy-induced peripheral neuropathy.
Topics: Adult; Antineoplastic Agents; Brazil; Cross-Sectional Studies; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Psychometrics; Severity of Illness Index; Surveys and Questionnaires; Taxoids | 2014 |
Chemoradiotherapy with taxane is superior to conventional surgery and radiotherapy in the management of cutaneous angiosarcoma: a multicentre, retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Chemoradiotherapy; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Scalp; Skin Neoplasms; Taxoids; Treatment Outcome | 2014 |
Cost-effectiveness analysis of docetaxel versus weekly paclitaxel in adjuvant treatment of regional breast cancer in New Zealand.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Docetaxel; Drug Administration Schedule; Female; Health Care Costs; Humans; Markov Chains; Monte Carlo Method; Neoplasm Staging; New Zealand; Paclitaxel; Quality-Adjusted Life Years; Survival Analysis; Taxoids | 2014 |
Relationship between chemotherapy and prognosis in different subtypes of node-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids; Treatment Outcome; Young Adult | 2014 |
Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hospitalization; Humans; Logistic Models; Medicare; Middle Aged; Neoplasm Staging; Paclitaxel; Registries; Risk Assessment; Risk Factors; SEER Program; Selection Bias; Taxoids; Texas; United States | 2014 |
Association of ABCB1, β tubulin I, and III with multidrug resistance of MCF7/DOC subline from breast cancer cell line MCF7.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Blotting, Western; Breast Neoplasms; Cell Proliferation; Cell Survival; Docetaxel; Doxorubicin; Drug Resistance, Multiple; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; MCF-7 Cells; Methotrexate; Multidrug Resistance-Associated Protein 2; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Taxoids; Tubulin | 2014 |
Abcc10 status affects mammary tumour growth, metastasis, and docetaxel treatment response.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Mice, Knockout; Mice, SCID; Multidrug Resistance-Associated Proteins; Neoplasm Transplantation; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Taxoids; Tissue Array Analysis; Tumor Burden | 2014 |
Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Thoracic Neoplasms | 2014 |
Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational Aurora A kinase inhibitor MLN8237 (alisertib).
Topics: Animals; Antineoplastic Agents; Area Under Curve; Aurora Kinase A; Azepines; Cell Line, Tumor; Docetaxel; Drug Administration Schedule; Female; Humans; Mice; Mice, Inbred BALB C; Mice, SCID; Neoplasm Transplantation; Neoplasms, Experimental; Paclitaxel; Pyrimidines; Taxoids; Translational Research, Biomedical | 2014 |
Efficacy of taxane-based regimens in a first-line setting for recurrent and/or metastatic Chinese patients with esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Taxoids | 2014 |
The quest for a simple bioactive analog of paclitaxel as a potential anticancer agent.
Topics: Antineoplastic Agents; Binding Sites; Docetaxel; Paclitaxel; Protein Binding; Taxoids; Thermodynamics; Tubulin; Water | 2014 |
Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mexico; Middle Aged; Paclitaxel; Patient Selection; Taxoids; Treatment Outcome | 2014 |
Dendrimer-TPGS mixed micelles for enhanced solubility and cellular toxicity of taxanes.
Topics: Animals; Cell Death; Cell Line; Cell Survival; Dendrimers; Docetaxel; Hemolysis; Humans; Hydrogen-Ion Concentration; Micelles; Paclitaxel; Particle Size; Polyethylene Glycols; Rats; Solubility; Spectroscopy, Fourier Transform Infrared; Static Electricity; Taxoids; Vitamin E; X-Ray Diffraction | 2014 |
Second-line treatment for pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Leucovorin; Metformin; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2014 |
Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Heterozygote; Humans; Lung Neoplasms; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Polymorphism, Genetic; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2014 |
Drug selection and dosing in pregnant cancer patients: insights from clinical pharmacokinetics.
Topics: Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Neoplasms; Paclitaxel; Pregnancy; Taxoids | 2014 |
Outcomes of immediate perforator flap reconstruction after skin-sparing mastectomy following neoadjuvant chemotherapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Docetaxel; Epirubicin; Etoposide; Female; Fluorouracil; Humans; Mammaplasty; Mastectomy, Subcutaneous; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Perforator Flap; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2015 |
A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Platinum; Prognosis; Pyrimidines; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2014 |
Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Comparative Genomic Hybridization; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression; Humans; Inhibitory Concentration 50; Paclitaxel; Taxoids | 2014 |
Mixed molecular weight copolymer nanoparticles for the treatment of drug-resistant tumors: formulation development and cytotoxicity.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Bridged-Ring Compounds; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Delayed-Action Preparations; Docetaxel; Drug Carriers; Drug Resistance, Neoplasm; Humans; Micelles; Molecular Weight; Nanoparticles; Paclitaxel; Particle Size; Polyesters; Polyethylene Glycols; Polymers; Taxoids | 2014 |
ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer.
Topics: Adenocarcinoma, Clear Cell; Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Ifosfamide; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Predictive Value of Tests; Sensitivity and Specificity; Taxoids | 2014 |
Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design.
Topics: Aged; Clinical Trials, Phase II as Topic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Paclitaxel; Piperidines; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome; Urologic Neoplasms; Urothelium | 2015 |
Protein kinase A type II-α regulatory subunit regulates the response of prostate cancer cells to taxane treatment.
Topics: Bridged-Ring Compounds; Cell Line, Tumor; Cyclic AMP-Dependent Protein Kinases; Docetaxel; Humans; Male; Paclitaxel; Prostatic Neoplasms; Protein Kinase Inhibitors; Taxoids | 2014 |
SNPs and taxane toxicity in breast cancer patients.
Topics: Aged; Breast Neoplasms; Bridged-Ring Compounds; Cytochrome P-450 CYP3A; DNA-Binding Proteins; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Endonucleases; Female; Genetic Association Studies; Humans; Middle Aged; Mucositis; Paclitaxel; Polymorphism, Single Nucleotide; Taxoids | 2014 |
Nedaplatin or oxaliplatin combined with paclitaxel and docetaxel as first-line treatment for patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Retrospective Studies; Taxoids | 2014 |
Safety of spinal radiotherapy in metastatic cancer patients receiving bevacizumab therapy: a bi-institutional case series.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Combined Modality Therapy; Docetaxel; Female; Humans; Male; Middle Aged; Paclitaxel; Retrospective Studies; Spinal Cord Neoplasms; Spine; Taxoids | 2015 |
C6 ceramide dramatically enhances docetaxel-induced growth inhibition and apoptosis in cultured breast cancer cells: a mechanism study.
Topics: Adenylate Kinase; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Survival; Ceramides; Cisplatin; Docetaxel; Drug Synergism; ErbB Receptors; Female; HEK293 Cells; Humans; Hydroxamic Acids; MAP Kinase Kinase 4; MCF-7 Cells; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Paclitaxel; Proteolysis; Taxoids; TOR Serine-Threonine Kinases; Vorinostat | 2015 |
Population-based assessment of emergency room visits and hospitalizations among women receiving adjuvant chemotherapy for early breast cancer.
Topics: Adult; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Emergency Service, Hospital; Female; Hospitalization; Humans; Middle Aged; Ontario; Paclitaxel; Retrospective Studies; Taxoids | 2015 |
Ramucirumab combination improves OS and PFS in NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Therapy, Combination; Humans; Lung Neoplasms; Paclitaxel; Ramucirumab; Stomach Neoplasms; Survival Analysis; Taxoids | 2014 |
Simultaneous determination of seven taxoids in rat plasma by UPLC-MS/MS and pharmacokinetic study after oral administration of Taxus yunnanensis extracts.
Topics: Administration, Oral; Alkaloids; Animals; Bridged-Ring Compounds; Chromatography, High Pressure Liquid; Docetaxel; Male; Methyl Ethers; Paclitaxel; Plant Extracts; Plasma; Rats; Rats, Sprague-Dawley; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Taxoids; Taxus | 2015 |
Predictive role of neutrophil gelatinase-associated lipocalin in early diagnosis of platin-induced renal injury.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carboplatin; Cisplatin; Creatinine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lipocalin-2; Lipocalins; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Proto-Oncogene Proteins; Taxoids | 2015 |
RB1 polymorphism contributes to the efficacy of platinum-taxanes in advanced squamous cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Retinoblastoma Protein; Survival Rate; Taxoids; Young Adult | 2015 |
Efficacy of dose dense doxorubicin and cyclophosphamide followed by paclitaxel versus conventional dose doxorubicin, cyclophosphamide followed by paclitaxel or docetaxel in patients with node-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2015 |
Combination chemotherapy with S-1 and docetaxel for cutaneous angiosarcoma resistant to paclitaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Drug Resistance, Neoplasm; Female; Hemangiosarcoma; Humans; Oxonic Acid; Paclitaxel; Skin Neoplasms; Taxoids; Tegafur | 2015 |
[Safe treatment of lung squamous cell carcinoma with nanoparticle albumin-bound Paclitaxel in a patient with a previous hypersensitivity reaction after docetaxel administration].
Topics: Albumins; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Drug Hypersensitivity; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 2015 |
Genome-wide association study of myelosuppression in non-small-cell lung cancer patients with platinum-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Blood Platelets; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Genome-Wide Association Study; Hemoglobins; Humans; Leukocytes; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Taxoids; Vinblastine; Vinorelbine | 2016 |
Long term HER2+ metastatic breast cancer survivors treated by trastuzumab: Results from the French cohort study LHORA.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; France; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Retrospective Studies; Survivors; Taxoids; Trastuzumab | 2015 |
Homology modelling and molecular docking of MDR1 with chemotherapeutic agents in non-small cell lung cancer.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Binding Sites; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Mice; Molecular Docking Simulation; Molecular Sequence Data; Paclitaxel; Sequence Alignment; Structural Homology, Protein; Taxoids; Thermodynamics | 2015 |
Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in Non-Small-Cell Lung Cancer: Findings From the Florida Initiative for Quality Cancer Care.
Topics: Academic Medical Centers; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Florida; Gemcitabine; Humans; Lung Neoplasms; Male; Medical Audit; Middle Aged; Paclitaxel; Pneumonectomy; Practice Patterns, Physicians'; Quality of Health Care; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2015 |
Elucidating the mechanism of action of the clinically approved taxanes: a comprehensive comparison of local and allosteric effects.
Topics: Allosteric Site; Docetaxel; Humans; Microtubules; Molecular Docking Simulation; Molecular Dynamics Simulation; Paclitaxel; Protein Multimerization; Protein Structure, Secondary; Taxoids; Tubulin; Tubulin Modulators | 2015 |
Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adenosine Triphosphatases; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cation Transport Proteins; Cisplatin; Copper-Transporting ATPases; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutathione S-Transferase pi; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1 | 2015 |
Designing and Testing of Novel Taxanes to Probe the Highly Complex Mechanisms by Which Taxanes Bind to Microtubules and Cause Cytotoxicity to Cancer Cells.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Blotting, Western; Cell Death; Cell Line, Tumor; Docetaxel; Drug Design; Humans; Inhibitory Concentration 50; Microtubules; Molecular Docking Simulation; Paclitaxel; Permeability; Polymerization; Taxoids; Thermodynamics; Tubulin | 2015 |
Peloruside A Inhibits Growth of Human Lung and Breast Tumor Xenografts in an Athymic nu/nu Mouse Model.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Proliferation; Docetaxel; Female; Humans; Inhibitory Concentration 50; Lactones; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/Intergroup study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Humans; Kaplan-Meier Estimate; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Taxoids | 2015 |
Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemoradiotherapy; Chemotherapy, Adjuvant; Cross-Sectional Studies; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Letrozole; Middle Aged; Nitriles; Paclitaxel; Receptor, ErbB-2; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2015 |
Circulating endothelial cells for evaluation of tumor response in non-small cell lung cancer patients receiving first-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Endothelial Cells; Etoposide; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Paclitaxel; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Innovative use of the taxol binding peptide overcomes key challenges of stable and high drug loading in polymeric nanomicelles.
Topics: Amino Acid Sequence; Antineoplastic Agents; Binding Sites; Bridged-Ring Compounds; Cell Line, Tumor; Docetaxel; Drug Carriers; Drug Delivery Systems; Humans; Micelles; Molecular Sequence Data; Neoplasms; Paclitaxel; Peptides; Polyethylene Glycols; Taxoids | 2015 |
Retrospective analysis of second-line chemotherapy outcomes with paclitaxel or docetaxel in correlation with STMN1 polymorphism in advanced non-small cell lung cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Retrospective Studies; Stathmin; Taxoids; Treatment Outcome | 2016 |
Effects of Chemotherapy Regimen and Radiation Modality on Hematologic Toxicities in Patients Receiving Definitive Platinum-based Doublet Chemoradiation for Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Etoposide; Female; Hemoglobins; Humans; Leukopenia; Logistic Models; Lung Neoplasms; Lymphopenia; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neutropenia; Paclitaxel; Proportional Hazards Models; Radiation Injuries; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retrospective Studies; Severity of Illness Index; Survival Rate; Taxoids; Thrombocytopenia | 2017 |
Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials, Phase II as Topic; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Multivariate Analysis; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Risk Factors; Salvage Therapy; Taxoids; Time Factors; Treatment Outcome; Urologic Neoplasms; Urothelium | 2016 |
Stemness and chemotherapeutic drug resistance induced by EIF5A2 overexpression in esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Eukaryotic Translation Initiation Factor 5A; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Neoplastic Stem Cells; Paclitaxel; Peptide Initiation Factors; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; Taxoids | 2015 |
Anaplastic Thyroid Carcinoma, Version 2.2015.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Doxorubicin; Humans; Paclitaxel; Radiotherapy, Intensity-Modulated; Taxoids; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Thyroidectomy | 2015 |
Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Time Factors; Topotecan | 2015 |
Neoadjuvant Chemotherapy in Technically Unresectable Oral Cancers: Does Human Papillomavirus Make a Difference?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Docetaxel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mouth Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Papillomaviridae; Papillomavirus Infections; Prognosis; Survival Rate; Taxoids; Young Adult | 2015 |
[Efficacy and safety analysis of paclitaxel liposome and docetaxel for the neoadjuvant chemotherapy of breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Liposomes; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 2015 |
Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Docetaxel; ErbB Receptors; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Philadelphia; Proportional Hazards Models; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2015 |
SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Azepines; Azocines; Benzhydryl Compounds; Camptothecin; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Paclitaxel; Signal Transduction; Taxoids; Time Factors; Topoisomerase Inhibitors; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
The α7-nicotinic acetylcholine receptor mediates the sensitivity of gastric cancer cells to taxanes.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Humans; Nicotinic Agonists; Nicotinic Antagonists; Paclitaxel; RNA, Small Interfering; Signal Transduction; Stomach Neoplasms; Taxoids | 2016 |
Predictive factors for survival and correlation to toxicity in advanced Stage III non-small cell lung cancer patients with concurrent chemoradiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Radiation Injuries; Radiotherapy, Conformal; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Concentration-dependent radiosensitizing effect of docetaxel in esophageal squamous cell carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Cycle Checkpoints; Cell Division; Cell Line, Tumor; DNA Breaks, Double-Stranded; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Paclitaxel; Radiation Tolerance; Radiation-Sensitizing Agents; Taxoids | 2016 |
Nobiletin enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cancer cells.
Topics: Adsorption; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Cell Cycle; Cell Line, Tumor; Docetaxel; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Flavones; Fluorouracil; Humans; Intracellular Space; Models, Biological; Molecular Docking Simulation; Paclitaxel; Rhodamine 123; Signal Transduction; Taxoids; Treatment Outcome | 2015 |
Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Desensitization, Immunologic; Docetaxel; Drug Hypersensitivity; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Retrospective Studies; Risk Assessment; Severity of Illness Index; Skin Tests; Taxoids; Treatment Outcome | 2016 |
Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Retrospective Studies; Taxoids | 2016 |
Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for the treatment of primary peritoneal serous carcinoma: Results of a Chinese retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; China; Cisplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Docetaxel; Female; Humans; Hyperthermia, Induced; Kaplan-Meier Estimate; Middle Aged; Mitomycin; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Taxoids | 2016 |
Preparation of HIFU-triggered tumor-targeted hyaluronic acid micelles for controlled drug release and enhanced cellular uptake.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Coumarins; Delayed-Action Preparations; Docetaxel; Drug Compounding; Drug Delivery Systems; Drug Liberation; Endocytosis; Fluorescent Dyes; Humans; Hyaluronan Receptors; Hyaluronic Acid; Kinetics; Micelles; Paclitaxel; Polyethylene Glycols; Taxoids; Ultrasonic Waves | 2016 |
Effects of Cinnamon (C. zeylanicum) Bark Oil Against Taxanes-Induced Damages in Sperm Quality, Testicular and Epididymal Oxidant/Antioxidant Balance, Testicular Apoptosis, and Sperm DNA Integrity.
Topics: Animals; Antioxidants; Apoptosis; Biomarkers; Cinnamomum zeylanicum; DNA Fragmentation; Docetaxel; Epididymis; Male; Oils, Volatile; Oxidative Stress; Paclitaxel; Protective Agents; Rats, Wistar; Spermatozoa; Taxoids; Testis; Testosterone | 2016 |
Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Anti-malarial Drugs Primaquine and Chloroquine Have Different Sensitization Effects with Anti-mitotic Drugs in Resistant Cancer Cells.
Topics: Antimalarials; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Chloroquine; Docetaxel; Drug Resistance, Neoplasm; Humans; Mitosis; Paclitaxel; Primaquine; Taxoids; Vinblastine; Vinorelbine | 2016 |
Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
ERCC1 Expression Can Predict Response to Platinum-Based Induction Chemotherapy in Head and Neck Cancer Cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cisplatin; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Real-Time Polymerase Chain Reaction; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Taxoids | 2016 |
Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Docetaxel; Fallopian Tube Neoplasms; Female; Guideline Adherence; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Taxoids | 2016 |
Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Recurrence; Taxoids; Trastuzumab; Treatment Outcome | 2016 |
Natural history of postural instability in breast cancer patients treated with taxane-based chemotherapy: A pilot study.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Male; Middle Aged; Paclitaxel; Pilot Projects; Postural Balance; Taxoids | 2016 |
Ferrocenyl Paclitaxel and Docetaxel Derivatives: Impact of an Organometallic Moiety on the Mode of Action of Taxanes.
Topics: Cell Cycle; Docetaxel; Humans; Molecular Docking Simulation; Organometallic Compounds; Paclitaxel; Taxoids; Tubulin | 2016 |
Safe administration of docetaxel after weekly paclitaxel-induced acute pancreatitis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pancreatitis; Taxoids | 2017 |
Influence of Chemotherapy on the Antioxidant Status of Human Skin.
Topics: Adult; Aged; Antineoplastic Agents; Antioxidants; Carotenoids; Docetaxel; Doxorubicin; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Skin; Taxoids | 2016 |
Pharmaceutical development of an oral tablet formulation containing a spray dried amorphous solid dispersion of docetaxel or paclitaxel.
Topics: Docetaxel; Drug Compounding; Drug Liberation; Drug Stability; Ethanol; Paclitaxel; Powders; Solubility; Tablets; Taxoids; tert-Butyl Alcohol; Water | 2016 |
Myelosuppression by chemotherapy in obese patients with gynecological cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Female; Genital Neoplasms, Female; Hematologic Diseases; Humans; Ideal Body Weight; Japan; Middle Aged; Obesity; Paclitaxel; Retrospective Studies; Taxoids; Thinness; Young Adult | 2016 |
Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Capecitabine; Chemoradiotherapy; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gastrectomy; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2016 |
Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Taxoids; Tumor Burden | 2016 |
The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Taxoids | 2016 |
Rates of major complications during neoadjuvant and adjuvant chemotherapy for early breast cancer: An off study population.
Topics: Acute Coronary Syndrome; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy-Induced Febrile Neutropenia; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Incidence; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pulmonary Embolism; Retrospective Studies; Risk Factors; Sentinel Lymph Node Biopsy; Stroke; Taxoids; Thromboembolism; Venous Thrombosis | 2016 |
[Second-line treatment for metastatic or locally advanced gastric cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Humans; Irinotecan; Molecular Targeted Therapy; Paclitaxel; Ramucirumab; Salvage Therapy; Stomach Neoplasms; Taxoids | 2016 |
Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Ductal, Breast; Combined Modality Therapy; Docetaxel; Drug Interactions; Female; Humans; Paclitaxel; Taxoids; Time Factors; Trastuzumab | 2017 |
Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Methotrexate; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Paclitaxel; Prognosis; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Taxoids; Treatment Outcome; Young Adult | 2017 |
Designing geriatric-specific trials in advanced lung cancer: What, who and how to study?
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Paclitaxel; Vinorelbine | 2017 |
Targeting Taxanes to Castration-Resistant Prostate Cancer Cells by Nanobubbles and Extracorporeal Shock Waves.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Movement; Chitosan; Docetaxel; Drug Carriers; Drug Liberation; High-Energy Shock Waves; Humans; Male; Nanostructures; Paclitaxel; Particle Size; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2016 |
Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Drug Resistance, Neoplasm; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Polyethylene Glycols; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2017 |
Paclitaxel-resistant cancer cell-derived secretomes elicit ABCB1-associated docetaxel cross-resistance and escape from apoptosis through FOXO3a-driven glycolytic regulation.
Topics: Adenosine Triphosphate; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Cell-Derived Microparticles; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Forkhead Box Protein O3; Gene Silencing; Glucose; Glycolysis; Humans; Interferon-alpha; Interferons; Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-akt; RNA Interference; Secretory Vesicles; Signal Transduction; Taxoids; TNF-Related Apoptosis-Inducing Ligand | 2017 |
Microtubule stabilisers docetaxel and paclitaxel reduce spindle damage and maintain the developmental competence of in vitro-mature bovine oocytes during vitrification.
Topics: Animals; Cattle; Cell Nucleus; Cryopreservation; Docetaxel; Female; In Vitro Oocyte Maturation Techniques; Oocytes; Paclitaxel; Spindle Apparatus; Taxoids; Tubulin Modulators; Vitrification | 2017 |
ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.
Topics: Adenocarcinoma; Ado-Trastuzumab Emtansine; Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Dosage; Genes, erbB-2; Humans; Lung Neoplasms; Male; Maytansine; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Quinazolines; Retrospective Studies; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2017 |
Application of sequential factorial design and orthogonal array composite design (OACD) to study combination of 5 prostate cancer drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Cell Line, Tumor; Cisplatin; Docetaxel; Doxorubicin; Drug Interactions; Humans; Male; Models, Statistical; Paclitaxel; Prostatic Neoplasms; Regression Analysis; Taxoids | 2017 |
Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Paclitaxel; Proportional Hazards Models; Receptor, ErbB-2; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome | 2017 |
Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; Inflammation Mediators; Interleukin-6; Interleukin-8; Isothiocyanates; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; NF-kappa B p52 Subunit; Paclitaxel; Phenotype; Signal Transduction; Sulfoxides; Taxoids; Time Factors; Transcription Factor RelA; Transcription, Genetic; Transfection; Triple Negative Breast Neoplasms; Tubulin Modulators; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Personalized chemotherapy selection for breast cancer using gene expression profiles.
Topics: Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Therapy; Female; Humans; Male; Models, Biological; Paclitaxel; Precision Medicine; Taxoids; Transcriptome | 2017 |
Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Middle Aged; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Prognosis; Taxoids | 2017 |
Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition.
Topics: Antineoplastic Agents, Phytogenic; Cadherins; Carcinoma; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Fibronectins; Gene Expression; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; MicroRNAs; Ovarian Neoplasms; Paclitaxel; Polymerization; Taxoids; Tubulin; Tumor Suppressor Protein p53; Vimentin; Vinblastine | 2017 |
Cholic acid-based novel micellar nanoplatform for delivering FDA-approved taxanes.
Topics: Antineoplastic Agents; Bridged-Ring Compounds; Cell Line, Tumor; Cholic Acid; Docetaxel; Drug Carriers; Humans; Micelles; Nanoparticles; Neoplasms; Paclitaxel; Taxoids | 2017 |
Prognostic Index for Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Third-Generation Agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Leukocytes; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2017 |
Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions.
Topics: Adult; Aged; Albumins; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Drug Hypersensitivity; Female; Gemcitabine; Genital Neoplasms, Female; Humans; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Retreatment; Retrospective Studies; Taxoids; Thrombocytopenia | 2017 |
A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Fluorouracil; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Pilot Projects; Prognosis; Retrospective Studies; Risk Assessment; Survival Analysis; Taxoids | 2018 |
Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Male; Middle Aged; Netherlands; Paclitaxel; Pemetrexed; Registries; Small Cell Lung Carcinoma; Taxoids; Vinblastine; Vinorelbine | 2017 |
On Uterine Angiosarcomas: 2 Additional Cases.
Topics: Antineoplastic Agents; Carboplatin; Disease-Free Survival; Docetaxel; Fatal Outcome; Female; Hemangiosarcoma; Humans; Lung; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Metastasis; Paclitaxel; Uterine Neoplasms; Uterus | 2017 |
The effect of the nitroxide pirolin on oxidative stress induced by doxorubicin and taxanes in the rat brain.
Topics: Animals; Antineoplastic Agents; Brain; Catalase; Comet Assay; Cyclic N-Oxides; Docetaxel; Doxorubicin; Male; Neuroprotective Agents; Nitric Oxide Synthase Type I; Oxidative Stress; Paclitaxel; Poly (ADP-Ribose) Polymerase-1; Rats, Wistar; Sulfhydryl Compounds; Superoxide Dismutase; Taxoids; Thiobarbituric Acid Reactive Substances; Tumor Necrosis Factor-alpha | 2017 |
Lungs in White Induced by Docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Lung Diseases, Interstitial; Male; Paclitaxel; Taxoids | 2017 |
Comparative Toxicity and Effectiveness of Trastuzumab-Based Chemotherapy Regimens in Older Women With Early-Stage Breast Cancer.
Topics: Administrative Claims, Healthcare; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Comparative Effectiveness Research; Cyclophosphamide; Databases, Factual; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Medicare; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Propensity Score; Retrospective Studies; SEER Program; Taxoids; Time Factors; Trastuzumab; Treatment Outcome; United States | 2017 |
Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Lymphocytes, Tumor-Infiltrating; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Patient Selection; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Retrospective Studies; T-Lymphocytes, Cytotoxic; Taxoids; Time Factors; Trastuzumab; Treatment Outcome | 2017 |
Long-term peripheral neuropathy symptoms in breast cancer survivors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Cancer Survivors; Cross-Sectional Studies; Docetaxel; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Peripheral Nervous System Diseases; Prevalence; Retrospective Studies; Taxoids | 2017 |
RNA-sequencing dissects the transcriptome of polyploid cancer cells that are resistant to combined treatments of cisplatin with paclitaxel and docetaxel.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Humans; Paclitaxel; Real-Time Polymerase Chain Reaction; RNA, Small Interfering; Taxoids; Transcriptome | 2017 |
Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer.
Topics: Aged; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Treatment Outcome | 2017 |
Benefit of combination chemotherapy and radiation stratified by grade of stage IIIC endometrial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy, Adjuvant; Cisplatin; Cohort Studies; Docetaxel; Doxorubicin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Retrospective Studies; Taxoids | 2017 |
Breast Cancer Survivorship Care Variations Between Adjuvant Chemotherapy Regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cancer Survivors; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Insurance Claim Review; Lymph Node Excision; Mastectomy; Middle Aged; Office Visits; Paclitaxel | 2018 |
Synergistic Effect of Eicosapentaenoic Acid on Antiproliferative Action of Anticancer Drugs in a Cancer Cell Line Model.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Drug Synergism; Eicosapentaenoic Acid; Fluorouracil; Humans; Paclitaxel | 2017 |
[Clinical analysis of 36 cases of advanced non-small cell lung cancer (NSCLC) with performance status (PS) scores between 2 and 4].
Topics: Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Hypoxia; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Remission Induction; Response Evaluation Criteria in Solid Tumors; Severity of Illness Index; Taxoids | 2017 |
Symptom clusters using the Brief Pain Inventory in patients with breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Cancer Pain; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Pain Measurement; Prospective Studies; Quality of Life; Taxoids | 2017 |
Novel sulforaphane-enabled self-microemulsifying delivery systems (SFN-SMEDDS) of taxanes: Formulation development and in vitro cytotoxicity against breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Chemistry, Pharmaceutical; Docetaxel; Drug Delivery Systems; Emulsions; Excipients; Female; Humans; Isothiocyanates; MCF-7 Cells; Paclitaxel; Solubility; Sulfoxides; Taxoids | 2018 |
Docetaxel promotes the generation of anti-tumorigenic human macrophages.
Topics: Antineoplastic Agents; Carcinogenesis; Cell Differentiation; Dendritic Cells; Docetaxel; Female; Humans; Immunity, Innate; Macrophages; Monocytes; Myeloid Cells; Neoplasms; Paclitaxel; T-Lymphocytes; Taxoids | 2018 |
miR-613 inhibits cell migration and invasion by downregulating Daam1 in triple-negative breast cancer.
Topics: 3' Untranslated Regions; Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Cell Movement; Cyclophosphamide; Docetaxel; Down-Regulation; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Kaempferols; Lymphatic Metastasis; MCF-7 Cells; Microfilament Proteins; MicroRNAs; Neoplasm Invasiveness; Paclitaxel; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; Signal Transduction; Triple Negative Breast Neoplasms | 2018 |
Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition.
Topics: Biomarkers, Tumor; Bridged-Ring Compounds; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Humans; Mutation; Neoplastic Stem Cells; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2018 |
The microbial flora of taxane therapy-associated nail disease in cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Bacteria; Breast Neoplasms; Dermatomycoses; Docetaxel; Female; Fungi; Humans; Paclitaxel; Paronychia; Skin Diseases, Bacterial; Taxoids | 2018 |
Drug-target network of taxanes revealed by data mining.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Computational Biology; Cytochrome P-450 CYP2C8; Data Mining; Databases, Factual; Docetaxel; ErbB Receptors; Humans; Molecular Targeted Therapy; Paclitaxel; Protein Interaction Mapping; Software; Taxoids | 2018 |
Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast; Cell Line, Tumor; Docetaxel; Female; Humans; Immunoconjugates; Maytansine; Mice; Mice, Nude; Paclitaxel; Syndecan-1; Treatment Outcome; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2018 |
Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Cell Cycle Proteins; Cell Death; Cell Division; Cell Line, Tumor; Docetaxel; Drug Synergism; Female; Humans; MCF-7 Cells; Mice; Mitosis; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2018 |
Comparison of efficacy and toxicity of second-line combination chemotherapy regimens in patients with advanced urothelial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Urologic Neoplasms | 2018 |
Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Databases, Factual; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Stomach Neoplasms; Treatment Outcome | 2018 |
Pre-clinical evaluation of EC1456, a folate-tubulysin anti-cancer therapeutic.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Evaluation, Preclinical; Folic Acid; Humans; Mice, Nude; Neoplasms; Oligopeptides; Paclitaxel; Pipecolic Acids; Topotecan; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
The LncRNA H19/miR-193a-3p axis modifies the radio-resistance and chemotherapeutic tolerance of hepatocellular carcinoma cells by targeting PSEN1.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Hepatocytes; Histones; Humans; Ku Autoantigen; MicroRNAs; Paclitaxel; Presenilin-1; Rad51 Recombinase; Radiation Tolerance; RNA, Long Noncoding; Signal Transduction; Vinorelbine; X-Rays | 2018 |
Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Female; Humans; Japan; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Prospective Studies; Safety; Survival Rate; Young Adult | 2019 |
UV spectroscopy and least square matching for high throughput discrimination of taxanes in commercial formulations and compounded bags.
Topics: Calibration; Docetaxel; Drug Compounding; Least-Squares Analysis; Paclitaxel; Spectrophotometry, Ultraviolet; Taxoids | 2018 |
Role of zein incorporation on hydrophobic drug-loading capacity and colloidal stability of phospholipid nanoparticles.
Topics: Celecoxib; Colloids; Curcumin; Docetaxel; Drug Carriers; Hydrophobic and Hydrophilic Interactions; Nanoparticles; Paclitaxel; Particle Size; Phospholipids; Surface Properties; Zein | 2018 |
Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patients.
Topics: Aged; Bortezomib; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Genome-Wide Association Study; Humans; Male; Middle Aged; Multiple Myeloma; Nervous System; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Risk Factors; Taxoids; Vincristine | 2018 |
Retrospective evaluation of a rechallenge protocol in patients experiencing hypersensitivity reactions with prior chemotherapy in a tertiary hospital.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Docetaxel; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Oxaliplatin; Paclitaxel; Premedication; Retrospective Studies; Tertiary Care Centers | 2019 |
Different Nanoformulations Alter the Tissue Distribution of Paclitaxel, Which Aligns with Reported Distinct Efficacy and Safety Profiles.
Topics: Animals; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Compounding; Female; Mice; Nanoparticles; Paclitaxel; Tandem Mass Spectrometry | 2018 |
Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Practice Patterns, Physicians'; Prognosis; Retrospective Studies; Survival Rate; Trastuzumab; Young Adult | 2019 |
Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cohort Studies; Docetaxel; Female; Humans; Incidence; Medicare; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; SEER Program; United States | 2019 |
Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Mastectomy; Mastectomy, Segmental; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Taxoids; Triple Negative Breast Neoplasms | 2019 |
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Cohort Studies; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Italy; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Liver Neoplasms; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Peritoneal Neoplasms; Platinum Compounds; Progression-Free Survival; Proportional Hazards Models; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Treatment Failure | 2019 |
Nivolumab therapy for lung cancer with tracheo-parenchymal fistula: A case report.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Immunological; Bevacizumab; Carboplatin; Chemoradiotherapy; Docetaxel; Fistula; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nivolumab; Paclitaxel; Treatment Outcome | 2018 |
Value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non-predominant lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Pemetrexed; Retrospective Studies; Survival Rate; Vinorelbine | 2019 |
Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Cell Line, Tumor; Cisplatin; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Herpesvirus 4, Human; Humans; Liposomes; Male; Middle Aged; Nasopharyngeal Carcinoma; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Taxoids | 2018 |
Towards risk-stratified induction regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Clinical Trials, Phase II as Topic; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Paclitaxel; Papillomavirus Infections; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome | 2019 |
Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2019 |
High-Density Lipoprotein-Mimicking Nanodiscs for Chemo-immunotherapy against Glioblastoma Multiforme.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Delivery Systems; Female; Flow Cytometry; Glioblastoma; Humans; Immunohistochemistry; Immunotherapy; Lipoproteins, HDL; Lomustine; Mice; Models, Biological; Paclitaxel; Rats; T-Lymphocytes | 2019 |
Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case-Control Study.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Breast Neoplasms; Case-Control Studies; Constitutive Androstane Receptor; Docetaxel; Female; Glucuronosyltransferase; Humans; Middle Aged; Outcome Assessment, Health Care; Paclitaxel; Peripheral Nervous System Diseases; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Prognosis; Receptors, Cytoplasmic and Nuclear | 2019 |
Quantitative and qualitative control of antineoplastic preparations: Gravimetry versus HPLC.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Docetaxel; Humans; Paclitaxel; Quality Control; Reproducibility of Results | 2019 |
Second-line systemic therapies for metastatic urothelial carcinoma: a population-based cohort analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Treatment Outcome; Urologic Neoplasms; Urothelium | 2019 |
Retrospective comparison of two consecutive cohorts of adjuvant chemotherapy regimens of cyclophosphamide with either docetaxel or paclitaxel in older patients with early breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Humans; Paclitaxel; Retrospective Studies | 2019 |
Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Oncologists; Paclitaxel; Patient Reported Outcome Measures; Peripheral Nervous System Diseases; Self Report; Young Adult | 2019 |
Cost-Effectiveness of Docetaxel and Paclitaxel for Adjuvant Treatment of Early Breast Cancer: Adaptation of a Model-Based Economic Evaluation From the United Kingdom to South Africa.
Topics: Breast Neoplasms; Cost-Benefit Analysis; Developing Countries; Docetaxel; Female; Humans; Middle Aged; Models, Economic; Paclitaxel; Quality-Adjusted Life Years; South Africa; United Kingdom | 2019 |
Synthesis and Cytotoxicity of 7,9-
Topics: Bridged-Ring Compounds; Cell Death; Docetaxel; HeLa Cells; Humans; Macrocyclic Compounds; Molecular Docking Simulation; Paclitaxel; Structural Homology, Protein; Taxoids; Tubulin | 2019 |
TS-1 add-on therapy in Japanese patients with triple-negative breast cancer after neoadjuvant or adjuvant chemotherapy: a feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Epirubicin; Feasibility Studies; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Silicates; Survival Rate; Titanium; Triple Negative Breast Neoplasms | 2020 |
Involvement of the MDR1 gene and glycolipids in anticancer drug-resistance of human ovarian carcinoma-derived cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Carcinoma; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Female; Glycolipids; Humans; Hydrophobic and Hydrophilic Interactions; Ovarian Neoplasms; Paclitaxel | 2019 |
G protein-coupled receptor kinase 5 modifies cancer cell resistance to paclitaxel.
Topics: Acetylation; Apoptosis; Biocatalysis; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; G-Protein-Coupled Receptor Kinase 3; G-Protein-Coupled Receptor Kinase 5; G-Protein-Coupled Receptor Kinases; HeLa Cells; Histone Deacetylase 6; Histones; Humans; MAP Kinase Signaling System; Paclitaxel; Phosphorylation; Phosphoserine; Protein Binding; Tubulin | 2019 |
Multicomponent Conjugates of Anticancer Drugs and Monoclonal Antibody with PAMAM Dendrimers to Increase Efficacy of HER-2 Positive Breast Cancer Therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dendrimers; Docetaxel; Drug Interactions; Drug Liberation; Fluorescent Dyes; Humans; Paclitaxel; Receptor, ErbB-2; Surface Properties; Trastuzumab; Treatment Outcome | 2019 |
In utero exposure to breast cancer treatment: a population-based perinatal outcome study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Australia; Breast Neoplasms; Carboplatin; Case-Control Studies; Cesarean Section; Cohort Studies; Congenital Abnormalities; Continuous Positive Airway Pressure; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Gestational Age; Humans; Infant, Low Birth Weight; Infant, Newborn; Infant, Small for Gestational Age; Labor, Induced; New Zealand; Paclitaxel; Perinatal Death; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, First; Pregnancy Trimester, Second; Premature Birth; Prospective Studies; Respiratory Distress Syndrome, Newborn; Stillbirth; Tamoxifen; Trastuzumab | 2019 |
CDK4/6 inhibition mitigates stem cell damage in a novel model for taxane-induced alopecia.
Topics: Alopecia; Antineoplastic Agents; Bridged-Ring Compounds; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Docetaxel; Humans; Keratinocytes; Models, Theoretical; Organ Culture Techniques; Paclitaxel; Piperazines; Protein Kinase Inhibitors; Pyridines; Stem Cells; Taxoids | 2019 |
Taxane-Induced Peripheral Neuropathy: Objective and Subjective Comparison Between Paclitaxel and Docetaxel in Patients With Breast Cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cross-Sectional Studies; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life | 2019 |
Definitive alopecia post-docetaxel.
Topics: Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2020 |
Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; ErbB Receptors; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Mutation; Paclitaxel; Pemetrexed; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic | 2019 |
Characterization of infections and hypogammaglobulinemia treated with the combination of pertuzumab and trastuzumab.
Topics: Adult; Agammaglobulinemia; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Docetaxel; Female; Gram-Positive Bacterial Infections; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2020 |
Clinicopathological values of PD-L1 expression in HER2-positive breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Breast Neoplasms; Docetaxel; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Neoadjuvant Therapy; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Trastuzumab | 2019 |
Safety and tolerability of cryocompression as a method of enhanced limb hypothermia to reduce taxane-induced peripheral neuropathy.
Topics: Adult; Aged; Cryotherapy; Docetaxel; Extremities; Female; Humans; Hypothermia, Induced; Male; Middle Aged; Neoplasms; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Pilot Projects; Retrospective Studies; Treatment Outcome | 2020 |
Potential cross-reactivity of polysorbate 80 and cremophor: A case report.
Topics: Adult; Antiemetics; Docetaxel; Drug Interactions; Female; Humans; Paclitaxel; Pharmaceutical Vehicles; Polyethylene Glycols; Polysorbates | 2020 |
Synthesis of Taxol and Docetaxel by Using 10-Deacetyl-7-xylosyltaxanes.
Topics: Acetylation; Chromatography, High Pressure Liquid; Docetaxel; Magnetic Resonance Spectroscopy; Oxidation-Reduction; Paclitaxel; Taxoids | 2020 |
The clinical value and usage of inflammatory and nutritional markers in survival prediction for gastric cancer patients with neoadjuvant chemotherapy and D2 lymphadenectomy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Platelets; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Follow-Up Studies; Hemoglobins; Humans; Inflammation; Lymph Node Excision; Lymphocytes; Male; Middle Aged; Neoadjuvant Therapy; Neutrophils; Nomograms; Oxaliplatin; Paclitaxel; Prognosis; Prospective Studies; Stomach Neoplasms; Survival Rate | 2020 |
Computational Cancer Cell Models to Guide Precision Breast Cancer Medicine.
Topics: Breast Neoplasms; Cell Line, Tumor; Computer Simulation; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Evaluation, Preclinical; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Precision Medicine; Tamoxifen; Transcriptome | 2020 |
Chemotherapy-induced peripheral neuropathy among patients with ovarian cancer.
Topics: Adult; Antineoplastic Agents; Case-Control Studies; China; Docetaxel; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Surveys and Questionnaires | 2020 |
Consolidation chemotherapy in early-stage cervical cancer patients with lymph node metastasis after radical hysterectomy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Consolidation Chemotherapy; Docetaxel; Female; Humans; Hysterectomy; Liposomes; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Retrospective Studies; Uterine Cervical Neoplasms | 2020 |
Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Crizotinib; Deoxycytidine; Docetaxel; Female; Gemcitabine; Histocompatibility Antigens Class II; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oncogene Fusion; Paclitaxel; Pemetrexed; Platinum Compounds; Progression-Free Survival; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Retrospective Studies; Treatment Outcome | 2020 |
Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Japan; Middle Aged; NAV1.7 Voltage-Gated Sodium Channel; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Survival Rate | 2020 |
Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Comorbidity; Cyclophosphamide; Deprescriptions; Docetaxel; Doxorubicin; Drug Tapering; Etoposide; Female; Functional Status; Humans; Lung Neoplasms; Male; Middle Aged; Netherlands; Paclitaxel; Practice Patterns, Physicians'; Progression-Free Survival; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Topotecan | 2020 |
Delayed docetaxel extravasation in case of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2020 |
Binding modes of cabazitaxel with the different human β-tubulin isotypes: DFT and MD studies.
Topics: Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Microtubules; Molecular Docking Simulation; Molecular Dynamics Simulation; Paclitaxel; Taxoids; Thermodynamics; Tubulin; Tubulin Modulators | 2020 |
Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Docetaxel; Doxorubicin; Female; Humans; Ifosfamide; Indazoles; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Progression-Free Survival; Pyrimidines; Retrospective Studies; Sulfonamides; Treatment Outcome; Uterine Neoplasms | 2020 |
Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome; United States | 2020 |
Call for assessing treatment-induced gonadotoxicity of platinum-based chemotherapy in early breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Ovary; Paclitaxel; Primary Ovarian Insufficiency; Randomized Controlled Trials as Topic; Treatment Outcome; Triple Negative Breast Neoplasms | 2020 |
Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unresectable head and neck cancer patients ineligible for combination treatment with docetaxel, cisplatin, and 5-fluorouracil.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Docetaxel; Feasibility Studies; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Paclitaxel; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2020 |
Simultaneous Determination of Docetaxel and Celecoxib in Porous Microparticles and Rat Plasma by Liquid-Liquid Extraction and HPLC with UV Detection: in vitro and in vivo Validation and Application.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Chromatography, High Pressure Liquid; Docetaxel; Drug Monitoring; Limit of Detection; Liquid-Liquid Extraction; Male; Microspheres; Paclitaxel; Porosity; Rats; Rats, Wistar; Reproducibility of Results; Spectrophotometry, Ultraviolet | 2020 |
Efficacy and safety analysis of paclitaxel, docetaxel and liposomal paclitaxel after neoadjuvant therapy in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2 | 2020 |
Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Survival Analysis; Treatment Outcome | 2020 |
Correlation between microRNA-766 expression in patients with advanced gastric cancer and the efficacy of platinum-containing chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; MicroRNAs; Middle Aged; Neoplasm Staging; Oxaliplatin; Paclitaxel; Stomach Neoplasms; Treatment Outcome; Tumor Burden | 2020 |
A multiple-targets alkaloid nuciferine overcomes paclitaxel-induced drug resistance in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Aporphines; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line, Tumor; Docetaxel; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice, Inbred BALB C; Molecular Targeted Therapy; Neoplasm Proteins; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Xenograft Model Antitumor Assays | 2020 |
Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan | 2020 |
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; DNA Repair-Deficiency Disorders; Docetaxel; Drug Therapy; Humans; Male; Middle Aged; Paclitaxel; Platinum Compounds; Prostatic Neoplasms; Retrospective Studies | 2020 |
Nab-paclitaxel-based regimens with docetaxel-based regimens as neoadjuvant treatment for early breast cancer.
Topics: Aged; Albumins; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Docetaxel; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2 | 2021 |
Ophthalmic adverse effects of taxanes: The Mayo Clinic experience.
Topics: Docetaxel; Humans; Macular Edema; Middle Aged; Paclitaxel; Retrospective Studies; Taxoids | 2022 |
Hyperthermia During Intraperitoneal Chemotherapy With Paclitaxel or Docetaxel for Ovarian Cancer: Is There Any Benefit?
Topics: Cell Cycle; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Docetaxel; Female; G2 Phase; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Mitosis; Ovarian Neoplasms; Paclitaxel | 2020 |
Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Digestive System Diseases; Docetaxel; Fatigue; Female; Fluorouracil; Hematologic Diseases; Humans; Male; Middle Aged; Nail Diseases; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Retrospective Studies; Stomach Neoplasms; Taxoids; Tunisia | 2021 |
Population Pharmacokinetics of Docetaxel, Paclitaxel, Doxorubicin and Epirubicin in Pregnant Women with Cancer: A Study from the International Network of Cancer, Infertility and Pregnancy (INCIP).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Infertility; Neoplasms; Paclitaxel; Pregnancy; Pregnant Women; Taxoids | 2021 |
Pronociceptive Roles of Schwann Cell-Derived Galectin-3 in Taxane-Induced Peripheral Neuropathy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Blood Proteins; Cell Movement; Chemotaxis; Clodronic Acid; Disease Models, Animal; Docetaxel; Female; Galectins; Humans; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Paclitaxel; Pain Perception; Peripheral Nervous System Diseases; Prospective Studies; Rats; Schwann Cells; Sciatic Nerve; Up-Regulation | 2021 |
Comparative study of oral and IV dexamethasone premedication in the prevention of docetaxel induced allergic reactions.
Topics: Dexamethasone; Docetaxel; Drug Hypersensitivity; Humans; Paclitaxel; Premedication; Retrospective Studies | 2022 |
Single nucleotide polymorphisms to predict taxanes toxicities and effectiveness in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Albumins; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP3A; Docetaxel; Female; Genotype; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Pharmacogenetics; Polymorphism, Single Nucleotide; Prospective Studies; Taxoids | 2021 |
Fast and accurate procedure to perform SCF or DFT calculation for large molecules.
Topics: Algorithms; Computational Chemistry; Density Functional Theory; Docetaxel; Insulin; Manganese Compounds; Models, Molecular; Molecular Conformation; Paclitaxel; Quantum Theory; Spectrophotometry, Ultraviolet | 2021 |
Natural history of nasal vestibulitis associated with paclitaxel, docetaxel, and other chemotherapy agents: a Minnesota Cancer Clinical Trials Network (MNCCTN) study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Minnesota; Neoplasms; Paclitaxel | 2021 |
Molecular Analysis of
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Transcription Factors; Lung Neoplasms; Male; Neoplasm Proteins; Paclitaxel; Protein Isoforms; Survival Rate | 2021 |
Autophagy inhibition and microRNA‑199a‑5p upregulation in paclitaxel‑resistant A549/T lung cancer cells.
Topics: A549 Cells; Autophagy; Cell Line, Tumor; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; MicroRNAs; Oxaliplatin; Paclitaxel; Sequestosome-1 Protein; Topotecan; Up-Regulation; Vinorelbine | 2021 |
Fixed erythrodysesthesia plaques at sites of intravenous docetaxel infusion: an unusual cutaneous reaction to chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hand-Foot Syndrome; Humans; Infusions, Intravenous; Paclitaxel | 2022 |
Do Steroids Matter? A Retrospective Review of Premedication for Taxane Chemotherapy and Hypersensitivity Reactions.
Topics: Antineoplastic Agents, Phytogenic; California; Dexamethasone; Docetaxel; Drug Hypersensitivity; Drug Prescriptions; Drug Utilization; Electronic Health Records; Female; Humans; Male; Paclitaxel; Practice Patterns, Physicians'; Premedication; Retrospective Studies; Risk Assessment; Risk Factors; Steroids; Time Factors; Treatment Outcome | 2021 |
Selective and Marked Blockade of Endothelial Sprouting Behavior Using Paclitaxel and Related Pharmacologic Agents.
Topics: Angiogenesis Inhibitors; Animals; Blood Vessels; Cells, Cultured; Docetaxel; Endothelial Cells; Endothelium, Vascular; Epothilones; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Inbred C57BL; Morphogenesis; Neovascularization, Pathologic; Neovascularization, Physiologic; Paclitaxel | 2021 |
Synergistic Interactions of Cannabidiol with Chemotherapeutic Drugs in MCF7 Cells: Mode of Interaction and Proteomics Analysis of Mechanisms.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cannabidiol; Cell Line, Tumor; Cell Survival; Dactinomycin; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Irinotecan; MCF-7 Cells; Paclitaxel; Proteome; Proteomics; Vinorelbine | 2021 |
Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases | 2022 |
Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2021 |
Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Topics: Aged; Bridged-Ring Compounds; Disease Progression; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids; Treatment Outcome | 2021 |
COVID-19 vaccines tolerated in patients with paclitaxel and docetaxel allergy.
Topics: COVID-19; COVID-19 Vaccines; Docetaxel; Humans; Hypersensitivity; Paclitaxel; SARS-CoV-2 | 2022 |
Mechanisms of influence of the microtubule over-stabilizing ligands on the structure and intrinsic dynamics of α,β-Tubulin.
Topics: Docetaxel; Guanosine Diphosphate; Guanosine Triphosphate; Ligands; Microtubules; Models, Molecular; Molecular Conformation; Paclitaxel; Protein Conformation; Tubulin | 2022 |
Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Epitopes; Fluorouracil; Humans; Paclitaxel; Prospective Studies | 2022 |
Folic Acid and Chitosan-Functionalized Gold Nanorods and Triangular Silver Nanoplates for the Delivery of Anticancer Agents.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Chitosan; Docetaxel; Folic Acid; G2 Phase Cell Cycle Checkpoints; Gold; HeLa Cells; Humans; Metal Nanoparticles; Nanotubes; Paclitaxel; Silver | 2022 |
Self-emulsifying Drug Delivery System for Oral Anticancer Therapy: Constraints and Recent Development.
Topics: Administration, Oral; Antineoplastic Agents; Biological Availability; Chemistry, Pharmaceutical; Docetaxel; Doxorubicin; Drug Delivery Systems; Emulsions; Etoposide; Fluorouracil; Humans; Paclitaxel; Solubility; Surface-Active Agents | 2022 |
Allergy testing for Cremophor in a patient with cervical cancer with infusion reactions to paclitaxel and docetaxel.
Topics: Docetaxel; Female; Humans; Hypersensitivity; Paclitaxel; Polyethylene Glycols; Taxoids; Uterine Cervical Neoplasms | 2022 |
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Humans; Immune Checkpoint Inhibitors; Ipilimumab; Lung Neoplasms; Nivolumab; Paclitaxel; Pemetrexed | 2022 |
Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China.
Topics: Cost-Benefit Analysis; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Immunotherapy; Nivolumab; Paclitaxel | 2022 |
Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line; Cisplatin; Crizotinib; Docetaxel; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Microtubule Proteins; Mutation; Paclitaxel; Protein Kinase Inhibitors; Pyrazoles; Tumor Suppressor Protein p53 | 2022 |
Simultaneous estimation of paclitaxel and erlotinib in plasma by liquid chromatography/(+) electrospray tandem mass spectrometry: application in formulation development and pharmacokinetics.
Topics: Acetonitriles; Chromatography, High Pressure Liquid; Chromatography, Liquid; Docetaxel; Erlotinib Hydrochloride; Paclitaxel; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Water | 2022 |
Neural correlates in functional brain mapping among breast cancer survivors receiving different chemotherapy regimens: a qEEG/HEG-based investigation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Mapping; Breast Neoplasms; Cancer Survivors; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Neurotoxicity Syndromes; Paclitaxel | 2022 |
Risk of Ocular Adverse Events With Taxane-Based Chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Child; Docetaxel; Female; Humans; Lacrimal Apparatus Diseases; Macular Edema; Middle Aged; Optic Nerve Diseases; Paclitaxel; Retrospective Studies; Tamoxifen; Taxoids | 2022 |
Triple negative breast cancer: approved treatment options and their mechanisms of action.
Topics: Docetaxel; Doxorubicin; Epirubicin; Humans; Paclitaxel; Triple Negative Breast Neoplasms; United States | 2023 |
Additive Interactions between Betulinic Acid and Two Taxanes in In Vitro Tests against Four Human Malignant Melanoma Cell Lines.
Topics: Antineoplastic Agents; Betulinic Acid; Cell Line; Docetaxel; Humans; In Vitro Techniques; Melanoma; Melanoma, Cutaneous Malignant; Paclitaxel; Pentacyclic Triterpenes; Skin Neoplasms; Taxoids | 2022 |
Development and application of a liquid chromatography coupled to mass spectrometry method for the simultaneous determination of 23 antineoplastic drugs at trace levels.
Topics: Antineoplastic Agents; Busulfan; Carboplatin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Docetaxel; Doxorubicin; Epirubicin; Etoposide; Fluorouracil; Ganciclovir; Humans; Idarubicin; Ifosfamide; Irinotecan; Methanol; Methotrexate; Oxaliplatin; Paclitaxel; Pemetrexed; Tandem Mass Spectrometry; Topotecan; Vinblastine; Vincristine; Water | 2022 |
A patient with advanced lung squamous cell carcinoma who failed to benefit from albumin bound paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus pembrolizumab: a case report.
Topics: Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2022 |
PROSPECTS OF NEOADJUVANT CHEMORADIOTHERAPY IN PATIENTS WITH STAGE III A NON-SMALL CELL LUNG CANCER AS A METHOD OF IMPROVING SURVIVAL.
Topics: Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2022 |
Prospective Study Investigating the Efficacy and Safety of a Scalp Cooling Device for the Prevention of Alopecia in Women Undergoing (Neo)Adjuvant Chemotherapy for Breast Cancer.
Topics: Adult; Alopecia; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Humans; Paclitaxel; Prospective Studies; Scalp; Taxoids | 2022 |
Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Patient Reported Outcome Measures; Peripheral Nervous System Diseases; Prospective Studies; Quality of Life; Taxoids | 2022 |
Salvage Chemotherapy with Cisplatin, Ifosfamide, and Paclitaxel in Aggressive Variant of Metastatic Castration-Resistant Prostate Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Humans; Male; Paclitaxel; Prostatic Neoplasms, Castration-Resistant; Proteomics; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2022 |
The role of carboplatin in combination with paclitaxel in patients with castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Humans; Male; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2022 |
Nanoparticle albumin-bound paclitaxel-based neoadjuvant regimen: A promising treatment option for HER2-low-positive breast cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Lipopolysaccharides; Nanoparticles; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Treatment Outcome | 2023 |
Efficacy and safety evaluation of PSOX, DOF and SOX regimens as neoadjuvant chemotherapy for advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Retrospective Studies; Stomach Neoplasms | 2022 |
A five arm natural history study of nasal vestibulitis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Prospective Studies | 2023 |
STEAP1 Knockdown Decreases the Sensitivity of Prostate Cancer Cells to Paclitaxel, Docetaxel and Cabazitaxel.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Humans; Male; Oxidoreductases; Paclitaxel; Prostate; Prostatic Neoplasms; Taxoids | 2023 |
A Three-Step Taxane Titration Protocol Decreases Hypersensitivity Reactions During First and Second Exposures.
Topics: Docetaxel; Drug Hypersensitivity; Epinephrine; Humans; Paclitaxel; Prospective Studies; Taxoids | 2023 |
Reduction-Responsive Docetaxel Prodrug Encapsulated within Human Serum Albumin Nanoparticles for Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Carriers; Humans; Mice; Nanoparticles; Neoplasms; Paclitaxel; Prodrugs; Serum Albumin, Human | 2023 |
Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2023 |
The impact of nutritional status in nivolumab-treated patients with advanced esophageal cancer.
Topics: Antineoplastic Agents, Immunological; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Nivolumab; Nutritional Status; Paclitaxel; Retrospective Studies | 2023 |
Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Comparative Effectiveness Study Using US Electronic Health Records.
Topics: Breast Neoplasms; Docetaxel; Electronic Health Records; Female; Humans; Paclitaxel; Retrospective Studies; Taxoids; Trastuzumab | 2023 |
Synergy, Additivity and Antagonism between Esculetin and Six Commonly Used Chemotherapeutics in Various Malignant Melanoma Cell Lines-An Isobolographic Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; Cisplatin; Cytostatic Agents; Docetaxel; Epirubicin; Humans; Melanoma; Mitoxantrone; Paclitaxel; Vemurafenib | 2023 |
Computational analysis of drug resistance of taxanes bound to human β-tubulin mutant (D26E).
Topics: Animals; Docetaxel; Drug Resistance, Neoplasm; Humans; Paclitaxel; Swine; Taxoids; Tubulin | 2023 |
The Association Between Taxane Use and Lacrimal Disorders.
Topics: Docetaxel; Humans; Lacrimal Apparatus Diseases; Paclitaxel; Taxoids; United States | 2023 |
Semi-physiological Enriched Population Pharmacokinetic Modelling to Predict the Effects of Pregnancy on the Pharmacokinetics of Cytotoxic Drugs.
Topics: Antineoplastic Agents; Child; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Models, Biological; Neoplasms; Paclitaxel; Pregnancy | 2023 |
μMESH-Enabled Sustained Delivery of Molecular and Nanoformulated Drugs for Glioblastoma Treatment.
Topics: Animals; Cell Line, Tumor; Docetaxel; Glioblastoma; Nanoparticles; Paclitaxel; Pharmaceutical Preparations; Polymers; Polyvinyl Alcohol | 2023 |
Clinical benefit of switching from paclitaxel to docetaxel or vice versa in cutaneous angiosarcoma patients resistant to first taxane chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hemangiosarcoma; Humans; Paclitaxel; Skin Neoplasms; Taxoids | 2023 |
Tumor-derived exosomes RNA expression profiling identifies the prognosis, immune characteristics, and treatment in HR+/HER2-breast cancer.
Topics: Breast Neoplasms; Docetaxel; Exosomes; Female; Humans; Paclitaxel; Prognosis | 2023 |
Efficacy comparisons of solvent-based paclitaxel, liposomal paclitaxel, nanoparticle albumin-bound paclitaxel, and docetaxel after neoadjuvant systemic treatment in breast cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Nanoparticles; Neoadjuvant Therapy; Paclitaxel; Retrospective Studies; Taxoids | 2023 |
Immunotherapy as a later-line option for
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Lung Neoplasms; Paclitaxel; Taxoids | 2023 |
[Drugs from nature. The biology of taxane].
Topics: Animals; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Docetaxel; Humans; Taxoids; Taxus | 2005 |
Taxus baccata allergy in a breast cancer patient.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Immunologic; Drug Hypersensitivity; Female; Humans; Taxoids; Taxus | 2012 |